Lectures in English
Lectures in Spanish

Dr Stacy Loeb gives frequent lectures around the world on prostate cancer and the use of social media in medicine. Lectures are shown on the map and are listed below the map by region.


All

Australia

21st Asia-Pacific Prostate Cancer Conference

Australia (Virtual). October 2020

Topic: Key Papers in Detection and Localized Prostate Cancer, Women in Urology and Leveraging Social Media

Category: Prostate Cancer, Social Media, Representation


Clinical Oncology Society of Australia

Adelaide, Australia – November 12-14, 2019

Lecture topics: Latest developments in prostate cancer surgery and active surveillance; Promise and peril of social media for clinicians, researchers and patients

Category: Prostate Cancer Treatment, Active Surveillance, Social Media


2018 Prostate Cancer World Congress

Brisbane Australia . August 22-246, 2018

Lecture Topic: Active surveillance for prostate cancer, Social media in prostate cancer

Category: Prostate Cancer, Social Media


USANZ New Zealand Section

Tauranga, New Zealand . October 11-13, 2017

Lecture Topic: Localized prostate cancer update, active surveillance, prostate cancer markers, social media

Category: prostate cancer, social media


Astellas Prostate Cancer Meeting

Hobart, Australia. April 8, 2017

Lecture topic: Markers and Prostate Cancer Screening

Category: Prostate Cancer


Astellas Prostate Cancer Meeting

Melbourne, Australia. April 7, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer


Astellas Prostate Cancer Meeting

Sydney, Australia. April 5-6, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer


Astellas Prostate Cancer Meeting

Adelaide, Australia. April 4, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer


Astellas Prostate Cancer Meeting

Brisbane, Australia. April 3, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer


Macquarie University Markers Symposium

Sidney, Australia. September 2016

Lecture Topics: Prostate Cancer Markers

Category: Prostate Cancer, Markers


Prostate Cancer World Congress

Cairns, Australia. August 2015

Lecture Topics: Key publications in prostate cancer, Active Surveillance for prostate cancer, Updates to Gleason grading, Social Media and Prostate Cancer.

Category: Prostate Cancer


Prostate Cancer World Congress

 Melbourne, Australia. August 2013

Lecture Topics: Practice changing publications in Prostate Cancer, Smarter PSA Screening with Isoforms and Kinetics, Selecting patients for Prostate Biopsy, Selection and monitoring during Active Surveillance

Category: Prostate Cancer


Australian Prostate Cancer Conference

 Melbourne, Australia. August 2012

Lecture Topics: Prostate biopsy complications, Overdiagnosis and Overtreatment of Prostate Cancer

Category: Prostate Complications


Brazil

Paulista Congress of Urology

Brazil (Virtual). October 2020

Topic: Prostate Cancer Screening, Markers and Genetic Testing

Category: Prostate Cancer, Genetics


International Continence Society

Rio de Janiero, Brazil. October 2014

Lecture Topic: Social Media in Medicine

Category: Social media


Canada

Société Internationale d’Urologie

Montreal (Virtual). April 2020

Topic: Webinar on Economic and Financial Burden of COVID-19

Category: COVID-19


Queens University Visiting Professor

Kingston, Ontario – October 18-19, 2018

Lecture Topics: Social Media in Men’s Health (6th Annual Alvaro and Diane Morales Public Lecture in Men’s Health); Active Surveillance for Prostate Cancer.

Category: Men’s Health, Social Media, Prostate Cancer, Active Surveillance


Canadian Urological Association 2017 Meeting

Toronto, Canada- June 24-27, 2017

Lecture topics: Optimizing Active Surveillance for Prostate Cancer, Serum and Urine Markers to Select Patient for Initial and Repeat Prostate Biopsy

Category: Prostate cancer


Issues & Controversies in Urologic Cancer (ICUC) Conference 2017

Mony Tremblant, Canada. January 19-21, 2017

Lecture Topics: Prostate Cancer Markers, Active Surveillance, Prostate Biopsy

Category: Prostate Cancer


The 10th Atlantic Uro Oncology Meeting

 Halifax, Canada. November 14, 2015

Lecture Topics: Prostate Cancer Markers and Active Surveillance

Category: Prostate Cancer


Visiting professor at University of Toronto

 Toronto, Canada. October 2014

Lecture Topics: Prostate Biopsy, Active Surveillance

Category: Prostate Cancer


Colombia

1ER CURSO BIENAL DE INNOVACÍON UROLÓGICA SOCIEDAD COLOMBIANA DE UROLOGÍA

 Barranquilla, Colombia. October 2015

Lecture Topics (all in Spanish):  Prostate -specific Antigen and Biomarkers, Prevention and Management of Prostate Biopsy Complications, Active Surveillance

Category: Prostate Cancer


Second Update Course in Urology (Curso de Actualización en Urología)

 Barranquilla, Colombia. March 2015

Lecture Topics: Prostate cancer screening, prostate cancer markers, prostate biopsy

Category: Prostate Cancer


Visiting Professor at Fundación Santa Fe de Bogotá Fundación

 Barranquilla, Colombia. March 2015

Lecture Topics: Prostate Cancer Screening, Serum and Urine Markers for Prostate Cancer, Contemporary Prostate Biopsy, Active Surveillance, Social Media in Urology

Categories: Prostate Cancer, Social Media


Sociedad Colombiana de Urologia

Cartagena, Colombia. March 2014

Lectures Topics: PSA screening, Risks of Prostate Biopsy, Active Surveillance, Prostate MRI-based Detection, Castration Resistant Prostate Cancer, and Twitter in Urology

Categories: Prostate Cancer, Social Media


Costa Rica

Congreso Centroamericano y del Caribe de Urología y II Highlights of the 2014 American Urological Association Meeting

San Jose, Costa Rica. August 2014

Lectures on: Active surveillance for prostate cancer, Highlights of the AUA meeting on Localized Prostate Cancer

Category: Prostate Cancer


Dominican Republic

Sociedad Dominicana de Urologia

 Punta Cana, Dominican Republic. November 2013

Lectures Topics: PSA Screening, Prostate Cancer Markers, and Prostate Biopsy Complications

Category: Prostate Cancer


England

Royal Society of Medicine

UK (Virtual). June 2020

Topic: COVID-19 and Active Surveillance

Category: Prostate Cancer, COVID-19


European Association of Urology 2017 Congress

London, England. 2017

Lecture topic: Social Media

Category: Social Media


Royal Society of Medicine Urology Section Prostate Cancer Conference

London, England. Ocrober 21, 2016

Lecture topic: Active Surveillance- USA Perspective

Category: Prostate Cancer


Germany

Association of Academic European Urologists (AAEU)

Dresden, Germany . December 15-16, 2017

Lecture Topic: Active surveillance for prostate cancer

Category: Prostate Cancer


Heinrich Warner Symposium

Hamburgo, Germany. June 23-24, 2017

Lecture Topic: Clinical Use of Markers in Localized Prostate Cancer

Category: Prostate Cancer


European Association of Urology

Munich, Germany. March 11-14, 2016

Lecture Topics: Prostate Cancer Markers

Category: Prostate Cancer


Heinrich Warner Symposium

Hamburg, Germany. January 2015

Lecture Topics : Genomic and Epigenetic Variations in Prostate Cancer

Category: Prostate Cancer


Hong Kong

Chinese University of Hong Kong Urology Symposium

Hong Kong (Virtual). November 2020

Topic: Prostate Cancer Screening: Evidence, Guidelines and Implementation; Updates on Prostate Cancer in 2019-2020

Category: Prostate Cancer


Hungary

International Genitourinary Cancer Symposium (IGUCC 3)

Budapest, Hungary. March 2011

Lecture Topics: Debate on Active Surveillance, Panel on Controversies in Prostate Cancer

Category: Prostate Cancer


Ireland

John Fitzpatrick Irish Prostate Cancer Conference

Ireland. April 21-22, 2016

Lecture Topics: Smarter Prostate Cancer Screening; Prostate Cancer Treatment

Category: Prostate Cancer


Israel

Friends of Israel Urology Symposium

Israel. July 7-8, 2016

Lecture Topics: Active Surveillance, Prostate Cancer Treatment

Category: Prostate Cancer


Urological Research Society meeting

Jerusalem, Israel. September 2015

Lecture Topic: Utilization of Active Surveillance

Category: Prostate Cancer


Friends of Israel Urological Symposium

Tel Aviv, Israel. July 2012

Lecture Topic: Prostate Cancer Screening

Category: Prostate Cancer


Italy

Surgery in the 3rd Millennium: The Future is Female

Milan, Italy – April 4-5, 2019

Lecture Topics: When not to do surgery: expanding active surveillance for low-risk prostate cancer; Moderation for Retzius-Sparing Robotic Prostatectomy

Category: Prostate Cancer, Active Surveillance, Surgical Technique


Association of Academic European Urologists (AAEU) Meeting

Rome, Italy . November 30, 2018

Lecture Topic: Prostate Cancer Journal Club #ProstateJC on Twitter

Category: Social Media, Prostate Cancer


State-of-the-Art Lecture, Association of Academic European Urologists

Roma, Italy .November, 2018

Lecture Topic: Prostate Cancer Journal Club #ProstateJC on Twitter

Category: Social Media, Prostate Cancer


iTRUST International Translational Research Uro-Sciences Team

Roma, Italy .September 26-27, 2018

Lecture Topic: Social Media & Cancer Care: Where are we going?

Category: Cancer, Social Media


Global Congress on Prostate Cancer (PROSCA)

 Rome, Italy. February 2015

Lecture topic: PSA Screening Yes or No

Category: Prostate Cancer


European Association of Urology Guidelines Office Chairs Meeting

Florence, Italy. October 2014

Lecture Topic: Social Media in Urology

Category: Social Media


International Genitourinary Cancer Symposium (IGUCC 5)

Rome, Italy. April 2013

Lectures Topic: Nature vs Nurture in Prostate Cancer, and Prostate Specific Antigen Velocity

Category: Prostate Cancer


Korea

Annual Meeting of the Korean Urological Association

Seoul, Korea. October 12-15, 2016

Lecture Topics: Prostate Cancer Markers, Active Surveillance, BPH

Category: Prostate Cancer, Benign Prostatic Hyperplasia

 

 


Mexico

Sociedad Mexicana de Urología/ American Urological Association Curso Conjunto

Acapulco, Mexico. February 3-4, 2017

Lecture Topics: Prostate Cancer Screening, Prostate Biopsy, Prostate MRI, Active Surveillance, Radical Prostatectomy, Radiation Therapy

Category: Prostate Cancer


Asociación Mexicana de Urología Oncológica (Acapulco, Mexico)

Acapulco, Mexico. July 20-22, 2016

Lecture topics:Social media, Prostate Cancer Markers, Prostate Biopsy Complications, Active Surveillance

Category: Prostate Cancer, Social Media


Colegio Mexicano de Urologia (Puebla, Mexico)

Puebla, Mexico. April 14-16, 2016

Lecture Topics (Spanish): Association of PDE5 inhibitors with risk of melanoma and Prostate Cancer; Active Surveillance for Prostate Cancer Gleason grading updates for Prostate Cancer

Category: Prostate Cancer, Erectile Dysfunction Medications, Men’s Health


CONGRESO ANUAL ASOCIACION NACIONAL DE UROLOGOS EGRESADOS DEL CENTRO MEDICO NACIONAL LA RAZA (ANUER) de México

México City. January 28-30, 2016

Lecture Topics (all in Spanish): Smarter screening for Prostate Cancer, Prostate Cancer Markers

Category:  Prostate Cancer


Congreso Anual Asociacion Nacional de Urologos Egresados del Centro Medico Nacional La Raza (ANUER)

Mexico City, Mexico. January 2015 

Lectures Topics: Implications of Discontinuing PSA Screening, Identifying Clinically Significant vs. Indolent Prostate Cancer, Twitter in Urology

Categories: Prostate Cancer, Social Media


Colegio Mexicano de Urologia

Acapulco, Mexico. April 2014

Lecture Topics: Cost Effectiveness of PSA Screening, Markers and Nomograms for Prostate Cancer

Category: Prostate Cancer


Sociedad Mexicana de Urologia

 Merida, Mexico. November 2013

Lectures topics: Prostate Cancer Screening, Prostate Cancer Markers, Prostate Biopsy complications and Social Media

Categories: Prostate Cancer, Social Media


Colegio Mexicano de Urologia

Cancun, Mexico. April 2013

Lectures Topics: Prostate Cancer Biomarkers and Active Surveillance

Category: Prostate Cancer


Colegio Mexicano de Urologia

León, Mexico, April 2012

Lectures Topic: Prostate Cancer Screening

Category: Prostate Cancer


Netherlands

Active Surveillance for Low Risk Prostate Cancer Conference

Amsterdam, Netherlands. February 2014

Lecture topic: Risk based prediction models for indolent Prostate Cancer

Category: Prostate Cancer


Erasmus University Medical Center

Rotterdam, Netherlands. November 2010

Lecture Topic: Prostate Cancer

Category: Prostate Cancer


Online Lectures

Sexual Medicine Society of North America Journal Club

USA (Virtual). March 2021

Topic: Roles and Attitudes Toward Social Media Platforms Amongst Urology Trainees

Category: Social Media


NYU Department of Population Health

NYC (Virtual). March 2021

Topic: Social Media Best Practices Workshop

Category: Social Media


ASCO Genitourinary Symposium

USA (Virtual). February 2021

Topic: Moderator

Category: Prostate Cancer


Grand Rounds, Weill Cornell University Urology

NYC (Virtual). January 2021

Topic: Promise and Peril of Digital Technology in Urology

Category: Social Media


Chinese University of Hong Kong Urology Symposium

Hong Kong (Virtual). November 2020

Topic: Prostate Cancer Screening: Evidence, Guidelines and Implementation; Updates on Prostate Cancer in 2019-2020

Category: Prostate Cancer


Society of Urologic Oncology Young Urologic Oncologists Lecture Series

USA (Virtual). November 2020

Topic: Use of Social Media in Urology

Category: Social Media


21st Asia-Pacific Prostate Cancer Conference

Australia (Virtual). October 2020

Topic: Key Papers in Detection and Localized Prostate Cancer, Women in Urology and Leveraging Social Media

Category: Prostate Cancer, Social Media, Representation


Paulista Congress of Urology

Brazil (Virtual). October 2020

Topic: Prostate Cancer Screening, Markers and Genetic Testing

Category: Prostate Cancer, Genetics


Global Men’s Health Summit

Panama (Virtual). October 2020

Topic: Early Detection, Diagnosis and Risk Stratification of Prostate Cancer

Category: Prostate Cancer


Sexual Medicine Society of North America

USA (Virtual). October 2020

Topic: Social Media in Sexual Medicine

Category: Men’s Health, Social Media


Memorial Sloan Kettering Cancer Center

NYC (Virtual). October 2020

Topic: Social Media in Prostate Cancer

Category: Prostate Cancer, Social Media


Texas A&M University College of Medicine Health & Wellness Grand Rounds

Texas (Virtual). October 2020

Topic: Online Professionalism and the Pros/Cons of Social Media for Medical Trainees and Health Professionals

Category: Social Media


Weill Cornell University Urology

NYC (Virtual). August 2020

Topic: Prostate Cancer Screening

Category: Prostate Cancer


Association for Healthcare Social Media

Pennsylvania (Virtual). August 2020

Topic: Researching Social Media

Category: Social Media


Royal Society of Medicine

UK (Virtual). June 2020

Topic: COVID-19 and Active Surveillance

Category: Prostate Cancer, COVID-19


Texas A&M Baylor, Scott & White Health Graduate Medical Education

Texas (Virtual). May 2020

Topic: Social Media

Category: Social Media


EMPIRE Lecture Series

NY (Virtual). May 2020

Topic: Social Media for Urologists

Category: Social Media


International Volunteers in Urology

Ghana (Virtual). April 2020

Topic: Virtual Visiting Professor Panel Discussion on COVID-19

Category: COVID-19


Société Internationale d’Urologie

Montreal (Virtual). April 2020

Topic: Webinar on Economic and Financial Burden of COVID-19

Category: COVID-19


Surgery in the 3rd Millenium: The Future is Female

Milan, Italy  . April 12-13, 2018

Lecture Topic: Active surveillance for prostate cancer

Category: Prostate Cancer


Cancer Research & Oncology Virtual Conference

Dr Stacy Loeb presented on “Active Surveillance: Trends in Use, Patient Selection and Monitoring”
Category: prostate cancer
Location: http://www.labroots.com/webcast/id/554


XXVII Congreso Venezolano de Urología, Congreso de Actualización en Urología Oncológica

Lecture topic: Nuevas marcardores en el cáncer de próstata (en español)

Category: prostate cancer

Location: via Skype to Venezuela


Panama

Global Men’s Health Summit

Panama (Virtual). October 2020

Topic: Early Detection, Diagnosis and Risk Stratification of Prostate Cancer

Category: Prostate Cancer


XXXV Congreso Confederación Americana de Urología

Panama. October 2016

Lecture Topics: Prostate Cancer Active Surveillance, SelectMDx and ConfirmMDx Prostate Cancer Markers, Social Media in Urology

Categories: Prostate Cancer, Social Media


Philippines

Philippines Society of Uro-Oncology

Manila, Philippines. September 2014

Lectures topic: Smarter PSA screening, Novel Prostate Cancer Markers, and Active Surveillance

Category: Prostate Cancer


Portugal

PROSCA 2017

Lisbon, Portugal. June 28-30, 2017

Lecture topics: Screening for prostate cancer: where do we stand?

Category: Prostate Cancer


American Urological Association New York Section Meeting

Lisbon, Portugal. September 10-12, 2015
Lecture Topic: Markers in Screening and Active Surveillance
Category: Prostate Cancer


Russia

Russian Ministry of Health, Institute of Urology

Moscow, Russia. March 2014

Lecture topic: PSA Screening Cost-Effectiveness, Prostate Cancer Markers

Category: Prostate Cancer


South Africa

World Congress of Endourology 2016

Capetown, South Africa. November 8-12, 2016
Lecture topic: Social media in urology
Category: Social Media


Spain

Challenges in Laparoscopy and Robotics

Barcelona, Spain – July 3-4, 2019

Lecture Topics: Social Media in Prostate Cancer, Robotic Prostatectomy Moderation

Category: prostate cancer, surgical technique, social media


European Association of Urology 2015

Madrid, Spain. March 2015

Lecture Topics: Prognostic Factors in the Prostate Histology, Social Media

Categories: Prostate Cancer, Social Media, Erectile Dysfunction


International Genitourinary Cancer Symposium (IGUCC 6)

Madrid, Spain. February 2014

Lecture topic: Smarter Prostate Cancer Screening

Category: Prostate Cancer


Sweden

Uppsala University Honorary Doctorate

Uppsala, Sweden. January 2020

Lecture Topic: International Collaboration Using Swedish Registry Data to Improve Health

Category: Prostate Cancer, Men’s Health, Drug Safety


European Association of Urology 2014 Congress

Stockholm, Sweden. April 2014

Lecture Topic: Invited lecture on Standardizing Report and Outcome of Surgery in Prostate Cancer

Category: Prostate Cancer


ACME meeting

Hemavan, Sweden. January 2012

Lecture topic: Prostate Cancer Risk among immigrants to Sweden

Category: Prostate Cancer


Switzerland

Hot Topics in Uro-Oncology

Zurich, Switzerland – January 25, 2019

Lecture Topic: Prostate Cancer Screening in the Era of MRI and Novel Biomarkers

Category: Prostate Cancer, MRI, Screening, Markers


USA

Sexual Medicine Society of North America Journal Club

USA (Virtual). March 2021

Topic: Roles and Attitudes Toward Social Media Platforms Amongst Urology Trainees

Category: Social Media


NYU Department of Population Health

NYC (Virtual). March 2021

Topic: Social Media Best Practices Workshop

Category: Social Media


ASCO Genitourinary Symposium

USA (Virtual). February 2021

Topic: Moderator

Category: Prostate Cancer


Grand Rounds, Weill Cornell University Urology

NYC (Virtual). January 2021

Topic: Promise and Peril of Digital Technology in Urology

Category: Social Media


Society of Urologic Oncology Young Urologic Oncologists Lecture Series

USA (Virtual). November 2020

Topic: Use of Social Media in Urology

Category: Social Media


Sexual Medicine Society of North America

USA (Virtual). October 2020

Topic: Social Media in Sexual Medicine

Category: Men’s Health, Social Media


Memorial Sloan Kettering Cancer Center

NYC (Virtual). October 2020

Topic: Social Media in Prostate Cancer

Category: Prostate Cancer, Social Media


Texas A&M University College of Medicine Health & Wellness Grand Rounds

Texas (Virtual). October 2020

Topic: Online Professionalism and the Pros/Cons of Social Media for Medical Trainees and Health Professionals

Category: Social Media


Weill Cornell University Urology

NYC (Virtual). August 2020

Topic: Prostate Cancer Screening

Category: Prostate Cancer


Association for Healthcare Social Media

Pennsylvania (Virtual). August 2020

Topic: Researching Social Media

Category: Social Media


Texas A&M Baylor, Scott & White Health Graduate Medical Education

Texas (Virtual). May 2020

Topic: Social Media

Category: Social Media


EMPIRE Lecture Series

NY (Virtual). May 2020

Topic: Social Media for Urologists

Category: Social Media


Memorial Sloan Kettering Cancer Center

New York, NY – December 17, 2019

Lecture topic: Social Media and Academics

Category: Social media


Culture Leap

Malibu, CA – November 7, 2019

Lecture Topic: Role of Social Media in Science Information

Category: Social media


Division of General Internal Medicine, NYU

NY, NY – October 8, 2019
Lecture Topic: The Promise and Peril of Social Media in Prostate Cancer
Category: Social Media, Prostate Cancer

 

 


Inspire Seminar Series, Manhattan Veterans Affairs

NY, NY – October 17, 2019
Lecture Topic: The Promise and Peril of Social Media in Prostate Cancer
Category: Social Media, Prostate Cancer

 

 


Prostate Cancer Foundation 2019 Retreat

Carlsbad, CA – October 1-4, 2019

Lecture Topics: Panel at the PCF Women’s Forum on Navigating Confidence; Moderator and Presenter about Online Information and Side Effects at PCF-Us TOO Patient Advocacy Session

Category: Women In Science, Prostate Cancer, Social Media, Survivorship


American Association of Clinical Urologists (AACU)

Washington DC –  October 12-14, 2019

Lecture Topic: Online Presence for Urologists, Clinical Urology in 2019 (Panel)

Category: Social Media, Urology


Hackensack University Medical Center Visiting Professor

Hackensack, New Jersey – October 15, 2019

Lecture Topic: Social Media in Medicine

Category: Social Media


Northeastern Section of the American Urological Association

Syracuse, NY – September, 2019

Lecture topics: Reducing prostate cancer overtreatment with active surveillance; Biomarkers-  how do we use them

Category: Prostate Cancer, Active Surveillance, Markers


American Urological Association 2019 Annual Meeting

Chicago, IL – May 2-5, 2019

Lecture Topics: Plenary on Top 10 Apps for Wellness, Work and Study; Prostate Cancer Update Course

Category: Apps, Social Media, Prostate Cancer


University of California San Francisco Urology Grand Rounds

San Francisco, CA  – January 9, 2019

Lecture Topic: Social Media in Urology

Category: Social Media


Henry Ford Vattikuti Urology Institute Visiting Professor

Detroit, MI – December 11-12, 2018

Lecture topics: Active Surveillance, Social Media

Category: Prostate cancer, active surveillance, social media


American Urological Association 2018 Meeting

San Francisco, CA.  May 18-22, 2018

Lecture topic: Optimizing Technique and Selection for Prostate Biopsy, Prostate Cancer Press Conferences, Prostate Cancer Updates Course

Category: Prostate Cancer


LA Live Advanced Robotic & Open Surgery Symposium

Los Angeles, CA.  May 16-17, 2018

Lecture topic: Active surveillance for prostate cancer, Live surgery panel

Category: Prostate Cancer


3rd Annual USC L.A. Live Practical Urology Conference

Los Angeles, California . February 1-3, 2018

Lecture Topic:Using markers to improve selection for prostate biopsy, prostate biopsy complications

Category: Prostate Cancer


Society of Women in Urology

Las Vegas, Nevada. January 19-21, 2018

Lecture Topic: Genomic markers for prostate cancer, social media

Category: Prostate Cancer, Social Media


Chairman’s Rounds at Johns Hopkins Hospital

Baltimore, Maryland. November 16, 2017

Lecture Topic: Update on active surveillance and dissemination of knowledge in urology

Category: prostate cancer, social media, dissemination and implementation science (D&I)


Prostate Cancer Foundation 24th Annual Scientific Retreat

Washington, DC . October 4-7, 2017

Lecture Topic: Women in science panel, poster on crowdfunding in prostate cancer

Category: Women in science, Social Media


Grand Rounds at Washington University

St, Louis, Missouri. June 9, 2017

Lecture Topic: Social media in urology

Category: Social media


Grand Rounds at University of Pennsylvania

Philadelphia, Pennsylvania. May 18, 2017

Lecture Topic: Biomarkers in the diagnosis and management of localized prostate cancer

Category: Prostate Cancer


Royal Society of Medicine Winter Meeting

Lake Tahoe (Northstar, California).  January 28-30, 2017

Lecture Topics: Urology Highlights of 2016 as Seen Through the Eyes of Twitter, What Has Happened to Screening for Prostate Cancer in the US?

Categories: Social Media, Prostate Cancer


LA Live 2nd University of Southern California Annual Conference: Practical Urology

Los Angeles, California. January 26, 2017

Lecture Topic: Prostate Cancer Markers

Category: Prostate Cancer Markers


Prostate Cancer Foundation 2016 Scientific Retreat

 Carlsbad, California. October 26-29, 2016

Lecture topic: Social media in prostate cancer

Category: Social Media


Advanced Robotic Urology and Prostate Cancer Update (Napa, California)Advanced Robotic Urology and Prostate Cancer Update

Napa, California. August 2016

Lecture Topics: Who to Biopsy and Rebiopsy, Tissue-Based Markers for Prostate Cancer Risk Stratification, Biomarker Panel

Category: Prostate Cancer, Biopsy, Markers


Visiting professor at University of Rochester

Rochester, New York. June 8, 2016

Lecture Topic: Markers in Prostate Cancer Screening and Active Surveillance

Category: Prostate Cancer


American Society of Clinical Oncology (ASCO) 2016 Annual Meeting

Chicago, Illinois. June 3-5, 2016

Lecture Topic: Active Surveillance for Prostate Cancer

Category: Prostate Cancer


American Urological Association (AUA) 2016 Annual Meeting

USA. May 2016

Lecture Topics: Dr Loeb gave a plenary presentation on Prostate Cancer Screening and participated on a panel with Drs Scardino, Catalona, and Hamdy. She also presented a late-breaking abstract at the plenary on Testosterone therapy and Prostate Cancer risk. Dr Loeb also gave invited lectures on Prostate Cancer at the International Prostate Forum and on Social Media at the BAUS/BJUI/USANZ plenary. She chaired the AUA press conference on Prostate Cancer and served as faculty for the Prostate Cancer Updates course.

Categories: Prostate Cancer, Men’s Health, Testosterone, Social Media


Visiting Professor at SUNY Downstate

New York.  March 23, 2016

Lecture Topics: Prostate Biopsy Indications, Active Surveillance

Category: Prostate Cancer


UNIVERSITY OF SOUTHERN CALIFORNIA INSTITUTE OF UROLOGY 1ST ANNUAL PRACTICAL UROLOGY CONFERENCE

California, USA. February 4-6, 2016

Lecture Topics: Prostate Xancer surgical Masterclass, Biomarkers and Active Surveillance for Prostate Cancer, Social Media in Urology

Category: Prostate Cancer, Social Media


Society of Women in Urology (SWIU)

USA. January 22-23, 2016

Lecture Topic: Serum, Urine and Tissue Markers in Prostate Cancer

Category: Prostate cancer


26th International Prostate Cancer Update (IPCU)

Colorado, USA. January 20-22, 2016

Lecture Topics: When to do prostate biopsy: Role for PSA and novel biomarkers

Category: Prostate cancer


Visiting Professor at the Division of Urology at Albany Medical College

USA. October 2015

Lecture Topics: Markers in Prostate Cancer Screening and Active Surveillance, Social Media in Urology

Categories: Prostate cancer, Social media


Florida Urological Society meeting

Florida, USA. September 2015

Lectures topics: 1) The Dilemma of an Elevated PSA: The Role of New Biomarkers to Determine When to Biopsy, 2) 4K Score, 3) Social Media in Urology

Categories: Prostate Cancer, Social Media


NYC Urological Research Society 2016

New York, Usa. Sptember 2015

Lecture topic: Decipher test in potential candidates for Active Surveillance

Category: Prostate Cancer, Active Surveillance, Markers


FDUS Future Directions in Urology

Colorado, USA. August 2015

Lecture topic: Social Media in Urology

Category: Social Media


West Africa

International Volunteers in Urology

Ghana (Virtual). April 2020

Topic: Virtual Visiting Professor Panel Discussion on COVID-19

Category: COVID-19


NORTH AMERICA

Active

Exploring Variation in the Use of Conservative Management for Prostate Cancer in the Veterans Affairs Healthcare System

Loeb S, Byrne NK, Wang B, Makarov DV, Becker D, Wise DR, Lepor H, Walter D.

 “Exploring Variation in the Use of Conservative Management for Prostate Cancer in the Veterans Affairs Healthcare System.”

European Urology. 2020 Feb 22:S0302-2838(20)30101-9. PMID: 32098730.

Link: https://pubmed.ncbi.nlm.nih.gov/32098730/


Untitled

Butler SS, Loeb S, Cole AP, Zaslowe-Dude C, Muralidhar V, Kim DW, Schaeffer EM, Trinh QD, Nguyen PL, Mahal BA.

 “United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015. Prostate Cancer Prostatic Dis.”

 2019 Oct 7 epub. PMID: 31591454.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31591454


Untitled

Loeb S.

 ” Overactive Surveillance: Is “Conservative” Management for Low-risk Prostate Cancer Too Aggressive?”

 Eur Urol. 2019 May epub. PMID:31060823.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31060823


Untitled

Loeb S, Folkvaljon Y, Bratt O, Robinson D, Stattin P.

 “Defining Intermediate-Risk Prostate Cancer Suitable for Active Surveillance.”

 Journal of Urology. 2018 Sep 18 epub. PMID: 30240688.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30240688


Loeb S, Byrne N, Makarov DV, Lepor H, Walter D.

“Use of Conservative Management for Low-Risk Prostate Cancer in the Veterans Affairs Integrated Health Care System From 2005-2015.”

JAMA. 2018 Jun 5; 319(21):2231-2233. PMID: 29800017

Link: https://www.ncbi.nlm.nih.gov/pubmed/29800017

In the U.S. Veterans Affairs healthcare system, we found a substantial increase in the use of conservative management for low-risk prostate cancer over the past decade. By 2015, 72% of veterans <65 years and 79% ages ≥65 with low-risk prostate cancer were managed conservatively.


Untitled

Loeb S, Curnyn C, Walter D, Fagerlin A, Siebert U, Mühlberger N, Braithwaite RS, Schwartz MD, Lepor H, Sedlander E.

 “Health state utilities among contemporary prostate cancer patients on active surveillance.”

Translational Andrology and Urology. 2018 Apr; 7(2):197-202. PMID: 29732277.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29732277


Loeb S, Curnyn C, Walter D, Fagerlin A, Siebert U, Mühlberger N, Braithwaite RS, Schwartz MD, Lepor H, Sedlander E.

“Health state utilities among contemporary prostate cancer patients on active surveillance.”

Translational Andrology and Urology. 2018 Apr; 7(2):197-202. PMID: 29732277.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29732277


Untitled

Loeb S, Tosoian JJ.

 “Biomarkers in Active Surveillance.”

 Translational Andrology and Urology 2018 Feb; 7(1):155-159. PMID: 29594029.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29594029


Untitled

Loeb S.

 “Active Surveillance for Prostate Cancer.”

 Reviews in Urology 2018; 20: 101-103. PMID: 30288148.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30288148


Loeb S.

 ” Active Surveillance Offers Functional Advantages Without Impacting Survival for Low-risk Prostate Cancer.”

European Urology. 2017 Nov 20. PMID: 29169932

Link: https://www.ncbi.nlm.nih.gov/pubmed/29169932


Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Sedlander E.

 “Informational needs during active surveillance for prostate cancer: A qualitative study.”

Patient Education Counseling 2017 Sep 1 epub.  PMID: 28886974

Link: https://www.ncbi.nlm.nih.gov/pubmed/28886974


Loeb S, Zhou Q, Siebert U, Rochau U, Jahn B, Mühlberger N, Carter HB, Lepor H, Braithwaite RS.  

“Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions”.

European Urology 2017 Aug 22 epub.  PMID: 28844371

Link: https://www.ncbi.nlm.nih.gov/pubmed/28844371

We designed a Markov model showing that active surveillance extends life more than watchful waiting, particularly for men with higher risk features, but this is partly offset by decrements in quality of life from delayed treatment. Trade-offs about the intensity of surveillance should be discussed with patients.


Loeb S, Ross AE.  

“Genomic testing for localized prostate cancer: where do we go from here?” 

Current Opinion in Urology. 2017 Jun 28 epub. PMID: 28661898

    Link: https://www.ncbi.nlm.nih.gov/pubmed/28621058

 


Choyke PL and Loeb S.

“Active Surveillance of Prostate Cancer.” 

Oncology (Williston Park) 2017; 31 (1).

PMID 8090626

Link: https://www.ncbi.nlm.nih.gov/pubmed/28090626


Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Sedlander E.

 “A Qualitative Study on Decision-Making by Prostate Cancer Physicians during Active Surveillance.”

BJU International. 2016 epub.  PMID: 27611479.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27611479


Loeb S, Folkvaljon Y, Curnyn C, Robinson D, Bratt O, Stattin P.

“Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden”.

JAMA Oncology. 2016 Oct 20. PMID: 27768168.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27768168

Using nationwide Sweden data, this study showed that by 2014, active surveillance was selected by 91% of very low risk, 74% of low risk and 19% of intermediate risk patients across the country.  These rates are the highest yet reported internationally. Dissociating diagnosis from treatment in men with a low risk of progression can decrease the rate of overtreatment.


Loeb S. Editorial Comment on

“Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices.” 

Journal of Urology 2016 epub Nov 28. PMID: 27908693.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27908693


Tosoian JJ, Carter HB, Lepor A, Loeb S.

Active surveillance for prostate cancer: current evidence and contemporary state of practice.”

Nature Reviews Urology 2016 Mar 8 epub. PMID: 26954332.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26954332


Tosoian JJ, Loeb S, Epstein JI, Turkbey B, Choyke PL, Schaeffer EM.

“Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools.”

American Society of Clinical Oncology Educational Book. 2016;35:e235-45. PMID: 27249729

Link: http://www.ncbi.nlm.nih.gov/pubmed/26954332


Loeb S, Folkvaljon Y, Robinson D, Makarov DV, Bratt O, Garmo H, and Stattin P.

“Immediate versus delayed prostatectomy: Nationwide population-based study.”

Scandinavian Journal of Urology 2016 Apr 12 epub. PMID: 27067998.

Link: http://www.ncbi.nlm.nih.gov/pubmed/27067998


Loeb S, Curnyn C, Sedlander E.

“Perspectives of Prostate Cancer Patients on Gleason Scores and the New Grade Groups: Initial Qualitative Study.”

European Urology 2016 Jun 6 epub. PMID: 27283215.

Link: http://www.ncbi.nlm.nih.gov/pubmed/27283215


Loeb S, Walter D, Curnyn C, Gold HT, Lepor H, Makarov DV.

“How Active is Active Surveillance? Intensity of Follow-Up During Active Surveillance for Prostate Cancer in the United States.”

Journal of Urology 2016 Mar 2 epub. PMID: 26946161.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26946161


Reviews/Editorials

Murphy DG, Loeb S.

“Prostate Cancer: Growth of AS in the USA Signals Reduction in Overtreatment.”

Nature Reviews Urology 2015 epub. PMID: 26390970.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26390970


Reviews/Editorials

Loeb S.

“Re: Long-Term Follow-up of a Large Active Surveillance Cohort of Patients with Prostate Cancer.”

European Urology 2015 Nov; 68: 907. PMID: 26460874.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26460874


Other Original Papers

Griffin C, Yu X, Loeb S, Desireddi VN, Han M, and Catalona WJ.

“Pathologic Features after Radical Prostatectomy for Potential Candidates for Active Monitoring.”

Journal of Urology, September 2007; 178: 860.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17631347


Other Original Papers

Thaxton CS, Loeb S, Roehl KA, Kan D, and Catalona WJ.

“Treatment Outcomes of Radical Prostatectomy in Potential Candidates for 3 Published Active Surveillance Programs.”

Urology, February 2010; 75: 414.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3072831/


Other Original Papers

Tosoian JJ, Loeb S, Kettermann A, Landis P, Elliot DJ, Epstein JI, Partin AW, Carter HB, and Sokoll LJ.

“Accuracy of PCA3 Measurement in Predicting Short-Term Biopsy Progression in an Active Surveillance Program.”

Journal of Urology, February 2010; 183: 534.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20006883


Other Original Papers

O’Brien D, Loeb S, Carvalhal GF, McGuire BB, Kan D, Hofer MD, Casey JT, Helfand BT, and Catalona WJ.

“Delay of Surgery in Men with Low Risk Prostate Cancer.”

Journal of Urology June 2011; 185: 2143. PMID: 21496847.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21496847


Key Papers

Loeb S, Bruinsma SM, Nicholson J, Briganti A, Pickles T, Kakehi Y, Carlsson SV, Roobol MJ.

“Active Surveillance for Prostate Cancer: A Systematic Review of Clinicopathologic Variables and Biomarkers for Risk Stratification.”

European Urology 2014 Oct epub. PMID: 25457014

Link: http://www.ncbi.nlm.nih.gov/pubmed/25457014

This systematic review examined the utility of markers, genetic factors and risk stratification for active surveillance. The patient factors associated with active surveillance outcomes in some studies include age, race, and family history. Multiple studies provide consistent evidence that a lower percentage of free PSA, a higher Prostate Health Index (PHI), a higher PSA density (PSAD), and greater biopsy core involvement at baseline predict a greater risk of progression. During follow-up, serial measurements of PHI and PSAD, as well as repeat biopsy results, predict later biopsy progression. No conclusive data support the use of genetic tests in active surveillance. 


Reviews/Editorials

Loeb S, Carter HB, Schwartz M, Fagerlin A, Braithwaite RS, Lepor H.

“Heterogeneity in active surveillance protocols worldwide.”

Reviews in Urology 2014;16(4):202-3. PMID: 25548550.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4274180/


Loeb S, Folkvaljon Y, Makarov DV, Bratt O, Bill-Axelson A, Stattin P.

“Five-Year Nationwide Follow-up Study of Active Surveillance for Prostate Cancer.”

Eur Urol 2014, June epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24993868


Other Original Papers

Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R.

“Overdiagnosis and Overtreatment of Prostate Cancer.”

European Urology 2014; epub Jan 9. PMID: 24439788

Link: http://www.ncbi.nlm.nih.gov/pubmed/24439788


Other Original Papers

Vellekoop A, Loeb S, Folkvaljon Y, Stattin P.

“Population-Based Study of Predictors for Adverse Pathology Among Candidates for Active Surveillance With Gleason 6 Prostate Cancer.”

Journal of Urology 2013 epub September 23.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24071481


Key Papers

Loeb S, Berglund A, Stattin P.

“Population-Based Study of Utilization and Determinants of Active Surveillance and Watchful Waiting for Low- and Intermediate-Risk Prostate Cancer”

Journal of Urology 2013 May 29 epub. PMID: 23727309

Link: http://www.ncbi.nlm.nih.gov/pubmed/23727309

Using nationwide Sweden data, this study showed that from 2007 to 2011, active surveillance was selected by 59% of very low risk, 41% of low risk and 16% of intermediate risk patients across the country. These rates are the highest yet reported internationally. Dissociating diagnosis from treatment in men with a low risk of progression can decrease the rate of overtreatment.


Reviews/Editorials

Loeb S.

“Does Delaying Prostate Cancer Treatment Miss the Window of Curability?”

European Urology 2013 epub Apr 8. PMID: 23619388

Link: http://www.ncbi.nlm.nih.gov/pubmed/23619388


Key Papers

Tosoian JJ, Loeb S, Feng Z, Isharwal S, Landis P, Elliot DJ, Veltri R, Epstein JI, Partin AW, Carter HB, Trock B, Sokoll LJ.

“Association of [-2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer.”

Journal of Urology October 2012; 188: 1131-6. PMID: 22901577.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22901577

Longitudinal measurements of the Prostate Health Index (phi) during active surveillance were a robust predictor of biopsy reclassification (C-index 0.82). These results have since been validated in other surveillance populations. Since PSA kinetics are unreliable and biopsies are invasive, phi offers another non-invasive test that can be used to monitor patients during active surveillance.


Key Papers

Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, Feng Z, Carter HB, and Walsh PC.

“Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.”

Journal of Clinical Oncology, June 2010; 28: 2810.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20439642

PSA doubling time and PSA velocity are frequently used to monitor patients during active surveillance. Among men in the Johns Hopkins active surveillance program, PSA kinetics during active surveillance were not reliable predictors of adverse pathology on repeat biopsy. This suggests that PSA kinetics should not be used as a trigger for intervention during active surveillance.


Reviews/Editorials

Loeb S and Catalona WJ.

“Counterpoint: the case for active treatment.”

Journal of the National Comprehensive Cancer Network, August 2007; 5: 699.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17692174


Reviews/Editorials

Loeb S and Catalona WJ.

“Early versus delayed intervention for prostate cancer: the case for early intervention.”

Nature Clinical Practice Urology, July 2007; 4: 348.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17563779


Active Surveillance

Exploring Variation in the Use of Conservative Management for Prostate Cancer in the Veterans Affairs Healthcare System

Loeb S, Byrne NK, Wang B, Makarov DV, Becker D, Wise DR, Lepor H, Walter D.

 “Exploring Variation in the Use of Conservative Management for Prostate Cancer in the Veterans Affairs Healthcare System.”

European Urology. 2020 Feb 22:S0302-2838(20)30101-9. PMID: 32098730.

Link: https://pubmed.ncbi.nlm.nih.gov/32098730/


Untitled

Butler SS, Loeb S, Cole AP, Zaslowe-Dude C, Muralidhar V, Kim DW, Schaeffer EM, Trinh QD, Nguyen PL, Mahal BA.

 “United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015. Prostate Cancer Prostatic Dis.”

 2019 Oct 7 epub. PMID: 31591454.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31591454


Untitled

Loeb S.

 ” Overactive Surveillance: Is “Conservative” Management for Low-risk Prostate Cancer Too Aggressive?”

 Eur Urol. 2019 May epub. PMID:31060823.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31060823


Untitled

Loeb S, Folkvaljon Y, Bratt O, Robinson D, Stattin P.

 “Defining Intermediate-Risk Prostate Cancer Suitable for Active Surveillance.”

 Journal of Urology. 2018 Sep 18 epub. PMID: 30240688.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30240688


Untitled

Loeb S, Curnyn C, Walter D, Fagerlin A, Siebert U, Mühlberger N, Braithwaite RS, Schwartz MD, Lepor H, Sedlander E.

 “Health state utilities among contemporary prostate cancer patients on active surveillance.”

Translational Andrology and Urology. 2018 Apr; 7(2):197-202. PMID: 29732277.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29732277


Untitled

Loeb S, Tosoian JJ.

 “Biomarkers in Active Surveillance.”

 Translational Andrology and Urology 2018 Feb; 7(1):155-159. PMID: 29594029.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29594029


Untitled

Loeb S.

 “Active Surveillance for Prostate Cancer.”

 Reviews in Urology 2018; 20: 101-103. PMID: 30288148.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30288148


Loeb S.

 ” Active Surveillance Offers Functional Advantages Without Impacting Survival for Low-risk Prostate Cancer.”

European Urology. 2017 Nov 20. PMID: 29169932

Link: https://www.ncbi.nlm.nih.gov/pubmed/29169932


Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Sedlander E.

 “Informational needs during active surveillance for prostate cancer: A qualitative study.”

Patient Education Counseling 2017 Sep 1 epub.  PMID: 28886974

Link: https://www.ncbi.nlm.nih.gov/pubmed/28886974


Loeb S, Zhou Q, Siebert U, Rochau U, Jahn B, Mühlberger N, Carter HB, Lepor H, Braithwaite RS.  

“Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions”.

European Urology 2017 Aug 22 epub.  PMID: 28844371

Link: https://www.ncbi.nlm.nih.gov/pubmed/28844371

We designed a Markov model showing that active surveillance extends life more than watchful waiting, particularly for men with higher risk features, but this is partly offset by decrements in quality of life from delayed treatment. Trade-offs about the intensity of surveillance should be discussed with patients.


Loeb S, Ross AE.  

“Genomic testing for localized prostate cancer: where do we go from here?” 

Current Opinion in Urology. 2017 Jun 28 epub. PMID: 28661898

    Link: https://www.ncbi.nlm.nih.gov/pubmed/28621058

 


Choyke PL and Loeb S.

“Active Surveillance of Prostate Cancer.” 

Oncology (Williston Park) 2017; 31 (1).

PMID 8090626

Link: https://www.ncbi.nlm.nih.gov/pubmed/28090626


Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Sedlander E.

 “A Qualitative Study on Decision-Making by Prostate Cancer Physicians during Active Surveillance.”

BJU International. 2016 epub.  PMID: 27611479.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27611479


Loeb S, Folkvaljon Y, Curnyn C, Robinson D, Bratt O, Stattin P.

“Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden”.

JAMA Oncology. 2016 Oct 20. PMID: 27768168.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27768168

Using nationwide Sweden data, this study showed that by 2014, active surveillance was selected by 91% of very low risk, 74% of low risk and 19% of intermediate risk patients across the country.  These rates are the highest yet reported internationally. Dissociating diagnosis from treatment in men with a low risk of progression can decrease the rate of overtreatment.


Loeb S. Editorial Comment on

“Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices.” 

Journal of Urology 2016 epub Nov 28. PMID: 27908693.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27908693


Africa

International Volunteers in Urology

Ghana (Virtual). April 2020

Topic: Virtual Visiting Professor Panel Discussion on COVID-19

Category: COVID-19


World Congress of Endourology 2016

Capetown, South Africa. November 8-12, 2016
Lecture topic: Social media in urology
Category: Social Media


ASIA

Chinese University of Hong Kong Urology Symposium

Hong Kong (Virtual). November 2020

Topic: Prostate Cancer Screening: Evidence, Guidelines and Implementation; Updates on Prostate Cancer in 2019-2020

Category: Prostate Cancer


21st Asia-Pacific Prostate Cancer Conference

Australia (Virtual). October 2020

Topic: Key Papers in Detection and Localized Prostate Cancer, Women in Urology and Leveraging Social Media

Category: Prostate Cancer, Social Media, Representation


Clinical Oncology Society of Australia

Adelaide, Australia – November 12-14, 2019

Lecture topics: Latest developments in prostate cancer surgery and active surveillance; Promise and peril of social media for clinicians, researchers and patients

Category: Prostate Cancer Treatment, Active Surveillance, Social Media


2018 Prostate Cancer World Congress

Brisbane Australia . August 22-246, 2018

Lecture Topic: Active surveillance for prostate cancer, Social media in prostate cancer

Category: Prostate Cancer, Social Media


USANZ New Zealand Section

Tauranga, New Zealand . October 11-13, 2017

Lecture Topic: Localized prostate cancer update, active surveillance, prostate cancer markers, social media

Category: prostate cancer, social media


Astellas Prostate Cancer Meeting

Hobart, Australia. April 8, 2017

Lecture topic: Markers and Prostate Cancer Screening

Category: Prostate Cancer


Astellas Prostate Cancer Meeting

Melbourne, Australia. April 7, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer


Astellas Prostate Cancer Meeting

Sydney, Australia. April 5-6, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer


Astellas Prostate Cancer Meeting

Adelaide, Australia. April 4, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer


Astellas Prostate Cancer Meeting

Brisbane, Australia. April 3, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer


Annual Meeting of the Korean Urological Association

Seoul, Korea. October 12-15, 2016

Lecture Topics: Prostate Cancer Markers, Active Surveillance, BPH

Category: Prostate Cancer, Benign Prostatic Hyperplasia

 

 


Macquarie University Markers Symposium

Sidney, Australia. September 2016

Lecture Topics: Prostate Cancer Markers

Category: Prostate Cancer, Markers


Prostate Cancer World Congress

Cairns, Australia. August 2015

Lecture Topics: Key publications in prostate cancer, Active Surveillance for prostate cancer, Updates to Gleason grading, Social Media and Prostate Cancer.

Category: Prostate Cancer


Philippines Society of Uro-Oncology

Manila, Philippines. September 2014

Lectures topic: Smarter PSA screening, Novel Prostate Cancer Markers, and Active Surveillance

Category: Prostate Cancer


Prostate Cancer World Congress

 Melbourne, Australia. August 2013

Lecture Topics: Practice changing publications in Prostate Cancer, Smarter PSA Screening with Isoforms and Kinetics, Selecting patients for Prostate Biopsy, Selection and monitoring during Active Surveillance

Category: Prostate Cancer


Australian Prostate Cancer Conference

 Melbourne, Australia. August 2012

Lecture Topics: Prostate biopsy complications, Overdiagnosis and Overtreatment of Prostate Cancer

Category: Prostate Complications


Australia

21st Asia-Pacific Prostate Cancer Conference

Australia (Virtual). October 2020

Topic: Key Papers in Detection and Localized Prostate Cancer, Women in Urology and Leveraging Social Media

Category: Prostate Cancer, Social Media, Representation


Clinical Oncology Society of Australia

Adelaide, Australia – November 12-14, 2019

Lecture topics: Latest developments in prostate cancer surgery and active surveillance; Promise and peril of social media for clinicians, researchers and patients

Category: Prostate Cancer Treatment, Active Surveillance, Social Media


2018 Prostate Cancer World Congress

Brisbane Australia . August 22-246, 2018

Lecture Topic: Active surveillance for prostate cancer, Social media in prostate cancer

Category: Prostate Cancer, Social Media


USANZ New Zealand Section

Tauranga, New Zealand . October 11-13, 2017

Lecture Topic: Localized prostate cancer update, active surveillance, prostate cancer markers, social media

Category: prostate cancer, social media


Astellas Prostate Cancer Meeting

Hobart, Australia. April 8, 2017

Lecture topic: Markers and Prostate Cancer Screening

Category: Prostate Cancer


Astellas Prostate Cancer Meeting

Melbourne, Australia. April 7, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer


Astellas Prostate Cancer Meeting

Sydney, Australia. April 5-6, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer


Astellas Prostate Cancer Meeting

Adelaide, Australia. April 4, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer


Astellas Prostate Cancer Meeting

Brisbane, Australia. April 3, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer


Macquarie University Markers Symposium

Sidney, Australia. September 2016

Lecture Topics: Prostate Cancer Markers

Category: Prostate Cancer, Markers


Prostate Cancer World Congress

Cairns, Australia. August 2015

Lecture Topics: Key publications in prostate cancer, Active Surveillance for prostate cancer, Updates to Gleason grading, Social Media and Prostate Cancer.

Category: Prostate Cancer


Prostate Cancer World Congress

 Melbourne, Australia. August 2013

Lecture Topics: Practice changing publications in Prostate Cancer, Smarter PSA Screening with Isoforms and Kinetics, Selecting patients for Prostate Biopsy, Selection and monitoring during Active Surveillance

Category: Prostate Cancer


Australian Prostate Cancer Conference

 Melbourne, Australia. August 2012

Lecture Topics: Prostate biopsy complications, Overdiagnosis and Overtreatment of Prostate Cancer

Category: Prostate Complications


Benign Disease

BenignDisease

An Evaluation of the Readability and Content-Quality of Pelvic Organ Prolapse YouTube Transcripts

Herbert AS, Nemirovsky A, Hess DS, Walter D, Abraham NE, Loeb S, Malik RD.

“An Evaluation of the Readability and Content-Quality of Pelvic Organ Prolapse YouTube Transcripts.”

Urology 2021; S0090-4295(21)00266-1. PMID: 33775787.

Link: https://pubmed.ncbi.nlm.nih.gov/33775787/


Fake News about Benign Prostate Hyperplasia on YouTube

Loeb S.

“Fake News about Benign Prostate Hyperplasia on YouTube.”

British Journal of Urology International. 2020 Apr;125(4):477-478. PMID: 32250050

Link: https://pubmed.ncbi.nlm.nih.gov/32250050/


Pelvic Organ Prolapse on YouTube: Evaluation of Consumer Information

Herbert AS, Nemirovsky A, Hess DS, Walter D, Abraham NE, Loeb S, Malik RD.

“Pelvic Organ Prolapse on YouTube: Evaluation of Consumer Information.”

British Journal of Urology International 2020 Feb 10 epub.  PMID: 32039554.

Link: https://pubmed.ncbi.nlm.nih.gov/32039554/


Key Paper

Loeb S, Folkvaljon Y, Lambe M, Robinson D, Garmo H, Ingvar C, Stattin P.

“Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.”

JAMA 2015; 313: 2449-55. PMID: 26103029.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26103029

A recent study suggested a possible link between phosphodiesterase inhibitors used for erectile dysfunction and risk of malignant melanoma. Through a large collaboration with the national registries of Sweden, we performed a large study that raised questions about a causal relationship including lack of a dose-response relationship. Instead, the observed association between erectile dysfunction drugs and melanoma likely reflects shared risk factors including lifestyle and socioeconomic status.


Genetic Sequence Variants are Associated with Severity of Lower Urinary Tract Symptoms and Prostate Cancer Susceptibility.

Helfand BT, Hu Q, Loeb S, McVary KT, Catalona WJ.

“Genetic Sequence Variants are Associated with Severity of Lower Urinary Tract Symptoms and Prostate Cancer Susceptibility.”

Journal of Uroloy 2012 epub November. PMID: 23159463.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23159463


Novel Technique for Fragment Removal After Percutaneous Management of Large-Volume Neobladder Calculi.

Loeb S, Semins MJ, and Matlaga BR.

“Novel Technique for Fragment Removal After Percutaneous Management of Large-Volume Neobladder Calculi.”

Urology, August 2012; 80: 474. PMID: 22857764.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22857764


Unusual Presentation of a Mullerian Remnant in an Infant with Recurrent Epididymo-orchitis.

Gupta AD, Loeb S, Stec A, and Wang MH.

“Unusual Presentation of a Mullerian Remnant in an Infant with Recurrent Epididymo-orchitis.”

Urology December 2011; 78: 1414-6. PMID: 21676451.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21676451


Prestenting Improves Ureteroscopic Stone-Free Rates.

Rubenstein RA, Zhao LC, Loeb S, Shore DM, and Nadler RB.

“Prestenting Improves Ureteroscopic Stone-Free Rates.”

J Endourol, November 2007; 21: 1277.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18042014


Contemporary Management of Urosepsis: Updated Critical Care Guidelines.

Loeb S, Vardi IY, and Nadler RB.

“Contemporary Management of Urosepsis: Updated Critical Care Guidelines.”

Contemporary Urology, July 2005


Biomarkers

Concordance and Performance of 4KScore and SelectMDx for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer

Wysock JS, Becher E, Persily J, Loeb S, Lepor H.

“Concordance and Performance of 4KScore and SelectMDx for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer.”

Urology. 2020 Apr 12:S0090-4295(20)30339-3. PMID: 32294481

Link: https://pubmed.ncbi.nlm.nih.gov/32294481/


Untitled

Fine ND, LaPolla F, Epstein M, Loeb S, Dani H.

” Genomic Classifiers for Treatment Selection in Newly Diagnosed Prostate Cancer.”

 BJU International 2019 May epub. PMID:31055874.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31055874


Loeb S, Tosoian JJ.

 “Biomarkers in Active Surveillance. “

BJU International. 2018 May 22. PMID: 29786946

    Link: https://www.ncbi.nlm.nih.gov/pubmed/29594029c


Loeb S, Tosoian JJ.

 “Biomarkers in Active Surveillance.”

Translational Andrology and Urology 2018 Feb; 7(1):155-159. PMID: 29594029.

    Link: https://www.ncbi.nlm.nih.gov/pubmed/29594029


Punnen S, Freedland SJ, Polascik TJ, Loeb S, Risk MC, Savage S, Mathur SC, Uchio E, Dong Y, Silberstein JL.

” A Multi-institutional Prospective Trial in the Veterans Affairs Health System confirms the 4Kscore maintains its Predictive value among African American Men.”

Journal of Urology 2017, epub Dec 6. PMID: 29223389

Link: https://www.ncbi.nlm.nih.gov/pubmed/29223389


Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choeurng V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll PR, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL

” Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.”

Journal of Clinical Oncology. 2017 Nov 29 epub. PMID: 29185869.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29185869


Loeb S, Dani H.

 “Whom to Biopsy: Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators.”

Urol Clin North Am. 2017 Nov; 44(4):517-524. PMID: 29107268

    Link: https://www.ncbi.nlm.nih.gov/pubmed/29107268


Dani H, Loeb S.

“The Role of Prostate Cancer Biomarkers in Undiagnosed Men.”

Current Opinion Urology 2017; 27: 210-216. PMID 28212119

Link: https://www.ncbi.nlm.nih.gov/pubmed/28212119


Loeb S.

“Biomarkers for Prostate Biopsy and Risk Stratification of Newly Diagnosed Prostate Cancer Patients.”

Urology Practice. 2017 Jul;4(4):315-321. PMID: 29104903

Link: https://www.ncbi.nlm.nih.gov/pubmed/29104903


Loeb S, Ross AE.

 “Genomic testing for localized prostate cancer: where do we go from here?”

 Current Opinion in Urology. 2017 Jun 28 epub. PMID: 28661898

    Link: https://www.ncbi.nlm.nih.gov/pubmed/28661898


Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, Partin AW, Sokoll L, Chan DW, Bangma CH, van Schaik RH, Slawin KM, Marks LS, Catalona WJ.

“Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer”

BJU International. 2016 Oct 15. PMID:27743489

Link: https://www.ncbi.nlm.nih.gov/pubmed/27743489


Lepor A, Catalona WJ, Loeb S.

“The Prostate Health Index: Its Utility in Prostate Cancer Detection. Urologic Clinics North America.”  

2016 Feb;43(1):1-6. PMID: 26614024

Link: http://www.ncbi.nlm.nih.gov/pubmed/26614024


Loeb S, Lilja H, Vickers A.

“Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer.”

Current Opinion in Urology 2016 Jun 3 epub. PMID: 27262138

Link: http://www.ncbi.nlm.nih.gov/pubmed/27262138


Other Original Articles

Bostrӧm PJ, Bjartell AS, Catto JW, Eggener SE, Lilja H, Loeb S, Schalken J, Schlomm T, and Cooperberg MR.

“Genomic Predictors of Outcome in Prostate Cancer.”

European Urology 2015 epub. PMID: 25913390.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25913390


Reviews/Editorials

Loeb S.

“Prostate Biopsy Decisions: One Size Fits All Approach with Total PSA is Out and a Multivariable Approach with the Prostate Health Index is In.”

BJU International 2015 June epub. PMID: 26054000.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26054000


Other Original Articles

Loeb S, Bruinsma SM, Nicholson J, Briganti A, Pickles T, Kakehi Y, Carlsson SV, Roobol MJ.

“Active Surveillance for Prostate Cancer: A Systematic Review of Clinicopathologic Variables and Biomarkers for Risk Stratification.”

European Urology 2014 Oct epub. PMID: 25457014

Link: http://www.ncbi.nlm.nih.gov/pubmed/25457014


Reviews/Editorials

Loeb S.

“Time to replace prostate-specific antigen (PSA) with the Prostate Health Index (PHI)? Yet more evidence that PHI consistently outperforms PSA across diverse populations.”

BJU International 2015; 115: 500. PMID: 25808708

Link: http://www.ncbi.nlm.nih.gov/pubmed/25808708


Other Original Articles

Loeb S, Sokoll LJ, Broyles DL, Bangma CH, van Schaik RH, Klee GG, Wei JT, Sanda MG, Partin AW, Slawin KM, Marks LS, Mizrahi IA, Shin SS, Cruz AB, Chan DW, Roberts WL, Catalona WJ.

“Prospective Multicenter Evaluation of the Beckman Coulter Prostate Health Index Using WHO Calibration.”

Journal of Urology 2012; epub November. PMID: 23206426.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23206426


Reviews/Editorials

Loeb S.

“Prostate cancer: Predicting prostate biopsy results- PCA3 versus phi.”

Nature Reviews Urology 2015 epub Feb 3. PMID: 25644161

Link: http://www.ncbi.nlm.nih.gov/pubmed/25644161

 


Other Original Articles

Tosoian JJ, Loeb S, Feng Z, Isharwal S, Landis P, Elliot DJ, Veltri R, Epstein JI, Partin AW, Carter HB, Trock B, Sokoll LJ.

“Association of [-2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer.”

Journal of Urology 2012; 188: 1131-6. PMID: 22901577.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22901577


Reviews/Editorials

Lundon D, Loeb S.

“Prostate-Specific Antigen Velocity Risk Count to Discern Significant From Indolent Prostate Cancer.”

Reviews in Urology 2014; 16: 154. PMID: 25337050.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191640/


Other Original Articles

Nichols JH, Loeb S, Metter EJ, Ferrucci L, Carter HB.

“The Relationship Between Prostate Volume and Prostate-Specific Antigen Variability: Data from the Baltimore Longitudinal Study of Aging and the Johns Hopkins Active Surveillance Program.”

BJU International 2012; 109: 1304-8. PMID: 22093443.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22093443


Reviews/Editorials

Loeb S. Editorial Comment on

“Low percentage of free prostate-specific antigen (PSA) is a strong predictor of later detection of prostate cancer among Japanese men with serum levels of total PSA of 4.0 ng/mL or less”

Urology 2014; 84: 1167. PMID: 25443924.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25443924


Other Original Articles

Roobol MJ, van Vugt HA, Loeb S, Zhu X, Bul M, Bangma CH, van Leenders AG, Steyerberg EW, and Schroder FH.

“Prediction of Prostate Cancer Risk: The Role of Prostate Volume and Digital Rectal Examination in the ERSPC Risk Calculators.”

European Urology 2012; 61: 577-83. PMID: 22104592.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22104592


Reviews/Editorials

Loeb S, Catalona WJ.

“The Prostate Health Index: A New Test for the Detection of Prostate Cancer.”

Therapeutic Advances in Urology 2014; 6: 74. PMID: 24688603

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943368/


Other Original Articles

Makarov DV, Loeb S, Magheli A, Zhao K, Humphreys E, Gonzalgo ML, Partin AW, and Han M.

“Significance of Preoperative PSA Velocity in Men with Low Serum PSA and Normal DRE.”

World Journal of Urology 2011; 29: 11.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21153643


Reviews/Editorials

Loeb S.

“Editorial Comment on: A Commentary on PSA Velocity and doubling time for clinical decisions in prostate cancer”

Urology 2014; 83: 596. PMID: 24581522

Link: http://www.ncbi.nlm.nih.gov/pubmed/24581522


Other Original Articles

Loeb S, Carter HB, Schaeffer EM, Kettermann A, Ferrucci L, and Metter EJ.

“Distribution of PSA Velocity by Total PSA Levels: Data from the Baltimore Longitudinal Study of Aging.”

Urology January 2011; 77: 143.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21195835


Reviews/Editorials

Loeb S. Editorial Comment on

“Prostate-Specific Antigen Density: Toward a Better Cutoff to Identify Better Candidates for Active Surveillance.”

Urology 2014; 84: 371.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24925831


Reviews/Editorials

Loeb S.

“Prostate Health Index (PHI): Golden Bullet or Just Another Prostate Cancer Marker?”

European Urology epub 2013 Feb 14. PMID: 23453055

Link: http://www.ncbi.nlm.nih.gov/pubmed/23453055

 


Other Original Articles

Le BV, Griffin CR, Loeb S, Carvalhal GF, Kan D, Baumann NA, and Catalona WJ.

“[-2] Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study.”

Journal of Urology 2010; 183: 1355.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20171670


Reviews/Editorials

Loeb S.

“Prostate Cancer: Prostate Health Index- Improving Screening in Men with a Positive Family History.”

Nature Reviews in Urology 2013; 10: 497

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943368/


Other Original Articles

Tosoian JJ, Loeb S, Kettermann A, Landis P, Elliot DJ, Epstein JI, Partin AW, Carter HB, and Sokoll LJ.

“Accuracy of PCA3 Measurement in Predicting Short-Term Biopsy Progression in an Active Surveillance Program.”

Journal of Urology, February 2010; 183: 534.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20006883


Reviews/Editorials

Loeb S, Carter HB.

“Point: Impact of Prostate-Specific Antigen Velocity on Management Decisions and Recommendations.”

Journal of the National Comprehensive Cancer Network 2013; 11: 281. PMID: 23486454

Link: http://www.ncbi.nlm.nih.gov/pubmed/23486454


Other Original Articles

Kettermann AE, Ferrucci L, Trock BJ, Metter EJ, Loeb S and Carter HB.

“Interpretation of the prostate-specific antigen history in assessing life-threatening prostate cancer.”

BJU International 2010 epub.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928882/


Reviews/Editorials

Loeb S.

“An Examination of the Dynamic Changes in Prostate-Specific Antigen Occurring in a Population-Based Cohort of Men Over Time.”

BJU International August 2012; 110: 381-2. PMID: 22313542.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22313542


Other Original Articles

Loeb S, Kan D, Yu X, Roehl KA, and Catalona WJ.

“Preoperative Prostate Specific Antigen Doubling Time is Not a Useful Predictor of Biochemical Progression After Radical Prostatectomy.”

Journal of Urology, May 2010; 183: 1816.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20303104


Reviews/Editorials

Loeb S.

“Editorial comment re: Longitudinal Changes of Benign Prostate-Specific Antigen and [-2]ProProstate-Specific Antigen in Seven Years in a Community-Based Sample of Men.”

Urology, March 2012; 79: 661. PMID: 22386421.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22386421


Other Original Articles

Loeb S, Roehl KA, Helfand BT, Kan D, and Catalona WJ.

“Can PSA Velocity Thresholds Reduce the Detection of Insignificant Prostate Cancer?”

Journal of Urology 2010; 183: 112.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140466/

 


Reviews/Editorials

Loeb S, Metter EJ, and Carter HB.

“Re: An Empirical Evaluation of Guidelines on Prostate-Specific Antigen Velocity in Prostate Cancer Detection.”

Journal of the National Cancer Institute November 2011; 103: 1636. PMID: 21926375.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21926375


Other Original Articles

Loeb S, Kettermann A, Carter HB, Metter EJ, Ferrucci L, and Walsh PC.

“Prostate Volume Changes Over Time: Results From the Baltimore Longitudinal Study of Aging.”

Journal of Urology 2009 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19683305


Other Original Articles

Loeb S, Sutherland DE, D’Amico AV, Roehl KA, and Catalona WJ.

“PSA Velocity is Associated with Gleason Score in Radical Prostatectomy Specimen: Marker for Prostate Cancer Aggressiveness.”

Urology, June 2008 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/18571700


Reviews/Editorials

Loeb S.

“Prediction of Outcomes After Radical Prostatectomy in Patients Diagnosed with Prostate Cancer of Biopsy Gleason Score ≥8 Via Contemporary Multi (≥12)-Core Prostate Biopsy.”

BJU International 2011; 108: 222. PMID: 21718432.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21718432


Reviews/Editorials

Loeb S. Editorial comment re:

“Prostate Specific Antigen Velocity per Prostate Volume: A Novel Tool for Prostate Biopsy Prediction.”

Urology 2011; 78: 879. PMID: 21982006

Link: http://www.ncbi.nlm.nih.gov/pubmed/21982006


Other Original Articles

Loeb S, Kettermann A, Ferrucci L, Landis P, Metter EJ, and Carter HB.

“PSA Doubling Time Versus PSA Velocity to Predict High-Risk Prostate Cancer: Data from the Baltimore Longitudinal Study of Aging.”

European Urology, July 2008 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/18614274


Reviews/Editorials

Loeb S and Carter HB.

“Should prostate-specific antigen velocity be abandoned?”

Asian Journal of Andrology 2011; 12: 359. PMID: 21499277.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3739355/


Other Original Articles

Martin NE, Chen MH, Catalona WJ, Loeb S, Roehl KA, and D’Amico AV.

“The Influence of Serial Prostate-Specific Antigen Screening on the PSA Velocity at Diagnosis.”

Cancer, 2008; 113: 717.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18615505

 


Reviews/Editorials

Loeb S.

“Editorial Comment Re: Evaluation of Prostate Specific Antigen Acceleration for Prostate Cancer Diagnosis.”

Journal of Urology March 2011; 185: 826. PMID: 21239022.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21239022


Other Original Articles

Loeb S, Kettermann A, Carter HB, Ferrucci L, Metter EJ, and Walsh PC.

“Does Prostate Growth Confound PSA Velocity: Data from the Baltimore Longitudinal Study of Aging.”

Journal of Urology, 2008; 180: 1314

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2575041/


Reviews/Editorials

Loeb S and Partin AW.

“PCA3 Urinary Biomarker for Prostate Cancer.”

Reviews in Urology Fall 2010; 12: e205. PMID: 21234266.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020285/


Other Original Articles

Meeks JJ, Thaxton CS, Loeb S, Roehl KA, Helfand BT, and Catalona WJ.

“Comparison of PSA Velocity of Screened Versus Referred Patients with Prostate Cancer.”

Journal of Urology 2008; 179: 1340.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18289590


Reviews/Editorials

Tosoian J and Loeb S.

“PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer.”

TheScientificWorldJOURNAL: TSW Urology October 2010; 10: 1919–1931.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20890581


Other Original Articles

Eggener SE, Yossepowitch O, Roehl KA, Loeb S, Yu X, and Catalona WJ.

“The Relationship of PSA Velocity to Histologic Findings in a Prostate Cancer Screening Program.”

Urology 2008; 71: 1016.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18358515


Reviews/Editorials

Loeb S and Carter HB.

“Limitations and Use of PSA Derivatives in the Screening and Risk Stratification of Prostate Cancer.”

Urologic Oncology: Seminars and Original Investigations, Nov-Dec 2009; 27: 583.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19879470


Other Original Articles

Loeb S, Roehl KA, Yu X, Han M, and Catalona WJ.

“Use of PSAV to Follow Patients with Isolated High-Grade Prostatic Intraepithelial Neoplasia (HG-PIN) on Prostate Biopsy.”

Urology, January 2007; 69: 108.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17270629


Other Original Articles

Loeb S, Roehl KA, Catalona WJ, and Nadler RB.

“PSA Velocity Threshold for Predicting Prostate Cancer in Young Men.”

Journal of Urology, March 2007; 177: 899.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17296371


Reviews/Editorials

Loeb S.

“Prostate Cancer: Is PSA Velocity Useful?”

Nature Reviews Urology, June 2009; 6: 305.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19498408


Reviews/Editorials

Loeb S and Carter HB.

“Words of Wisdom: Re: Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.”

European Urology, February 2009; 55: 523.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19606535


Other Original Articles

Yu X, Loeb S, Han M, Suarez BK, Roehl KA, and Catalona WJ.

“The Association Between Total PSA and PSA Velocity.”

Journal of Urology, April 2007; 177: 1298.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17382716


Reviews/Editorials

Loeb S, Kettermann A, Ferrucci L, Landis P, Metter EJ, and Carter HB.

“The Optimal Application of Prostate-Specific Antigen (PSA) Velocity to Predict High-Risk Disease.”

European Urology, November 2008 54: 978.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2603630/


Other Original Articles

Loeb S, Yu X, Roehl KA, Nadler RB and Catalona WJ.

“PSA Velocity Thresholds in Men with Total PSA <4 ng/ml.”

Journal of Urology, December 2007; 178; 2348.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17936844


Reviews/Editorials

Makarov DV, Loeb S, Getzenberg RH, and Partin AW.

“Biomarkers for Prostate Cancer.”

Annual Reviews in Medicine, October 2008 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/18947298


Other Original Articles

Loeb S, Roehl KA, Catalona WJ, and Nadler RB.

“Is the Utility of PSA Velocity for Prostate Cancer Detection Affected by Age?”

BJU International, April 2008; 101: 817.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18321315


Other Original Articles

Yu X, Han M, Loeb S, Gashti SN, Yeh JT, Roehl KA, and Catalona WJ.

“Comparison of Different Methods for Calculating PSA Velocity: Importance of Time Interval Prior to Diagnosis of Prostate Cancer.”

Journal of Urology, December 2006; 176: 2427.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17085120


Reviews/Editorials

Loeb S.

“Does PCA3 Help Identify Clinically Significant Prostate Cancer?”

European Urology, July 2008 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/18684556


Other Original Articles

Loeb S, Han M, Roehl KA, Antenor JV, and Catalona WJ.

“Accuracy of Prostate Weight Estimation by Digital Rectal Exam (DRE) Versus Transrectal Ultrasonography (TRUS).”

Journal of Urology, January 2005; 173: 63-5.

Link: http://www.ncbi.nlm.nih.gov/pubmed/15592029


Reviews/Editorials

Loeb S and Catalona WJ.

“Cancer Biomarkers: Discovery and Validation.”

Cancer Letters, January 2007

 


Key Papers

Loeb S, Sanda MG, Broyles DL, Shin SS, Bangma CH, Wei JT, Partin AW, Klee GG, Slawin KM, Marks LS, van Schaik RH, Chan DW, Sokoll LJ, Cruz AB, Mizrahi IA, Catalona WJ.

“The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer.”

Journal of Urology 2014 Nov 15 epub. PMID:25463993

Link: http://www.ncbi.nlm.nih.gov/pubmed/25463993

Among men from the US FDA registration trial, we found that the Prostate Health Index was a better predictor of clinically significant prostate cancer compared to any of its component parts (total, free or -2proPSA). At the 90% sensitivity cut point for phi (a score less than 28.6), 30% of patients could have been spared an unnecessary biopsy for benign disease or insignificant prostate cancer compared to 21.7% using percent free PSA.


Key Papers

Loeb S, Metter EJ, Kan D, Roehl KA, Catalona WJ.

“Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer.”

BJU International. 2012 Feb;109(4):508-13. PMID: 22296334

Link: http://www.ncbi.nlm.nih.gov/pubmed/22296334

Sustained rises in PSA indicate a significantly greater risk of prostate cancer, particularly high-grade disease. Men with 2 successive PSA velocity measurements >0.4 ng/ml/year (a “risk count” of 2) have an 8-fold increased risk of prostate cancer and 5.4-fold increased risk of Gleason 8-10 disease on biopsy compared to those with ≤1 serial PSAV exceeding 0.4 (risk count 0-1), adjusting for age and PSA level. Compared to PSA alone, PSA velocity risk count may reduce unnecessary biopsies and overdiagnosis of low-risk prostate cancer


Key Papers

Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL, Shin SS, Cruz AB, Chan DW, Sokoll LJ, Roberts WL, van Schaik RH, Mizrahi IA.

“A Multicenter Study of [-2] Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range.”

Journal of Urology May 2011; 185: 1650. PMID: 21419439.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21419439

This prospective, multicenter US trial led to the FDA approval of the Prostate Health Index (phi) in 2012. Phi is a new serum marker test combining total, free and -2proPSA. Among 892 men undergoing prostate biopsy at PSA levels of 2-10 ng/ml, phi was more specific for prostate cancer than either total or free PSA.


Other Original Articles

Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, Feng Z, Carter HB, and Walsh PC.

“Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.”

Journal of Clinical Oncology 2010; 28: 2810.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20439642


BioMarkers

Concordance and Performance of 4KScore and SelectMDx for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer

Wysock JS, Becher E, Persily J, Loeb S, Lepor H.

“Concordance and Performance of 4KScore and SelectMDx for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer.”

Urology. 2020 Apr 12:S0090-4295(20)30339-3. PMID: 32294481

Link: https://pubmed.ncbi.nlm.nih.gov/32294481/


Untitled

Fine ND, LaPolla F, Epstein M, Loeb S, Dani H.

” Genomic Classifiers for Treatment Selection in Newly Diagnosed Prostate Cancer.”

 BJU International 2019 May epub. PMID:31055874.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31055874


Loeb S, Tosoian JJ.

 “Biomarkers in Active Surveillance. “

BJU International. 2018 May 22. PMID: 29786946

    Link: https://www.ncbi.nlm.nih.gov/pubmed/29594029c


Loeb S, Tosoian JJ.

 “Biomarkers in Active Surveillance.”

Translational Andrology and Urology 2018 Feb; 7(1):155-159. PMID: 29594029.

    Link: https://www.ncbi.nlm.nih.gov/pubmed/29594029


Punnen S, Freedland SJ, Polascik TJ, Loeb S, Risk MC, Savage S, Mathur SC, Uchio E, Dong Y, Silberstein JL.

” A Multi-institutional Prospective Trial in the Veterans Affairs Health System confirms the 4Kscore maintains its Predictive value among African American Men.”

Journal of Urology 2017, epub Dec 6. PMID: 29223389

Link: https://www.ncbi.nlm.nih.gov/pubmed/29223389


Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choeurng V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll PR, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL

” Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.”

Journal of Clinical Oncology. 2017 Nov 29 epub. PMID: 29185869.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29185869


Loeb S, Dani H.

 “Whom to Biopsy: Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators.”

Urol Clin North Am. 2017 Nov; 44(4):517-524. PMID: 29107268

    Link: https://www.ncbi.nlm.nih.gov/pubmed/29107268


Dani H, Loeb S.

“The Role of Prostate Cancer Biomarkers in Undiagnosed Men.”

Current Opinion Urology 2017; 27: 210-216. PMID 28212119

Link: https://www.ncbi.nlm.nih.gov/pubmed/28212119


Loeb S.

“Biomarkers for Prostate Biopsy and Risk Stratification of Newly Diagnosed Prostate Cancer Patients.”

Urology Practice. 2017 Jul;4(4):315-321. PMID: 29104903

Link: https://www.ncbi.nlm.nih.gov/pubmed/29104903


Loeb S, Ross AE.

 “Genomic testing for localized prostate cancer: where do we go from here?”

 Current Opinion in Urology. 2017 Jun 28 epub. PMID: 28661898

    Link: https://www.ncbi.nlm.nih.gov/pubmed/28661898


Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, Partin AW, Sokoll L, Chan DW, Bangma CH, van Schaik RH, Slawin KM, Marks LS, Catalona WJ.

“Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer”

BJU International. 2016 Oct 15. PMID:27743489

Link: https://www.ncbi.nlm.nih.gov/pubmed/27743489


Lepor A, Catalona WJ, Loeb S.

“The Prostate Health Index: Its Utility in Prostate Cancer Detection. Urologic Clinics North America.”  

2016 Feb;43(1):1-6. PMID: 26614024

Link: http://www.ncbi.nlm.nih.gov/pubmed/26614024


Loeb S, Lilja H, Vickers A.

“Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer.”

Current Opinion in Urology 2016 Jun 3 epub. PMID: 27262138

Link: http://www.ncbi.nlm.nih.gov/pubmed/27262138


Other Original Articles

Bostrӧm PJ, Bjartell AS, Catto JW, Eggener SE, Lilja H, Loeb S, Schalken J, Schlomm T, and Cooperberg MR.

“Genomic Predictors of Outcome in Prostate Cancer.”

European Urology 2015 epub. PMID: 25913390.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25913390


Reviews/Editorials

Loeb S.

“Prostate Biopsy Decisions: One Size Fits All Approach with Total PSA is Out and a Multivariable Approach with the Prostate Health Index is In.”

BJU International 2015 June epub. PMID: 26054000.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26054000


Other Original Articles

Loeb S, Bruinsma SM, Nicholson J, Briganti A, Pickles T, Kakehi Y, Carlsson SV, Roobol MJ.

“Active Surveillance for Prostate Cancer: A Systematic Review of Clinicopathologic Variables and Biomarkers for Risk Stratification.”

European Urology 2014 Oct epub. PMID: 25457014

Link: http://www.ncbi.nlm.nih.gov/pubmed/25457014


Reviews/Editorials

Loeb S.

“Time to replace prostate-specific antigen (PSA) with the Prostate Health Index (PHI)? Yet more evidence that PHI consistently outperforms PSA across diverse populations.”

BJU International 2015; 115: 500. PMID: 25808708

Link: http://www.ncbi.nlm.nih.gov/pubmed/25808708


Other Original Articles

Loeb S, Sokoll LJ, Broyles DL, Bangma CH, van Schaik RH, Klee GG, Wei JT, Sanda MG, Partin AW, Slawin KM, Marks LS, Mizrahi IA, Shin SS, Cruz AB, Chan DW, Roberts WL, Catalona WJ.

“Prospective Multicenter Evaluation of the Beckman Coulter Prostate Health Index Using WHO Calibration.”

Journal of Urology 2012; epub November. PMID: 23206426.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23206426


Reviews/Editorials

Loeb S.

“Prostate cancer: Predicting prostate biopsy results- PCA3 versus phi.”

Nature Reviews Urology 2015 epub Feb 3. PMID: 25644161

Link: http://www.ncbi.nlm.nih.gov/pubmed/25644161

 


Other Original Articles

Tosoian JJ, Loeb S, Feng Z, Isharwal S, Landis P, Elliot DJ, Veltri R, Epstein JI, Partin AW, Carter HB, Trock B, Sokoll LJ.

“Association of [-2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer.”

Journal of Urology 2012; 188: 1131-6. PMID: 22901577.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22901577


Reviews/Editorials

Lundon D, Loeb S.

“Prostate-Specific Antigen Velocity Risk Count to Discern Significant From Indolent Prostate Cancer.”

Reviews in Urology 2014; 16: 154. PMID: 25337050.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191640/


Other Original Articles

Nichols JH, Loeb S, Metter EJ, Ferrucci L, Carter HB.

“The Relationship Between Prostate Volume and Prostate-Specific Antigen Variability: Data from the Baltimore Longitudinal Study of Aging and the Johns Hopkins Active Surveillance Program.”

BJU International 2012; 109: 1304-8. PMID: 22093443.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22093443


Reviews/Editorials

Loeb S. Editorial Comment on

“Low percentage of free prostate-specific antigen (PSA) is a strong predictor of later detection of prostate cancer among Japanese men with serum levels of total PSA of 4.0 ng/mL or less”

Urology 2014; 84: 1167. PMID: 25443924.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25443924


Other Original Articles

Roobol MJ, van Vugt HA, Loeb S, Zhu X, Bul M, Bangma CH, van Leenders AG, Steyerberg EW, and Schroder FH.

“Prediction of Prostate Cancer Risk: The Role of Prostate Volume and Digital Rectal Examination in the ERSPC Risk Calculators.”

European Urology 2012; 61: 577-83. PMID: 22104592.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22104592


Reviews/Editorials

Loeb S, Catalona WJ.

“The Prostate Health Index: A New Test for the Detection of Prostate Cancer.”

Therapeutic Advances in Urology 2014; 6: 74. PMID: 24688603

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943368/


Other Original Articles

Makarov DV, Loeb S, Magheli A, Zhao K, Humphreys E, Gonzalgo ML, Partin AW, and Han M.

“Significance of Preoperative PSA Velocity in Men with Low Serum PSA and Normal DRE.”

World Journal of Urology 2011; 29: 11.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21153643


Reviews/Editorials

Loeb S.

“Editorial Comment on: A Commentary on PSA Velocity and doubling time for clinical decisions in prostate cancer”

Urology 2014; 83: 596. PMID: 24581522

Link: http://www.ncbi.nlm.nih.gov/pubmed/24581522


Other Original Articles

Loeb S, Carter HB, Schaeffer EM, Kettermann A, Ferrucci L, and Metter EJ.

“Distribution of PSA Velocity by Total PSA Levels: Data from the Baltimore Longitudinal Study of Aging.”

Urology January 2011; 77: 143.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21195835


Reviews/Editorials

Loeb S. Editorial Comment on

“Prostate-Specific Antigen Density: Toward a Better Cutoff to Identify Better Candidates for Active Surveillance.”

Urology 2014; 84: 371.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24925831


Reviews/Editorials

Loeb S.

“Prostate Health Index (PHI): Golden Bullet or Just Another Prostate Cancer Marker?”

European Urology epub 2013 Feb 14. PMID: 23453055

Link: http://www.ncbi.nlm.nih.gov/pubmed/23453055

 


Other Original Articles

Le BV, Griffin CR, Loeb S, Carvalhal GF, Kan D, Baumann NA, and Catalona WJ.

“[-2] Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study.”

Journal of Urology 2010; 183: 1355.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20171670


Reviews/Editorials

Loeb S.

“Prostate Cancer: Prostate Health Index- Improving Screening in Men with a Positive Family History.”

Nature Reviews in Urology 2013; 10: 497

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943368/


Other Original Articles

Tosoian JJ, Loeb S, Kettermann A, Landis P, Elliot DJ, Epstein JI, Partin AW, Carter HB, and Sokoll LJ.

“Accuracy of PCA3 Measurement in Predicting Short-Term Biopsy Progression in an Active Surveillance Program.”

Journal of Urology, February 2010; 183: 534.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20006883


Reviews/Editorials

Loeb S, Carter HB.

“Point: Impact of Prostate-Specific Antigen Velocity on Management Decisions and Recommendations.”

Journal of the National Comprehensive Cancer Network 2013; 11: 281. PMID: 23486454

Link: http://www.ncbi.nlm.nih.gov/pubmed/23486454


Other Original Articles

Kettermann AE, Ferrucci L, Trock BJ, Metter EJ, Loeb S and Carter HB.

“Interpretation of the prostate-specific antigen history in assessing life-threatening prostate cancer.”

BJU International 2010 epub.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928882/


Reviews/Editorials

Loeb S.

“An Examination of the Dynamic Changes in Prostate-Specific Antigen Occurring in a Population-Based Cohort of Men Over Time.”

BJU International August 2012; 110: 381-2. PMID: 22313542.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22313542


Other Original Articles

Loeb S, Kan D, Yu X, Roehl KA, and Catalona WJ.

“Preoperative Prostate Specific Antigen Doubling Time is Not a Useful Predictor of Biochemical Progression After Radical Prostatectomy.”

Journal of Urology, May 2010; 183: 1816.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20303104


Reviews/Editorials

Loeb S.

“Editorial comment re: Longitudinal Changes of Benign Prostate-Specific Antigen and [-2]ProProstate-Specific Antigen in Seven Years in a Community-Based Sample of Men.”

Urology, March 2012; 79: 661. PMID: 22386421.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22386421


Other Original Articles

Loeb S, Roehl KA, Helfand BT, Kan D, and Catalona WJ.

“Can PSA Velocity Thresholds Reduce the Detection of Insignificant Prostate Cancer?”

Journal of Urology 2010; 183: 112.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140466/

 


Reviews/Editorials

Loeb S, Metter EJ, and Carter HB.

“Re: An Empirical Evaluation of Guidelines on Prostate-Specific Antigen Velocity in Prostate Cancer Detection.”

Journal of the National Cancer Institute November 2011; 103: 1636. PMID: 21926375.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21926375


Other Original Articles

Loeb S, Kettermann A, Carter HB, Metter EJ, Ferrucci L, and Walsh PC.

“Prostate Volume Changes Over Time: Results From the Baltimore Longitudinal Study of Aging.”

Journal of Urology 2009 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19683305


Other Original Articles

Loeb S, Sutherland DE, D’Amico AV, Roehl KA, and Catalona WJ.

“PSA Velocity is Associated with Gleason Score in Radical Prostatectomy Specimen: Marker for Prostate Cancer Aggressiveness.”

Urology, June 2008 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/18571700


Reviews/Editorials

Loeb S.

“Prediction of Outcomes After Radical Prostatectomy in Patients Diagnosed with Prostate Cancer of Biopsy Gleason Score ≥8 Via Contemporary Multi (≥12)-Core Prostate Biopsy.”

BJU International 2011; 108: 222. PMID: 21718432.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21718432


Reviews/Editorials

Loeb S. Editorial comment re:

“Prostate Specific Antigen Velocity per Prostate Volume: A Novel Tool for Prostate Biopsy Prediction.”

Urology 2011; 78: 879. PMID: 21982006

Link: http://www.ncbi.nlm.nih.gov/pubmed/21982006


Other Original Articles

Loeb S, Kettermann A, Ferrucci L, Landis P, Metter EJ, and Carter HB.

“PSA Doubling Time Versus PSA Velocity to Predict High-Risk Prostate Cancer: Data from the Baltimore Longitudinal Study of Aging.”

European Urology, July 2008 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/18614274


Reviews/Editorials

Loeb S and Carter HB.

“Should prostate-specific antigen velocity be abandoned?”

Asian Journal of Andrology 2011; 12: 359. PMID: 21499277.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3739355/


Other Original Articles

Martin NE, Chen MH, Catalona WJ, Loeb S, Roehl KA, and D’Amico AV.

“The Influence of Serial Prostate-Specific Antigen Screening on the PSA Velocity at Diagnosis.”

Cancer, 2008; 113: 717.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18615505

 


Reviews/Editorials

Loeb S.

“Editorial Comment Re: Evaluation of Prostate Specific Antigen Acceleration for Prostate Cancer Diagnosis.”

Journal of Urology March 2011; 185: 826. PMID: 21239022.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21239022


Other Original Articles

Loeb S, Kettermann A, Carter HB, Ferrucci L, Metter EJ, and Walsh PC.

“Does Prostate Growth Confound PSA Velocity: Data from the Baltimore Longitudinal Study of Aging.”

Journal of Urology, 2008; 180: 1314

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2575041/


Reviews/Editorials

Loeb S and Partin AW.

“PCA3 Urinary Biomarker for Prostate Cancer.”

Reviews in Urology Fall 2010; 12: e205. PMID: 21234266.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020285/


Other Original Articles

Meeks JJ, Thaxton CS, Loeb S, Roehl KA, Helfand BT, and Catalona WJ.

“Comparison of PSA Velocity of Screened Versus Referred Patients with Prostate Cancer.”

Journal of Urology 2008; 179: 1340.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18289590


Reviews/Editorials

Tosoian J and Loeb S.

“PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer.”

TheScientificWorldJOURNAL: TSW Urology October 2010; 10: 1919–1931.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20890581


Other Original Articles

Eggener SE, Yossepowitch O, Roehl KA, Loeb S, Yu X, and Catalona WJ.

“The Relationship of PSA Velocity to Histologic Findings in a Prostate Cancer Screening Program.”

Urology 2008; 71: 1016.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18358515


Reviews/Editorials

Loeb S and Carter HB.

“Limitations and Use of PSA Derivatives in the Screening and Risk Stratification of Prostate Cancer.”

Urologic Oncology: Seminars and Original Investigations, Nov-Dec 2009; 27: 583.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19879470


Other Original Articles

Loeb S, Roehl KA, Yu X, Han M, and Catalona WJ.

“Use of PSAV to Follow Patients with Isolated High-Grade Prostatic Intraepithelial Neoplasia (HG-PIN) on Prostate Biopsy.”

Urology, January 2007; 69: 108.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17270629


Other Original Articles

Loeb S, Roehl KA, Catalona WJ, and Nadler RB.

“PSA Velocity Threshold for Predicting Prostate Cancer in Young Men.”

Journal of Urology, March 2007; 177: 899.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17296371


Reviews/Editorials

Loeb S.

“Prostate Cancer: Is PSA Velocity Useful?”

Nature Reviews Urology, June 2009; 6: 305.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19498408


Reviews/Editorials

Loeb S and Carter HB.

“Words of Wisdom: Re: Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.”

European Urology, February 2009; 55: 523.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19606535


Other Original Articles

Yu X, Loeb S, Han M, Suarez BK, Roehl KA, and Catalona WJ.

“The Association Between Total PSA and PSA Velocity.”

Journal of Urology, April 2007; 177: 1298.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17382716


Reviews/Editorials

Loeb S, Kettermann A, Ferrucci L, Landis P, Metter EJ, and Carter HB.

“The Optimal Application of Prostate-Specific Antigen (PSA) Velocity to Predict High-Risk Disease.”

European Urology, November 2008 54: 978.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2603630/


Other Original Articles

Loeb S, Yu X, Roehl KA, Nadler RB and Catalona WJ.

“PSA Velocity Thresholds in Men with Total PSA <4 ng/ml.”

Journal of Urology, December 2007; 178; 2348.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17936844


Reviews/Editorials

Makarov DV, Loeb S, Getzenberg RH, and Partin AW.

“Biomarkers for Prostate Cancer.”

Annual Reviews in Medicine, October 2008 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/18947298


Other Original Articles

Loeb S, Roehl KA, Catalona WJ, and Nadler RB.

“Is the Utility of PSA Velocity for Prostate Cancer Detection Affected by Age?”

BJU International, April 2008; 101: 817.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18321315


Other Original Articles

Yu X, Han M, Loeb S, Gashti SN, Yeh JT, Roehl KA, and Catalona WJ.

“Comparison of Different Methods for Calculating PSA Velocity: Importance of Time Interval Prior to Diagnosis of Prostate Cancer.”

Journal of Urology, December 2006; 176: 2427.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17085120


Reviews/Editorials

Loeb S.

“Does PCA3 Help Identify Clinically Significant Prostate Cancer?”

European Urology, July 2008 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/18684556


Other Original Articles

Loeb S, Han M, Roehl KA, Antenor JV, and Catalona WJ.

“Accuracy of Prostate Weight Estimation by Digital Rectal Exam (DRE) Versus Transrectal Ultrasonography (TRUS).”

Journal of Urology, January 2005; 173: 63-5.

Link: http://www.ncbi.nlm.nih.gov/pubmed/15592029


Reviews/Editorials

Loeb S and Catalona WJ.

“Cancer Biomarkers: Discovery and Validation.”

Cancer Letters, January 2007

 


Key Papers

Loeb S, Sanda MG, Broyles DL, Shin SS, Bangma CH, Wei JT, Partin AW, Klee GG, Slawin KM, Marks LS, van Schaik RH, Chan DW, Sokoll LJ, Cruz AB, Mizrahi IA, Catalona WJ.

“The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer.”

Journal of Urology 2014 Nov 15 epub. PMID:25463993

Link: http://www.ncbi.nlm.nih.gov/pubmed/25463993

Among men from the US FDA registration trial, we found that the Prostate Health Index was a better predictor of clinically significant prostate cancer compared to any of its component parts (total, free or -2proPSA). At the 90% sensitivity cut point for phi (a score less than 28.6), 30% of patients could have been spared an unnecessary biopsy for benign disease or insignificant prostate cancer compared to 21.7% using percent free PSA.


Key Papers

Loeb S, Metter EJ, Kan D, Roehl KA, Catalona WJ.

“Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer.”

BJU International. 2012 Feb;109(4):508-13. PMID: 22296334

Link: http://www.ncbi.nlm.nih.gov/pubmed/22296334

Sustained rises in PSA indicate a significantly greater risk of prostate cancer, particularly high-grade disease. Men with 2 successive PSA velocity measurements >0.4 ng/ml/year (a “risk count” of 2) have an 8-fold increased risk of prostate cancer and 5.4-fold increased risk of Gleason 8-10 disease on biopsy compared to those with ≤1 serial PSAV exceeding 0.4 (risk count 0-1), adjusting for age and PSA level. Compared to PSA alone, PSA velocity risk count may reduce unnecessary biopsies and overdiagnosis of low-risk prostate cancer


Key Papers

Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL, Shin SS, Cruz AB, Chan DW, Sokoll LJ, Roberts WL, van Schaik RH, Mizrahi IA.

“A Multicenter Study of [-2] Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range.”

Journal of Urology May 2011; 185: 1650. PMID: 21419439.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21419439

This prospective, multicenter US trial led to the FDA approval of the Prostate Health Index (phi) in 2012. Phi is a new serum marker test combining total, free and -2proPSA. Among 892 men undergoing prostate biopsy at PSA levels of 2-10 ng/ml, phi was more specific for prostate cancer than either total or free PSA.


Other Original Articles

Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, Feng Z, Carter HB, and Walsh PC.

“Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.”

Journal of Clinical Oncology 2010; 28: 2810.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20439642


Blog

Urology Care Foundation- A Great Source of Patient Information

I recently returned from a meeting of the Technology and Publications Committee of the Urology Care Foundation.  This is the official foundation of the American Urological Association, which provides educational materials and other resources for patients.
One particularly impressive resource that our committee oversees is the patient magazine called Urology Health Extra.  Here is a link to the current issue: http://www.urologyhealth.org/patient-magazine/current-issue. It has timely information on urologic conditions reviewed by experts, presented in a reader-friendly format.  I highly recommend this as an excellent resource for patients, and suggest that urology offices order free copies of this for their waiting rooms (http://www.urologyhealth.org/educational-materials/magazine-subscription-bulk).
In addition to these printed materials, our committee plans to expand the digital initiatives of the Urology Care Foundation. Stay tuned for much more on Twitter, Facebook, YouTube, Instagram and Pinterest this coming year!
Urology Care Foundation


Welcome to Dr. Stacy Loeb’s blog!

Welcome to Dr. Stacy Loeb’s blog!  Stay tuned to this section for urology updates, research findings and conference highlights. Check the publications tab for previous research related to:
  • prostate cancer: PSA Screening, biomarkers, genetics, epidemiology, prostate biopsy, staging, active surveillance, treatment.
  • other urology topics: surgical technique, uro-oncology, benign disease
  • social media


Brazil

Paulista Congress of Urology

Brazil (Virtual). October 2020

Topic: Prostate Cancer Screening, Markers and Genetic Testing

Category: Prostate Cancer, Genetics


International Continence Society

Rio de Janiero, Brazil. October 2014

Lecture Topic: Social Media in Medicine

Category: Social media


Canada

Société Internationale d’Urologie

Montreal (Virtual). April 2020

Topic: Webinar on Economic and Financial Burden of COVID-19

Category: COVID-19


Queens University Visiting Professor

Kingston, Ontario – October 18-19, 2018

Lecture Topics: Social Media in Men’s Health (6th Annual Alvaro and Diane Morales Public Lecture in Men’s Health); Active Surveillance for Prostate Cancer.

Category: Men’s Health, Social Media, Prostate Cancer, Active Surveillance


Canadian Urological Association 2017 Meeting

Toronto, Canada- June 24-27, 2017

Lecture topics: Optimizing Active Surveillance for Prostate Cancer, Serum and Urine Markers to Select Patient for Initial and Repeat Prostate Biopsy

Category: Prostate cancer


Issues & Controversies in Urologic Cancer (ICUC) Conference 2017

Mony Tremblant, Canada. January 19-21, 2017

Lecture Topics: Prostate Cancer Markers, Active Surveillance, Prostate Biopsy

Category: Prostate Cancer


The 10th Atlantic Uro Oncology Meeting

 Halifax, Canada. November 14, 2015

Lecture Topics: Prostate Cancer Markers and Active Surveillance

Category: Prostate Cancer


Visiting professor at University of Toronto

 Toronto, Canada. October 2014

Lecture Topics: Prostate Biopsy, Active Surveillance

Category: Prostate Cancer


Colombia

1ER CURSO BIENAL DE INNOVACÍON UROLÓGICA SOCIEDAD COLOMBIANA DE UROLOGÍA

 Barranquilla, Colombia. October 2015

Lecture Topics (all in Spanish):  Prostate -specific Antigen and Biomarkers, Prevention and Management of Prostate Biopsy Complications, Active Surveillance

Category: Prostate Cancer


Second Update Course in Urology (Curso de Actualización en Urología)

 Barranquilla, Colombia. March 2015

Lecture Topics: Prostate cancer screening, prostate cancer markers, prostate biopsy

Category: Prostate Cancer


Visiting Professor at Fundación Santa Fe de Bogotá Fundación

 Barranquilla, Colombia. March 2015

Lecture Topics: Prostate Cancer Screening, Serum and Urine Markers for Prostate Cancer, Contemporary Prostate Biopsy, Active Surveillance, Social Media in Urology

Categories: Prostate Cancer, Social Media


Sociedad Colombiana de Urologia

Cartagena, Colombia. March 2014

Lectures Topics: PSA screening, Risks of Prostate Biopsy, Active Surveillance, Prostate MRI-based Detection, Castration Resistant Prostate Cancer, and Twitter in Urology

Categories: Prostate Cancer, Social Media


Colorado - USA

Conference Highlights

ConferenceHighlights

Nickel JC, Gorin MA, Alan W P, Loeb S, Ellen S, Chancellor MB, Assimos DG, Brawer MK, Brucker BM.

“Best of the 2016 AUA Annual Meeting: Highlights From the 2016 American Urological Association Annual Meeting, May 6-10, 2016, San Diego, CA.”

Reviews in Urology 2016;18(3):159-173.  PMID: 27833468.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27833468


Nickel JC, Gorin MA, Partin AW, Assimos D, Brawer M, Nicolai H, Chancellor MB, Goggins Á, Loeb S, Shapiro E.  

“Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL.”

Reviews in Urology 2015;17(3):179-89. PMID: 26543434

Link: http://www.ncbi.nlm.nih.gov/pubmed/26543434


Prostate Cancer Screening Highlights from the 29th European Association of Urology Congress Stockholm, Sweden, April 11-15, 2014.

Loeb S.

“Prostate Cancer Screening Highlights from the 29th European Association of Urology Congress Stockholm, Sweden, April 11-15, 2014.”

Reviews in Urology 2014; 16: 90. PMID: 25009450.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4080855/


Advances in Localized Prostate Cancer: Highlights From the 2012 Friends of Israel Urological Symposium, July 3-5, 2012, Tel Aviv, Israel.

Loeb S, Borin JF.

“Advances in Localized Prostate Cancer: Highlights From the 2012 Friends of Israel Urological Symposium, July 3-5, 2012, Tel Aviv, Israel.”

Reviews in Urology 2013; 15: 82.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784972/


Best of the 2013 AUA Annual Meeting: Highlights From the 2013 American Urological Association Meeting, May 4-8, 2013, San Diego, CA.

Loeb S, Assimos D, Chancellor MB, Nickel JC, Brawer MK, Kern AJ, Partin AW.

“Best of the 2013 AUA Annual Meeting: Highlights From the 2013 American Urological Association Meeting, May 4-8, 2013, San Diego, CA..”

Reviews in Urology 2013; 15: 72.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784971/


Best of 2012 AUA Annual Meeting: Highlights from the 2012 American Urological Association Meeting, May 19-23, 2012, Atlanta, GA.

Nickel JC, Partin AW, Nirmal J, Chancellor MB, Loeb S, Brawer MK, Assimos D, and Shapiro E.

“Best of 2012 AUA Annual Meeting: Highlights from the 2012 American Urological Association Meeting, May 19-23, 2012, Atlanta, GA.”

Reviews in Urology 2012; 14: 90-103. PMID: 23526762

Link: http://www.ncbi.nlm.nih.gov/pubmed/23526762


Prostate Cancer Screening and Surgical Management of Localized Disease: Highlights from the 27th Annual Congress of the European Association of Urology, February 24-28, 2012, Paris, France.

Loeb S.

“Prostate Cancer Screening and Surgical Management of Localized Disease: Highlights from the 27th Annual Congress of the European Association of Urology, February 24-28, 2012, Paris, France.”

Reviews in Urology 2012; 14: 87-9. PMID: 23526727

Link: http://www.ncbi.nlm.nih.gov/pubmed/23526727


Novel approaches to improve prostate cancer diagnosis and management in early-stage disease.

Marberger M, Barentsz J, Emberton M, Hugosson J, Loeb S, Klotz L, Koch M, Shariat SF, Vickers A.

“Novel approaches to improve prostate cancer diagnosis and management in early-stage disease.”

BJU International 2012; 109 Suppl 2: 1-7. PMID: 22257098.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22257098


Best of the AUA Annual Meeting: Highlights from the 2011 American Urological Association Meeting, May 14-19, 2011, Washington, DC.

Brawer MK, Loeb S, Partin AW, Nirmal J, Chancellor MB, Nickel JC, Rajfer J, Shapiro E, and Roehrborn CG.

“Best of the AUA Annual Meeting: Highlights from the 2011 American Urological Association Meeting, May 14-19, 2011, Washington, DC.”

Reviews in Urology 2011; 13: 151-72. PMID: 22114546.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2725309/


Innovation in Endourology and Minimally Invasive Surgery. Highlights from the 29th World Congress of Endourology and SWL 2011, November 30-December 3, 2011, Kyoto, Japan.

Loeb S and Borin JF.

“Innovation in Endourology and Minimally Invasive Surgery. Highlights from the 29th World Congress of Endourology and SWL 2011, November 30-December 3, 2011, Kyoto, Japan.”

Reviews in Urology 2012; 14: 28-30. PMID: 23172997.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502049/


Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL.

Brawer MK, Loeb S, Partin AW, Yoshimura N, Chancellor MB, Roehrborn CG, Assimos DG, Nickel JC, Shuch B, Pouliot F, Belldegrun AS, and Shapiro E.

“Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL.”

Reviews in Urology, Spring 2009; 11: 82.


Costa Rica

Congreso Centroamericano y del Caribe de Urología y II Highlights of the 2014 American Urological Association Meeting

San Jose, Costa Rica. August 2014

Lectures on: Active surveillance for prostate cancer, Highlights of the AUA meeting on Localized Prostate Cancer

Category: Prostate Cancer


Covid19

Telemedicine Usage Among Urologists During the COVID-19 Pandemic: Cross-Sectional Study

Dubin JM, Wyant WA, Balaji NC, Ong WL, Kettache RH, Haffaf M, Zouari S, Santillan D, Autrán Gómez AM, Sadeghi-Nejad H, Loeb S, Borin JF, Gomez Rivas J, Grummet J, Ramasamy R, Teoh JYC.

“Telemedicine Usage Among Urologists During the COVID-19 Pandemic: Cross-Sectional Study.”

J Med Internet Res. 2020 Nov 5;22(11):e21875. PMID: 33031047.

Link: https://pubmed.ncbi.nlm.nih.gov/33031047/

 


The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future

Wallis CJD, Catto JWF, Finelli A, Glaser AW, Gore JL, Loeb S, Morgan TM, Morgans AK, Mottet N, Neal R, O’Brien T, Odisho AY, Powles T, Skolarus TA, Smith AB, Szabados B, Klaassen Z, Spratt DE.

“The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future.”

Eur Urol. 2020 Nov;78(5):731-742. PMID: 32893062.

Link: https://pubmed.ncbi.nlm.nih.gov/32893062/

 


Urologic Services in Public Hospitals Suffered a Greater Detriment Than Private Hospitals During the Battle of COVID-19

Ong WLK, Lechmiannandan S, Loeb S, Teoh JY.

“Urologic Services in Public Hospitals Suffered a Greater Detriment Than Private Hospitals During the Battle of COVID-19.”

Urology. 2020 Oct; 144:269-270. Epub 2020 Jul 18.PMID: 32687841.

Link: https://pubmed.ncbi.nlm.nih.gov/32687841/

 


Telemedicine and Smart Working: Recommendations of the European Association of Urology

Rodriguez Socarrás M, Loeb S, Teoh JY, Ribal MJ, Bloemberg J, Catto J, N’Dow J, Van Poppel H, Gómez Rivas J.

“Telemedicine and Smart Working: Recommendations of the European Association of Urology”

Eur Urol. 2020 Dec;78(6):812-819. PMID: 32654801.

Link: https://pubmed.ncbi.nlm.nih.gov/32654801/

 


A Systematic Review on Guidelines and Recommendations for Urology Standard of Care During the COVID-19 Pandemic

Heldwein FL, Loeb S, Wroclawski ML, Sridhar AN, Carneiro A, Lima FS, Teoh JY.

“A Systematic Review on Guidelines and Recommendations for Urology Standard of Care During the COVID-19 Pandemic.”

Eur Urol Focus. 2020 Jun 5 epub. PMID: 32532703.

Link: https://pubmed.ncbi.nlm.nih.gov/32532703/

 


A Global Survey on the Impact of COVID-19 on Urological Services

Teoh JY, Ong WLK, Gonzalez-Padilla D, Castellani D, Dubin JM, Esperto F, Campi R, Gudaru K, Talwar R, Okhunov Z, Ng CF, Jain N, Gauhar V, Wong MC, Wroclawski ML, Tanidir Y, Rivas JG, Tiong HY, Loeb S; UroSoMe Working Group.

“A Global Survey on the Impact of COVID-19 on Urological Services.”

Eur Urol. 2020 May 26 epub. PMID: 32507625.

Link: https://pubmed.ncbi.nlm.nih.gov/32507625/

 


Dominican Republic

Sociedad Dominicana de Urologia

 Punta Cana, Dominican Republic. November 2013

Lectures Topics: PSA Screening, Prostate Cancer Markers, and Prostate Biopsy Complications

Category: Prostate Cancer


Drugsafety

 Key Papers


drug safety

 

 

  • Loeb S, Lambe M, Stattin P.

    “Re: Editorial Comment on Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma: D.F. Penson J Urol 2015; 194: 1710-1711.”

    Journal of Urology 2016 epub. PMID: 26783933

    Link: http://www.ncbi.nlm.nih.gov/pubmed/26783933

  • Loeb S, Gupta A. Losonczy L, Tosoian J, Walsh PC.

    “Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk?”

    Curr Opin Urol January 2013; 23: 2-4. PMID: 23159990.

 

  • Loeb S.

    “Invited Editorial Comment Re: Long-Term Fluoroquinolone Use Before the Prostate Biopsy May Increase the Risk of Sepsis Caused by Resistant Microorganisms.”

    Urology August 2011; 78: 255. PMID: 21820566.


England

Royal Society of Medicine

UK (Virtual). June 2020

Topic: COVID-19 and Active Surveillance

Category: Prostate Cancer, COVID-19


European Association of Urology 2017 Congress

London, England. 2017

Lecture topic: Social Media

Category: Social Media


Royal Society of Medicine Urology Section Prostate Cancer Conference

London, England. Ocrober 21, 2016

Lecture topic: Active Surveillance- USA Perspective

Category: Prostate Cancer


Epidemiology

Prostate Cancer. Nature Reviews Disease Primers

Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG.

“Prostate Cancer. Nature Reviews Disease Primers.” 

2021 Feb 4;7(1):9. PMID: 33542230

    Link: https://pubmed.ncbi.nlm.nih.gov/33542230/


Loeb S, Peskoe SB, Joshu CE, Huang WY, Hayes RB, Carter HB, Isaacs WB, Platz EA

“Do Environmental Factors Modify the Genetic Risk of Prostate Cancer?”

Cancer Epidemiology Biomarkers Prevention 2015; 24: 213. PMID: 25342390.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25342390

 

This study examined effect modification by environmental factors of the association between single nucleotide polymorphisms with prostate cancer risk.  Among men at high risk for prostate cancer based on their genotype, use of selenium was associated with a lower risk of advanced prostate cancer, while aspirin, ibuprofen and vegetables were associated with lower risk of nonadvanced prostate cancer.


Loeb S, Folkvaljon Y, Damber JE, Alukal J, Lambe M, Stattin P.  

“Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.” 

Journal of Clinical Oncology 2017;35(13):1430-1436.  PMID: 28447913.

    Link: https://www.ncbi.nlm.nih.gov/pubmed/28447913


Other Original Articles

Thomsen FB, Folkvaljon Y, Garmo H, Robinson D, Loeb S, Ingvar C, Lambe M, Stattin P.

“Risk of malignant melanoma in men with prostate cancer. Nationwide, population-based cohort study.”

International Journal of Cancer. 2015 Dec 14 epub. PMID: 26662367

Link: http://www.ncbi.nlm.nih.gov/pubmed/26662367


Reviews/Editorials

Loeb S, Gupta A. Losonczy L, Tosoian J, Walsh PC.

“Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk?”

Curr Opin Urol January 2013; 23: 2-4. PMID: 23159990.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23159990


Mullins JK, Loeb S.

“Environmental exposures and prostate cancer.”

Urologic Oncology: Seminars and Investigations, March 2012; 30: 216. PMID: 22385992.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22385992


REVIEWS/EDITORIALS

Mullins JK and Loeb S.

“Diabetes Mellitus and Prostate Cancer Risk.”

Expert Review of Endocrinology and Metabolism November 2010; 5: 787.


Other Original Articles

Loeb S, Carter HB, Schaeffer EM, Ling SM, Kettermann A, Ferrucci L, and Metter EJ.

“Bone Mineral Content and Prostate Cancer Risk: Data from the Baltimore Longitudinal Study of Aging.”

BJU International, July 2010; 106: 28.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20067459


Other Original Articles

Loeb S, Helfand BT, Kan D, Isaacs WB, and Catalona WJ.

“Does Diabetes Mellitus Modify the Association between 17q12 Risk Variant and Prostate Cancer Aggressiveness?”

BJU International, November 2009; 104: 1200.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19627283


Reviews/Editorials

Loeb S and Partin AW.

“Randomized Trials of Selenium, Vitamin E, or Vitamin C for Prostate Cancer Prevention.”

Reviews in Urology, Spring 2009; 11: 114.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2725311/


Loeb S and Schaeffer EM.

“Risk Factors, Prevention, and Early Detection of Prostate Cancer.”

Primary Care Clinics of North America, September 2009; 36: 603.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19616157


Other Original Articles

Loeb S, Kan D, Helfand BT, Gashti SN, Nadler RB, and Catalona WJ.

“Is Statin Use Associated with Prostate Cancer Aggressiveness?”

BJU International 2009, Nov 3 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19888973


Epidemiology

Prostate Cancer. Nature Reviews Disease Primers

Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG.

“Prostate Cancer. Nature Reviews Disease Primers.” 

2021 Feb 4;7(1):9. PMID: 33542230

    Link: https://pubmed.ncbi.nlm.nih.gov/33542230/


Loeb S, Peskoe SB, Joshu CE, Huang WY, Hayes RB, Carter HB, Isaacs WB, Platz EA

“Do Environmental Factors Modify the Genetic Risk of Prostate Cancer?”

Cancer Epidemiology Biomarkers Prevention 2015; 24: 213. PMID: 25342390.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25342390

 

This study examined effect modification by environmental factors of the association between single nucleotide polymorphisms with prostate cancer risk.  Among men at high risk for prostate cancer based on their genotype, use of selenium was associated with a lower risk of advanced prostate cancer, while aspirin, ibuprofen and vegetables were associated with lower risk of nonadvanced prostate cancer.


Loeb S, Folkvaljon Y, Damber JE, Alukal J, Lambe M, Stattin P.  

“Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.” 

Journal of Clinical Oncology 2017;35(13):1430-1436.  PMID: 28447913.

    Link: https://www.ncbi.nlm.nih.gov/pubmed/28447913


Other Original Articles

Thomsen FB, Folkvaljon Y, Garmo H, Robinson D, Loeb S, Ingvar C, Lambe M, Stattin P.

“Risk of malignant melanoma in men with prostate cancer. Nationwide, population-based cohort study.”

International Journal of Cancer. 2015 Dec 14 epub. PMID: 26662367

Link: http://www.ncbi.nlm.nih.gov/pubmed/26662367


Reviews/Editorials

Loeb S, Gupta A. Losonczy L, Tosoian J, Walsh PC.

“Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk?”

Curr Opin Urol January 2013; 23: 2-4. PMID: 23159990.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23159990


Mullins JK, Loeb S.

“Environmental exposures and prostate cancer.”

Urologic Oncology: Seminars and Investigations, March 2012; 30: 216. PMID: 22385992.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22385992


REVIEWS/EDITORIALS

Mullins JK and Loeb S.

“Diabetes Mellitus and Prostate Cancer Risk.”

Expert Review of Endocrinology and Metabolism November 2010; 5: 787.


Other Original Articles

Loeb S, Carter HB, Schaeffer EM, Ling SM, Kettermann A, Ferrucci L, and Metter EJ.

“Bone Mineral Content and Prostate Cancer Risk: Data from the Baltimore Longitudinal Study of Aging.”

BJU International, July 2010; 106: 28.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20067459


Other Original Articles

Loeb S, Helfand BT, Kan D, Isaacs WB, and Catalona WJ.

“Does Diabetes Mellitus Modify the Association between 17q12 Risk Variant and Prostate Cancer Aggressiveness?”

BJU International, November 2009; 104: 1200.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19627283


Reviews/Editorials

Loeb S and Partin AW.

“Randomized Trials of Selenium, Vitamin E, or Vitamin C for Prostate Cancer Prevention.”

Reviews in Urology, Spring 2009; 11: 114.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2725311/


Loeb S and Schaeffer EM.

“Risk Factors, Prevention, and Early Detection of Prostate Cancer.”

Primary Care Clinics of North America, September 2009; 36: 603.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19616157


Other Original Articles

Loeb S, Kan D, Helfand BT, Gashti SN, Nadler RB, and Catalona WJ.

“Is Statin Use Associated with Prostate Cancer Aggressiveness?”

BJU International 2009, Nov 3 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19888973


EUROPE

Uppsala University Honorary Doctorate

Uppsala, Sweden. January 2020

Lecture Topic: International Collaboration Using Swedish Registry Data to Improve Health

Category: Prostate Cancer, Men’s Health, Drug Safety


Royal Society of Medicine

UK (Virtual). June 2020

Topic: COVID-19 and Active Surveillance

Category: Prostate Cancer, COVID-19


Challenges in Laparoscopy and Robotics

Barcelona, Spain – July 3-4, 2019

Lecture Topics: Social Media in Prostate Cancer, Robotic Prostatectomy Moderation

Category: prostate cancer, surgical technique, social media


Surgery in the 3rd Millennium: The Future is Female

Milan, Italy – April 4-5, 2019

Lecture Topics: When not to do surgery: expanding active surveillance for low-risk prostate cancer; Moderation for Retzius-Sparing Robotic Prostatectomy

Category: Prostate Cancer, Active Surveillance, Surgical Technique


Hot Topics in Uro-Oncology

Zurich, Switzerland – January 25, 2019

Lecture Topic: Prostate Cancer Screening in the Era of MRI and Novel Biomarkers

Category: Prostate Cancer, MRI, Screening, Markers


Association of Academic European Urologists (AAEU) Meeting

Rome, Italy . November 30, 2018

Lecture Topic: Prostate Cancer Journal Club #ProstateJC on Twitter

Category: Social Media, Prostate Cancer


State-of-the-Art Lecture, Association of Academic European Urologists

Roma, Italy .November, 2018

Lecture Topic: Prostate Cancer Journal Club #ProstateJC on Twitter

Category: Social Media, Prostate Cancer


iTRUST International Translational Research Uro-Sciences Team

Roma, Italy .September 26-27, 2018

Lecture Topic: Social Media & Cancer Care: Where are we going?

Category: Cancer, Social Media


Association of Academic European Urologists (AAEU)

Dresden, Germany . December 15-16, 2017

Lecture Topic: Active surveillance for prostate cancer

Category: Prostate Cancer


European Association of Urology 2017 Congress

London, England. 2017

Lecture topic: Social Media

Category: Social Media


PROSCA 2017

Lisbon, Portugal. June 28-30, 2017

Lecture topics: Screening for prostate cancer: where do we stand?

Category: Prostate Cancer


Heinrich Warner Symposium

Hamburgo, Germany. June 23-24, 2017

Lecture Topic: Clinical Use of Markers in Localized Prostate Cancer

Category: Prostate Cancer


Royal Society of Medicine Urology Section Prostate Cancer Conference

London, England. Ocrober 21, 2016

Lecture topic: Active Surveillance- USA Perspective

Category: Prostate Cancer


European Association of Urology

Munich, Germany. March 11-14, 2016

Lecture Topics: Prostate Cancer Markers

Category: Prostate Cancer


Friends of Israel Urology Symposium

Israel. July 7-8, 2016

Lecture Topics: Active Surveillance, Prostate Cancer Treatment

Category: Prostate Cancer


John Fitzpatrick Irish Prostate Cancer Conference

Ireland. April 21-22, 2016

Lecture Topics: Smarter Prostate Cancer Screening; Prostate Cancer Treatment

Category: Prostate Cancer


Heinrich Warner Symposium

Hamburg, Germany. January 2015

Lecture Topics : Genomic and Epigenetic Variations in Prostate Cancer

Category: Prostate Cancer


Urological Research Society meeting

Jerusalem, Israel. September 2015

Lecture Topic: Utilization of Active Surveillance

Category: Prostate Cancer


American Urological Association New York Section Meeting

Lisbon, Portugal. September 10-12, 2015
Lecture Topic: Markers in Screening and Active Surveillance
Category: Prostate Cancer


Friends of Israel Urological Symposium

Tel Aviv, Israel. July 2012

Lecture Topic: Prostate Cancer Screening

Category: Prostate Cancer


Active Surveillance for Low Risk Prostate Cancer Conference

Amsterdam, Netherlands. February 2014

Lecture topic: Risk based prediction models for indolent Prostate Cancer

Category: Prostate Cancer


Russian Ministry of Health, Institute of Urology

Moscow, Russia. March 2014

Lecture topic: PSA Screening Cost-Effectiveness, Prostate Cancer Markers

Category: Prostate Cancer


Global Congress on Prostate Cancer (PROSCA)

 Rome, Italy. February 2015

Lecture topic: PSA Screening Yes or No

Category: Prostate Cancer


European Association of Urology Guidelines Office Chairs Meeting

Florence, Italy. October 2014

Lecture Topic: Social Media in Urology

Category: Social Media


International Genitourinary Cancer Symposium (IGUCC 5)

Rome, Italy. April 2013

Lectures Topic: Nature vs Nurture in Prostate Cancer, and Prostate Specific Antigen Velocity

Category: Prostate Cancer


European Association of Urology 2015

Madrid, Spain. March 2015

Lecture Topics: Prognostic Factors in the Prostate Histology, Social Media

Categories: Prostate Cancer, Social Media, Erectile Dysfunction


International Genitourinary Cancer Symposium (IGUCC 6)

Madrid, Spain. February 2014

Lecture topic: Smarter Prostate Cancer Screening

Category: Prostate Cancer


Erasmus University Medical Center

Rotterdam, Netherlands. November 2010

Lecture Topic: Prostate Cancer

Category: Prostate Cancer


International Genitourinary Cancer Symposium (IGUCC 3)

Budapest, Hungary. March 2011

Lecture Topics: Debate on Active Surveillance, Panel on Controversies in Prostate Cancer

Category: Prostate Cancer


European Association of Urology 2014 Congress

Stockholm, Sweden. April 2014

Lecture Topic: Invited lecture on Standardizing Report and Outcome of Surgery in Prostate Cancer

Category: Prostate Cancer


ACME meeting

Hemavan, Sweden. January 2012

Lecture topic: Prostate Cancer Risk among immigrants to Sweden

Category: Prostate Cancer


Event

WALL STREET JOURNAL ARTICLE ON PROSTATE CANCER TESTS

Wall Street Journal New prostate cancer tests May 10_1


Genetics

Prostate Cancer. Nature Reviews Disease Primers

Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG.

“Prostate Cancer. Nature Reviews Disease Primers.”

2021 Feb 4;7(1):9. PMID: 33542230.

Link: https://pubmed.ncbi.nlm.nih.gov/33542230/


Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer

Loeb S. and Giri VN.

“Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer.”

Eur Urol Oncol. 2021 Feb;4(1):1-9. Epub 2020 Dec 31. PMID: 33390340

Link: https://pubmed.ncbi.nlm.nih.gov/33390340/


Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.

Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, O’Neil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG

“Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.”

Journal of Clinical Oncology 2020 Jun 9 epub. PMID: 32516092.

Link: https://pubmed.ncbi.nlm.nih.gov/32516092/

The 2019 Philadelphia Prostate Cancer Consensus Conference was a multidisciplinary conference including experts and other stakeholders to create a series of recommendations surrounding germline genetic evaluation for prostate cancer.


Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation.

Loeb S, Byrne N, Walter D, Makarov DV, Wise DR, Becker D, Giri VN.

“Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation.”

Cancer Treat Res Commun. 2020 Sep 28;25:100212. PMID: 33091732

Link: https://pubmed.ncbi.nlm.nih.gov/33091732/


Loeb S, Braithwaite RS, Hayes RB.

Utility of single nucleotide polymorphisms in prostate biopsy decisions.” 

Reviews in Urology 2012; 14: 115-7.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602735/


Loeb S. Editorial Comment on

Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.”

Urology 2015; 85: 170. PMID: 25530380.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25530379


Lynch HT, Kosoko-Lasaki O, Leslie SW, Rendell M, Shaw T, Snyder C, D’Amico AV, Buxbaum S, Isaacs WB, Loeb S, Moul JW, Powell I.

Screening for Familial and Hereditary Prostate Cancer.

International Journal of Cancer.

2015 Dec 5 epub. PMID: 26638190

Link: http://www.ncbi.nlm.nih.gov/pubmed/26638190


Other Original Articles

Bostrӧm PJ, Bjartell AS, Catto JW, Eggener SE, Lilja H, Loeb S, Schalken J, Schlomm T, and Cooperberg MR.

“Genomic Predictors of Outcome in Prostate Cancer.”

European Urology 2015 epub. PMID: 25913390.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25913390


Other Original Articles

Loeb S, Peskoe SB, Joshu CE, Huang WY, Hayes RB, Carter HB, Isaacs WB, Platz EA.

“Do Environmental Factors Modify the Genetic Risk of Prostate Cancer?”

Cancer Epidemiology Biomarkers Prevention 2015; 24: 213. PMID: 25342390.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25342390


Other Original Articles

Reinhardt D, Helfand BT, Cooper PR, Roehl KA, Catalona WJ, and Loeb S.

“Prostate Cancer Risk Alleles are Associated with Prostate Cancer Tumor Volume and Prostate Size.”

Journal of Urology 2013; epub Dec 14. PMID: 24345439

Link: http://www.ncbi.nlm.nih.gov/pubmed/24345439


Other Original Articles

Helfand BT, Hu Q, Loeb S, McVary KT, Catalona WJ.

“Genetic Sequence Variants are Associated with Severity of Lower Urinary Tract Symptoms and Prostate Cancer Susceptibility.”

Journal of Uroloy 2012 epub November. PMID: 23159463.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23159463


Other Original Articles

Cooper PR, McGuire BB, Helfand BT, Loeb S, Hu Q, and Catalona WJ.

“Prostate Cancer Risk Alleles and Their Associations with Other Malignancies.”

Urology October 2011; 78: 970 .e 15-20. PMID: 21820706.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3190015/


Other Original Articles

Helfand BT, Fought AJ, Loeb S, Meeks JJ, Kan D, and Catalona WJ.

“Genetic prostate cancer risk assessment: common variants in 9 genomic regions are associated with cumulative risk.”

Journal of Urology, August 2010; 184: 501.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20620408


Other Original Articles

Helfand BT, Loeb S, Kan D, Catalona WJ.

“Number of prostate cancer risk alleles may identify possibly ‘insignificant’ disease.”

BJU International, June 2010 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20590552


Reviews/Editorials

Loeb S. Editorial Comment on

“Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.”

Urology 2015; 85: 170. PMID: 25530380.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25530379


Other Original Articles

Loeb S, Helfand BT, Kan D, Isaacs WB, and Catalona WJ.

“Does Diabetes Mellitus Modify the Association between 17q12 Risk Variant and Prostate Cancer Aggressiveness?”

BJU International, November 2009; 104: 1200.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19627283


Donin N, Loeb S, Cooper PF, Roehl KA, Baumann NA, Catalona WJ, Helfand BT.

Genetically-Adjusted PSA Values May Prevent Delayed Biopsies in African-American Men.”

BJU International 2014 Jan epub.PMID: 24712975

Link: http://www.ncbi.nlm.nih.gov/pubmed/24712975

 


Other Original Articles

Donin N, Loeb S, Cooper PF, Roehl KA, Baumann NA, Catalona WJ, Helfand BT.

“Genetically-Adjusted PSA Values May Prevent Delayed Biopsies in African-American Men.”

BJU International 2014 Jan epub. PMID: 24712975

Link: http://www.ncbi.nlm.nih.gov/pubmed/24712975


Other Original Articles

Grin B, Loeb S, Roehl K, Cooper PR, Catalona WJ, Helfand BT.

“A rare 8q24 single nucleotide polymorphism (SNP) predisposes North American men to prostate cancer and possibly more aggressive disease.”

BJU International 2014, June epub. PMID: 24952954.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24952954


Key Papers

Helfand BT, Loeb S, Hu Q, Cooper PR, Roehl KA, McGuire BB, Baumann NA, Catalona WJ.

“Personalized PSA Testing Using Genetic Variants May Reduce Unnecessary Biopsies.”

Journal of Urology 2012; epub December. PMID: 23246478.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631301/

Correcting the PSA level for a man’s genotype could potentially reduce the number of men referred for prostate biopsy by up to 20%, while reducing the number of potentially delayed diagnoses by 3% for men with genetically lower PSA levels.


Key Papers

Loeb S, Drevin L, Robinson D, Holmberg E, Carlsson S, Lambe M, Stattin P.

“Risk of localized and advanced prostate cancer among immigrants versus native-born Swedish men: a nation-wide population-based study.”

Cancer Causes Control 2012; December epub. PMID: 23266834.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23266834

First-generation immigrants to Sweden (a high risk country for prostate cancer) have a lower risk of all stages of prostate cancer compared to native-born men, especially men who immigrated to Sweden recently or at an older age.


Reviews/Editorials

Loeb S, Braithwaite RS, Hayes RB.

“Utility of single nucleotide polymorphisms in prostate biopsy decisions.”

Reviews in Urology 2012; 14: 115-7.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602735/


Reviews/Editorials

Loeb S.

“Germline Sequence Variants and Prostate Specific Antigen Interpretation.”

Clinical Chemistry May 2011; 57: 662-3. PMID: 21411622.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21411622


Loeb S.
“Germline Sequence Variants and Prostate Specific Antigen Interpretation.”

Clinical Chemistry May 2011; 57: 662-3.  PMID: 21411622.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21411622


Helfand BT, Loeb S, Meeks JJ, Fought AJ, Kan D, and Catalona WJ.

“Pathological Outcomes Associated with the 17q Prostate Cancer Risk Variants.”

Journal of Urology, June 2009; 181: 2502.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19371897


Key Papers

Loeb S, Carter HB, Walsh PC, Isaacs WB, Kettermann A, Tanaka T, Ferrucci L, and Metter EJ.

“Single Nucleotide Polymorphisms and the Likelihood of Prostate Cancer at a Given Prostate-Specific Antigen Level.”

Journal of Urology, July 2009; 182: 101.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19450841

Genotype influences the risk of prostate cancer per unit increase in PSA. Prostate cancer risk stratification using PSA and genotype together could improve PSA test performance.

 


Other Original Articles

Helfand BT, Loeb S, Meeks JJ, Fought AJ, Kan D, and Catalona WJ.

“Pathological Outcomes Associated with the 17q Prostate Cancer Risk Variants.”

Journal of Urology, June 2009; 181: 2502.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19371897


Reviews/Editorials

Loeb S and Partin AW.

“Single Nucleotide Polymorphisms and Prostate Cancer Susceptibility.”

Reviews in Urology, Fall 2008; 10: 304.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2615108/


Loeb S and Partin AW.

“Single Nucleotide Polymorphisms and Prostate Cancer Susceptibility.”

Reviews in Urology, Fall 2008; 10: 304.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2615108/

 


Helfand BT, Loeb S, Cashy J, Meeks JJ, Thaxton CS, Han M, and Catalona WJ.

“Tumor Characteristics of Carriers and Noncarriers of the deCODE 8q24 Prostate Cancer Susceptibility Alleles.”

Journal of Urology, June 2008; 179: 2197.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18423739


Other Original Articles

Helfand BT, Loeb S, Cashy J, Meeks JJ, Thaxton CS, Han M, and Catalona WJ.

“Tumor Characteristics of Carriers and Noncarriers of the deCODE 8q24 Prostate Cancer Susceptibility Alleles.”

Journal of Urology, June 2008; 179: 2197.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18423739


Other Original Articles

Roehl KA, Loeb S, Antefnor JA, Corbin N, and Catalona WJ.

“Characteristics of Patients with Familial Prostate Cancer Versus Sporadic Cases.”

Journal of Urology, December 2006; 176: 2438.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17085123


Roehl KA, Loeb S, Antefnor JA, Corbin N, and Catalona WJ.

“Characteristics of Patients with Familial Prostate Cancer Versus Sporadic Cases.”

Journal of Urology, December 2006; 176: 2438.
Link: http://www.ncbi.nlm.nih.gov/pubmed/17085123


Genetics

Prostate Cancer. Nature Reviews Disease Primers

Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG.

“Prostate Cancer. Nature Reviews Disease Primers.”

2021 Feb 4;7(1):9. PMID: 33542230.

Link: https://pubmed.ncbi.nlm.nih.gov/33542230/


Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer

Loeb S. and Giri VN.

“Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer.”

Eur Urol Oncol. 2021 Feb;4(1):1-9. Epub 2020 Dec 31. PMID: 33390340

Link: https://pubmed.ncbi.nlm.nih.gov/33390340/


Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.

Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, O’Neil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG

“Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.”

Journal of Clinical Oncology 2020 Jun 9 epub. PMID: 32516092.

Link: https://pubmed.ncbi.nlm.nih.gov/32516092/

The 2019 Philadelphia Prostate Cancer Consensus Conference was a multidisciplinary conference including experts and other stakeholders to create a series of recommendations surrounding germline genetic evaluation for prostate cancer.


Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation.

Loeb S, Byrne N, Walter D, Makarov DV, Wise DR, Becker D, Giri VN.

“Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation.”

Cancer Treat Res Commun. 2020 Sep 28;25:100212. PMID: 33091732

Link: https://pubmed.ncbi.nlm.nih.gov/33091732/


Loeb S, Braithwaite RS, Hayes RB.

Utility of single nucleotide polymorphisms in prostate biopsy decisions.” 

Reviews in Urology 2012; 14: 115-7.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602735/


Loeb S. Editorial Comment on

Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.”

Urology 2015; 85: 170. PMID: 25530380.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25530379


Lynch HT, Kosoko-Lasaki O, Leslie SW, Rendell M, Shaw T, Snyder C, D’Amico AV, Buxbaum S, Isaacs WB, Loeb S, Moul JW, Powell I.

Screening for Familial and Hereditary Prostate Cancer.

International Journal of Cancer.

2015 Dec 5 epub. PMID: 26638190

Link: http://www.ncbi.nlm.nih.gov/pubmed/26638190


Other Original Articles

Bostrӧm PJ, Bjartell AS, Catto JW, Eggener SE, Lilja H, Loeb S, Schalken J, Schlomm T, and Cooperberg MR.

“Genomic Predictors of Outcome in Prostate Cancer.”

European Urology 2015 epub. PMID: 25913390.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25913390


Other Original Articles

Loeb S, Peskoe SB, Joshu CE, Huang WY, Hayes RB, Carter HB, Isaacs WB, Platz EA.

“Do Environmental Factors Modify the Genetic Risk of Prostate Cancer?”

Cancer Epidemiology Biomarkers Prevention 2015; 24: 213. PMID: 25342390.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25342390


Other Original Articles

Reinhardt D, Helfand BT, Cooper PR, Roehl KA, Catalona WJ, and Loeb S.

“Prostate Cancer Risk Alleles are Associated with Prostate Cancer Tumor Volume and Prostate Size.”

Journal of Urology 2013; epub Dec 14. PMID: 24345439

Link: http://www.ncbi.nlm.nih.gov/pubmed/24345439


Other Original Articles

Helfand BT, Hu Q, Loeb S, McVary KT, Catalona WJ.

“Genetic Sequence Variants are Associated with Severity of Lower Urinary Tract Symptoms and Prostate Cancer Susceptibility.”

Journal of Uroloy 2012 epub November. PMID: 23159463.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23159463


Other Original Articles

Cooper PR, McGuire BB, Helfand BT, Loeb S, Hu Q, and Catalona WJ.

“Prostate Cancer Risk Alleles and Their Associations with Other Malignancies.”

Urology October 2011; 78: 970 .e 15-20. PMID: 21820706.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3190015/


Other Original Articles

Helfand BT, Fought AJ, Loeb S, Meeks JJ, Kan D, and Catalona WJ.

“Genetic prostate cancer risk assessment: common variants in 9 genomic regions are associated with cumulative risk.”

Journal of Urology, August 2010; 184: 501.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20620408


Other Original Articles

Helfand BT, Loeb S, Kan D, Catalona WJ.

“Number of prostate cancer risk alleles may identify possibly ‘insignificant’ disease.”

BJU International, June 2010 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20590552


Reviews/Editorials

Loeb S. Editorial Comment on

“Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.”

Urology 2015; 85: 170. PMID: 25530380.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25530379


Other Original Articles

Loeb S, Helfand BT, Kan D, Isaacs WB, and Catalona WJ.

“Does Diabetes Mellitus Modify the Association between 17q12 Risk Variant and Prostate Cancer Aggressiveness?”

BJU International, November 2009; 104: 1200.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19627283


Donin N, Loeb S, Cooper PF, Roehl KA, Baumann NA, Catalona WJ, Helfand BT.

Genetically-Adjusted PSA Values May Prevent Delayed Biopsies in African-American Men.”

BJU International 2014 Jan epub.PMID: 24712975

Link: http://www.ncbi.nlm.nih.gov/pubmed/24712975

 


Other Original Articles

Donin N, Loeb S, Cooper PF, Roehl KA, Baumann NA, Catalona WJ, Helfand BT.

“Genetically-Adjusted PSA Values May Prevent Delayed Biopsies in African-American Men.”

BJU International 2014 Jan epub. PMID: 24712975

Link: http://www.ncbi.nlm.nih.gov/pubmed/24712975


Other Original Articles

Grin B, Loeb S, Roehl K, Cooper PR, Catalona WJ, Helfand BT.

“A rare 8q24 single nucleotide polymorphism (SNP) predisposes North American men to prostate cancer and possibly more aggressive disease.”

BJU International 2014, June epub. PMID: 24952954.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24952954


Key Papers

Helfand BT, Loeb S, Hu Q, Cooper PR, Roehl KA, McGuire BB, Baumann NA, Catalona WJ.

“Personalized PSA Testing Using Genetic Variants May Reduce Unnecessary Biopsies.”

Journal of Urology 2012; epub December. PMID: 23246478.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631301/

Correcting the PSA level for a man’s genotype could potentially reduce the number of men referred for prostate biopsy by up to 20%, while reducing the number of potentially delayed diagnoses by 3% for men with genetically lower PSA levels.


Key Papers

Loeb S, Drevin L, Robinson D, Holmberg E, Carlsson S, Lambe M, Stattin P.

“Risk of localized and advanced prostate cancer among immigrants versus native-born Swedish men: a nation-wide population-based study.”

Cancer Causes Control 2012; December epub. PMID: 23266834.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23266834

First-generation immigrants to Sweden (a high risk country for prostate cancer) have a lower risk of all stages of prostate cancer compared to native-born men, especially men who immigrated to Sweden recently or at an older age.


Reviews/Editorials

Loeb S, Braithwaite RS, Hayes RB.

“Utility of single nucleotide polymorphisms in prostate biopsy decisions.”

Reviews in Urology 2012; 14: 115-7.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602735/


Reviews/Editorials

Loeb S.

“Germline Sequence Variants and Prostate Specific Antigen Interpretation.”

Clinical Chemistry May 2011; 57: 662-3. PMID: 21411622.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21411622


Loeb S.
“Germline Sequence Variants and Prostate Specific Antigen Interpretation.”

Clinical Chemistry May 2011; 57: 662-3.  PMID: 21411622.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21411622


Helfand BT, Loeb S, Meeks JJ, Fought AJ, Kan D, and Catalona WJ.

“Pathological Outcomes Associated with the 17q Prostate Cancer Risk Variants.”

Journal of Urology, June 2009; 181: 2502.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19371897


Key Papers

Loeb S, Carter HB, Walsh PC, Isaacs WB, Kettermann A, Tanaka T, Ferrucci L, and Metter EJ.

“Single Nucleotide Polymorphisms and the Likelihood of Prostate Cancer at a Given Prostate-Specific Antigen Level.”

Journal of Urology, July 2009; 182: 101.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19450841

Genotype influences the risk of prostate cancer per unit increase in PSA. Prostate cancer risk stratification using PSA and genotype together could improve PSA test performance.

 


Other Original Articles

Helfand BT, Loeb S, Meeks JJ, Fought AJ, Kan D, and Catalona WJ.

“Pathological Outcomes Associated with the 17q Prostate Cancer Risk Variants.”

Journal of Urology, June 2009; 181: 2502.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19371897


Reviews/Editorials

Loeb S and Partin AW.

“Single Nucleotide Polymorphisms and Prostate Cancer Susceptibility.”

Reviews in Urology, Fall 2008; 10: 304.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2615108/


Loeb S and Partin AW.

“Single Nucleotide Polymorphisms and Prostate Cancer Susceptibility.”

Reviews in Urology, Fall 2008; 10: 304.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2615108/

 


Helfand BT, Loeb S, Cashy J, Meeks JJ, Thaxton CS, Han M, and Catalona WJ.

“Tumor Characteristics of Carriers and Noncarriers of the deCODE 8q24 Prostate Cancer Susceptibility Alleles.”

Journal of Urology, June 2008; 179: 2197.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18423739


Other Original Articles

Helfand BT, Loeb S, Cashy J, Meeks JJ, Thaxton CS, Han M, and Catalona WJ.

“Tumor Characteristics of Carriers and Noncarriers of the deCODE 8q24 Prostate Cancer Susceptibility Alleles.”

Journal of Urology, June 2008; 179: 2197.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18423739


Other Original Articles

Roehl KA, Loeb S, Antefnor JA, Corbin N, and Catalona WJ.

“Characteristics of Patients with Familial Prostate Cancer Versus Sporadic Cases.”

Journal of Urology, December 2006; 176: 2438.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17085123


Roehl KA, Loeb S, Antefnor JA, Corbin N, and Catalona WJ.

“Characteristics of Patients with Familial Prostate Cancer Versus Sporadic Cases.”

Journal of Urology, December 2006; 176: 2438.
Link: http://www.ncbi.nlm.nih.gov/pubmed/17085123


Germany

Association of Academic European Urologists (AAEU)

Dresden, Germany . December 15-16, 2017

Lecture Topic: Active surveillance for prostate cancer

Category: Prostate Cancer


Heinrich Warner Symposium

Hamburgo, Germany. June 23-24, 2017

Lecture Topic: Clinical Use of Markers in Localized Prostate Cancer

Category: Prostate Cancer


European Association of Urology

Munich, Germany. March 11-14, 2016

Lecture Topics: Prostate Cancer Markers

Category: Prostate Cancer


Heinrich Warner Symposium

Hamburg, Germany. January 2015

Lecture Topics : Genomic and Epigenetic Variations in Prostate Cancer

Category: Prostate Cancer


Grants Completed

Grants Current

Hong Kong

Chinese University of Hong Kong Urology Symposium

Hong Kong (Virtual). November 2020

Topic: Prostate Cancer Screening: Evidence, Guidelines and Implementation; Updates on Prostate Cancer in 2019-2020

Category: Prostate Cancer


Hungary

International Genitourinary Cancer Symposium (IGUCC 3)

Budapest, Hungary. March 2011

Lecture Topics: Debate on Active Surveillance, Panel on Controversies in Prostate Cancer

Category: Prostate Cancer


Ireland

John Fitzpatrick Irish Prostate Cancer Conference

Ireland. April 21-22, 2016

Lecture Topics: Smarter Prostate Cancer Screening; Prostate Cancer Treatment

Category: Prostate Cancer


Israel

Friends of Israel Urology Symposium

Israel. July 7-8, 2016

Lecture Topics: Active Surveillance, Prostate Cancer Treatment

Category: Prostate Cancer


Urological Research Society meeting

Jerusalem, Israel. September 2015

Lecture Topic: Utilization of Active Surveillance

Category: Prostate Cancer


Friends of Israel Urological Symposium

Tel Aviv, Israel. July 2012

Lecture Topic: Prostate Cancer Screening

Category: Prostate Cancer


Italy

Surgery in the 3rd Millennium: The Future is Female

Milan, Italy – April 4-5, 2019

Lecture Topics: When not to do surgery: expanding active surveillance for low-risk prostate cancer; Moderation for Retzius-Sparing Robotic Prostatectomy

Category: Prostate Cancer, Active Surveillance, Surgical Technique


Association of Academic European Urologists (AAEU) Meeting

Rome, Italy . November 30, 2018

Lecture Topic: Prostate Cancer Journal Club #ProstateJC on Twitter

Category: Social Media, Prostate Cancer


State-of-the-Art Lecture, Association of Academic European Urologists

Roma, Italy .November, 2018

Lecture Topic: Prostate Cancer Journal Club #ProstateJC on Twitter

Category: Social Media, Prostate Cancer


iTRUST International Translational Research Uro-Sciences Team

Roma, Italy .September 26-27, 2018

Lecture Topic: Social Media & Cancer Care: Where are we going?

Category: Cancer, Social Media


Global Congress on Prostate Cancer (PROSCA)

 Rome, Italy. February 2015

Lecture topic: PSA Screening Yes or No

Category: Prostate Cancer


European Association of Urology Guidelines Office Chairs Meeting

Florence, Italy. October 2014

Lecture Topic: Social Media in Urology

Category: Social Media


International Genitourinary Cancer Symposium (IGUCC 5)

Rome, Italy. April 2013

Lectures Topic: Nature vs Nurture in Prostate Cancer, and Prostate Specific Antigen Velocity

Category: Prostate Cancer


Key Article

Loeb S, Vonesh EF, Metter EJ, Carter HB, Gann PH, and Catalona WJ.

“What is the true number-needed-to-screen and treat to save a life with prostate-specific antigen (PSA) testing?” 

Journal of Clinical Oncology January 2011; 29: 464.
Link: http://www.ncbi.nlm.nih.gov/pubmed/21189374

Although number needed to screen (NNS) and number needed to treat (NNT) are useful statistics to assess the benefits and harms of an intervention, in a survival study setting such as the European Randomized Study of Screening for Prostate Cancer (ERSPC), NNS and NNT are time specific, and reporting values at one time point may lead to misinterpretation of results. We developed a model predicting that the NNS in this trial would decrease from 837 at year 10 to 503 at year 12, and NNT would decrease from 29 to 18.


Schaeffer EM, Carter HB, Kettermann A, Loeb S, Ferrucci L, Landis P, Trock BJ, and Metter EJ.

“Prostate Specific Antigen Testing Among the Elderly: When to Stop?” 

Journal of Urology, April 2009; 181: 1606.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19246059

 

Men ages 75-80 with PSA levels <3 ng/ml are unlikely to die of or experience aggressive prostate cancer during their remaining life, suggesting that PSA testing might be safely discontinued for these men.

 


Loeb S, Carter HB, Catalona WJ, Moul JW, and Schroder FH.

“Baseline Prostate-Specific Antigen Testing at a Young Age.”

European Urology January 2012; 61: 1-7. PMID: 21862205.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21862205

This study reviews the published literature showing that baseline PSA measurements at a young age are significant predictors of later prostate cancer diagnosis and disease-specific outcomes. Baseline PSA testing should be offered to young men for risk stratification and to guide screening protocols


Loeb S, Roehl KA, Antenor JV, Catalona WJ, Suarez BK, and Nadler RB.

“Baseline Prostate Specific Antigen (PSA) Compared with Median PSA for Age Group as Predictor of Prostate Cancer Risk in Men Under 60 Years of Age”

Urology, February 2006; 67: 316.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16442597

In the general US population, the median PSA level is 0.7 ng/ml in the 40’s and 0.9 ng/ml in the 50’s. Young men with a baseline PSA level above the age-specific median are at significantly greater risk of future prostate cancer diagnosis and aggressive disease. Baseline PSA at a young age is a stronger predictor of prostate cancer than race, family history or digital rectal examination.


Murphy DG, Ahlering T, Catalona WJ, Crowe H, Crowe J, Clarke N, Cooperberg M, Gillatt D, Gleave M, Loeb S, Roobol M, Sartor O, Pickles T, Wooten A, Walsh PC, Costello AJ.

“The Melbourne Consensus Statement on the Early Detection of Prostate Cancer.”

British Journal of Urology International 2012 epub Nov 8. PMID: 24206066

Link: http://www.ncbi.nlm.nih.gov/pubmed/24206066

In light of numerous conflicting recommendations about prostate cancer screening, in August 2013 a multidisciplinary group convened in Melbourne, Australia to create consensus practice guidelines. Key areas of consensus are that level 1 evidence shows that prostate cancer screening saves lives among men ages 50-69, but that biopsy decisions should be made using PSA as part of a multivariable approach and that diagnosis must be uncoupled from treatment.


Key Papers

Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.

Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, O’Neil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG

“Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.”

Journal of Clinical Oncology 2020 Jun 9 epub. PMID: 32516092.

Link: https://pubmed.ncbi.nlm.nih.gov/32516092/

The 2019 Philadelphia Prostate Cancer Consensus Conference was a multidisciplinary conference including experts and other stakeholders to create a series of recommendations surrounding germline genetic evaluation for prostate cancer.


Untitled

Loeb S, Sengupta S, Butaney M, Macaluso JN Jr, Czarniecki SW, Robbins R, Braithwaite RS, Gao L, Byrne N, Walter D, Langford A.

“Dissemination of Misinformative and Biased Information about Prostate Cancer on YouTube.

European Urology. 2018 Nov 27 epub. PMID: 30502104.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30502104

In this study, we examined the first 150 YouTube videos about prostate cancer, showing that the majority had potentially biased and/or misinformative information in the video or comments.


Loeb S, Byrne N, Makarov DV, Lepor H, Walter D.

“Use of Conservative Management for Low-Risk Prostate Cancer in the Veterans Affairs Integrated Health Care System From 2005-2015.”

JAMA. 2018 Jun 5; 319(21):2231-2233. PMID: 29800017

Link: https://www.ncbi.nlm.nih.gov/pubmed/29800017

In the U.S. Veterans Affairs healthcare system, we found a substantial increase in the use of conservative management for low-risk prostate cancer over the past decade. By 2015, 72% of veterans <65 years and 79% ages ≥65 with low-risk prostate cancer were managed conservatively.


Loeb S, Zhou Q, Siebert U, Rochau U, Jahn B, Mühlberger N, Carter HB, Lepor H, Braithwaite RS.  

“Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions”.

European Urology 2017 Aug 22 epub.  PMID: 28844371

Link: https://www.ncbi.nlm.nih.gov/pubmed/28844371

We designed a Markov model showing that active surveillance extends life more than watchful waiting, particularly for men with higher risk features, but this is partly offset by decrements in quality of life from delayed treatment. Trade-offs about the intensity of surveillance should be discussed with patients.


Liss MA, Ehdaie B, Loeb S, Meng MV, Raman JD, Spears V, Stroup SP.  

“An Update of the American Urological Association White Paper on the Prevention and Treatment of the More Common Complications Related to Prostate Biopsy.” 

Journal of  Urology  2017 Mar 29 epub. PMID: 28363690

Link: https://www.ncbi.nlm.nih.gov/pubmed/28363690

This is an updated American Urological Association White Paper with guidance on the prevention and treatment of prostate biopsy complications.


Loeb S, Peskoe SB, Joshu CE, Huang WY, Hayes RB, Carter HB, Isaacs WB, Platz EA

“Do Environmental Factors Modify the Genetic Risk of Prostate Cancer?”

Cancer Epidemiology Biomarkers Prevention 2015; 24: 213. PMID: 25342390.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25342390

 

This study examined effect modification by environmental factors of the association between single nucleotide polymorphisms with prostate cancer risk.  Among men at high risk for prostate cancer based on their genotype, use of selenium was associated with a lower risk of advanced prostate cancer, while aspirin, ibuprofen and vegetables were associated with lower risk of nonadvanced prostate cancer.


 Key Papers


Loeb S, Roupret M, Van Oort I, N’dow J, Van Gurp M, Bloemberg J, Darraugh JA, Ribal M. 

“Novel Use of Twitter to Disseminate and Evaluate Adherence with Clinical Guidelines by the European Association of Urology”.

BJU Int. 2017 Feb 7 epub.  PMID: 28170154

Link: https://www.ncbi.nlm.nih.gov/pubmed/28170154

Herein, we demonstrate a proof-of-principal study on the use of twitter as a platform for the dissemination and real-time evaluation of the European Association of Urology clinical guidelines. These strategies can be considered by other medical societies to increase the reach and obtain rapid feedback on guidelines recommendations.


Loeb S, Folkvaljon Y, Curnyn C, Robinson D, Bratt O, Stattin P.

“Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden”.

JAMA Oncology. 2016 Oct 20. PMID: 27768168.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27768168

Using nationwide Sweden data, this study showed that by 2014, active surveillance was selected by 91% of very low risk, 74% of low risk and 19% of intermediate risk patients across the country.  These rates are the highest yet reported internationally. Dissociating diagnosis from treatment in men with a low risk of progression can decrease the rate of overtreatment.


Danneman D, Drevin L, Delahunt B, Samaratunga H, Robinson D, Bratt O, Loeb S, Stattin P, Egevad L.

“The Accuracy of Prostate Biopsies for Predicting Gleason Score in Radical Prostatectomy Specimens. Nationwide trends 2000-2012.” BJU International. 2016 Feb 25 epub. PMID:26918298.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26918298

 

Loeb S, Folkvaljon Y, Robinson D, Lissbrant IF, Egevad L, Stattin P.

“Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort.”  European Urology. 2015 Dec 17 epub. PMID: 26707871

Link: http://www.ncbi.nlm.nih.gov/pubmed/26707871


Loeb S, Curnyn C, Sedlander E.

“Perspectives of Prostate Cancer Patients on Gleason Scores and the New Grade Groups: Initial Qualitative Study.”

European Urology 2016 Jun 6 epub. PMID: 27283215.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24439788

This is the first qualitative study to ask patients their perspectives on Gleason grading, which is a significant source of confusion. The majority of patients agreed that they would prefer to be told they have grade group 1 versus Gleason 6 cancer, and that this would encourage the use of active surveillance.


Loeb S, Drevin L, Robinson D, Holmberg E, Carlsson S, Lambe M, Stattin P.

“Risk of localized and advanced prostate cancer among immigrants versus native-born Swedish men: a nation-wide population-based study.” 

Cancer Causes Control 2012;

December epub.  PMID: 23266834.
Link: http://www.ncbi.nlm.nih.gov/pubmed/23266834

 

First-generation immigrants to Sweden (a high risk country for prostate cancer) have a lower risk of all stages of prostate cancer compared to native-born men, especially men who immigrated to Sweden recently or at an older age.


Helfand BT, Loeb S, Hu Q, Cooper PR, Roehl KA, McGuire BB, Baumann NA, Catalona WJ.
“Personalized PSA Testing Using Genetic Variants May Reduce Unnecessary Biopsies.” 

Journal of Urology 2012; epub December. PMID: 23246478.
Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631301/


Key Articles

Loeb S, Carter HB, Walsh PC, Isaacs WB, Kettermann A, Tanaka T, Ferrucci L, and Metter EJ.

“Single Nucleotide Polymorphisms and the Likelihood of Prostate Cancer at a Given Prostate-Specific Antigen Level.”

Journal of Urology, July 2009; 182: 101.
Link: http://www.ncbi.nlm.nih.gov/pubmed/19450841

 

Genotype influences the risk of prostate cancer per unit increase in PSA. Prostate cancer risk stratification using PSA and genotype together could improve PSA test performance.


Key Article

Key Articles
Loeb S, Peskoe SB, Joshu CE, Huang WY, Hayes RB, Carter HB, Isaacs WB, Platz EA “Do Environmental Factors Modify the Genetic Risk of Prostate Cancer?” Cancer Epidemiology Biomarkers Prevention 2015; 24: 213. PMID: 25342390.
Link: http://www.ncbi.nlm.nih.gov/pubmed/25342390

This study examined effect modification by environmental factors of the association between single nucleotide polymorphisms with prostate cancer risk. Among men at high risk for prostate cancer based on their genotype, use of selenium was associated with a lower risk of advanced prostate cancer, while aspirin, ibuprofen and vegetables were associated with lower risk of nonadvanced prostate cancer.


Key Papers

Bratt O, Folkvaljon Y, Hjalm Eriksson M, Akre O, Carlsson S, Drevin L, Franck Lissbrant I, Makarov D, Loeb S, Stattin P.

“Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer.”

European Urology 2015 epub. PMID: 25813688.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25813688

Using data from national Swedish registries, this study showed that many healthy men in their seventies live for at least another 10 years. Despite this long life expectancy, men in their seventies with high-risk nonmetastatic prostate cancer often did not receive treatment with radical prostatectomy or radiotherapy, possibly because their life expectancy was underestimated. This study highlights the need for improved clinical decision-making, which should incorporate an assessment of the patient’s life expectancy.


Key Papers

Loeb S, Zhu X, Schroder FH, Roobol MJ.

“Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.”

BJU International epub Sept 21, 2012. PMID: 22998182.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22998182

This study compared the outcomes of prostate cancer treatment between men in the screening and control arms of the European Randomized Study of Prostate Cancer Screening (ERSPC). Men from the screening arm had a significantly higher progression-free survivial, metastasis-free survival, and cancer-specific survival compared to controls. Improved surgical outcomes among screened men appeared to be mediated by the lower tumor volume at diagnosis. These results show that early detection and successful treatment go hand-in-hand.


Key Papers

Loeb S, Feng Z, Ross A, Trock BJ, Humphreys EB, and Walsh PC.

“Can We Stop Prostate Specific Antigen Testing 10 Years After Radical Prostatectomy?”

Journal of Urology August 2011; 186: 500. PMID: 21679999.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21679999

Patients often ask whether it is necessary to continue PSA testing indefinitely after radical prostatectomy. In the Johns Hopkins radical prostatectomy database, 77% of all biochemical recurrences occurred within the first 5 years, 17% from 5-10 years, 6% from 10-15 years and only 1.5% more than 15 years after surgery. For men with an undetectable prostate specific antigen at 10 years the actuarial probability of biochemical recurrence and metastasis at 20 years varied by stage and grade, with no metastases in patients with low-grade disease at prostatectomy. A single patient with an undetectable prostate specific antigen at 10 years died of prostate cancer within 20 years after radical prostatectomy. This suggests that less intense monitoring is possible beyond 10 years, particularly for men with favorable tumor features.


Key Papers

Loeb S, Makarov DV, Schaeffer EM, Humphreys EB, and Walsh PC.

“Prostate-specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomy.”

Journal of Urology, July 2010; 184: 157.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20483148

In men with newly diagnosed prostate cancer, bone metastases are uncommon at PSA levels <20 ng/ml. However, after radical prostatectomy bone metastases may occur at much lower PSA levels. Among 193 hormone naïve men who developed bone metastases after radical prostatectomy, bone scan conversion occurred at a PSA <10, 10-100 and >100 ng/ml in 26%, 51% and 23% men, respectively. 


Key Papers

Mullins JK, Feng Z, Trock BJ, Epstein JI, Walsh PC, Loeb S.

“The Impact of Anatomical Radical Retropubic Prostatectomy on Cancer Control: The 30-Year Anniversary.”

Journal of Urology epub October 18, 2012. PMID: 23083655.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23083655

A total of 4,478 men underwent anatomical radical retropubic prostatectomy by Dr Patrick C. Walsh at the Johns Hopkins Medical Institutions from 1982-2011. To commemorate the 30th anniversary of the anatomic RRP, the long-term outcomes were examined. The overall 25-year progression-free, metastasis-free and cancer specific survival rates were 68%, 84% and 86%, respectively, although there were significant differences in treatment outcomes between men treated in the pre-PSA and PSA eras. Anatomical RRP continues to represent the gold standard in the surgical management of clinically localized prostate cancer to which alternate treatment options should be compared.


Key Papers

Loeb S, Bruinsma SM, Nicholson J, Briganti A, Pickles T, Kakehi Y, Carlsson SV, Roobol MJ.

“Active Surveillance for Prostate Cancer: A Systematic Review of Clinicopathologic Variables and Biomarkers for Risk Stratification.”

European Urology 2014 Oct epub. PMID: 25457014

Link: http://www.ncbi.nlm.nih.gov/pubmed/25457014

This systematic review examined the utility of markers, genetic factors and risk stratification for active surveillance. The patient factors associated with active surveillance outcomes in some studies include age, race, and family history. Multiple studies provide consistent evidence that a lower percentage of free PSA, a higher Prostate Health Index (PHI), a higher PSA density (PSAD), and greater biopsy core involvement at baseline predict a greater risk of progression. During follow-up, serial measurements of PHI and PSAD, as well as repeat biopsy results, predict later biopsy progression. No conclusive data support the use of genetic tests in active surveillance. 


Key Papers

Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R.

“Overdiagnosis and Overtreatment of Prostate Cancer.”

European Urology 2014; epub Jan 9. PMID: 24439788

Link: http://www.ncbi.nlm.nih.gov/pubmed/24439788

This systematic review of epidemiological, clinical and autopsy studies found a very wide of estimates for prostate cancer overdiagnosis from 1.7-67%. Published estimates of overtreatment vary widely based on patient features and may be declining internationally. Careful patient selection for screening and reducing overtreatment are important to preserve the benefits and reduce the downstream harms of prostate-specific antigen testing. 


Key Papers

Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, Rosario DJ, Scattoni V, and Lotan Y.

“Systematic Review of Complications of Prostate Biopsy.”

European Urology 2013; June epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23787356

This systematic review of prostate biopsy complications found that hematuria and hematospermia are most common, but are typically mild and self-limiting. Severe rectal bleeding is uncommon. Despite antimicrobial prophylaxis, infectious complications are increasing over time and are the most common reason for hospitalization after biopsy. Pain may occur at several stages of prostate biopsy and can be mitigated by anesthetic agents and anxiety-reduction techniques. Up to 25% of men have transient LUTS after biopsy, and <2% have frank urinary retention, with slightly higher rates reported after transperineal template biopsy. Biopsy-related mortality is rare.


Key Papers

Makarov DV, Loeb S, Ulmert D, Drevin L, Lambe M, Stattin P.

“Prostate Cancer Imaging Trends After a Nationwide Effort to Discourage Inappropriate Prostate Cancer Imaging.”

Journal of the National Cancer Institute (JNCI) 2013 July epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23853055

Imaging is very important for staging of high-risk prostate cancer, but is not recommended for low-risk disease. This study demonstrated that a nationwide Swedish campaign successfully reduced inappropriate imaging for low risk prostate cancer (from 45% to 3%), but also was associated with a slight reduction in appropriate imaging in high-risk patients.


Key Papers

Loeb S, Sanda MG, Broyles DL, Shin SS, Bangma CH, Wei JT, Partin AW, Klee GG, Slawin KM, Marks LS, van Schaik RH, Chan DW, Sokoll LJ, Cruz AB, Mizrahi IA, Catalona WJ.

“The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer.”

Journal of Urology 2014 Nov 15 epub. PMID:25463993

Link: http://www.ncbi.nlm.nih.gov/pubmed/25463993

Among men from the US FDA registration trial, we found that the Prostate Health Index was a better predictor of clinically significant prostate cancer compared to any of its component parts (total, free or -2proPSA). At the 90% sensitivity cut point for phi (a score less than 28.6), 30% of patients could have been spared an unnecessary biopsy for benign disease or insignificant prostate cancer compared to 21.7% using percent free PSA.


Key Papers

Murphy DG, Loeb S, Basto MY, Challacombe B, Trinh QD, Leveridge M, Morgan T, Dasgupta P, Bultitude M.

“Engaging Responsibly with Social Media: the BJUI Guidelines.”

BJU International 2014 Apr epub. PMID: 24774415

Link: http://www.ncbi.nlm.nih.gov/pubmed/24774415

This paper summarizes the British Journal of Urology International guidelines for physicians to engage responsibly with social media. They emphasize the importance of considering that online content may exist forever and be available to everyone, that doctors should identify themselves and that the views they express are their own. Digital behavior should align with professional standards, avoiding any impropriety or breach of patient privacy.


drug safety

 

 

  • Loeb S, Lambe M, Stattin P.

    “Re: Editorial Comment on Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma: D.F. Penson J Urol 2015; 194: 1710-1711.”

    Journal of Urology 2016 epub. PMID: 26783933

    Link: http://www.ncbi.nlm.nih.gov/pubmed/26783933

  • Loeb S, Gupta A. Losonczy L, Tosoian J, Walsh PC.

    “Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk?”

    Curr Opin Urol January 2013; 23: 2-4. PMID: 23159990.

 

  • Loeb S.

    “Invited Editorial Comment Re: Long-Term Fluoroquinolone Use Before the Prostate Biopsy May Increase the Risk of Sepsis Caused by Resistant Microorganisms.”

    Urology August 2011; 78: 255. PMID: 21820566.


Key Papers

Loeb S, Berglund A, Stattin P.

“Population-Based Study of Utilization and Determinants of Active Surveillance and Watchful Waiting for Low- and Intermediate-Risk Prostate Cancer”

Journal of Urology 2013 May 29 epub. PMID: 23727309

Link: http://www.ncbi.nlm.nih.gov/pubmed/23727309

Using nationwide Sweden data, this study showed that from 2007 to 2011, active surveillance was selected by 59% of very low risk, 41% of low risk and 16% of intermediate risk patients across the country. These rates are the highest yet reported internationally. Dissociating diagnosis from treatment in men with a low risk of progression can decrease the rate of overtreatment.


Key Papers

Helfand BT, Loeb S, Hu Q, Cooper PR, Roehl KA, McGuire BB, Baumann NA, Catalona WJ.

“Personalized PSA Testing Using Genetic Variants May Reduce Unnecessary Biopsies.”

Journal of Urology 2012; epub December. PMID: 23246478.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631301/

Correcting the PSA level for a man’s genotype could potentially reduce the number of men referred for prostate biopsy by up to 20%, while reducing the number of potentially delayed diagnoses by 3% for men with genetically lower PSA levels.


Key Papers

Murphy DG, Ahlering T, Catalona WJ, Crowe H, Crowe J, Clarke N, Cooperberg M, Gillatt D, Gleave M, Loeb S, Roobol M, Sartor O, Pickles T, Wooten A, Walsh PC, Costello AJ.

“The Melbourne Consensus Statement on the Early Detection of Prostate Cancer.”

British Journal of Urology International 2012 epub Nov 8. PMID: 24206066

Link: http://www.ncbi.nlm.nih.gov/pubmed/24206066

 In light of numerous conflicting recommendations about prostate cancer screening, in August 2013 a multidisciplinary group convened in Melbourne, Australia to create consensus practice guidelines. Key areas of consensus are that level 1 evidence shows that prostate cancer screening saves lives among men ages 50-69, but that biopsy decisions should be made using PSA as part of a multivariable approach and that diagnosis must be uncoupled from treatment.


Key Papers

Loeb S, Drevin L, Robinson D, Holmberg E, Carlsson S, Lambe M, Stattin P.

“Risk of localized and advanced prostate cancer among immigrants versus native-born Swedish men: a nation-wide population-based study.”

Cancer Causes Control 2012; December epub. PMID: 23266834.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23266834

First-generation immigrants to Sweden (a high risk country for prostate cancer) have a lower risk of all stages of prostate cancer compared to native-born men, especially men who immigrated to Sweden recently or at an older age.


Key Papers

Tosoian JJ, Loeb S, Feng Z, Isharwal S, Landis P, Elliot DJ, Veltri R, Epstein JI, Partin AW, Carter HB, Trock B, Sokoll LJ.

“Association of [-2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer.”

Journal of Urology October 2012; 188: 1131-6. PMID: 22901577.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22901577

Longitudinal measurements of the Prostate Health Index (phi) during active surveillance were a robust predictor of biopsy reclassification (C-index 0.82). These results have since been validated in other surveillance populations. Since PSA kinetics are unreliable and biopsies are invasive, phi offers another non-invasive test that can be used to monitor patients during active surveillance.


Key Papers

Loeb S, van den Heuvel S, Zhu X, Bangma CH, Schröder FH, Roobol MJ.

“Infectious Complications and Hospital Admissions After Prostate Biopsy in a European Randomized Trial.”

European Urology June 2012; 61: 1110-4. PMID: 22244150

Link: http://www.ncbi.nlm.nih.gov/pubmed/22244150

Among men undergoing prostate biopsy in the European Randomized Study of Screening for Prostate Cancer (ERSPC), 4% developed a fever and 0.8% were admitted to the hospital. Although the risk of hospitalization for infection increased over time, the absolute frequency was low. Because this same trial showed that screening reduces advanced disease and prostate cancer death, the risk of biopsy-related complications should not dissuade healthy men with a sufficient life expectancy to benefit from early detection from undergoing an indicated prostate biopsy.


Key Papers

Loeb S, Metter EJ, Kan D, Roehl KA, Catalona WJ.

“Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer.”

BJU International. 2012 Feb;109(4):508-13. PMID: 22296334

Link: http://www.ncbi.nlm.nih.gov/pubmed/22296334

Sustained rises in PSA indicate a significantly greater risk of prostate cancer, particularly high-grade disease. Men with 2 successive PSA velocity measurements >0.4 ng/ml/year (a “risk count” of 2) have an 8-fold increased risk of prostate cancer and 5.4-fold increased risk of Gleason 8-10 disease on biopsy compared to those with ≤1 serial PSAV exceeding 0.4 (risk count 0-1), adjusting for age and PSA level. Compared to PSA alone, PSA velocity risk count may reduce unnecessary biopsies and overdiagnosis of low-risk prostate cancer


Key Papers

Loeb S, Carter HB, Catalona WJ, Moul JW, and Schroder FH.

Baseline Prostate-Specific Antigen Testing at a Young Age.

European Urology January 2012; 61: 1-7. PMID: 21862205.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21862205

This study reviews the published literature showing that baseline PSA measurements at a young age are significant predictors of later prostate cancer diagnosis and disease-specific outcomes. Baseline PSA testing should be offered to young men for risk stratification and to guide screening protocols.

 


Key Papers

Loeb S, Carter HB, Berndt SI, Ricker W, and Schaeffer EM.

“Complications After Prostate Biopsy: Data From SEER-Medicare.”

Journal of Urology November 2011; 186: 1830. PMID: 21926375.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21944136

This was the first paper to call attention to the increasing risk of hospitalization for infection after prostate biopsy in the United States. Careful patient selection for prostate biopsy is essential to minimize the potential downstream harms of prostate cancer screening, and this paper has been cited by numerous guidelines


Key Papers

Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL, Shin SS, Cruz AB, Chan DW, Sokoll LJ, Roberts WL, van Schaik RH, Mizrahi IA.

“A Multicenter Study of [-2] Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range.”

Journal of Urology May 2011; 185: 1650. PMID: 21419439.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21419439

This prospective, multicenter US trial led to the FDA approval of the Prostate Health Index (phi) in 2012. Phi is a new serum marker test combining total, free and -2proPSA. Among 892 men undergoing prostate biopsy at PSA levels of 2-10 ng/ml, phi was more specific for prostate cancer than either total or free PSA.


Key Papers

Loeb S, Vonesh EF, Metter EJ, Carter HB, Gann PH, and Catalona WJ.

“What is the true number-needed-to-screen and treat to save a life with prostate-specific antigen (PSA) testing?”

Journal of Clinical Oncology January 2011; 29: 464.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21189374

Although number needed to screen (NNS) and number needed to treat (NNT) are useful statistics to assess the benefits and harms of an intervention, in a survival study setting such as the European Randomized Study of Screening for Prostate Cancer (ERSPC), NNS and NNT are time specific, and reporting values at one time point may lead to misinterpretation of results. We developed a model predicting that the NNS in this trial would decrease from 837 at year 10 to 503 at year 12, and NNT would decrease from 29 to 18.


Key Papers

Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, Feng Z, Carter HB, and Walsh PC.

“Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.”

Journal of Clinical Oncology, June 2010; 28: 2810.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20439642

PSA doubling time and PSA velocity are frequently used to monitor patients during active surveillance. Among men in the Johns Hopkins active surveillance program, PSA kinetics during active surveillance were not reliable predictors of adverse pathology on repeat biopsy. This suggests that PSA kinetics should not be used as a trigger for intervention during active surveillance.


Key Papers

Loeb S, Schaeffer EM, Trock BJ, Humphreys EB, Epstein JI, and Walsh PC.

“What are the Outcomes of Radical Prostatectomy for High-Risk Prostate Cancer?”

Urology 2009, Nov 19 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19931898

Historically most men with D’Amico high-risk prostate cancer (clinical stage ≥T2c, biopsy Gleason score 8-10, or prostate-specific antigen >20 ng/mL) were treated with combined radiation therapy and hormonal therapy. This study shows that surgical treatment for carefully selected high risk patients can result in long-term progression–free survival.   At 10 years, biochemical recurrence-free survival was 68%, metastasis-free survival was 84%, and prostate cancer-specific survival was 92%. The 10-year rate of freedom from any hormonal therapy was 71%. Of the 3 high-risk criteria, a biopsy Gleason score of 8-10 (vs ≤7) was the strongest independent predictor of biochemical recurrence, metastases, and prostate cancer death.


Key Papers

Loeb S, Carter HB, Walsh PC, Isaacs WB, Kettermann A, Tanaka T, Ferrucci L, and Metter EJ.

“Single Nucleotide Polymorphisms and the Likelihood of Prostate Cancer at a Given Prostate-Specific Antigen Level.”

Journal of Urology, July 2009; 182: 101.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19450841

Genotype influences the risk of prostate cancer per unit increase in PSA. Prostate cancer risk stratification using PSA and genotype together could improve PSA test performance.

 


Key Papers

Schaeffer EM, Carter HB, Kettermann A, Loeb S, Ferrucci L, Landis P, Trock BJ, and Metter EJ.

“Prostate Specific Antigen Testing Among the Elderly: When to Stop?”

Journal of Urology, April 2009; 181: 1606.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19246059

Men ages 75-80 with PSA levels <3 ng/ml are unlikely to die of or experience aggressive prostate cancer during their remaining life, suggesting that PSA testing might be safely discontinued for these men.


Key Papers

Loeb S, Roehl KA, Antenor JV, Catalona WJ, Suarez BK, and Nadler RB.

“Baseline Prostate Specific Antigen (PSA) Compared with Median PSA for Age Group as Predictor of Prostate Cancer Risk in Men Under 60 Years of Age”

Urology, February 2006; 67: 316.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16442597

In the general US population, the median PSA level is 0.7 ng/ml in the 40’s and 0.9 ng/ml in the 50’s. Young men with a baseline PSA level above the age-specific median are at significantly greater risk of future prostate cancer diagnosis and aggressive disease. Baseline PSA at a young age is a stronger predictor of prostate cancer than race, family history or digital rectal examination.

 


Korea

Annual Meeting of the Korean Urological Association

Seoul, Korea. October 12-15, 2016

Lecture Topics: Prostate Cancer Markers, Active Surveillance, BPH

Category: Prostate Cancer, Benign Prostatic Hyperplasia

 

 


Latin America

Paulista Congress of Urology

Brazil (Virtual). October 2020

Topic: Prostate Cancer Screening, Markers and Genetic Testing

Category: Prostate Cancer, Genetics


Global Men’s Health Summit

Panama (Virtual). October 2020

Topic: Early Detection, Diagnosis and Risk Stratification of Prostate Cancer

Category: Prostate Cancer


Sociedad Mexicana de Urología/ American Urological Association Curso Conjunto

Acapulco, Mexico. February 3-4, 2017

Lecture Topics: Prostate Cancer Screening, Prostate Biopsy, Prostate MRI, Active Surveillance, Radical Prostatectomy, Radiation Therapy

Category: Prostate Cancer


XXXV Congreso Confederación Americana de Urología

Panama. October 2016

Lecture Topics: Prostate Cancer Active Surveillance, SelectMDx and ConfirmMDx Prostate Cancer Markers, Social Media in Urology

Categories: Prostate Cancer, Social Media


Asociación Mexicana de Urología Oncológica (Acapulco, Mexico)

Acapulco, Mexico. July 20-22, 2016

Lecture topics:Social media, Prostate Cancer Markers, Prostate Biopsy Complications, Active Surveillance

Category: Prostate Cancer, Social Media


Colegio Mexicano de Urologia (Puebla, Mexico)

Puebla, Mexico. April 14-16, 2016

Lecture Topics (Spanish): Association of PDE5 inhibitors with risk of melanoma and Prostate Cancer; Active Surveillance for Prostate Cancer Gleason grading updates for Prostate Cancer

Category: Prostate Cancer, Erectile Dysfunction Medications, Men’s Health


CONGRESO ANUAL ASOCIACION NACIONAL DE UROLOGOS EGRESADOS DEL CENTRO MEDICO NACIONAL LA RAZA (ANUER) de México

México City. January 28-30, 2016

Lecture Topics (all in Spanish): Smarter screening for Prostate Cancer, Prostate Cancer Markers

Category:  Prostate Cancer


Sociedad Dominicana de Urologia

 Punta Cana, Dominican Republic. November 2013

Lectures Topics: PSA Screening, Prostate Cancer Markers, and Prostate Biopsy Complications

Category: Prostate Cancer


Congreso Centroamericano y del Caribe de Urología y II Highlights of the 2014 American Urological Association Meeting

San Jose, Costa Rica. August 2014

Lectures on: Active surveillance for prostate cancer, Highlights of the AUA meeting on Localized Prostate Cancer

Category: Prostate Cancer


International Continence Society

Rio de Janiero, Brazil. October 2014

Lecture Topic: Social Media in Medicine

Category: Social media


1ER CURSO BIENAL DE INNOVACÍON UROLÓGICA SOCIEDAD COLOMBIANA DE UROLOGÍA

 Barranquilla, Colombia. October 2015

Lecture Topics (all in Spanish):  Prostate -specific Antigen and Biomarkers, Prevention and Management of Prostate Biopsy Complications, Active Surveillance

Category: Prostate Cancer


Second Update Course in Urology (Curso de Actualización en Urología)

 Barranquilla, Colombia. March 2015

Lecture Topics: Prostate cancer screening, prostate cancer markers, prostate biopsy

Category: Prostate Cancer


Visiting Professor at Fundación Santa Fe de Bogotá Fundación

 Barranquilla, Colombia. March 2015

Lecture Topics: Prostate Cancer Screening, Serum and Urine Markers for Prostate Cancer, Contemporary Prostate Biopsy, Active Surveillance, Social Media in Urology

Categories: Prostate Cancer, Social Media


Congreso Anual Asociacion Nacional de Urologos Egresados del Centro Medico Nacional La Raza (ANUER)

Mexico City, Mexico. January 2015 

Lectures Topics: Implications of Discontinuing PSA Screening, Identifying Clinically Significant vs. Indolent Prostate Cancer, Twitter in Urology

Categories: Prostate Cancer, Social Media


Sociedad Colombiana de Urologia

Cartagena, Colombia. March 2014

Lectures Topics: PSA screening, Risks of Prostate Biopsy, Active Surveillance, Prostate MRI-based Detection, Castration Resistant Prostate Cancer, and Twitter in Urology

Categories: Prostate Cancer, Social Media


Colegio Mexicano de Urologia

Acapulco, Mexico. April 2014

Lecture Topics: Cost Effectiveness of PSA Screening, Markers and Nomograms for Prostate Cancer

Category: Prostate Cancer


Sociedad Mexicana de Urologia

 Merida, Mexico. November 2013

Lectures topics: Prostate Cancer Screening, Prostate Cancer Markers, Prostate Biopsy complications and Social Media

Categories: Prostate Cancer, Social Media


Colegio Mexicano de Urologia

Cancun, Mexico. April 2013

Lectures Topics: Prostate Cancer Biomarkers and Active Surveillance

Category: Prostate Cancer


Colegio Mexicano de Urologia

León, Mexico, April 2012

Lectures Topic: Prostate Cancer Screening

Category: Prostate Cancer


lectures

Sexual Medicine Society of North America Journal Club

USA (Virtual). March 2021

Topic: Roles and Attitudes Toward Social Media Platforms Amongst Urology Trainees

Category: Social Media


NYU Department of Population Health

NYC (Virtual). March 2021

Topic: Social Media Best Practices Workshop

Category: Social Media


ASCO Genitourinary Symposium

USA (Virtual). February 2021

Topic: Moderator

Category: Prostate Cancer


Grand Rounds, Weill Cornell University Urology

NYC (Virtual). January 2021

Topic: Promise and Peril of Digital Technology in Urology

Category: Social Media


Society of Urologic Oncology Young Urologic Oncologists Lecture Series

USA (Virtual). November 2020

Topic: Use of Social Media in Urology

Category: Social Media


21st Asia-Pacific Prostate Cancer Conference

Australia (Virtual). October 2020

Topic: Key Papers in Detection and Localized Prostate Cancer, Women in Urology and Leveraging Social Media

Category: Prostate Cancer, Social Media, Representation


Sexual Medicine Society of North America

USA (Virtual). October 2020

Topic: Social Media in Sexual Medicine

Category: Men’s Health, Social Media


Memorial Sloan Kettering Cancer Center

NYC (Virtual). October 2020

Topic: Social Media in Prostate Cancer

Category: Prostate Cancer, Social Media


Texas A&M University College of Medicine Health & Wellness Grand Rounds

Texas (Virtual). October 2020

Topic: Online Professionalism and the Pros/Cons of Social Media for Medical Trainees and Health Professionals

Category: Social Media


Weill Cornell University Urology

NYC (Virtual). August 2020

Topic: Prostate Cancer Screening

Category: Prostate Cancer


Association for Healthcare Social Media

Pennsylvania (Virtual). August 2020

Topic: Researching Social Media

Category: Social Media


Texas A&M Baylor, Scott & White Health Graduate Medical Education

Texas (Virtual). May 2020

Topic: Social Media

Category: Social Media


EMPIRE Lecture Series

NY (Virtual). May 2020

Topic: Social Media for Urologists

Category: Social Media


Société Internationale d’Urologie

Montreal (Virtual). April 2020

Topic: Webinar on Economic and Financial Burden of COVID-19

Category: COVID-19


Memorial Sloan Kettering Cancer Center

New York, NY – December 17, 2019

Lecture topic: Social Media and Academics

Category: Social media


Culture Leap

Malibu, CA – November 7, 2019

Lecture Topic: Role of Social Media in Science Information

Category: Social media


Clinical Oncology Society of Australia

Adelaide, Australia – November 12-14, 2019

Lecture topics: Latest developments in prostate cancer surgery and active surveillance; Promise and peril of social media for clinicians, researchers and patients

Category: Prostate Cancer Treatment, Active Surveillance, Social Media


Division of General Internal Medicine, NYU

NY, NY – October 8, 2019
Lecture Topic: The Promise and Peril of Social Media in Prostate Cancer
Category: Social Media, Prostate Cancer

 

 


Inspire Seminar Series, Manhattan Veterans Affairs

NY, NY – October 17, 2019
Lecture Topic: The Promise and Peril of Social Media in Prostate Cancer
Category: Social Media, Prostate Cancer

 

 


Prostate Cancer Foundation 2019 Retreat

Carlsbad, CA – October 1-4, 2019

Lecture Topics: Panel at the PCF Women’s Forum on Navigating Confidence; Moderator and Presenter about Online Information and Side Effects at PCF-Us TOO Patient Advocacy Session

Category: Women In Science, Prostate Cancer, Social Media, Survivorship


American Association of Clinical Urologists (AACU)

Washington DC –  October 12-14, 2019

Lecture Topic: Online Presence for Urologists, Clinical Urology in 2019 (Panel)

Category: Social Media, Urology


Hackensack University Medical Center Visiting Professor

Hackensack, New Jersey – October 15, 2019

Lecture Topic: Social Media in Medicine

Category: Social Media


Northeastern Section of the American Urological Association

Syracuse, NY – September, 2019

Lecture topics: Reducing prostate cancer overtreatment with active surveillance; Biomarkers-  how do we use them

Category: Prostate Cancer, Active Surveillance, Markers


American Urological Association 2019 Annual Meeting

Chicago, IL – May 2-5, 2019

Lecture Topics: Plenary on Top 10 Apps for Wellness, Work and Study; Prostate Cancer Update Course

Category: Apps, Social Media, Prostate Cancer


Surgery in the 3rd Millennium: The Future is Female

Milan, Italy – April 4-5, 2019

Lecture Topics: When not to do surgery: expanding active surveillance for low-risk prostate cancer; Moderation for Retzius-Sparing Robotic Prostatectomy

Category: Prostate Cancer, Active Surveillance, Surgical Technique


Hot Topics in Uro-Oncology

Zurich, Switzerland – January 25, 2019

Lecture Topic: Prostate Cancer Screening in the Era of MRI and Novel Biomarkers

Category: Prostate Cancer, MRI, Screening, Markers


University of California San Francisco Urology Grand Rounds

San Francisco, CA  – January 9, 2019

Lecture Topic: Social Media in Urology

Category: Social Media


Henry Ford Vattikuti Urology Institute Visiting Professor

Detroit, MI – December 11-12, 2018

Lecture topics: Active Surveillance, Social Media

Category: Prostate cancer, active surveillance, social media


Association of Academic European Urologists (AAEU) Meeting

Rome, Italy . November 30, 2018

Lecture Topic: Prostate Cancer Journal Club #ProstateJC on Twitter

Category: Social Media, Prostate Cancer


State-of-the-Art Lecture, Association of Academic European Urologists

Roma, Italy .November, 2018

Lecture Topic: Prostate Cancer Journal Club #ProstateJC on Twitter

Category: Social Media, Prostate Cancer


iTRUST International Translational Research Uro-Sciences Team

Roma, Italy .September 26-27, 2018

Lecture Topic: Social Media & Cancer Care: Where are we going?

Category: Cancer, Social Media


2018 Prostate Cancer World Congress

Brisbane Australia . August 22-246, 2018

Lecture Topic: Active surveillance for prostate cancer, Social media in prostate cancer

Category: Prostate Cancer, Social Media


American Urological Association 2018 Meeting

San Francisco, CA.  May 18-22, 2018

Lecture topic: Optimizing Technique and Selection for Prostate Biopsy, Prostate Cancer Press Conferences, Prostate Cancer Updates Course

Category: Prostate Cancer


LA Live Advanced Robotic & Open Surgery Symposium

Los Angeles, CA.  May 16-17, 2018

Lecture topic: Active surveillance for prostate cancer, Live surgery panel

Category: Prostate Cancer


Surgery in the 3rd Millenium: The Future is Female

Milan, Italy  . April 12-13, 2018

Lecture Topic: Active surveillance for prostate cancer

Category: Prostate Cancer


Association of Academic European Urologists (AAEU)

Dresden, Germany . December 15-16, 2017

Lecture Topic: Active surveillance for prostate cancer

Category: Prostate Cancer


3rd Annual USC L.A. Live Practical Urology Conference

Los Angeles, California . February 1-3, 2018

Lecture Topic:Using markers to improve selection for prostate biopsy, prostate biopsy complications

Category: Prostate Cancer


Society of Women in Urology

Las Vegas, Nevada. January 19-21, 2018

Lecture Topic: Genomic markers for prostate cancer, social media

Category: Prostate Cancer, Social Media


Chairman’s Rounds at Johns Hopkins Hospital

Baltimore, Maryland. November 16, 2017

Lecture Topic: Update on active surveillance and dissemination of knowledge in urology

Category: prostate cancer, social media, dissemination and implementation science (D&I)


Prostate Cancer Foundation 24th Annual Scientific Retreat

Washington, DC . October 4-7, 2017

Lecture Topic: Women in science panel, poster on crowdfunding in prostate cancer

Category: Women in science, Social Media


Grand Rounds at Washington University

St, Louis, Missouri. June 9, 2017

Lecture Topic: Social media in urology

Category: Social media


Grand Rounds at University of Pennsylvania

Philadelphia, Pennsylvania. May 18, 2017

Lecture Topic: Biomarkers in the diagnosis and management of localized prostate cancer

Category: Prostate Cancer


Prostate Cancer World Congress

 Melbourne, Australia. August 2013

Lecture Topics: Practice changing publications in Prostate Cancer, Smarter PSA Screening with Isoforms and Kinetics, Selecting patients for Prostate Biopsy, Selection and monitoring during Active Surveillance

Category: Prostate Cancer


media

MedPage Today Interview on Viagra and Melanoma: Search for Link Inconclusive

6/2015 MedPage Today Interview on Viagra and Melanoma: Search for Link Inconclusive

http://www.medpagetoday.com/Urology/ErectileDysfunction/52272


Cancer Research and Oncology Virtual Conference: Lecture on Active Surveillance: Trends in Use, Patient Selection & Monitoring

10/2015 Cancer Research and Oncology Virtual Conference: Lecture on Active Surveillance: Trends in Use, Patient Selection & Monitoring September 30, 2015

Lecture topic: Active Surveillance: Trends in Use, Patient Selection and Monitoring

Category: prostate cancer

Location: online


Men Health

Men Health

  • Loeb S, Folkvaljon Y, Damber JE, Alukal J, Lambe M, Stattin P

     

    “Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.”

    Journal of Clinical Oncology 2017;35(13):1430-1436. PMID: 28447913.

    Link: https://www.ncbi.nlm.nih.gov/pubmed/28447913

    The relationship between testosterone replacement therapy and prostate cancer risk is controversial. We found no association between testosterone therapy and overall prostate cancer risk. Long-term testosterone therapy was associated with a significantly reduced risk of aggressive prostate cancer.

     

  • Loeb S, Folkvaljon Y, Lambe M, Robinson D, Garmo H, Ingvar C, Stattin P.

     

    Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.”

     

    JAMA 2015; 313: 2449-55. PMID: 26103029.

     

    Link: http://www.ncbi.nlm.nih.gov/pubmed/26103029

     

    A recent study suggested a possible link between phosphodiesterase inhibitors used for erectile dysfunction and risk of malignant melanoma. Through a large collaboration with the national registries of Sweden, we performed a large study that raised questions about a causal relationship including lack of a dose-response relationship. Instead, the observed association between erectile dysfunction drugs and melanoma likely reflects shared risk factors including lifestyle and socioeconomic status.

     

  • Loeb S, Folkvaljon Y, Robinson D, Schlomm T, Garmo H, Stattin P.

    “Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.

     

    European Urology. 2015 Dec 29 epub. PMID: 26743040

     

    Link: http://www.ncbi.nlm.nih.gov/pubmed/26743040

     

    A previous study from Germany reported a significantly increased risk of prostate cancer recurrence in men taking phosphodiesterase type 5 (PDE5) inhibitors after radical prostatectomy, which was subsequently refuted in an Italian study. We followed up on this issue using nationwide Swedish registry data, and confirmed that there is no association between PDE5 inhibitors with prostate cancer recurrence after treatment.

     


Mexico

Sociedad Mexicana de Urología/ American Urological Association Curso Conjunto

Acapulco, Mexico. February 3-4, 2017

Lecture Topics: Prostate Cancer Screening, Prostate Biopsy, Prostate MRI, Active Surveillance, Radical Prostatectomy, Radiation Therapy

Category: Prostate Cancer


Asociación Mexicana de Urología Oncológica (Acapulco, Mexico)

Acapulco, Mexico. July 20-22, 2016

Lecture topics:Social media, Prostate Cancer Markers, Prostate Biopsy Complications, Active Surveillance

Category: Prostate Cancer, Social Media


Colegio Mexicano de Urologia (Puebla, Mexico)

Puebla, Mexico. April 14-16, 2016

Lecture Topics (Spanish): Association of PDE5 inhibitors with risk of melanoma and Prostate Cancer; Active Surveillance for Prostate Cancer Gleason grading updates for Prostate Cancer

Category: Prostate Cancer, Erectile Dysfunction Medications, Men’s Health


CONGRESO ANUAL ASOCIACION NACIONAL DE UROLOGOS EGRESADOS DEL CENTRO MEDICO NACIONAL LA RAZA (ANUER) de México

México City. January 28-30, 2016

Lecture Topics (all in Spanish): Smarter screening for Prostate Cancer, Prostate Cancer Markers

Category:  Prostate Cancer


Congreso Anual Asociacion Nacional de Urologos Egresados del Centro Medico Nacional La Raza (ANUER)

Mexico City, Mexico. January 2015 

Lectures Topics: Implications of Discontinuing PSA Screening, Identifying Clinically Significant vs. Indolent Prostate Cancer, Twitter in Urology

Categories: Prostate Cancer, Social Media


Colegio Mexicano de Urologia

Acapulco, Mexico. April 2014

Lecture Topics: Cost Effectiveness of PSA Screening, Markers and Nomograms for Prostate Cancer

Category: Prostate Cancer


Sociedad Mexicana de Urologia

 Merida, Mexico. November 2013

Lectures topics: Prostate Cancer Screening, Prostate Cancer Markers, Prostate Biopsy complications and Social Media

Categories: Prostate Cancer, Social Media


Colegio Mexicano de Urologia

Cancun, Mexico. April 2013

Lectures Topics: Prostate Cancer Biomarkers and Active Surveillance

Category: Prostate Cancer


Colegio Mexicano de Urologia

León, Mexico, April 2012

Lectures Topic: Prostate Cancer Screening

Category: Prostate Cancer


Netherlands

Active Surveillance for Low Risk Prostate Cancer Conference

Amsterdam, Netherlands. February 2014

Lecture topic: Risk based prediction models for indolent Prostate Cancer

Category: Prostate Cancer


Erasmus University Medical Center

Rotterdam, Netherlands. November 2010

Lecture Topic: Prostate Cancer

Category: Prostate Cancer


news

WALL STREET JOURNAL ARTICLE ON PROSTATE CANCER TESTS

Wall Street Journal New prostate cancer tests May 10_1


Sirius XM Channel 110 Doctor Radio

Dr. Loeb

Hosts the Men’s Health Show on US/Canada satellite radio Sirius XM channel 110

On Wednesdays from 6-8pm EST.

https://www.siriusxm.com/doctorradio/weeklyschedule

 


Report: Forbes article about Viagra & Melanoma

Ever since a paper was released last year detailing cases of melanoma found in men taking the billion-dollar erectile dysfunction (ED) blockbuster Viagra, urologist Stacy Loeb of New York University has been fielding questions from worried patients about whether they should risk the little blue pill…

 


North America

Nutrition Media

New York University Langone Health Webinar

Plant-Based Diet: Impact for Health, the Environment, and Social Justice (Jan 15, 2021)


PIX11 News

Eat It to Beat It’ Challenge Promotes Prostate Cancer Awareness Month (Sept 16, 2020)


Plant Powered Metro New York

A Key To Men’s Health is in the Kitchen (July 8, 2020)


Online

Sexual Medicine Society of North America Journal Club

USA (Virtual). March 2021

Topic: Roles and Attitudes Toward Social Media Platforms Amongst Urology Trainees

Category: Social Media


NYU Department of Population Health

NYC (Virtual). March 2021

Topic: Social Media Best Practices Workshop

Category: Social Media


ASCO Genitourinary Symposium

USA (Virtual). February 2021

Topic: Moderator

Category: Prostate Cancer


Grand Rounds, Weill Cornell University Urology

NYC (Virtual). January 2021

Topic: Promise and Peril of Digital Technology in Urology

Category: Social Media


Chinese University of Hong Kong Urology Symposium

Hong Kong (Virtual). November 2020

Topic: Prostate Cancer Screening: Evidence, Guidelines and Implementation; Updates on Prostate Cancer in 2019-2020

Category: Prostate Cancer


Society of Urologic Oncology Young Urologic Oncologists Lecture Series

USA (Virtual). November 2020

Topic: Use of Social Media in Urology

Category: Social Media


21st Asia-Pacific Prostate Cancer Conference

Australia (Virtual). October 2020

Topic: Key Papers in Detection and Localized Prostate Cancer, Women in Urology and Leveraging Social Media

Category: Prostate Cancer, Social Media, Representation


Paulista Congress of Urology

Brazil (Virtual). October 2020

Topic: Prostate Cancer Screening, Markers and Genetic Testing

Category: Prostate Cancer, Genetics


Global Men’s Health Summit

Panama (Virtual). October 2020

Topic: Early Detection, Diagnosis and Risk Stratification of Prostate Cancer

Category: Prostate Cancer


Sexual Medicine Society of North America

USA (Virtual). October 2020

Topic: Social Media in Sexual Medicine

Category: Men’s Health, Social Media


Memorial Sloan Kettering Cancer Center

NYC (Virtual). October 2020

Topic: Social Media in Prostate Cancer

Category: Prostate Cancer, Social Media


Texas A&M University College of Medicine Health & Wellness Grand Rounds

Texas (Virtual). October 2020

Topic: Online Professionalism and the Pros/Cons of Social Media for Medical Trainees and Health Professionals

Category: Social Media


Weill Cornell University Urology

NYC (Virtual). August 2020

Topic: Prostate Cancer Screening

Category: Prostate Cancer


Association for Healthcare Social Media

Pennsylvania (Virtual). August 2020

Topic: Researching Social Media

Category: Social Media


Royal Society of Medicine

UK (Virtual). June 2020

Topic: COVID-19 and Active Surveillance

Category: Prostate Cancer, COVID-19


Texas A&M Baylor, Scott & White Health Graduate Medical Education

Texas (Virtual). May 2020

Topic: Social Media

Category: Social Media


EMPIRE Lecture Series

NY (Virtual). May 2020

Topic: Social Media for Urologists

Category: Social Media


International Volunteers in Urology

Ghana (Virtual). April 2020

Topic: Virtual Visiting Professor Panel Discussion on COVID-19

Category: COVID-19


Société Internationale d’Urologie

Montreal (Virtual). April 2020

Topic: Webinar on Economic and Financial Burden of COVID-19

Category: COVID-19


Surgery in the 3rd Millenium: The Future is Female

Milan, Italy  . April 12-13, 2018

Lecture Topic: Active surveillance for prostate cancer

Category: Prostate Cancer


Cancer Research & Oncology Virtual Conference

Dr Stacy Loeb presented on “Active Surveillance: Trends in Use, Patient Selection and Monitoring”
Category: prostate cancer
Location: http://www.labroots.com/webcast/id/554


XXVII Congreso Venezolano de Urología, Congreso de Actualización en Urología Oncológica

Lecture topic: Nuevas marcardores en el cáncer de próstata (en español)

Category: prostate cancer

Location: via Skype to Venezuela


Online Lectures

Sexual Medicine Society of North America Journal Club

USA (Virtual). March 2021

Topic: Roles and Attitudes Toward Social Media Platforms Amongst Urology Trainees

Category: Social Media


NYU Department of Population Health

NYC (Virtual). March 2021

Topic: Social Media Best Practices Workshop

Category: Social Media


ASCO Genitourinary Symposium

USA (Virtual). February 2021

Topic: Moderator

Category: Prostate Cancer


Grand Rounds, Weill Cornell University Urology

NYC (Virtual). January 2021

Topic: Promise and Peril of Digital Technology in Urology

Category: Social Media


Chinese University of Hong Kong Urology Symposium

Hong Kong (Virtual). November 2020

Topic: Prostate Cancer Screening: Evidence, Guidelines and Implementation; Updates on Prostate Cancer in 2019-2020

Category: Prostate Cancer


Society of Urologic Oncology Young Urologic Oncologists Lecture Series

USA (Virtual). November 2020

Topic: Use of Social Media in Urology

Category: Social Media


21st Asia-Pacific Prostate Cancer Conference

Australia (Virtual). October 2020

Topic: Key Papers in Detection and Localized Prostate Cancer, Women in Urology and Leveraging Social Media

Category: Prostate Cancer, Social Media, Representation


Paulista Congress of Urology

Brazil (Virtual). October 2020

Topic: Prostate Cancer Screening, Markers and Genetic Testing

Category: Prostate Cancer, Genetics


Global Men’s Health Summit

Panama (Virtual). October 2020

Topic: Early Detection, Diagnosis and Risk Stratification of Prostate Cancer

Category: Prostate Cancer


Sexual Medicine Society of North America

USA (Virtual). October 2020

Topic: Social Media in Sexual Medicine

Category: Men’s Health, Social Media


Memorial Sloan Kettering Cancer Center

NYC (Virtual). October 2020

Topic: Social Media in Prostate Cancer

Category: Prostate Cancer, Social Media


Texas A&M University College of Medicine Health & Wellness Grand Rounds

Texas (Virtual). October 2020

Topic: Online Professionalism and the Pros/Cons of Social Media for Medical Trainees and Health Professionals

Category: Social Media


Weill Cornell University Urology

NYC (Virtual). August 2020

Topic: Prostate Cancer Screening

Category: Prostate Cancer


Association for Healthcare Social Media

Pennsylvania (Virtual). August 2020

Topic: Researching Social Media

Category: Social Media


Royal Society of Medicine

UK (Virtual). June 2020

Topic: COVID-19 and Active Surveillance

Category: Prostate Cancer, COVID-19


Texas A&M Baylor, Scott & White Health Graduate Medical Education

Texas (Virtual). May 2020

Topic: Social Media

Category: Social Media


EMPIRE Lecture Series

NY (Virtual). May 2020

Topic: Social Media for Urologists

Category: Social Media


International Volunteers in Urology

Ghana (Virtual). April 2020

Topic: Virtual Visiting Professor Panel Discussion on COVID-19

Category: COVID-19


Société Internationale d’Urologie

Montreal (Virtual). April 2020

Topic: Webinar on Economic and Financial Burden of COVID-19

Category: COVID-19


Surgery in the 3rd Millenium: The Future is Female

Milan, Italy  . April 12-13, 2018

Lecture Topic: Active surveillance for prostate cancer

Category: Prostate Cancer


Cancer Research & Oncology Virtual Conference

Dr Stacy Loeb presented on “Active Surveillance: Trends in Use, Patient Selection and Monitoring”
Category: prostate cancer
Location: http://www.labroots.com/webcast/id/554


XXVII Congreso Venezolano de Urología, Congreso de Actualización en Urología Oncológica

Lecture topic: Nuevas marcardores en el cáncer de próstata (en español)

Category: prostate cancer

Location: via Skype to Venezuela


Orlando - Florida

Other Awards

Other Original Articles

Exploring Variation in the Use of Conservative Management for Prostate Cancer in the Veterans Affairs Healthcare System

Loeb S, Byrne NK, Wang B, Makarov DV, Becker D, Wise DR, Lepor H, Walter D.

 “Exploring Variation in the Use of Conservative Management for Prostate Cancer in the Veterans Affairs Healthcare System.”

European Urology. 2020 Feb 22:S0302-2838(20)30101-9. PMID: 32098730.

Link: https://pubmed.ncbi.nlm.nih.gov/32098730/


Concordance and Performance of 4KScore and SelectMDx for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer

Wysock JS, Becher E, Persily J, Loeb S, Lepor H.

“Concordance and Performance of 4KScore and SelectMDx for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer.”

Urology. 2020 Apr 12:S0090-4295(20)30339-3. PMID: 32294481

Link: https://pubmed.ncbi.nlm.nih.gov/32294481/


The Association of Veterans PSA Screening Rates with Changes in USPSTF Recommendations

Becker DJ, Rude T, Walter D, Wang C, Loeb S, Li H, Ciprut S, Kelly M, Zeliadt SB, Fagerlin A, Lepor H, Sherman S, Ravenell JE, Makarov DV.

“The Association of Veterans’ PSA Screening Rates with Changes in USPSTF Recommendations.”

J Natl Cancer Inst. 2020 Aug 14:djaa120.  PMID: 32797212

Link: https://pubmed.ncbi.nlm.nih.gov/32797212/


Prostate Cancer. Nature Reviews Disease Primers

Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG.

“Prostate Cancer. Nature Reviews Disease Primers.”

2021 Feb 4;7(1):9. PMID: 33542230.

Link: https://pubmed.ncbi.nlm.nih.gov/33542230/


Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer

Loeb S. and Giri VN.

“Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer.”

Eur Urol Oncol. 2021 Feb;4(1):1-9. Epub 2020 Dec 31. PMID: 33390340

Link: https://pubmed.ncbi.nlm.nih.gov/33390340/


Prostate Cancer. Nature Reviews Disease Primers

Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG.

“Prostate Cancer. Nature Reviews Disease Primers.” 

2021 Feb 4;7(1):9. PMID: 33542230

    Link: https://pubmed.ncbi.nlm.nih.gov/33542230/


Untitled

Butler SS, Loeb S, Cole AP, Zaslowe-Dude C, Muralidhar V, Kim DW, Schaeffer EM, Trinh QD, Nguyen PL, Mahal BA.

 “United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015. Prostate Cancer Prostatic Dis.”

 2019 Oct 7 epub. PMID: 31591454.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31591454


Untitled

Fine ND, LaPolla F, Epstein M, Loeb S, Dani H.

” Genomic Classifiers for Treatment Selection in Newly Diagnosed Prostate Cancer.”

 BJU International 2019 May epub. PMID:31055874.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31055874


Untitled

Loeb S, Folkvaljon Y, Bratt O, Robinson D, Stattin P.

 “Defining Intermediate-Risk Prostate Cancer Suitable for Active Surveillance.”

 Journal of Urology. 2018 Sep 18 epub. PMID: 30240688.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30240688


Untitled

Loeb S, Curnyn C, Walter D, Fagerlin A, Siebert U, Mühlberger N, Braithwaite RS, Schwartz MD, Lepor H, Sedlander E.

 “Health state utilities among contemporary prostate cancer patients on active surveillance.”

Translational Andrology and Urology. 2018 Apr; 7(2):197-202. PMID: 29732277.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29732277


Punnen S, Freedland SJ, Polascik TJ, Loeb S, Risk MC, Savage S, Mathur SC, Uchio E, Dong Y, Silberstein JL.

” A Multi-institutional Prospective Trial in the Veterans Affairs Health System confirms the 4Kscore maintains its Predictive value among African American Men.”

Journal of Urology 2017, epub Dec 6. PMID: 29223389

Link: https://www.ncbi.nlm.nih.gov/pubmed/29223389


Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choeurng V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll PR, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL

” Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.”

Journal of Clinical Oncology. 2017 Nov 29 epub. PMID: 29185869.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29185869


Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Sedlander E.

 “Informational needs during active surveillance for prostate cancer: A qualitative study.”

Patient Education Counseling 2017 Sep 1 epub.  PMID: 28886974

Link: https://www.ncbi.nlm.nih.gov/pubmed/28886974


Loeb S, Folkvaljon Y, Damber JE, Alukal J, Lambe M, Stattin P.  

“Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.” 

Journal of Clinical Oncology 2017;35(13):1430-1436.  PMID: 28447913.

    Link: https://www.ncbi.nlm.nih.gov/pubmed/28447913


Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Sedlander E.

 “A Qualitative Study on Decision-Making by Prostate Cancer Physicians during Active Surveillance.”

BJU International. 2016 epub.  PMID: 27611479.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27611479


Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, Partin AW, Sokoll L, Chan DW, Bangma CH, van Schaik RH, Slawin KM, Marks LS, Catalona WJ.

“Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer”

BJU International. 2016 Oct 15. PMID:27743489

Link: https://www.ncbi.nlm.nih.gov/pubmed/27743489


Crawford ED, Rosenberg MT, Partin AW, Cooperberg MR, Maccini M, Loeb S, Pettaway CA, Shore ND, Arangua P, Hoenemeyer J, Leveridge M, Leapman M, Pinto P, Thompson IM Jr, Carroll P, Eastham J, Gomella L, Klein EA.

“An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care.”

Urology. 2016 Jul 19 epub. PMID: 27450937.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27450937


Loeb S, Folkvaljon Y, Robinson D, Makarov DV, Bratt O, Garmo H, and Stattin P.

“Immediate versus delayed prostatectomy: Nationwide population-based study.”

Scandinavian Journal of Urology 2016 Apr 12 epub. PMID: 27067998.

Link: http://www.ncbi.nlm.nih.gov/pubmed/27067998


Sotelo R, Mora K. E, Perez L. H, Novoa J, Castillo M, Carmona O, De Andrade R, Loeb S, and Catalona WJ.

“Assay Standardization Bias: Different Prostate Cancer Detection Rates and Clinical Outcomes Resulting From Different Assays for Free and Total Prostate-Specific Antigen (PSA).” 

Urology, June 2007; 69: 1143.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17572203


Loeb S.

“Guideline of guidelines: prostate cancer screening.”

BJU International 2014 September; 114: 323.

PMID: 24981126.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23567643


Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation.

Loeb S, Byrne N, Walter D, Makarov DV, Wise DR, Becker D, Giri VN.

“Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation.”

Cancer Treat Res Commun. 2020 Sep 28;25:100212. PMID: 33091732

Link: https://pubmed.ncbi.nlm.nih.gov/33091732/


Loeb S, Helfand BT, Kan D, Isaacs WB, and Catalona WJ.

“Does Diabetes Mellitus Modify the Association between 17q12 Risk Variant and Prostate Cancer Aggressiveness?” 

BJU International, November 2009; 104: 1200.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19627283


Helfand BT, Loeb S, Kan D, Catalona WJ.

“Number of prostate cancer risk alleles may identify possibly ‘insignificant’ disease.” 

BJU International, June 2010 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20590552

 


Helfand BT, Fought AJ, Loeb S, Meeks JJ, Kan D, and Catalona WJ.

“Genetic prostate cancer risk assessment: common variants in 9 genomic regions are associated with cumulative risk.”

Journal of Urology, August 2010; 184: 501.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20620408


Cooper PR, McGuire BB, Helfand BT, Loeb S, Hu Q, and Catalona WJ.

“Prostate Cancer Risk Alleles and Their Associations with Other Malignancies.”

Urology October 2011; 78: 970 .e 15-20.

PMID: 21820706.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3190015/


Helfand BT, Hu Q, Loeb S, McVary KT, Catalona WJ.

“Genetic Sequence Variants are Associated with Severity of Lower Urinary Tract Symptoms and Prostate Cancer Susceptibility.” 

Journal of Uroloy 2012 epub November.

PMID: 23159463.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23159463


Reinhardt D, Helfand BT, Cooper PR, Roehl KA, Catalona WJ, and Loeb S.

“Prostate Cancer Risk Alleles are Associated with Prostate Cancer Tumor Volume and Prostate Size.”

Journal of Urology 2013; epub Dec 14.

PMID: 24345439

Link: http://www.ncbi.nlm.nih.gov/pubmed/24345439


Grin B, Loeb S, Roehl K, Cooper PR, Catalona WJ, Helfand BT.

“A rare 8q24 single nucleotide polymorphism (SNP) predisposes North American men to prostate cancer and possibly more aggressive disease.”

BJU International 2014, June epub.

PMID: 24952954.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24952954


Loeb S, Peskoe SB, Joshu CE, Huang WY, Hayes RB, Carter HB, Isaacs WB, Platz EA

“Do Environmental Factors Modify the Genetic Risk of Prostate Cancer?”

Cancer Epidemiology Biomarkers Prevention 2015; 24: 213. PMID: 25342390.
Link: http://www.ncbi.nlm.nih.gov/pubmed/25342390


Bostrӧm PJ, Bjartell AS, Catto JW, Eggener SE, Lilja H, Loeb S, Schalken J, Schlomm T, and Cooperberg MR.

“Genomic Predictors of Outcome in Prostate Cancer.”

European Urology 2015 epub. PMID: 25913390.
Link: http://www.ncbi.nlm.nih.gov/pubmed/25913390

 


Borghesi M, Ahmed H, Nam R, Schaeffer E, Schiavina R, Taneja S, Weidner W, Loeb S.

Complications After Systematic, Random, and Image-guided Prostate Biopsy.”

European Urology. 2016 Aug 16 epub.  PMID: 27543165.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27543165


Loeb S, Curnyn C, Sedlander E.

“Perspectives of Prostate Cancer Patients on Gleason Scores and the New Grade Groups: Initial Qualitative Study.”

European Urology 2016 Jun 6 epub. PMID: 27283215.

Link: http://www.ncbi.nlm.nih.gov/pubmed/27283215


Loeb S, Walter D, Curnyn C, Gold HT, Lepor H, Makarov DV.

“How Active is Active Surveillance? Intensity of Follow-Up During Active Surveillance for Prostate Cancer in the United States.”

Journal of Urology 2016 Mar 2 epub. PMID: 26946161.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26946161


Other Original Articles

Thomsen FB, Folkvaljon Y, Garmo H, Robinson D, Loeb S, Ingvar C, Lambe M, Stattin P.

“Risk of malignant melanoma in men with prostate cancer. Nationwide, population-based cohort study.”

International Journal of Cancer. 2015 Dec 14 epub. PMID: 26662367

Link: http://www.ncbi.nlm.nih.gov/pubmed/26662367


Other Original Articles

Bostrӧm PJ, Bjartell AS, Catto JW, Eggener SE, Lilja H, Loeb S, Schalken J, Schlomm T, and Cooperberg MR.

“Genomic Predictors of Outcome in Prostate Cancer.”

European Urology 2015 epub. PMID: 25913390.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25913390


Other Original Articles

Loeb S, Bruinsma SM, Nicholson J, Briganti A, Pickles T, Kakehi Y, Carlsson SV, Roobol MJ.

“Active Surveillance for Prostate Cancer: A Systematic Review of Clinicopathologic Variables and Biomarkers for Risk Stratification.”

European Urology 2014 Oct epub. PMID: 25457014

Link: http://www.ncbi.nlm.nih.gov/pubmed/25457014


Other Original Articles

Loeb S, Sokoll LJ, Broyles DL, Bangma CH, van Schaik RH, Klee GG, Wei JT, Sanda MG, Partin AW, Slawin KM, Marks LS, Mizrahi IA, Shin SS, Cruz AB, Chan DW, Roberts WL, Catalona WJ.

“Prospective Multicenter Evaluation of the Beckman Coulter Prostate Health Index Using WHO Calibration.”

Journal of Urology 2012; epub November. PMID: 23206426.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23206426


Other Original Articles

Tosoian JJ, Loeb S, Feng Z, Isharwal S, Landis P, Elliot DJ, Veltri R, Epstein JI, Partin AW, Carter HB, Trock B, Sokoll LJ.

“Association of [-2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer.”

Journal of Urology 2012; 188: 1131-6. PMID: 22901577.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22901577


Other Original Articles

Nichols JH, Loeb S, Metter EJ, Ferrucci L, Carter HB.

“The Relationship Between Prostate Volume and Prostate-Specific Antigen Variability: Data from the Baltimore Longitudinal Study of Aging and the Johns Hopkins Active Surveillance Program.”

BJU International 2012; 109: 1304-8. PMID: 22093443.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22093443


Other Original Articles

Roobol MJ, van Vugt HA, Loeb S, Zhu X, Bul M, Bangma CH, van Leenders AG, Steyerberg EW, and Schroder FH.

“Prediction of Prostate Cancer Risk: The Role of Prostate Volume and Digital Rectal Examination in the ERSPC Risk Calculators.”

European Urology 2012; 61: 577-83. PMID: 22104592.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22104592


Other Original Papers

Thaxton CS, Loeb S, Roehl KA, Kan D, and Catalona WJ.

“Treatment Outcomes of Radical Prostatectomy in Potential Candidates for 3 Published Active Surveillance Programs.”

Urology, February 2010; 75: 414.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3072831/


Other Original Articles

Makarov DV, Loeb S, Magheli A, Zhao K, Humphreys E, Gonzalgo ML, Partin AW, and Han M.

“Significance of Preoperative PSA Velocity in Men with Low Serum PSA and Normal DRE.”

World Journal of Urology 2011; 29: 11.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21153643


Other Original Articles

Loeb S, Carter HB, Schaeffer EM, Kettermann A, Ferrucci L, and Metter EJ.

“Distribution of PSA Velocity by Total PSA Levels: Data from the Baltimore Longitudinal Study of Aging.”

Urology January 2011; 77: 143.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21195835


Other Original Articles

Le BV, Griffin CR, Loeb S, Carvalhal GF, Kan D, Baumann NA, and Catalona WJ.

“[-2] Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study.”

Journal of Urology 2010; 183: 1355.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20171670


Other Original Articles

Tosoian JJ, Loeb S, Kettermann A, Landis P, Elliot DJ, Epstein JI, Partin AW, Carter HB, and Sokoll LJ.

“Accuracy of PCA3 Measurement in Predicting Short-Term Biopsy Progression in an Active Surveillance Program.”

Journal of Urology, February 2010; 183: 534.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20006883


Other Original Articles

Kettermann AE, Ferrucci L, Trock BJ, Metter EJ, Loeb S and Carter HB.

“Interpretation of the prostate-specific antigen history in assessing life-threatening prostate cancer.”

BJU International 2010 epub.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928882/


Other Original Articles

Loeb S, Kan D, Yu X, Roehl KA, and Catalona WJ.

“Preoperative Prostate Specific Antigen Doubling Time is Not a Useful Predictor of Biochemical Progression After Radical Prostatectomy.”

Journal of Urology, May 2010; 183: 1816.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20303104


Other Original Articles

Loeb S, Roehl KA, Helfand BT, Kan D, and Catalona WJ.

“Can PSA Velocity Thresholds Reduce the Detection of Insignificant Prostate Cancer?”

Journal of Urology 2010; 183: 112.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140466/

 


Other Original Articles

Loeb S, Kettermann A, Carter HB, Metter EJ, Ferrucci L, and Walsh PC.

“Prostate Volume Changes Over Time: Results From the Baltimore Longitudinal Study of Aging.”

Journal of Urology 2009 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19683305


Other Original Articles

Loeb S.

“Guideline of guidelines: prostate cancer screening.”

BJU International 2014 September; 114: 323. PMID: 24981126.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23567643


Other Original Articles

Loeb S, Sutherland DE, D’Amico AV, Roehl KA, and Catalona WJ.

“PSA Velocity is Associated with Gleason Score in Radical Prostatectomy Specimen: Marker for Prostate Cancer Aggressiveness.”

Urology, June 2008 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/18571700


Other Original Articles

Bostrӧm PJ, Bjartell AS, Catto JW, Eggener SE, Lilja H, Loeb S, Schalken J, Schlomm T, and Cooperberg MR.

“Genomic Predictors of Outcome in Prostate Cancer.”

European Urology 2015 epub. PMID: 25913390.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25913390


Other Original Articles

Loeb S, Kettermann A, Ferrucci L, Landis P, Metter EJ, and Carter HB.

“PSA Doubling Time Versus PSA Velocity to Predict High-Risk Prostate Cancer: Data from the Baltimore Longitudinal Study of Aging.”

European Urology, July 2008 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/18614274


Other Original Articles

Loeb S, Peskoe SB, Joshu CE, Huang WY, Hayes RB, Carter HB, Isaacs WB, Platz EA.

“Do Environmental Factors Modify the Genetic Risk of Prostate Cancer?”

Cancer Epidemiology Biomarkers Prevention 2015; 24: 213. PMID: 25342390.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25342390


Other Original Articles

Martin NE, Chen MH, Catalona WJ, Loeb S, Roehl KA, and D’Amico AV.

“The Influence of Serial Prostate-Specific Antigen Screening on the PSA Velocity at Diagnosis.”

Cancer, 2008; 113: 717.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18615505

 


Other Original Articles

Helfand BT, Loeb S, Hu Q, Cooper PR, Roehl KA, McGuire BB, Baumann NA, Catalona WJ.

“Personalized PSA Testing Using Genetic Variants May Reduce Unnecessary Biopsies.”

Journal of Urology 2012; epub December. PMID: 23246478.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631301/


Other Original Articles

Carvalhal GF, Daudi SN, Kan D, Mondo D, Roehl KA, Loeb S, and Catalona WJ.

“Correlation Between Serum Prostate-Specific Antigen and Cancer Volume in Prostate Glands of Different Sizes.”

Urology, September 2010 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20846711


Other Original Articles

Loeb S, Kettermann A, Carter HB, Ferrucci L, Metter EJ, and Walsh PC.

“Does Prostate Growth Confound PSA Velocity: Data from the Baltimore Longitudinal Study of Aging.”

Journal of Urology, 2008; 180: 1314

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2575041/


Other Original Articles

Reinhardt D, Helfand BT, Cooper PR, Roehl KA, Catalona WJ, and Loeb S.

“Prostate Cancer Risk Alleles are Associated with Prostate Cancer Tumor Volume and Prostate Size.”

Journal of Urology 2013; epub Dec 14. PMID: 24345439

Link: http://www.ncbi.nlm.nih.gov/pubmed/24345439


Other Original Articles

Meeks JJ, Thaxton CS, Loeb S, Roehl KA, Helfand BT, and Catalona WJ.

“Comparison of PSA Velocity of Screened Versus Referred Patients with Prostate Cancer.”

Journal of Urology 2008; 179: 1340.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18289590


Other Original Articles

Loeb S, Carter HB, Walsh PC, Isaacs WB, Kettermann A, Tanaka T, Ferrucci L, and Metter EJ.

“Single Nucleotide Polymorphisms and the Likelihood of Prostate Cancer at a Given Prostate-Specific Antigen Level.”

Journal of Urology, July 2009; 182: 101.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19450841


Other Original Articles

Eggener SE, Yossepowitch O, Roehl KA, Loeb S, Yu X, and Catalona WJ.

“The Relationship of PSA Velocity to Histologic Findings in a Prostate Cancer Screening Program.”

Urology 2008; 71: 1016.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18358515


Other Original Articles

Loeb S, Carter HB, Schaeffer EM, Ferrucci L, Kettermann A, and Metter EM.

“Should Prostate-specific Antigen be Adjusted for Body Mass Index? Data From the Baltimore Longitudinal Study of Aging.”

Journal of Urology, December 2009; 182: 2646.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19836806


Other Original Articles

Helfand BT, Hu Q, Loeb S, McVary KT, Catalona WJ.

“Genetic Sequence Variants are Associated with Severity of Lower Urinary Tract Symptoms and Prostate Cancer Susceptibility.”

Journal of Uroloy 2012 epub November. PMID: 23159463.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23159463


Other Original Articles

Loeb S, Roehl KA, Yu X, Han M, and Catalona WJ.

“Use of PSAV to Follow Patients with Isolated High-Grade Prostatic Intraepithelial Neoplasia (HG-PIN) on Prostate Biopsy.”

Urology, January 2007; 69: 108.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17270629


Other Original Articles

Meeks JJ, Loeb S, Helfand BT, Kan D, Smith ND, and Catalona WJ.

“Characteristics of Prostate Cancers Detected at Prostate-Specific Antigen Levels Less than 2.5 ng/ml.”

Journal of Urology, June 2009; 181: 2515.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19371879


Other Original Articles

Cooper PR, McGuire BB, Helfand BT, Loeb S, Hu Q, and Catalona WJ.

“Prostate Cancer Risk Alleles and Their Associations with Other Malignancies.”

Urology October 2011; 78: 970 .e 15-20. PMID: 21820706.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3190015/


Other Original Articles

Loeb S, Roehl KA, Catalona WJ, and Nadler RB.

“PSA Velocity Threshold for Predicting Prostate Cancer in Young Men.”

Journal of Urology, March 2007; 177: 899.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17296371


Other Original Articles

Loeb S, Chan DW, Sokoll L, Kan D, Mikolajczyk SD, Maggiore J, Mondo DM, Griffin CR, and Catalona WJ.

“PSA Standardization Bias Could Affect Clinical Decision-making.”

Journal of Urology, November 2008 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/18801532


Other Original Articles

Helfand BT, Fought AJ, Loeb S, Meeks JJ, Kan D, and Catalona WJ.

“Genetic prostate cancer risk assessment: common variants in 9 genomic regions are associated with cumulative risk.”

Journal of Urology, August 2010; 184: 501.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20620408


Other Original Articles

Yu X, Loeb S, Han M, Suarez BK, Roehl KA, and Catalona WJ.

“The Association Between Total PSA and PSA Velocity.”

Journal of Urology, April 2007; 177: 1298.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17382716


Other Original Articles

Okotie O, Roehl KA, Han M, Loeb S, Gashti SN, and Catalona WJ.

“Characteristics of Prostate Cancer Detected by Digital Rectal Examination Only.”

Urology December 2007; 70: 1117.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18158030


Other Original Articles

Helfand BT, Loeb S, Kan D, Catalona WJ.

“Number of prostate cancer risk alleles may identify possibly ‘insignificant’ disease.”

BJU International, June 2010 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20590552


Other Original Articles

Loeb S, Yu X, Roehl KA, Nadler RB and Catalona WJ.

“PSA Velocity Thresholds in Men with Total PSA <4 ng/ml.”

Journal of Urology, December 2007; 178; 2348.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17936844


Other Original Articles

Sotelo R, Mora K. E, Perez L. H, Novoa J, Castillo M, Carmona O, De Andrade R, Loeb S, and Catalona WJ.

“Assay Standardization Bias: Different Prostate Cancer Detection Rates and Clinical Outcomes Resulting From Different Assays for Free and Total Prostate-Specific Antigen (PSA).”

Urology, June 2007; 69: 1143.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17572203


Other Original Articles

Loeb S, Roehl KA, Catalona WJ, and Nadler RB.

“Is the Utility of PSA Velocity for Prostate Cancer Detection Affected by Age?”

BJU International, April 2008; 101: 817.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18321315


Other Original Articles

Roehl KA, Eggener SE, Loeb S, Smith ND, Antenor JAV, and Catalona WJ.

“Survival Results in Screen-Detected Prostate Cancer Patients Versus Physician-Referred Patients Treated With Radical Prostatectomy: Early Results.”

Urologic Oncology: Seminars and Original Investigations, November-December 2006; 24: 465.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17138126


Other Original Articles

Loeb S, Helfand BT, Kan D, Isaacs WB, and Catalona WJ.

“Does Diabetes Mellitus Modify the Association between 17q12 Risk Variant and Prostate Cancer Aggressiveness?”

BJU International, November 2009; 104: 1200.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19627283


Other Original Articles

Yu X, Han M, Loeb S, Gashti SN, Yeh JT, Roehl KA, and Catalona WJ.

“Comparison of Different Methods for Calculating PSA Velocity: Importance of Time Interval Prior to Diagnosis of Prostate Cancer.”

Journal of Urology, December 2006; 176: 2427.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17085120


Other Original Articles

Loeb S, Gonzalez CM, Roehl KA, Han M, Antenor JV, Yap RL, and Catalona WJ.

“Pathologic Characteristics of Prostate Cancer Detected Through Prostate-Specific Antigen- Based Screening”

Journal of Urology, March 2006; 175: 902.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16469576


Other Original Articles

Loeb S, Han M, Roehl KA, Antenor JV, and Catalona WJ.

“Accuracy of Prostate Weight Estimation by Digital Rectal Exam (DRE) Versus Transrectal Ultrasonography (TRUS).”

Journal of Urology, January 2005; 173: 63-5.

Link: http://www.ncbi.nlm.nih.gov/pubmed/15592029


Other Original Articles

Nadler RB, Loeb S, Roehl KA, Antenor JV, Eggener SE, and Catalona WJ.

“Use of 2.6 ng/ml Prostate Specific Antigen (PSA) Prompt for Biopsy for Men Over Age 60”

Journal of Urology, December 2005; 174: 2154.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16280754


Other Original Articles

Donin N, Loeb S, Cooper PF, Roehl KA, Baumann NA, Catalona WJ, Helfand BT.

“Genetically-Adjusted PSA Values May Prevent Delayed Biopsies in African-American Men.”

BJU International 2014 Jan epub. PMID: 24712975

Link: http://www.ncbi.nlm.nih.gov/pubmed/24712975


Donin N, Loeb S, Cooper PF, Roehl KA, Baumann NA, Catalona WJ, Helfand BT.

“Genetically-Adjusted PSA Values May Prevent Delayed Biopsies in African-American Men.”

BJU International 2014 Jan epub.

PMID: 24712975

Link: http://www.ncbi.nlm.nih.gov/pubmed/24712975


Donin N, Loeb S, Cooper PF, Roehl KA, Baumann NA, Catalona WJ, Helfand BT.

Genetically-Adjusted PSA Values May Prevent Delayed Biopsies in African-American Men.”

BJU International 2014 Jan epub.PMID: 24712975

Link: http://www.ncbi.nlm.nih.gov/pubmed/24712975

 


Other Original Articles

Lundstrom KJ, Drevin L, Carlsson S, Garmo H, Loeb S, Stattin P, Bill-Axelson A.

“Nationwide Population-Based Study of Infections After Transrectal Ultrasound Guided Prostate Biopsy.”

Journal of Urology 2014 May epub. PMID 24813343.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24813343


Other Original Articles

Donin N, Loeb S, Cooper PF, Roehl KA, Baumann NA, Catalona WJ, Helfand BT.

“Genetically-Adjusted PSA Values May Prevent Delayed Biopsies in African-American Men.”

BJU International 2014 Jan epub. PMID: 24712975

Link: http://www.ncbi.nlm.nih.gov/pubmed/24712975


Other Original Articles

Grin B, Loeb S, Roehl K, Cooper PR, Catalona WJ, Helfand BT.

“A rare 8q24 single nucleotide polymorphism (SNP) predisposes North American men to prostate cancer and possibly more aggressive disease.”

BJU International 2014, June epub. PMID: 24952954.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24952954


Other Original Articles

Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM.

“Is repeat prostate biopsy association with a greater risk of hospitalization? Data from SEER-Medicare.”

Journal of Urology epub Oct 9, 2012. PMID: 23063634.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23063634


Loeb S.
“Germline Sequence Variants and Prostate Specific Antigen Interpretation.”

Clinical Chemistry May 2011; 57: 662-3.  PMID: 21411622.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21411622


Other Original Articles

Loeb S, Carter HB, Schaeffer EM, Ling SM, Kettermann A, Ferrucci L, and Metter EJ.

“Bone Mineral Content and Prostate Cancer Risk: Data from the Baltimore Longitudinal Study of Aging.”

BJU International, July 2010; 106: 28.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20067459


Other Original Articles

Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, Feng Z, Carter HB, and Walsh PC.

“Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.”

Journal of Clinical Oncology 2010; 28: 2810.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20439642


Other Original Articles

Loeb S, Helfand BT, Kan D, Isaacs WB, and Catalona WJ.

“Does Diabetes Mellitus Modify the Association between 17q12 Risk Variant and Prostate Cancer Aggressiveness?”

BJU International, November 2009; 104: 1200.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19627283


Helfand BT, Loeb S, Meeks JJ, Fought AJ, Kan D, and Catalona WJ.

“Pathological Outcomes Associated with the 17q Prostate Cancer Risk Variants.”

Journal of Urology, June 2009; 181: 2502.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19371897


Other Original Articles

Loeb S, Kan D, Helfand BT, Gashti SN, Nadler RB, and Catalona WJ.

“Is Statin Use Associated with Prostate Cancer Aggressiveness?”

BJU International 2009, Nov 3 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19888973


Other Original Articles

Trock BJ, Guo CC, Gonzalgo ML, Magheli A, Loeb S, and Epstein JI.

“Impact of Tertiary Gleason Patterns on Biochemical Recurrence Following Radical Prostatectomy: Proposal for a Modified Gleason Scoring.”

Journal of Urology, August 2009 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19683280


Other Original Articles

Loeb S, Epstein JI, Humphreys EB, and Walsh PC.

“Does Perineural Invasion on Prostate Biopsy Predict Adverse Prostatectomy Outcomes?”

BJU International, August 2009 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19694710


Other Original Articles

Helfand BT, Loeb S, Meeks JJ, Fought AJ, Kan D, and Catalona WJ.

“Pathological Outcomes Associated with the 17q Prostate Cancer Risk Variants.”

Journal of Urology, June 2009; 181: 2502.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19371897


Loeb S and Partin AW.

“Single Nucleotide Polymorphisms and Prostate Cancer Susceptibility.”

Reviews in Urology, Fall 2008; 10: 304.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2615108/

 


Helfand BT, Loeb S, Cashy J, Meeks JJ, Thaxton CS, Han M, and Catalona WJ.

“Tumor Characteristics of Carriers and Noncarriers of the deCODE 8q24 Prostate Cancer Susceptibility Alleles.”

Journal of Urology, June 2008; 179: 2197.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18423739


Other Original Papers

Loeb S, Curnyn C, Walter D, Fagerlin A, Siebert U, Mühlberger N, Braithwaite RS, Schwartz MD, Lepor H, Sedlander E.

“Health state utilities among contemporary prostate cancer patients on active surveillance.”

Translational Andrology and Urology. 2018 Apr; 7(2):197-202. PMID: 29732277.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29732277


Other Original Papers

Griffin C, Yu X, Loeb S, Desireddi VN, Han M, and Catalona WJ.

“Pathologic Features after Radical Prostatectomy for Potential Candidates for Active Monitoring.”

Journal of Urology, September 2007; 178: 860.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17631347


Other Original Papers

Tosoian JJ, Loeb S, Kettermann A, Landis P, Elliot DJ, Epstein JI, Partin AW, Carter HB, and Sokoll LJ.

“Accuracy of PCA3 Measurement in Predicting Short-Term Biopsy Progression in an Active Surveillance Program.”

Journal of Urology, February 2010; 183: 534.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20006883


Other Original Papers

O’Brien D, Loeb S, Carvalhal GF, McGuire BB, Kan D, Hofer MD, Casey JT, Helfand BT, and Catalona WJ.

“Delay of Surgery in Men with Low Risk Prostate Cancer.”

Journal of Urology June 2011; 185: 2143. PMID: 21496847.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21496847


Other Papers

An Evaluation of the Readability and Content-Quality of Pelvic Organ Prolapse YouTube Transcripts

Herbert AS, Nemirovsky A, Hess DS, Walter D, Abraham NE, Loeb S, Malik RD.

“An Evaluation of the Readability and Content-Quality of Pelvic Organ Prolapse YouTube Transcripts.”

Urology. 2021; S0090-4295(21)00266-1. PMID: 33775787

Link: https://pubmed.ncbi.nlm.nih.gov/33775787/


Guidelines Office Dissemination Committee. A Systematic Review of the Use of Social Media for Dissemination of Clinical Practice Guidelines

Bhatt NR, Czarniecki SW, Borgmann H, van Oort IM, Esperto F, Pradere B, van Gurp M, Bloemberg J, Darraugh J, Rouprêt M, Loeb S, N’Dow J, Ribal MJ, Giannarini G; EAU

“Guidelines Office Dissemination Committee. A Systematic Review of the Use of Social Media for Dissemination of Clinical Practice Guidelines.”

Eur Urol Focus. 2020 Nov 7:S2405-4569(20)30292-3. PMID: 33172773

Link: https://pubmed.ncbi.nlm.nih.gov/33172773/


Quality of Bladder Cancer Information on YouTube

Loeb S, Reines K, Abu-Salha Y, French W, Butaney M, Macaluso JN Jr, Steinberg GD, Walter D, Byrne N, la Garza D, Smith AB.

“Quality of Bladder Cancer Information on YouTube.”

Eur Urol. 2020 Sep 30: S0302-2838(20)30706-5. PMID: 33010986

Link: https://pubmed.ncbi.nlm.nih.gov/33010986/


Global Survey of the Roles and Attitudes Toward Social Media Platforms Amongst Urology Trainees

Dubin JM, Greer AB, Patel P, Carrion DM, Paesano N, Kettache RH, Haffaf M, Zouari S, Santillan D, Zotter Z, Chung A, Horie S, Koo KC, Teoh JY, Autrán Gómez AM, Ramasamy R, Loeb S, Rivas JG.

“Global Survey of the Roles and Attitudes Toward Social Media Platforms Amongst Urology Trainees.”

Urology. 2020 Sep 18:S0090-4295(20)31139-0. PMID: 32950594

Link: https://pubmed.ncbi.nlm.nih.gov/32950594/


Social Media Coverage of Scientific Articles Immediately After Publication Predicts Subsequent Citations- #SoMe_Impact Score: Observational Analysis

Sathianathen NJ, Lane Iii R, Murphy DG, Loeb S, Bakker C, Lamb AD, Weight CJ.

“Social Media Coverage of Scientific Articles Immediately After Publication Predicts Subsequent Citations- #SoMe_Impact Score: Observational Analysis.”

Journal of Medical Internet Research. 2020 Apr 17;22(4):e12288. PMID: 32301733

Link: https://pubmed.ncbi.nlm.nih.gov/32301733/


#ILookLikeAUrologist: Using Twitter to Discuss Diversity and Inclusion in Urology

Loeb S, Byrne NK, Thakker S, Walter D, Katz MS.

“#ILookLikeAUrologist: Using Twitter to Discuss Diversity and Inclusion in Urology.”

European Urology Focus. 2020 Apr 12:S2405-4569(20)30093-6. PMID: 32295754

Link: https://pubmed.ncbi.nlm.nih.gov/32295754/


Racial Disparities and Online Health Information: YouTube and Prostate Cancer Clinical Trials

Borno HT, Zhang S, Bakke B, Bell A, Zuniga KB, Li P, Chao K, Sabol A, Killeen T, Hong H, Walter D, Loeb S.

“Racial Disparities and Online Health Information: YouTube and Prostate Cancer Clinical Trials.”

British Journal of Urology International. 2020 Apr 10 epub. PMID: 32275800

Link: https://pubmed.ncbi.nlm.nih.gov/32275800/


Fake News about Benign Prostate Hyperplasia on YouTube

Loeb S.

“Fake News about Benign Prostate Hyperplasia on YouTube.”

British Journal of Urology International. 2020 Apr;125(4):477-478. PMID: 32250050

Link: https://pubmed.ncbi.nlm.nih.gov/32250050/


Global Survey Evaluating Drawbacks of Social Media Usage for Practicing Urologists

Dubin JM, Greer AB, Patel P, Carrion DM, Paesano N, Kettache RH, Haffaf M, Zouari S, Santillan D, Zotter Z, Chung A, Horie S, Koo KC, Teoh JYC, Autrán Gómez AM, Gomez Rivas J, Ramasamy R, Loeb S.

“Global Survey Evaluating Drawbacks of Social Media Usage for Practicing Urologists.”

BJU International. 2020 Mar 9 epub. PMID: 32147930.

Link: https://pubmed.ncbi.nlm.nih.gov/32147930/


Evaluating and Optimizing the Use of Social Media in Urology

Loeb S, Murphy DG.

“Evaluating and Optimizing the Use of Social Media in Urology.”

European Urology Focus. 2020 May 15;6(3):425-426. Epub 2020 Feb 29. PMID: 32127328.

Link: https://pubmed.ncbi.nlm.nih.gov/32127328/


Pelvic Organ Prolapse on YouTube: Evaluation of Consumer Information

Herbert AS, Nemirovsky A, Hess DS, Walter D, Abraham NE, Loeb S, Malik RD.

“Pelvic Organ Prolapse on YouTube: Evaluation of Consumer Information.”

British Journal of Urology International 2020 Feb 10 epub.  PMID: 32039554.

Link: https://pubmed.ncbi.nlm.nih.gov/32039554/


Using data from an online health community to examine the impact of prostate cancer on sleep

Robbins R, Jean-Louis G, Chanko N, Combs P, Byrne N, Loeb S.

“Using data from an online health community to examine the impact of prostate cancer on sleep.”

British Journal of Urology International. 2020 Jan 3 epub.  PMID: 31899938.

Link: https://pubmed.ncbi.nlm.nih.gov/31899938/


Using data from an online health community to examine the impact of prostate cancer on sleep.

Robbins R, Jean-Louis G, Chanko N, Combs P, Byrne N, Loeb S.

“Using data from an online health community to examine the impact of prostate cancer on sleep.”

British Journal of Urology International. 2020 Jan 3 epub.  PMID: 31899938.

Link: https://pubmed.ncbi.nlm.nih.gov/31899938/


Prostate Cancer. Nature Reviews Disease Primers

Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG.

“Prostate Cancer. Nature Reviews Disease Primers.”

2021 Feb 4;7(1):9. PMID: 33542230.

Link: https://pubmed.ncbi.nlm.nih.gov/33542230/


Racial Disparities and Online Health Information: YouTube and Prostate Cancer Clinical Trials

Borno HT, Zhang S, Bakke B, Bell A, Zuniga KB, Li P, Chao K, Sabol A, Killeen T, Hong H, Walter D, Loeb S.

“Racial Disparities and Online Health Information: YouTube and Prostate Cancer Clinical Trials.”

British Journal of Urology International. 2020 Apr 10 epub. PMID: 32275800.

Link: https://pubmed.ncbi.nlm.nih.gov/32275800/


A Clinical Reminder Order Check Intervention to Improve Guideline-concordant Imaging Practices for Men With Prostate Cancer: A Pilot Study

Ciprut SE, Kelly MD, Walter D, Hoffman R, Becker DJ, Loeb S, Sedlander E, Tenner CT, Sherman SE, Zeliadt SB, Makarov DV.

“A Clinical Reminder Order Check Intervention to Improve Guideline-concordant Imaging Practices for Men With Prostate Cancer: A Pilot Study.”

Urology. 2020 Nov;145:113-119. Epub 2020 Jul 25.PMID: 32721517.

Link: https://pubmed.ncbi.nlm.nih.gov/32721517/


Loeb S, Taylor J, Borin JF, Mihalcea R, Perez-Rosas V, Byrne N, Chiang AL, Langford A.

“Fake News: Spread of Misinformation about Urological Conditions on Social Media.”

European Urology Focus. 2019 Dec 21 epub.  PMID: 31874796.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31874796


Untitled

Loeb S, Salter CA, Nelson CJ, Mulhall JP, Wittmann D.

“A Call to Arms: Increasing Our Understanding of the Impact of Prostate Cancer on the Sexual Health of Partners.”

Journal of Sexual Medicine. 2019 Dec 10 epub. PMID: 31836299.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31836299


Untitled

Thangasamy IA, Loeb S, Sathianathen NJ, Leveridge M, Stork B, Davies BJ, Woo HH.

“Evaluating the Effectiveness of an Online Journal Club: Experience from the International Urology Journal Club.”

European Urology Focus. 2019 Oct 31 epub.PMID:31679867.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31679867


Untitled

Taylor J, Loeb S.

“Guideline of guidelines: social media in urology.”

British Journal of Urology International. 2019 Oct 20 epub. PMID: 31631471.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31631471


Untitled

Chandrasekar T, Goldberg H, Klaassen Z, Wallis CJD, Leong JY, Liem S, Teplitsky S, Noorani R, Loeb S.

“Twitter and academic Urology in the United States and Canada: a comprehensive assessment of the Twitterverse in 2019.”

British Journal of Urology International. 2019 Oct 10 epub. PMID: 31602782.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31602782


Untitled

Langford AT, Roberts T, Gupta J, Orellana KT, Loeb S.

“Impact of the Internet on Patient-Physician Communication.”

Eur Urol Focus. 2019 Sep 30 epub. PMID: 31582312.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31582312


Untitled

Teoh JY, Mackenzie G, Smith M, Yuen SK, Gudaru K, Leow J, Leung CH, Ng CF, Loeb S.

“Understanding the Composition of a Successful Tweet in Urology.”

Eur Urol Focus. 2019 Aug 27 epub. PMID:31471219.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31471219


Untitled

Loeb S, Carrick T, Frey C, Titus T.

“Increasing Social Media Use in Urology: 2017 American Urological Association Survey.”

European Urology Focus. 2019 Jul 24 epub. PMID: 31351900

Link: https://www.ncbi.nlm.nih.gov/pubmed/31351900

 


Untitled

Loeb S, Cazzaniga W, Robinson D, Garmo H, Stattin P.

“Opioid Use After Radical Prostatectomy: Nationwide, Population-Based Study in Sweden.”

J Urol. 2019 Jul 17 epub. PMID:31584849

Link: https://www.ncbi.nlm.nih.gov/pubmed/31584849


Untitled

Stork B, Loeb S.

“The Urology Care Foundation – trusted online resources in an era of misinformation.”

Nature Reviews Urology 2019 Jul 12 epub. PMID: 31300752

Link: https://www.ncbi.nlm.nih.gov/pubmed/31300752

 


Untitled

Loeb S, Katz MS, Stork B.

“Update on the Urology Tag Ontology: Standardized Hashtags for Social Media in Urology.”

Eur Urol. 2019 Jun epub. PMID: 31164252

Link: https://www.ncbi.nlm.nih.gov/pubmed/31164252


Untitled

Langford A, Loeb S.

“Perceived Patient-Provider Communication Quality and Sociodemographic Factors Associated With Watching Health-Related Videos on YouTube: A Cross-Sectional Analysis.”

J Med Internet Res. 2019 May 17;21(5):e13512. PMID:31102372.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31102372


Untitled

Becker DJ, Iyengar AD, Punekar SR, Ng J, Zaman A, Loeb S, Becker KD, Makarov D.

“Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression. “

Anticancer Res.2019 May;39(5):2467-2473. PMID: 31092441.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31092441


Untitled

Ke Y, Taylor J, Gao L, Wang H, Zhao H, Byrne N, Modgil V, Butaney M, Makarov DV, Prabhu V, Loeb S.

“Twitter response to the 2018 US Preventive Services Task Force guidelines on prostate cancer screening.”

BJU International 2019 Feb 27 epub. PMID: 30811805

Link: https://www.ncbi.nlm.nih.gov/pubmed/30811805


Untitled

Drangsholt S, Walter D, Ciprut S, Lepor A, Sedlander E, Curnyn C, Loeb S, Malloy P, Winn AN, Makarov DV.

” Quantifying downstream impact of inappropriate staging imaging in a cohort of veterans with low- and intermediate-risk incident prostate cancer.”

Urologic Oncology 2019 Feb;37(2):145-149. PMID: 30578160.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30578160


Untitled

Loeb S, Taylor J, Butaney M, Byrne NK, Gao L, Soule HR, Miyahira AK.

“Twitter-based Prostate Cancer Journal Club (#ProstateJC) Promotes Multidisciplinary Global Scientific Discussion and Research Dissemination.”

European Urology 2019 Jan 30 epub. PMID: 30711329.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30711329

 


Borgmann H, Cooperberg M, Murphy D, Loeb S, N’Dow J, Ribal MJ, Woo H, Rouprêt M, Winterbottom A, Wijburg C, Wirth M, Catto J, Kutikov A

 “Online Professionalism-2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media”

European Urology 2018 Aug epub..  PMID: 30177286.

    Link: https://www.ncbi.nlm.nih.gov/pubmed/30177286


Untitled

Stattin P, Sandin F, Loeb S, Robinson D, Lissbrant IF, Lambe M.

“Public online reporting from a nationwide population-based clinical prostate cancer register.”

BJU International 2018 Jul; 122(1):8-10. PMID: 29577561.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29577561/a>


Untitled

Stattin P, Sandin F, Loeb S, Robinson D, Lissbrant IF, Lambe M.

” Public online reporting from a nationwide population-based clinical prostate cancer register”

BJU International 2018 Jul; 122(1):8-10. PMID: 29577561.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29577561


Stattin P, Sandin F, Loeb S, Robinson D, Lissbrant IF, Lambe M. .

 “Public online reporting from a nationwide population-based clinical prostate cancer register. “

BJU International 2018 Jul; 122(1):8-10. PMID: 29577561.

    Link: https://www.ncbi.nlm.nih.gov/pubmed/29577561


Loeb S, Taneja S, Walter D, Zweifach S, Byrne N.

“Crowd-Funding for Prostate Cancer and Breast Cancer. “

BJU International. 2018 May 22. PMID: 29786946

Link: https://www.ncbi.nlm.nih.gov/pubmed/29786946


Untitled

Loeb S, Katz MS, Langford A, Byrne N, Ciprut S.

“Prostate Cancer and Social Media.”

Nature Reviews Urology 2018 Apr 11. PMID: 29643501.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29643501

 


Loeb S, Katz MS, Langford A, Byrne N, Ciprut S.

 “Prostate Cancer and Social Media.”

Nature Reviews Urology 2018 Apr 11. PMID: 29643501.

    Link: https://www.ncbi.nlm.nih.gov/pubmed/29643501


Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choeurng V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll PR, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL.

“Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.”

 Journal of Clinical Oncology. 2017 Nov 29 epub. PMID: 29185869.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29185869


Ciprut S, Curnyn C, Davuluri M, Sternberg K, Loeb S.

 “Twitter Activity Associated with US News and World Report Reputation Scores for Urology Departments.”

 Urology. 2017 Jun 29 epub.  PMID: 28669746.

    Link: https://www.ncbi.nlm.nih.gov/pubmed/28669746


Sternberg KM, Loeb SL, Canes D, Donnelly L, Tsai MH.

“The use of Twitter to facilitate sharing of clinical expertise in urology.”

J Am Med Inform Assoc. 2017 epub Jun 7. PMID: 28591771.

 Link: https://www.ncbi.nlm.nih.gov/pubmed/28591771


Loeb S, Stork B, Gold HT, Stout NK, Makarov DV, Weight C, Borgmann H.

“Tweet this: how advocacy for breast and prostate cancers stacks up on social media.”

BJU International 2017 May epub.  PMID: 28471484

    Link: http://www.ncbi.nlm.nih.gov/pubmed/2847148


O’Connor EM, Nason GJ, O’Kelly F, Manecksha RP, Loeb S.

“Newsworthiness vs scientific impact: are the most highly cited urology papers the most widely disseminated in the media?”

BJU International 2017 Apr 18 epub.  PMID: 28418091

    Link: https://www.ncbi.nlm.nih.gov/pubmed/28418091


Loeb S, Meyer C, Krasnova A, Curnyn C, Reznor G, Lepor H, Kibel AS, Trinh QD.

“Risk of Small Bowel Obstruction After Robot-Assisted Versus Open Radical Prostatectomy.”

Journal of Endourology  2016 Sep 11 epub.  PMID: 27615204

Link: https://www.ncbi.nlm.nih.gov/pubmed/27615204


Thomsen FB, Folkvaljon Y, Brasso K, Loeb S, Robinson D, Egevad L, Stattin P.

Prognostic implications of 2005 Gleason grade modification. Population-based study of biochemical recurrence following radical prostatectomy.”

Journal of Surgical Oncology. 2016 Aug 11 epub. PMID: 27511833.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27511833


Adam M, Tennstedt P, Lanwehr D, Tilki D, Steuber T, Beyer B, Thederan I, Heinzer H, Haese A, Salomon G, Budäus L, Michl U, Pehrke D, Stattin P, Bernard J, Klaus B, Pompe RS, Petersen C, Huland H, Graefen M, Schwarz R, Huber W, Loeb S, Schlomm T.

“Functional Outcomes and Quality of Life After Radical Prostatectomy Only Versus a Combination of Prostatectomy with Radiation and Hormonal Therapy. European Urology.”

2016 Nov 22. PMID: 27887941

Link: https://www.ncbi.nlm.nih.gov/pubmed/27887941


Borghmann H, Loeb S, Salem J, Thomas C, Haferkamp A, Murphy DG, Tsaur I.

“Activity, content, contributors, and influencers of the twitter discussion on urologic oncology.”

Urologic Oncology 2016 epub. PMID: 27036217.

Link: http://www.ncbi.nlm.nih.gov/pubmed/27036217


Mata DA, Tilak G, Loeb S, Ramasamy R.

“Curating a Digital Identity: What Urologists Need to Know About Social Media.”

Urology 2016 Jul 6 epub. PMID: 27395795.

Link: http://www.ncbi.nlm.nih.gov/pubmed/27395795


Björklund J, Folkvaljon Y, Cole A, Carlsson S, Robinson D, Loeb S, Stattin P, Akre O.  

“Ninety-Day Postoperative Mortality after Robot-assisted Laparoscopic Prostatectomy and Retropubic Radical Prostatectomy. Nation-wide population-based study.”  

BJU International 2016 Jan 13 epub.  PMID: 26762928

Link: http://www.ncbi.nlm.nih.gov/pubmed/26762928


Loeb S, Folkvaljon Y, Robinson D, Makarov DV, Bratt O, Garmo H, and Stattin P.

“Immediate versus delayed prostatectomy: Nationwide population-based study.”

Scandinavian Journal of Urology 2016 Apr 12 epub. PMID: 27067998

Link: http://www.ncbi.nlm.nih.gov/pubmed/27067998


Men Health

  • Loeb S, Folkvaljon Y, Damber JE, Alukal J, Lambe M, Stattin P

     

    “Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.”

    Journal of Clinical Oncology 2017;35(13):1430-1436. PMID: 28447913.

    Link: https://www.ncbi.nlm.nih.gov/pubmed/28447913

    The relationship between testosterone replacement therapy and prostate cancer risk is controversial. We found no association between testosterone therapy and overall prostate cancer risk. Long-term testosterone therapy was associated with a significantly reduced risk of aggressive prostate cancer.

     

  • Loeb S, Folkvaljon Y, Lambe M, Robinson D, Garmo H, Ingvar C, Stattin P.

     

    Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.”

     

    JAMA 2015; 313: 2449-55. PMID: 26103029.

     

    Link: http://www.ncbi.nlm.nih.gov/pubmed/26103029

     

    A recent study suggested a possible link between phosphodiesterase inhibitors used for erectile dysfunction and risk of malignant melanoma. Through a large collaboration with the national registries of Sweden, we performed a large study that raised questions about a causal relationship including lack of a dose-response relationship. Instead, the observed association between erectile dysfunction drugs and melanoma likely reflects shared risk factors including lifestyle and socioeconomic status.

     

  • Loeb S, Folkvaljon Y, Robinson D, Schlomm T, Garmo H, Stattin P.

    “Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.

     

    European Urology. 2015 Dec 29 epub. PMID: 26743040

     

    Link: http://www.ncbi.nlm.nih.gov/pubmed/26743040

     

    A previous study from Germany reported a significantly increased risk of prostate cancer recurrence in men taking phosphodiesterase type 5 (PDE5) inhibitors after radical prostatectomy, which was subsequently refuted in an Italian study. We followed up on this issue using nationwide Swedish registry data, and confirmed that there is no association between PDE5 inhibitors with prostate cancer recurrence after treatment.

     


Loeb S, Folkvaljon Y, Robinson D, Lissbrant IF, Egevad L, Stattin P.

“Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort.” 

European Urology. 2015 Dec 17 epub. PMID: 26707871

Link: http://www.ncbi.nlm.nih.gov/pubmed/26707871


Danneman D, Drevin L, Delahunt B, Samaratunga H, Robinson D, Bratt O, Loeb S, Stattin P, Egevad L.

“The Accuracy of Prostate Biopsies for Predicting Gleason Score in Radical Prostatectomy Specimens. Nationwide trends 2000-2012.”

BJU International. 2016 Feb 25 epub. PMID:26918298.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26918298


Borgmann H, Woelm JH, Merseburger A, Nestler T, Salem J, Brandt MP, Haferkamp A, Loeb S.

Qualitative Twitter analysis of participants, tweet strategies, and tweet content at a major urologic conference.”  

Canadian Urological Association Journal 2016 Jan-Feb;10(1-2):39-44. PMID: 26977205.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26977205


Sun M, Choueiri TK, Hamnvik OR, Preston MA, De Velasco G, Jiang W, Loeb S, Nguyen PL, Trinh QD.

“Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.”  

JAMA Oncology 2015 Dec 23:1-8 epub. PMID: 26720632

Link: http://www.ncbi.nlm.nih.gov/pubmed/26720632


Borgmann H, DeWitt S, Tsaur I, Haferkamp A, Loeb S.

 “Novel survey disseminated through Twitter supports its utility for networking, disseminating research, advocacy, clinical practice and other professional goals.”

 Canadian Urological Association Journal. 2015 Sep-Oct;9(9-10):E713-7. Epub 2015 Oct 13. PMID: 26664662

Link: http://www.ncbi.nlm.nih.gov/pubmed/26664662


Other Papers

Loeb S. Editorial Comment on

“Digital Identity: Develop One Before You’re Given One”

Urology 2015; 85: 1222. PMID: 26099864.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26099864


Other Papers

Banks JA, McGuire BB, Loeb S, Shrestha S, Helfand BT, Catalona WJ.

“Bacteriuria and antibiotic resistance in catheter urine specimens following radical prostatectomy.”

Urologic Oncology 2012, epub Jan 25. PMID: 22285005.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22285005


Other Papers

Loeb S, Schaeffer EM, Chan DW, Carter HB, Walsh PC, and Sokoll LJ.

“Investigation of Human Anti-Mouse Antibodies As Potential Cause of Postprostatectomy PSA Elevation.”

Urology, May 2009; 73: 947.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19394489


Other Papers

Loeb S, Roehl KA, Viprikasit DP, and Catalona WJ.

“Long-Term Rates of Undetectable PSA with Initial Observation and Delayed Salvage Radiotherapy after Radical Prostatectomy.”

European Urology, July 2008; 54: 88.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18400368


Other Papers

Bratt O, Folkvaljon Y, Loeb S, Klotz L, Egevad L, Stattin P.

“Upper Limit of Cancer Extent on Biopsy Defining Very Low Risk Prostate Cancer.”

BJU International 2014, July epub. PMID: 25053197.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25053197


Other Papers

Ohmann EL, Loeb S, Robinson D, Bill-Axelson A, Berglund A, and Stattin P.

“Nationwide Population-Based Study of Prostate Cancer Stage Migration Between and Within Clinical Risk Categories.”

Scandinavian Journal of Urology 2014 March epub. PMID: 24581522

Link: http://www.ncbi.nlm.nih.gov/pubmed/24611795


Other Papers

McGuire BB, Helfand BT, Loeb S, Hu Q, O’Brien D, Cooper P, Yang X, and Catalona WJ.

“Outcomes in Patients with Gleason Score 8-10 Prostate Cancer: Relation to Preoperative PSA Level.”

BJU International June 2012; 109: 1764-9. PMID: 22017732.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22017732


Other Papers

Loeb S, Carvalhal GF, Kan D, Desai A, and Catalona WJ.

“External Validation of the Cancer of the Prostate Risk Assessment (CAPRA) Score in a Single-Surgeon Radical Prostatectomy Series.”

Urologic Oncology: Seminars and Original Investigations, September 2010 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20822930


Other Papers

Loeb S, Schaeffer EM, Trock BJ, Humphreys EB, Epstein JI, and Walsh PC.

“What are the Outcomes of Radical Prostatectomy for High-Risk Prostate Cancer?”

Urology 2009, Nov 19 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19931898


Other Papers

Helfand BT, Mongiu AK, Kan D, Kim DY, Loeb S, Roehl KA, Meeks JJ, Smith ND, and Catalona WJ.

“Outcomes of Radical Prostatectomy for Patients with Clinical Stage T1a and T1b Disease.”

BJU International, February 2009 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/19239451


Other Papers

Loeb S, Hernandez DH, Mangold LA, Humphreys EB, Agro M, Walsh PC, Partin AW, and Han M.

“Progression after Radical Prostatectomy for Men in their Thirties Compared to Older Men.”

BJU International, June 2008; 101: 1503.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18341626


Other Papers

Loeb S, Roehl KA, Thaxton CS, and Catalona WJ.

“Combined Prostate-Specific Antigen Density and Biopsy Features to Predict ‘Clinically Insignificant’ Prostate Cancer.”

Urology, July 2008; 72: 143.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18436287

 


Other Papers

Loeb S, Yu X, Nadler RB, Roehl KA, Han M, Hawkins SA, and Catalona WJ.

“Does Body Mass Index Affect Outcomes Following Radical Prostatectomy?”

Journal of Urology, January 2007; 177: 102.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17162013


Other Papers

Graif T, Yu Y, Loeb S, Gashti SN, Griffin S, Han M, Roehl KA, Suarez BK, and Catalona WJ.

“Underdiagnosis and Overdiagnosis of Prostate Cancer.”

Journal of Urology 2007; 178: 88.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17499308


Other Papers

Okotie O, Roehl KA, Han M, Loeb S, Gashti SN, and Catalona WJ.

“Characteristics of Prostate Cancer Detected by Digital Rectal Examination Only.”

Urology 2007; 70: 1117.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18158030


Other Papers

Loeb S, Gonzalez CM, Roehl KA, Han M, Antenor JV, Yap RL, and Catalona WJ.

“Pathologic Characteristics of Prostate Cancer Detected Through Prostate-Specific Antigen- Based Screening”

Journal of Urology, March 2006; 175: 902.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16469576


Other Papers

Loeb S, Yu X, Roehl KA, Antenor JV, Han M, and Catalona WJ.

“Lymphovascular Invasion in Radical Prostatectomy Specimens: Prediction of Adverse Pathology and Biochemical Progression”

Urology, July 2006; 68: 99.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16806410


Other Papers

Borgmann H, Wölm JH, Vallo S, Mager R, Huber J, Breyer J, Salem J, Loeb S, Haferkamp A, Tsaur I.

“Prostate Cancer on the Web- Expedient Tool for Patients’ Decision-Making?”

Journal of Cancer Education 2015 epub Aug 4. PMID: 26234650.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26234650


Other Papers

Loeb S.

“Social media makes global urology meetings truly global.”

BJU International 2015 Feb; 115(2):175. PMID: 25604713

Link: http://www.ncbi.nlm.nih.gov/pubmed/25604713


Prabhu V, Lee T, Loeb S, Holmes JH, Gold HT, Lepor H, Penson DF, and Makarov DV.

“Twitter Response to the United States Preventive Services Task Force Recommendations Against Screening with Prostate Specific Antigen.” 

BJU International 2014 epub.

PMID: 24661474

Link: http://www.ncbi.nlm.nih.gov/pubmed/24661474

 


Other Papers

Bayne CE, Murphy DG, Loeb S.

“#Urology is Trending in Social Media.”

Reviews in Urology 2014; 16: 152. PMID: 25337049.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191639/


Other Papers

Carlsson S, Drevin L, Loeb S, Widmark A, Frank Lissbrant I, Robinson D, Johansson E, Stattin P, and Fransson P.

“Population-based study of long-term functional outcomes after prostate cancer treatment.”

BJU International 2014 epub. PMID: 25959859.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25959859


Loeb S, Folkvaljon Y, Makarov DV, Bratt O, Bill-Axelson A, Stattin P.

“Five-Year Nationwide Follow-up Study of Active Surveillance for Prostate Cancer.”

Eur Urol 2014, June epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24993868


Other Papers

Loeb S, Catto J, Kutikov A.

“Social Media Offers Unprecedented Opportunities for Vibrant Exchange of Professional Ideas Across Continents.”

European Urology 2014 March epub. PMID 24630683

Link: http://www.ncbi.nlm.nih.gov/pubmed/24630683


Other Original Papers

Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R.

“Overdiagnosis and Overtreatment of Prostate Cancer.”

European Urology 2014; epub Jan 9. PMID: 24439788

Link: http://www.ncbi.nlm.nih.gov/pubmed/24439788


Use of Social Media in Urology: Data from the American Urological Association

Loeb S, Bayne CE, Frey C, Davies BJ, Averch TD, Woo HH, Stork B, Cooperberg MR, Eggener SE.

“Use of Social Media in Urology: Data from the American Urological Association.”

British Journal of Urology International 2013 epub Nov 26. PMID: 24274744

Link: http://www.ncbi.nlm.nih.gov/pubmed/24274744


Other Papers

Vellekoop A, Loeb S, Folkvaljon Y, Stattin P.

“Population-Based Study of Predictors for Adverse Pathology Among Candidates for Active Surveillance With Gleason 6 Prostate Cancer.”

Journal of Urology 2013 epub September 23.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24071481


Other Original Papers

Vellekoop A, Loeb S, Folkvaljon Y, Stattin P.

“Population-Based Study of Predictors for Adverse Pathology Among Candidates for Active Surveillance With Gleason 6 Prostate Cancer.”

Journal of Urology 2013 epub September 23.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24071481


Other Papers

McGuire BB, Helfand BT, Loeb S, Hu Q, O’Brien D, Cooper P, Yang X, and Catalona WJ.

“Outcomes in Patients with Gleason Score 8-10 Prostate Cancer: Relation to Preoperative PSA Level.”

BJU International June 2012; 109: 1764-9. PMID: 22017732.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22017732


Other Papers

O’Brien D, Loeb S, Carvalhal GF, McGuire BB, Kan D, Hofer MD, Casey JT, Helfand BT, and Catalona WJ.

“Delay of Surgery in Men with Low Risk Prostate Cancer.”

Journal of Urology 2011; 185: 2143. PMID: 21496847.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21496847


Other Papers

Carvalhal GF, Griffin CR, Kan D, Loeb S, and Catalona WJ.

“Reducing Blood Loss in Open Radical Retropubic Prostatectomy with Prophylactic Periprostatic Sutures.”

BJU International 2010; 105: 1222.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19888968


Other Papers

Loeb S, Epstein JI, Ross AE, Schultz L, Humphreys EB, and Jarow JP.

“Benign Prostate Glands at the Bladder Neck Margin in Robotic vs. Open Radical Prostatectomy.”

BJU International 2010; 104: 1446

Link: http://www.ncbi.nlm.nih.gov/pubmed/20346031


Other Papers

Makarov DV, Loeb S, Landman AB, Nielsen ME, Gross CP, Leslie DL, Penson DF, and Desai RA.

“Regional Variation in Total Cost per Radical Prostatectomy in the Heathcare Cost and Utilization Project Nationwide Inpatient Sample Database.”

Journal of Urology 2010; 183: 1504.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20172559


Other Papers

Thaxton CS, Loeb S, Roehl KA, Kan D, and Catalona WJ.

“Treatment Outcomes of Radical Prostatectomy in Potential Candidates for 3 Published Active Surveillance Programs.”

Urology 2010; 75: 414.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3072831/


Other Papers

Loeb S, Carvalhal GF, Kan D, Desai A, and Catalona WJ.

“External Validation of the Cancer of the Prostate Risk Assessment (CAPRA) Score in a Single-Surgeon Radical Prostatectomy Series.”

Urologic Oncology: Seminars and Original Investigations, September 2010 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20822930


Other Papers

Helfand BT, Mongiu AK, Kan D, Kim DY, Loeb S, Roehl KA, Meeks JJ, Smith ND, and Catalona WJ.

“Outcomes of Radical Prostatectomy for Patients with Clinical Stage T1a and T1b Disease.”

BJU International 2009 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/19239451


Other Papers

Loeb S, Epstein JI, Humphreys EB, and Walsh PC.

“Does Perineural Invasion on Prostate Biopsy Predict Adverse Prostatectomy Outcomes?”

BJU International, August 2009 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19694710


Other Papers

Trock BJ, Guo CC, Gonzalgo ML, Magheli A, Loeb S, and Epstein JI.

“Impact of Tertiary Gleason Patterns on Biochemical Recurrence Following Radical Prostatectomy: Proposal for a Modified Gleason Scoring.”

Journal of Urology, August 2009 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19683280


Other Papers

Nguyen PL, Chen MH, Catalona WJ, Alexander BM, Roehl KA, Loeb S, and D’Amico AV.

“Biochemical Recurrence Following Radical Prostatectomy for Prevalent vs. Incident Cases of Prostate Cancer: Implications for Management.”

Cancer 2008 (epub)

Link: http://www.ncbi.nlm.nih.gov/pubmed/18932254


Other Papers

Loeb S, Roehl KA, Helfand BT, and Catalona WJ.

“Complications of open radical retropubic prostatectomy in potential candidates for active monitoring.”

Urology 2008; 72: 887.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18329080


Other Papers

Loeb S, Hernandez DH, Mangold LA, Humphreys EB, Agro M, Walsh PC, Partin AW, and Han M.

“Progression after Radical Prostatectomy for Men in their Thirties Compared to Older Men.”

BJU International, June 2008; 101: 1503.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18341626


Other Papers

Griffin C, Yu X, Loeb S, Desireddi VN, Han M, and Catalona WJ.

“Pathologic Features after Radical Prostatectomy for Potential Candidates for Active Monitoring.”

Journal of Urology 2007; 178: 860.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17631347


Other Papers

Loeb S, Yu X, Nadler RB, Roehl KA, Han M, Hawkins SA, and Catalona WJ.

“Does Body Mass Index Affect Outcomes Following Radical Prostatectomy?”

Journal of Urology 2007; 177: 102.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17162013


Other Topics

International Volunteers in Urology Virtual Visiting Professor Panel Discussion on COVID-19 (5/4/20)


Bill Martinez Live – Empowering Men to Take Charge of Their Life for Men’s Health Month

https://billmartinezlive.com/stacy-loeb-june-13-2019/


Interview on Katz’s Corner

Interview on Katz’s Corner on 77 WABC Radio about Erectile Dysfunction Medications and Risk of Melanoma (June 28, 2015)

https://audioboom.com/boos/3323526-6-28-15-dr-stacy-loeb-prostate-cancer-supplements


MedPage Today Interview on Viagra and Melanoma: Search for Link Inconclusive

6/2015 MedPage Today Interview on Viagra and Melanoma: Search for Link Inconclusive

http://www.medpagetoday.com/Urology/ErectileDysfunction/52272


Other urology topics

Men Health

  • Loeb S, Folkvaljon Y, Damber JE, Alukal J, Lambe M, Stattin P

     

    “Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.”

    Journal of Clinical Oncology 2017;35(13):1430-1436. PMID: 28447913.

    Link: https://www.ncbi.nlm.nih.gov/pubmed/28447913

    The relationship between testosterone replacement therapy and prostate cancer risk is controversial. We found no association between testosterone therapy and overall prostate cancer risk. Long-term testosterone therapy was associated with a significantly reduced risk of aggressive prostate cancer.

     

  • Loeb S, Folkvaljon Y, Lambe M, Robinson D, Garmo H, Ingvar C, Stattin P.

     

    Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.”

     

    JAMA 2015; 313: 2449-55. PMID: 26103029.

     

    Link: http://www.ncbi.nlm.nih.gov/pubmed/26103029

     

    A recent study suggested a possible link between phosphodiesterase inhibitors used for erectile dysfunction and risk of malignant melanoma. Through a large collaboration with the national registries of Sweden, we performed a large study that raised questions about a causal relationship including lack of a dose-response relationship. Instead, the observed association between erectile dysfunction drugs and melanoma likely reflects shared risk factors including lifestyle and socioeconomic status.

     

  • Loeb S, Folkvaljon Y, Robinson D, Schlomm T, Garmo H, Stattin P.

    “Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.

     

    European Urology. 2015 Dec 29 epub. PMID: 26743040

     

    Link: http://www.ncbi.nlm.nih.gov/pubmed/26743040

     

    A previous study from Germany reported a significantly increased risk of prostate cancer recurrence in men taking phosphodiesterase type 5 (PDE5) inhibitors after radical prostatectomy, which was subsequently refuted in an Italian study. We followed up on this issue using nationwide Swedish registry data, and confirmed that there is no association between PDE5 inhibitors with prostate cancer recurrence after treatment.

     


Panama

Global Men’s Health Summit

Panama (Virtual). October 2020

Topic: Early Detection, Diagnosis and Risk Stratification of Prostate Cancer

Category: Prostate Cancer


XXXV Congreso Confederación Americana de Urología

Panama. October 2016

Lecture Topics: Prostate Cancer Active Surveillance, SelectMDx and ConfirmMDx Prostate Cancer Markers, Social Media in Urology

Categories: Prostate Cancer, Social Media


Philippines

Philippines Society of Uro-Oncology

Manila, Philippines. September 2014

Lectures topic: Smarter PSA screening, Novel Prostate Cancer Markers, and Active Surveillance

Category: Prostate Cancer


Portugal

PROSCA 2017

Lisbon, Portugal. June 28-30, 2017

Lecture topics: Screening for prostate cancer: where do we stand?

Category: Prostate Cancer


American Urological Association New York Section Meeting

Lisbon, Portugal. September 10-12, 2015
Lecture Topic: Markers in Screening and Active Surveillance
Category: Prostate Cancer


Post-Treatment

PostTreatment

Using data from an online health community to examine the impact of prostate cancer on sleep.

Robbins R, Jean-Louis G, Chanko N, Combs P, Byrne N, Loeb S.

“Using data from an online health community to examine the impact of prostate cancer on sleep.”

British Journal of Urology International. 2020 Jan 3 epub.  PMID: 31899938.

Link: https://pubmed.ncbi.nlm.nih.gov/31899938/


Untitled

Loeb S, Salter CA, Nelson CJ, Mulhall JP, Wittmann D.

“A Call to Arms: Increasing Our Understanding of the Impact of Prostate Cancer on the Sexual Health of Partners.”

Journal of Sexual Medicine. 2019 Dec 10 epub. PMID: 31836299.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31836299


Untitled

Loeb S, Cazzaniga W, Robinson D, Garmo H, Stattin P.

“Opioid Use After Radical Prostatectomy: Nationwide, Population-Based Study in Sweden.”

J Urol. 2019 Jul 17 epub. PMID:31584849

Link: https://www.ncbi.nlm.nih.gov/pubmed/31584849


Other Papers

Banks JA, McGuire BB, Loeb S, Shrestha S, Helfand BT, Catalona WJ.

“Bacteriuria and antibiotic resistance in catheter urine specimens following radical prostatectomy.”

Urologic Oncology 2012, epub Jan 25. PMID: 22285005.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22285005


Other Papers

Loeb S, Schaeffer EM, Chan DW, Carter HB, Walsh PC, and Sokoll LJ.

“Investigation of Human Anti-Mouse Antibodies As Potential Cause of Postprostatectomy PSA Elevation.”

Urology, May 2009; 73: 947.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19394489


Other Papers

Loeb S, Roehl KA, Viprikasit DP, and Catalona WJ.

“Long-Term Rates of Undetectable PSA with Initial Observation and Delayed Salvage Radiotherapy after Radical Prostatectomy.”

European Urology, July 2008; 54: 88.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18400368


Key Papers

Loeb S, Feng Z, Ross A, Trock BJ, Humphreys EB, and Walsh PC.

“Can We Stop Prostate Specific Antigen Testing 10 Years After Radical Prostatectomy?”

Journal of Urology August 2011; 186: 500. PMID: 21679999.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21679999

Patients often ask whether it is necessary to continue PSA testing indefinitely after radical prostatectomy. In the Johns Hopkins radical prostatectomy database, 77% of all biochemical recurrences occurred within the first 5 years, 17% from 5-10 years, 6% from 10-15 years and only 1.5% more than 15 years after surgery. For men with an undetectable prostate specific antigen at 10 years the actuarial probability of biochemical recurrence and metastasis at 20 years varied by stage and grade, with no metastases in patients with low-grade disease at prostatectomy. A single patient with an undetectable prostate specific antigen at 10 years died of prostate cancer within 20 years after radical prostatectomy. This suggests that less intense monitoring is possible beyond 10 years, particularly for men with favorable tumor features.


Key Papers

Loeb S, Makarov DV, Schaeffer EM, Humphreys EB, and Walsh PC.

“Prostate-specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomy.”

Journal of Urology, July 2010; 184: 157.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20483148

In men with newly diagnosed prostate cancer, bone metastases are uncommon at PSA levels <20 ng/ml. However, after radical prostatectomy bone metastases may occur at much lower PSA levels. Among 193 hormone naïve men who developed bone metastases after radical prostatectomy, bone scan conversion occurred at a PSA <10, 10-100 and >100 ng/ml in 26%, 51% and 23% men, respectively. 


Prostate

Liss MA, Ehdaie B, Loeb S, Meng MV, Raman JD, Spears V, Stroup SP.  

“An Update of the American Urological Association White Paper on the Prevention and Treatment of the More Common Complications Related to Prostate Biopsy.” 

Journal of  Urology  2017 Mar 29 epub. PMID: 28363690

Link: https://www.ncbi.nlm.nih.gov/pubmed/28363690

This is an updated American Urological Association White Paper with guidance on the prevention and treatment of prostate biopsy complications.


Loeb S.

When is a Negative Prostate Biopsy Really Negative? Repeat Biopsies in Detection and Active Surveillance.”

Journal of Urology 2017 epub. PMID 28110035

Link: https://www.ncbi.nlm.nih.gov/pubmed/28110035


Borghesi M, Ahmed H, Nam R, Schaeffer E, Schiavina R, Taneja S, Weidner W, Loeb S.

Complications After Systematic, Random, and Image-guided Prostate Biopsy.”

European Urology. 2016 Aug 16 epub.  PMID: 27543165.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27543165


Reviews/Editorials

Loeb S, Montorsi F, Catto JW.

“Future-Proofing Gleason Grading: What to Call Gleason 6 Prostate Cancer?”

European Urology 2015 epub. PMID: 25769986.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25769986


Reviews/Editorials

Loeb S. Editorial Comment on:

“For Single Dosing, Levofloxacin is Superior to Ciprofloxacin When Combined With an Aminoglycoside in Preventing Severe Infections After Prostate Biopsy.”

Urology 2015 epub. PMID: 25863839.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25863839


Reviews/Editorials

Loeb S. Editorial comment on

“Prevalence and predictive factors of harboring fluoroquinolone-resistant and extended-spectrum β-lactamase-producing rectal flora in Hong Kong Chinese men undergoing transrectal ultrasound-guided prostate biopsy.”

Urology 2015; 85: 21-2. PMID 25530360

Link: http://www.ncbi.nlm.nih.gov/pubmed/25530360


Reviews/Editorials

Loeb S. Editorial Comment on:

“Outcomes of Fecal Carriage of Extended-Spectrum β-Lactamase After Transrectal Ultrasound-Guided Biopsy of the Prostate.”

Urology 2014 epub. PMID 25239260.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25239260


Reviews/Editorials

Davuluri M, Loeb S.

“Prevalence of Infections Associated with Prostate Biopsy.”

Reviews in Urology 2014; 16: 156. PMID: 25337051.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25337051


Reviews/Editorials

Loeb S. Editorial Comment on

“Incidence and management of extended-spectrum beta-lactamase and quinolone-resistant Escherichia coli infections after prostate biopsy.”

Urology 2014; 84: 1006-7. PMID: 25443895.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25443895


Reviews/Editorials

Loeb S.

“Is Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy Ready for ‘Prime Time’?”

European Urology 2014 Nov epub. PMID: 25465339.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25465339


Reviews/Editorials

Loeb S.

“Editorial comment on ‘Current Ability of Multiparametric Prostate MRI and Targeted Biopsy to Improve the Detection of Prostate Cancer’”

Urology Practice 2014 May; 1: 20.


Reviews/Editorials

Loeb S.

“Editorial Comment on: Serial Prostate Biopsy and Risk of Lower Urinary Tract Symptoms: Results From a Large, Single-Institution Active Surveillance Cohort.”

Urology 2014; 83 (1): 38-19. PMID: 24246328

Link: http://www.ncbi.nlm.nih.gov/pubmed/24246328


Reviews/Editorials

Loeb S.

“Editorial Comment on ‘Screening Rectal Culture to Identify Fluoroquinolone-Resistant Organisms Before Transrectal Prostate Biopsy: Do the Culture Results Between Office Visit and Biopsy Correlate?”

Urology 2013; 82: 71.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23806392


Reviews/Editorials

Vellekoop A and Loeb S.

“Editorial Comment on A Single Dose of 240 mg Gentamicin During Transrectal Prostate Biopsy Significantly Reduces Septic Complications.”

Urology 2013 epub August.

Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=23992969


Reviews/Editorials

Loeb S.

“Infection after Transrectal Ultrasonography-Guided Prostate Biopsy: Increased Relative Risks after Recent International Travel or Antibiotic Use.”

BJU International June 2012; 109: 1785-6. PMID: 22040375.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22040375


Reviews/Editorials

Loeb S, Van den Heuvel S, Zhu X, Bangma CH, Schroder FH, and Roobol MH.

“Reply from the Authors re: Alexandre R. Zlotta, Robert K. Nam. To Biopsy or Not to Biopsy- Thou Shall Think Twice.” Eur Urol. In press. DOI:10.1016/j.eururo.2012.01.055: Considerations for Prostate Biopsy Decisions.”

European Urology; 2012 March 8 epub.

Link: http://www.europeanurology.com/article/S0302-2838%2812%2900307-7/fulltext/reply-from-authors-re-alexandre-r-zlotta-robert-k-nam-to-biopsy-or-not-to-biopsy-x02014-thou-shall-think-twice-eur-urol-2012-61-1115-x02013-7


Reviews/Editorials

Loeb S.

“Invited Editorial Comment Re: Long-Term Fluoroquinolone Use Before the Prostate Biopsy May Increase the Risk of Sepsis Caused by Resistant Microorganisms.”

Urology August 2011; 78: 255. PMID: 21820566.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21820566


Reviews/Editorials

Loeb S.

“Prostate Biopsy: A Risk-Benefit Analysis.”

Journal of Urology, March 2010; 183: 852.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20089273


Key Papers

Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, Rosario DJ, Scattoni V, and Lotan Y.

“Systematic Review of Complications of Prostate Biopsy.”

European Urology 2013; June epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23787356

This systematic review of prostate biopsy complications found that hematuria and hematospermia are most common, but are typically mild and self-limiting. Severe rectal bleeding is uncommon. Despite antimicrobial prophylaxis, infectious complications are increasing over time and are the most common reason for hospitalization after biopsy. Pain may occur at several stages of prostate biopsy and can be mitigated by anesthetic agents and anxiety-reduction techniques. Up to 25% of men have transient LUTS after biopsy, and <2% have frank urinary retention, with slightly higher rates reported after transperineal template biopsy. Biopsy-related mortality is rare.


Reviews/Editorials

Loeb S, Schaeffer EM, and Epstein JI.

“The Vanishing Prostate Cancer Phenomenon.”

Urology, January 2010 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20079526


Other Original Articles

Lundstrom KJ, Drevin L, Carlsson S, Garmo H, Loeb S, Stattin P, Bill-Axelson A.

“Nationwide Population-Based Study of Infections After Transrectal Ultrasound Guided Prostate Biopsy.”

Journal of Urology 2014 May epub. PMID 24813343.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24813343


Other Original Articles

Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM.

“Is repeat prostate biopsy association with a greater risk of hospitalization? Data from SEER-Medicare.”

Journal of Urology epub Oct 9, 2012. PMID: 23063634.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23063634


Key Papers

Loeb S, van den Heuvel S, Zhu X, Bangma CH, Schröder FH, Roobol MJ.

“Infectious Complications and Hospital Admissions After Prostate Biopsy in a European Randomized Trial.”

European Urology June 2012; 61: 1110-4. PMID: 22244150

Link: http://www.ncbi.nlm.nih.gov/pubmed/22244150

Among men undergoing prostate biopsy in the European Randomized Study of Screening for Prostate Cancer (ERSPC), 4% developed a fever and 0.8% were admitted to the hospital. Although the risk of hospitalization for infection increased over time, the absolute frequency was low. Because this same trial showed that screening reduces advanced disease and prostate cancer death, the risk of biopsy-related complications should not dissuade healthy men with a sufficient life expectancy to benefit from early detection from undergoing an indicated prostate biopsy.


Key Papers

Loeb S, Carter HB, Berndt SI, Ricker W, and Schaeffer EM.

“Complications After Prostate Biopsy: Data From SEER-Medicare.”

Journal of Urology November 2011; 186: 1830. PMID: 21926375.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21944136

This was the first paper to call attention to the increasing risk of hospitalization for infection after prostate biopsy in the United States. Careful patient selection for prostate biopsy is essential to minimize the potential downstream harms of prostate cancer screening, and this paper has been cited by numerous guidelines


Other Original Articles

Trock BJ, Guo CC, Gonzalgo ML, Magheli A, Loeb S, and Epstein JI.

“Impact of Tertiary Gleason Patterns on Biochemical Recurrence Following Radical Prostatectomy: Proposal for a Modified Gleason Scoring.”

Journal of Urology, August 2009 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19683280


Other Original Articles

Loeb S, Epstein JI, Humphreys EB, and Walsh PC.

“Does Perineural Invasion on Prostate Biopsy Predict Adverse Prostatectomy Outcomes?”

BJU International, August 2009 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19694710


Prostate Biopsy

Loeb S.

When is a Negative Prostate Biopsy Really Negative? Repeat Biopsies in Detection and Active Surveillance.”

Journal of Urology 2017 epub. PMID 28110035

Link: https://www.ncbi.nlm.nih.gov/pubmed/28110035


Danneman D, Drevin L, Delahunt B, Samaratunga H, Robinson D, Bratt O, Loeb S, Stattin P, Egevad L.

“The Accuracy of Prostate Biopsies for Predicting Gleason Score in Radical Prostatectomy Specimens. Nationwide trends 2000-2012.” BJU International. 2016 Feb 25 epub. PMID:26918298.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26918298

 

Loeb S, Folkvaljon Y, Robinson D, Lissbrant IF, Egevad L, Stattin P.

“Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort.”  European Urology. 2015 Dec 17 epub. PMID: 26707871

Link: http://www.ncbi.nlm.nih.gov/pubmed/26707871


Borghesi M, Ahmed H, Nam R, Schaeffer E, Schiavina R, Taneja S, Weidner W, Loeb S.

Complications After Systematic, Random, and Image-guided Prostate Biopsy.”

European Urology. 2016 Aug 16 epub.  PMID: 27543165.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27543165


Prostate Cancer

Using data from an online health community to examine the impact of prostate cancer on sleep.

Robbins R, Jean-Louis G, Chanko N, Combs P, Byrne N, Loeb S.

“Using data from an online health community to examine the impact of prostate cancer on sleep.”

British Journal of Urology International. 2020 Jan 3 epub.  PMID: 31899938.

Link: https://pubmed.ncbi.nlm.nih.gov/31899938/


Prostate Cancer. Nature Reviews Disease Primers

Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG.

“Prostate Cancer. Nature Reviews Disease Primers.”

2021 Feb 4;7(1):9. PMID: 33542230.

Link: https://pubmed.ncbi.nlm.nih.gov/33542230/


Racial Disparities and Online Health Information: YouTube and Prostate Cancer Clinical Trials

Borno HT, Zhang S, Bakke B, Bell A, Zuniga KB, Li P, Chao K, Sabol A, Killeen T, Hong H, Walter D, Loeb S.

“Racial Disparities and Online Health Information: YouTube and Prostate Cancer Clinical Trials.”

British Journal of Urology International. 2020 Apr 10 epub. PMID: 32275800.

Link: https://pubmed.ncbi.nlm.nih.gov/32275800/


Exploring Variation in the Use of Conservative Management for Prostate Cancer in the Veterans Affairs Healthcare System

Loeb S, Byrne NK, Wang B, Makarov DV, Becker D, Wise DR, Lepor H, Walter D.

 “Exploring Variation in the Use of Conservative Management for Prostate Cancer in the Veterans Affairs Healthcare System.”

European Urology. 2020 Feb 22:S0302-2838(20)30101-9. PMID: 32098730.

Link: https://pubmed.ncbi.nlm.nih.gov/32098730/


A Clinical Reminder Order Check Intervention to Improve Guideline-concordant Imaging Practices for Men With Prostate Cancer: A Pilot Study

Ciprut SE, Kelly MD, Walter D, Hoffman R, Becker DJ, Loeb S, Sedlander E, Tenner CT, Sherman SE, Zeliadt SB, Makarov DV.

“A Clinical Reminder Order Check Intervention to Improve Guideline-concordant Imaging Practices for Men With Prostate Cancer: A Pilot Study.”

Urology. 2020 Nov;145:113-119. Epub 2020 Jul 25.PMID: 32721517.

Link: https://pubmed.ncbi.nlm.nih.gov/32721517/


Concordance and Performance of 4KScore and SelectMDx for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer

Wysock JS, Becher E, Persily J, Loeb S, Lepor H.

“Concordance and Performance of 4KScore and SelectMDx for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer.”

Urology. 2020 Apr 12:S0090-4295(20)30339-3. PMID: 32294481

Link: https://pubmed.ncbi.nlm.nih.gov/32294481/


Untitled

Loeb S, Salter CA, Nelson CJ, Mulhall JP, Wittmann D.

“A Call to Arms: Increasing Our Understanding of the Impact of Prostate Cancer on the Sexual Health of Partners.”

Journal of Sexual Medicine. 2019 Dec 10 epub. PMID: 31836299.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31836299


Untitled

Butler SS, Loeb S, Cole AP, Zaslowe-Dude C, Muralidhar V, Kim DW, Schaeffer EM, Trinh QD, Nguyen PL, Mahal BA.

 “United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015. Prostate Cancer Prostatic Dis.”

 2019 Oct 7 epub. PMID: 31591454.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31591454


Untitled

Loeb S, Cazzaniga W, Robinson D, Garmo H, Stattin P.

“Opioid Use After Radical Prostatectomy: Nationwide, Population-Based Study in Sweden.”

J Urol. 2019 Jul 17 epub. PMID:31584849

Link: https://www.ncbi.nlm.nih.gov/pubmed/31584849


Untitled

Becker DJ, Iyengar AD, Punekar SR, Ng J, Zaman A, Loeb S, Becker KD, Makarov D.

“Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression. “

Anticancer Res.2019 May;39(5):2467-2473. PMID: 31092441.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31092441


Untitled

Loeb S.

 ” Overactive Surveillance: Is “Conservative” Management for Low-risk Prostate Cancer Too Aggressive?”

 Eur Urol. 2019 May epub. PMID:31060823.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31060823


Untitled

Fine ND, LaPolla F, Epstein M, Loeb S, Dani H.

” Genomic Classifiers for Treatment Selection in Newly Diagnosed Prostate Cancer.”

 BJU International 2019 May epub. PMID:31055874.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31055874


Untitled

Drangsholt S, Walter D, Ciprut S, Lepor A, Sedlander E, Curnyn C, Loeb S, Malloy P, Winn AN, Makarov DV.

” Quantifying downstream impact of inappropriate staging imaging in a cohort of veterans with low- and intermediate-risk incident prostate cancer.”

Urologic Oncology 2019 Feb;37(2):145-149. PMID: 30578160.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30578160


Untitled

Loeb S, Folkvaljon Y, Bratt O, Robinson D, Stattin P.

 “Defining Intermediate-Risk Prostate Cancer Suitable for Active Surveillance.”

 Journal of Urology. 2018 Sep 18 epub. PMID: 30240688.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30240688


Untitled

Stattin P, Sandin F, Loeb S, Robinson D, Lissbrant IF, Lambe M.

“Public online reporting from a nationwide population-based clinical prostate cancer register.”

BJU International 2018 Jul; 122(1):8-10. PMID: 29577561.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29577561/a>


Untitled

Stattin P, Sandin F, Loeb S, Robinson D, Lissbrant IF, Lambe M.

” Public online reporting from a nationwide population-based clinical prostate cancer register”

BJU International 2018 Jul; 122(1):8-10. PMID: 29577561.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29577561


Stattin P, Sandin F, Loeb S, Robinson D, Lissbrant IF, Lambe M. .

 “Public online reporting from a nationwide population-based clinical prostate cancer register. “

BJU International 2018 Jul; 122(1):8-10. PMID: 29577561.

    Link: https://www.ncbi.nlm.nih.gov/pubmed/29577561


Untitled

Loeb S, Curnyn C, Walter D, Fagerlin A, Siebert U, Mühlberger N, Braithwaite RS, Schwartz MD, Lepor H, Sedlander E.

 “Health state utilities among contemporary prostate cancer patients on active surveillance.”

Translational Andrology and Urology. 2018 Apr; 7(2):197-202. PMID: 29732277.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29732277


Untitled

Loeb S, Tosoian JJ.

 “Biomarkers in Active Surveillance.”

 Translational Andrology and Urology 2018 Feb; 7(1):155-159. PMID: 29594029.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29594029


Untitled

Loeb S.

 “Active Surveillance for Prostate Cancer.”

 Reviews in Urology 2018; 20: 101-103. PMID: 30288148.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30288148


Punnen S, Freedland SJ, Polascik TJ, Loeb S, Risk MC, Savage S, Mathur SC, Uchio E, Dong Y, Silberstein JL.

” A Multi-institutional Prospective Trial in the Veterans Affairs Health System confirms the 4Kscore maintains its Predictive value among African American Men.”

Journal of Urology 2017, epub Dec 6. PMID: 29223389

Link: https://www.ncbi.nlm.nih.gov/pubmed/29223389


Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choeurng V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll PR, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL.

“Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.”

 Journal of Clinical Oncology. 2017 Nov 29 epub. PMID: 29185869.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29185869


Loeb S.

 ” Active Surveillance Offers Functional Advantages Without Impacting Survival for Low-risk Prostate Cancer.”

European Urology. 2017 Nov 20. PMID: 29169932

Link: https://www.ncbi.nlm.nih.gov/pubmed/29169932


Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choeurng V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll PR, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL

” Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.”

Journal of Clinical Oncology. 2017 Nov 29 epub. PMID: 29185869.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29185869


Loeb S, Dani H.

 “Whom to Biopsy: Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators.”

Urol Clin North Am. 2017 Nov; 44(4):517-524. PMID: 29107268

    Link: https://www.ncbi.nlm.nih.gov/pubmed/29107268


Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Sedlander E.

 “Informational needs during active surveillance for prostate cancer: A qualitative study.”

Patient Education Counseling 2017 Sep 1 epub.  PMID: 28886974

Link: https://www.ncbi.nlm.nih.gov/pubmed/28886974


Loeb S, Zhou Q, Siebert U, Rochau U, Jahn B, Mühlberger N, Carter HB, Lepor H, Braithwaite RS.  

“Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions”.

European Urology 2017 Aug 22 epub.  PMID: 28844371

Link: https://www.ncbi.nlm.nih.gov/pubmed/28844371

We designed a Markov model showing that active surveillance extends life more than watchful waiting, particularly for men with higher risk features, but this is partly offset by decrements in quality of life from delayed treatment. Trade-offs about the intensity of surveillance should be discussed with patients.


Loeb S.

“Biomarkers for Prostate Biopsy and Risk Stratification of Newly Diagnosed Prostate Cancer Patients.”

Urology Practice. 2017 Jul;4(4):315-321. PMID: 29104903

Link: https://www.ncbi.nlm.nih.gov/pubmed/29104903


Loeb S, Ross AE.  

“Genomic testing for localized prostate cancer: where do we go from here?” 

Current Opinion in Urology. 2017 Jun 28 epub. PMID: 28661898

    Link: https://www.ncbi.nlm.nih.gov/pubmed/28621058

 


Loeb S, Meyer C, Krasnova A, Curnyn C, Reznor G, Lepor H, Kibel AS, Trinh QD.

“Risk of Small Bowel Obstruction After Robot-Assisted Versus Open Radical Prostatectomy.”

Journal of Endourology  2016 Sep 11 epub.  PMID: 27615204

Link: https://www.ncbi.nlm.nih.gov/pubmed/27615204


Choyke PL and Loeb S.

“Active Surveillance of Prostate Cancer.” 

Oncology (Williston Park) 2017; 31 (1).

PMID 8090626

Link: https://www.ncbi.nlm.nih.gov/pubmed/28090626


Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Sedlander E.

 “A Qualitative Study on Decision-Making by Prostate Cancer Physicians during Active Surveillance.”

BJU International. 2016 epub.  PMID: 27611479.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27611479


Loeb S, Folkvaljon Y, Curnyn C, Robinson D, Bratt O, Stattin P.

“Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden”.

JAMA Oncology. 2016 Oct 20. PMID: 27768168.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27768168

Using nationwide Sweden data, this study showed that by 2014, active surveillance was selected by 91% of very low risk, 74% of low risk and 19% of intermediate risk patients across the country.  These rates are the highest yet reported internationally. Dissociating diagnosis from treatment in men with a low risk of progression can decrease the rate of overtreatment.


Loeb S.

When is a Negative Prostate Biopsy Really Negative? Repeat Biopsies in Detection and Active Surveillance.”

Journal of Urology 2017 epub. PMID 28110035

Link: https://www.ncbi.nlm.nih.gov/pubmed/28110035


Thomsen FB, Folkvaljon Y, Brasso K, Loeb S, Robinson D, Egevad L, Stattin P.

Prognostic implications of 2005 Gleason grade modification. Population-based study of biochemical recurrence following radical prostatectomy.”

Journal of Surgical Oncology. 2016 Aug 11 epub. PMID: 27511833.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27511833


Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, Partin AW, Sokoll L, Chan DW, Bangma CH, van Schaik RH, Slawin KM, Marks LS, Catalona WJ.

“Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer”

BJU International. 2016 Oct 15. PMID:27743489

Link: https://www.ncbi.nlm.nih.gov/pubmed/27743489


Crawford ED, Rosenberg MT, Partin AW, Cooperberg MR, Maccini M, Loeb S, Pettaway CA, Shore ND, Arangua P, Hoenemeyer J, Leveridge M, Leapman M, Pinto P, Thompson IM Jr, Carroll P, Eastham J, Gomella L, Klein EA.

“An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care.”

Urology. 2016 Jul 19 epub. PMID: 27450937.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27450937


Loeb S. Editorial Comment on

“Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices.” 

Journal of Urology 2016 epub Nov 28. PMID: 27908693.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27908693


Adam M, Tennstedt P, Lanwehr D, Tilki D, Steuber T, Beyer B, Thederan I, Heinzer H, Haese A, Salomon G, Budäus L, Michl U, Pehrke D, Stattin P, Bernard J, Klaus B, Pompe RS, Petersen C, Huland H, Graefen M, Schwarz R, Huber W, Loeb S, Schlomm T.

“Functional Outcomes and Quality of Life After Radical Prostatectomy Only Versus a Combination of Prostatectomy with Radiation and Hormonal Therapy. European Urology.”

2016 Nov 22. PMID: 27887941

Link: https://www.ncbi.nlm.nih.gov/pubmed/27887941


Danneman D, Drevin L, Delahunt B, Samaratunga H, Robinson D, Bratt O, Loeb S, Stattin P, Egevad L.

“The Accuracy of Prostate Biopsies for Predicting Gleason Score in Radical Prostatectomy Specimens. Nationwide trends 2000-2012.” BJU International. 2016 Feb 25 epub. PMID:26918298.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26918298

 

Loeb S, Folkvaljon Y, Robinson D, Lissbrant IF, Egevad L, Stattin P.

“Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort.”  European Urology. 2015 Dec 17 epub. PMID: 26707871

Link: http://www.ncbi.nlm.nih.gov/pubmed/26707871


Sotelo R, Mora K. E, Perez L. H, Novoa J, Castillo M, Carmona O, De Andrade R, Loeb S, and Catalona WJ.

“Assay Standardization Bias: Different Prostate Cancer Detection Rates and Clinical Outcomes Resulting From Different Assays for Free and Total Prostate-Specific Antigen (PSA).” 

Urology, June 2007; 69: 1143.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17572203


Loeb S.

“Guideline of guidelines: prostate cancer screening.”

BJU International 2014 September; 114: 323.

PMID: 24981126.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23567643


Loeb S, Vonesh EF, Metter EJ, Carter HB, Gann PH, and Catalona WJ.

“What is the true number-needed-to-screen and treat to save a life with prostate-specific antigen (PSA) testing?” 

Journal of Clinical Oncology January 2011; 29: 464.
Link: http://www.ncbi.nlm.nih.gov/pubmed/21189374

Although number needed to screen (NNS) and number needed to treat (NNT) are useful statistics to assess the benefits and harms of an intervention, in a survival study setting such as the European Randomized Study of Screening for Prostate Cancer (ERSPC), NNS and NNT are time specific, and reporting values at one time point may lead to misinterpretation of results. We developed a model predicting that the NNS in this trial would decrease from 837 at year 10 to 503 at year 12, and NNT would decrease from 29 to 18.


Schaeffer EM, Carter HB, Kettermann A, Loeb S, Ferrucci L, Landis P, Trock BJ, and Metter EJ.

“Prostate Specific Antigen Testing Among the Elderly: When to Stop?” 

Journal of Urology, April 2009; 181: 1606.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19246059

 

Men ages 75-80 with PSA levels <3 ng/ml are unlikely to die of or experience aggressive prostate cancer during their remaining life, suggesting that PSA testing might be safely discontinued for these men.

 


Loeb S, Carter HB, Catalona WJ, Moul JW, and Schroder FH.

“Baseline Prostate-Specific Antigen Testing at a Young Age.”

European Urology January 2012; 61: 1-7. PMID: 21862205.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21862205

This study reviews the published literature showing that baseline PSA measurements at a young age are significant predictors of later prostate cancer diagnosis and disease-specific outcomes. Baseline PSA testing should be offered to young men for risk stratification and to guide screening protocols


Loeb S, Roehl KA, Antenor JV, Catalona WJ, Suarez BK, and Nadler RB.

“Baseline Prostate Specific Antigen (PSA) Compared with Median PSA for Age Group as Predictor of Prostate Cancer Risk in Men Under 60 Years of Age”

Urology, February 2006; 67: 316.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16442597

In the general US population, the median PSA level is 0.7 ng/ml in the 40’s and 0.9 ng/ml in the 50’s. Young men with a baseline PSA level above the age-specific median are at significantly greater risk of future prostate cancer diagnosis and aggressive disease. Baseline PSA at a young age is a stronger predictor of prostate cancer than race, family history or digital rectal examination.


Murphy DG, Ahlering T, Catalona WJ, Crowe H, Crowe J, Clarke N, Cooperberg M, Gillatt D, Gleave M, Loeb S, Roobol M, Sartor O, Pickles T, Wooten A, Walsh PC, Costello AJ.

“The Melbourne Consensus Statement on the Early Detection of Prostate Cancer.”

British Journal of Urology International 2012 epub Nov 8. PMID: 24206066

Link: http://www.ncbi.nlm.nih.gov/pubmed/24206066

In light of numerous conflicting recommendations about prostate cancer screening, in August 2013 a multidisciplinary group convened in Melbourne, Australia to create consensus practice guidelines. Key areas of consensus are that level 1 evidence shows that prostate cancer screening saves lives among men ages 50-69, but that biopsy decisions should be made using PSA as part of a multivariable approach and that diagnosis must be uncoupled from treatment.


Loeb S, Helfand BT, Kan D, Isaacs WB, and Catalona WJ.

“Does Diabetes Mellitus Modify the Association between 17q12 Risk Variant and Prostate Cancer Aggressiveness?” 

BJU International, November 2009; 104: 1200.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19627283


Helfand BT, Loeb S, Kan D, Catalona WJ.

“Number of prostate cancer risk alleles may identify possibly ‘insignificant’ disease.” 

BJU International, June 2010 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20590552

 


Helfand BT, Fought AJ, Loeb S, Meeks JJ, Kan D, and Catalona WJ.

“Genetic prostate cancer risk assessment: common variants in 9 genomic regions are associated with cumulative risk.”

Journal of Urology, August 2010; 184: 501.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20620408


Cooper PR, McGuire BB, Helfand BT, Loeb S, Hu Q, and Catalona WJ.

“Prostate Cancer Risk Alleles and Their Associations with Other Malignancies.”

Urology October 2011; 78: 970 .e 15-20.

PMID: 21820706.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3190015/


Helfand BT, Hu Q, Loeb S, McVary KT, Catalona WJ.

“Genetic Sequence Variants are Associated with Severity of Lower Urinary Tract Symptoms and Prostate Cancer Susceptibility.” 

Journal of Uroloy 2012 epub November.

PMID: 23159463.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23159463


Reinhardt D, Helfand BT, Cooper PR, Roehl KA, Catalona WJ, and Loeb S.

“Prostate Cancer Risk Alleles are Associated with Prostate Cancer Tumor Volume and Prostate Size.”

Journal of Urology 2013; epub Dec 14.

PMID: 24345439

Link: http://www.ncbi.nlm.nih.gov/pubmed/24345439


Grin B, Loeb S, Roehl K, Cooper PR, Catalona WJ, Helfand BT.

“A rare 8q24 single nucleotide polymorphism (SNP) predisposes North American men to prostate cancer and possibly more aggressive disease.”

BJU International 2014, June epub.

PMID: 24952954.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24952954


Loeb S, Peskoe SB, Joshu CE, Huang WY, Hayes RB, Carter HB, Isaacs WB, Platz EA

“Do Environmental Factors Modify the Genetic Risk of Prostate Cancer?”

Cancer Epidemiology Biomarkers Prevention 2015; 24: 213. PMID: 25342390.
Link: http://www.ncbi.nlm.nih.gov/pubmed/25342390


Bostrӧm PJ, Bjartell AS, Catto JW, Eggener SE, Lilja H, Loeb S, Schalken J, Schlomm T, and Cooperberg MR.

“Genomic Predictors of Outcome in Prostate Cancer.”

European Urology 2015 epub. PMID: 25913390.
Link: http://www.ncbi.nlm.nih.gov/pubmed/25913390

 


Loeb S, Drevin L, Robinson D, Holmberg E, Carlsson S, Lambe M, Stattin P.

“Risk of localized and advanced prostate cancer among immigrants versus native-born Swedish men: a nation-wide population-based study.” 

Cancer Causes Control 2012;

December epub.  PMID: 23266834.
Link: http://www.ncbi.nlm.nih.gov/pubmed/23266834

 

First-generation immigrants to Sweden (a high risk country for prostate cancer) have a lower risk of all stages of prostate cancer compared to native-born men, especially men who immigrated to Sweden recently or at an older age.


Helfand BT, Loeb S, Hu Q, Cooper PR, Roehl KA, McGuire BB, Baumann NA, Catalona WJ.
“Personalized PSA Testing Using Genetic Variants May Reduce Unnecessary Biopsies.” 

Journal of Urology 2012; epub December. PMID: 23246478.
Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631301/


Key Articles

Loeb S, Carter HB, Walsh PC, Isaacs WB, Kettermann A, Tanaka T, Ferrucci L, and Metter EJ.

“Single Nucleotide Polymorphisms and the Likelihood of Prostate Cancer at a Given Prostate-Specific Antigen Level.”

Journal of Urology, July 2009; 182: 101.
Link: http://www.ncbi.nlm.nih.gov/pubmed/19450841

 

Genotype influences the risk of prostate cancer per unit increase in PSA. Prostate cancer risk stratification using PSA and genotype together could improve PSA test performance.


Key Article

Key Articles
Loeb S, Peskoe SB, Joshu CE, Huang WY, Hayes RB, Carter HB, Isaacs WB, Platz EA “Do Environmental Factors Modify the Genetic Risk of Prostate Cancer?” Cancer Epidemiology Biomarkers Prevention 2015; 24: 213. PMID: 25342390.
Link: http://www.ncbi.nlm.nih.gov/pubmed/25342390

This study examined effect modification by environmental factors of the association between single nucleotide polymorphisms with prostate cancer risk. Among men at high risk for prostate cancer based on their genotype, use of selenium was associated with a lower risk of advanced prostate cancer, while aspirin, ibuprofen and vegetables were associated with lower risk of nonadvanced prostate cancer.


Borghesi M, Ahmed H, Nam R, Schaeffer E, Schiavina R, Taneja S, Weidner W, Loeb S.

Complications After Systematic, Random, and Image-guided Prostate Biopsy.”

European Urology. 2016 Aug 16 epub.  PMID: 27543165.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27543165


Donin N, Loeb S, Cooper PF, Roehl KA, Baumann NA, Catalona WJ, Helfand BT.

“Genetically-Adjusted PSA Values May Prevent Delayed Biopsies in African-American Men.”

BJU International 2014 Jan epub.

PMID: 24712975

Link: http://www.ncbi.nlm.nih.gov/pubmed/24712975


Prostate Cancer - Lectures and Courses for Physicians

Prostate Cancer - Lectures for Patients/Community Outreach

Prostate Cancer - TV Appearances and Interviews

PSA Screening

Crawford ED, Rosenberg MT, Partin AW, Cooperberg MR, Maccini M, Loeb S, Pettaway CA, Shore ND, Arangua P, Hoenemeyer J, Leveridge M, Leapman M, Pinto P, Thompson IM Jr, Carroll P, Eastham J, Gomella L, Klein EA.

“An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care.”

Urology. 2016 Jul 19 epub. PMID: 27450937.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27450937


Sotelo R, Mora K. E, Perez L. H, Novoa J, Castillo M, Carmona O, De Andrade R, Loeb S, and Catalona WJ.

“Assay Standardization Bias: Different Prostate Cancer Detection Rates and Clinical Outcomes Resulting From Different Assays for Free and Total Prostate-Specific Antigen (PSA).” 

Urology, June 2007; 69: 1143.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17572203


Loeb S.

“Guideline of guidelines: prostate cancer screening.”

BJU International 2014 September; 114: 323.

PMID: 24981126.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23567643


Loeb S, Vonesh EF, Metter EJ, Carter HB, Gann PH, and Catalona WJ.

“What is the true number-needed-to-screen and treat to save a life with prostate-specific antigen (PSA) testing?” 

Journal of Clinical Oncology January 2011; 29: 464.
Link: http://www.ncbi.nlm.nih.gov/pubmed/21189374

Although number needed to screen (NNS) and number needed to treat (NNT) are useful statistics to assess the benefits and harms of an intervention, in a survival study setting such as the European Randomized Study of Screening for Prostate Cancer (ERSPC), NNS and NNT are time specific, and reporting values at one time point may lead to misinterpretation of results. We developed a model predicting that the NNS in this trial would decrease from 837 at year 10 to 503 at year 12, and NNT would decrease from 29 to 18.


Schaeffer EM, Carter HB, Kettermann A, Loeb S, Ferrucci L, Landis P, Trock BJ, and Metter EJ.

“Prostate Specific Antigen Testing Among the Elderly: When to Stop?” 

Journal of Urology, April 2009; 181: 1606.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19246059

 

Men ages 75-80 with PSA levels <3 ng/ml are unlikely to die of or experience aggressive prostate cancer during their remaining life, suggesting that PSA testing might be safely discontinued for these men.

 


Loeb S, Carter HB, Catalona WJ, Moul JW, and Schroder FH.

“Baseline Prostate-Specific Antigen Testing at a Young Age.”

European Urology January 2012; 61: 1-7. PMID: 21862205.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21862205

This study reviews the published literature showing that baseline PSA measurements at a young age are significant predictors of later prostate cancer diagnosis and disease-specific outcomes. Baseline PSA testing should be offered to young men for risk stratification and to guide screening protocols


Loeb S, Roehl KA, Antenor JV, Catalona WJ, Suarez BK, and Nadler RB.

“Baseline Prostate Specific Antigen (PSA) Compared with Median PSA for Age Group as Predictor of Prostate Cancer Risk in Men Under 60 Years of Age”

Urology, February 2006; 67: 316.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16442597

In the general US population, the median PSA level is 0.7 ng/ml in the 40’s and 0.9 ng/ml in the 50’s. Young men with a baseline PSA level above the age-specific median are at significantly greater risk of future prostate cancer diagnosis and aggressive disease. Baseline PSA at a young age is a stronger predictor of prostate cancer than race, family history or digital rectal examination.


Murphy DG, Ahlering T, Catalona WJ, Crowe H, Crowe J, Clarke N, Cooperberg M, Gillatt D, Gleave M, Loeb S, Roobol M, Sartor O, Pickles T, Wooten A, Walsh PC, Costello AJ.

“The Melbourne Consensus Statement on the Early Detection of Prostate Cancer.”

British Journal of Urology International 2012 epub Nov 8. PMID: 24206066

Link: http://www.ncbi.nlm.nih.gov/pubmed/24206066

In light of numerous conflicting recommendations about prostate cancer screening, in August 2013 a multidisciplinary group convened in Melbourne, Australia to create consensus practice guidelines. Key areas of consensus are that level 1 evidence shows that prostate cancer screening saves lives among men ages 50-69, but that biopsy decisions should be made using PSA as part of a multivariable approach and that diagnosis must be uncoupled from treatment.


Donin N, Loeb S, Cooper PF, Roehl KA, Baumann NA, Catalona WJ, Helfand BT.

“Genetically-Adjusted PSA Values May Prevent Delayed Biopsies in African-American Men.”

BJU International 2014 Jan epub.

PMID: 24712975

Link: http://www.ncbi.nlm.nih.gov/pubmed/24712975


PSA Screening

Crawford ED, Rosenberg MT, Partin AW, Cooperberg MR, Maccini M, Loeb S, Pettaway CA, Shore ND, Arangua P, Hoenemeyer J, Leveridge M, Leapman M, Pinto P, Thompson IM Jr, Carroll P, Eastham J, Gomella L, Klein EA.

“An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care.”

Urology. 2016 Jul 19 epub. PMID: 27450937.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27450937


Sotelo R, Mora K. E, Perez L. H, Novoa J, Castillo M, Carmona O, De Andrade R, Loeb S, and Catalona WJ.

“Assay Standardization Bias: Different Prostate Cancer Detection Rates and Clinical Outcomes Resulting From Different Assays for Free and Total Prostate-Specific Antigen (PSA).” 

Urology, June 2007; 69: 1143.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17572203


Loeb S.

“Guideline of guidelines: prostate cancer screening.”

BJU International 2014 September; 114: 323.

PMID: 24981126.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23567643


Loeb S, Vonesh EF, Metter EJ, Carter HB, Gann PH, and Catalona WJ.

“What is the true number-needed-to-screen and treat to save a life with prostate-specific antigen (PSA) testing?” 

Journal of Clinical Oncology January 2011; 29: 464.
Link: http://www.ncbi.nlm.nih.gov/pubmed/21189374

Although number needed to screen (NNS) and number needed to treat (NNT) are useful statistics to assess the benefits and harms of an intervention, in a survival study setting such as the European Randomized Study of Screening for Prostate Cancer (ERSPC), NNS and NNT are time specific, and reporting values at one time point may lead to misinterpretation of results. We developed a model predicting that the NNS in this trial would decrease from 837 at year 10 to 503 at year 12, and NNT would decrease from 29 to 18.


Schaeffer EM, Carter HB, Kettermann A, Loeb S, Ferrucci L, Landis P, Trock BJ, and Metter EJ.

“Prostate Specific Antigen Testing Among the Elderly: When to Stop?” 

Journal of Urology, April 2009; 181: 1606.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19246059

 

Men ages 75-80 with PSA levels <3 ng/ml are unlikely to die of or experience aggressive prostate cancer during their remaining life, suggesting that PSA testing might be safely discontinued for these men.

 


Loeb S, Carter HB, Catalona WJ, Moul JW, and Schroder FH.

“Baseline Prostate-Specific Antigen Testing at a Young Age.”

European Urology January 2012; 61: 1-7. PMID: 21862205.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21862205

This study reviews the published literature showing that baseline PSA measurements at a young age are significant predictors of later prostate cancer diagnosis and disease-specific outcomes. Baseline PSA testing should be offered to young men for risk stratification and to guide screening protocols


Loeb S, Roehl KA, Antenor JV, Catalona WJ, Suarez BK, and Nadler RB.

“Baseline Prostate Specific Antigen (PSA) Compared with Median PSA for Age Group as Predictor of Prostate Cancer Risk in Men Under 60 Years of Age”

Urology, February 2006; 67: 316.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16442597

In the general US population, the median PSA level is 0.7 ng/ml in the 40’s and 0.9 ng/ml in the 50’s. Young men with a baseline PSA level above the age-specific median are at significantly greater risk of future prostate cancer diagnosis and aggressive disease. Baseline PSA at a young age is a stronger predictor of prostate cancer than race, family history or digital rectal examination.


Murphy DG, Ahlering T, Catalona WJ, Crowe H, Crowe J, Clarke N, Cooperberg M, Gillatt D, Gleave M, Loeb S, Roobol M, Sartor O, Pickles T, Wooten A, Walsh PC, Costello AJ.

“The Melbourne Consensus Statement on the Early Detection of Prostate Cancer.”

British Journal of Urology International 2012 epub Nov 8. PMID: 24206066

Link: http://www.ncbi.nlm.nih.gov/pubmed/24206066

In light of numerous conflicting recommendations about prostate cancer screening, in August 2013 a multidisciplinary group convened in Melbourne, Australia to create consensus practice guidelines. Key areas of consensus are that level 1 evidence shows that prostate cancer screening saves lives among men ages 50-69, but that biopsy decisions should be made using PSA as part of a multivariable approach and that diagnosis must be uncoupled from treatment.


Donin N, Loeb S, Cooper PF, Roehl KA, Baumann NA, Catalona WJ, Helfand BT.

“Genetically-Adjusted PSA Values May Prevent Delayed Biopsies in African-American Men.”

BJU International 2014 Jan epub.

PMID: 24712975

Link: http://www.ncbi.nlm.nih.gov/pubmed/24712975


PSAScreening

The Association of Veterans PSA Screening Rates with Changes in USPSTF Recommendations

Becker DJ, Rude T, Walter D, Wang C, Loeb S, Li H, Ciprut S, Kelly M, Zeliadt SB, Fagerlin A, Lepor H, Sherman S, Ravenell JE, Makarov DV.

“The Association of Veterans’ PSA Screening Rates with Changes in USPSTF Recommendations.”

J Natl Cancer Inst. 2020 Aug 14:djaa120.  PMID: 32797212

Link: https://pubmed.ncbi.nlm.nih.gov/32797212/


Crawford ED, Rosenberg MT, Partin AW, Cooperberg MR, Maccini M, Loeb S, Pettaway CA, Shore ND, Arangua P, Hoenemeyer J, Leveridge M, Leapman M, Pinto P, Thompson IM Jr, Carroll P, Eastham J, Gomella L, Klein EA.

“An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care.”

Urology. 2016 Jul 19 epub. PMID: 27450937.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27450937


Loeb S.

“Will Changes to Prostate Cancer Screening Guidelines Preserve Benefits and Reduce Harms?” 

European Urology 2016 April epub. PMID: 27090973.

Link: http://www.ncbi.nlm.nih.gov/pubmed/27090973


Loeb S.

“Evidence-Based Versus Personalized Prostate Cancer Screening: Using Baseline Prostate-Specific Antigen Measurements to Individualize Screening.”

Journal of Clinical Oncology 2016 Jun 20 epub. PMID: 27325846.

Link: http://www.ncbi.nlm.nih.gov/pubmed/27325846


Loeb S, Lilja H, Vickers A.

“Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer.”

Current Opinion in Urology 2016 Jun 3 epub. PMID: 27262138

Link: http://www.ncbi.nlm.nih.gov/pubmed/27262138


Reviews/Editorials

Loeb S. Editorial Comment on

“Trends in Prostate Specific Antigen Screening, Prostate Biopsies, Urology Visits, and Prostate Cancer Treatments from 2000 to 2012.”

Urology 2015; 86: 504-5.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26282019


Reviews/Editorials

Loeb S. Editorial Comment on

“Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.”

Urology 2015; 85: 170. PMID: 25530380.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25530379


Reviews/Editorials

Loeb S, Cooperberg MR.

“Early Detection of Prostate Cancer.”

Urological Clinics of North America 2014 May epub. PMID: 24725496

Link: http://www.ncbi.nlm.nih.gov/pubmed/24725496


Reviews/Editorials

Vellekoop A and Loeb S.

“Update of Randomized Trials for Prostate Cancer Screening.”

Reviews in Urology 2013; 15: 37-9. PMID: 23671404

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651541/


Reviews/Editorials

Loeb S

“Use of Baseline Prostate-Specific Antigen Measurements to Personalize Prostate Cancer Screening.”

European Urology May 2012: 61: 875-6. PMID:22154726.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22154726


Reviews/Editorials

Roobol MJ, Bangma CH, Loeb S.

“Prostate-specific antigen screening can be beneficial to younger and at-risk men.”

CMAJ, May 2012 epub. PMID: 22566532.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3537779/


Reviews/Editorials

Loeb S, Carlsson S, and Braithwaite RS.

“Prostate Cancer: Modeling the Outcomes of Prostate Cancer Screening.”

Nature Reviews Urology, March 2012; 13: 183-5. PMID: 224106678.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22410678


Reviews/Editorials

Loeb S and Catalona WJ.

“PSA Should Drive Doing Prostate Biopsies.”

Urologic Oncology: Seminars and Original Investigations Jan-Feb 2012; 30: 1-2. PMID: 21458316.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21458316


Reviews/Editorials

Loeb S, Trock BJ.

“Re: Randomized Prostate Cancer Screening Trial: 20 Year Follow-up.”

European Urology 2011; 60: 1306. PMID: 22054407.

Link: http://www.europeanurology.com/article/S0302-2838%2811%2900989-4/fulltext/re-randomised-prostate-cancer-screening-trial-20-year-follow-up


Reviews/Editorials

Loeb S.

“Germline Sequence Variants and Prostate Specific Antigen Interpretation.”

Clinical Chemistry May 2011; 57: 662-3. PMID: 21411622.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21411622


Reviews/Editorials

Loeb S.

“Invited Editorial Comment Re: Variable Prostate-Specific Antigen Management Patterns by Nonurologist Providers at a Tertiary Medical Center.”

Urology August 2011; 78: 248. PMID: 21820564.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21820564


Reviews/Editorials

Loeb S.

“Use of Empiric Antibiotics in the Setting of an Increased Prostate Specific Antigen: Pro.”

Journal of Urology June 2011; 186: 17. PMID: 21571331.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21571331


Reviews/Editorials

Loeb S and Catalona WJ

“Prostate-specific antigen screening: pro.”

Current Opinion in Urology, May 2010; 20: 185.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20224413


Reviews/Editorials

Loeb S and Catalona WJ.

“Prostate Cancer: Utility of the Riskindicator Model in Screening.”

Nature Reviews Urology, April 2010; 7: 184.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20383184


Reviews/Editorials

Loeb S and Partin AW.

“What is the true mortality benefit of prostate-specific antigen screening?”

Reviews in Urology, Winter 2010; 12: 66.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859145/


Reviews/Editorials

Loeb S and Carter HB.

“Limitations and Use of PSA Derivatives in the Screening and Risk Stratification of Prostate Cancer.”

Urologic Oncology: Seminars and Original Investigations, Nov-Dec 2009; 27: 583.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19879470


Other Original Articles

Loeb S.

“Guideline of guidelines: prostate cancer screening.”

BJU International 2014 September; 114: 323. PMID: 24981126.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23567643


Reviews/Editorials

Loeb S and Schaeffer EM.

“Risk Factors, Prevention, and Early Detection of Prostate Cancer.”

Primary Care Clinics of North America, September 2009; 36: 603.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19616157


Reviews/Editorials

Loeb S and Partin AW.

“Randomized Trials of Prostate Cancer Screening.”

Reviews in Urology, Summer 2009; 11: 179.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2777067/


Reviews/Editorials

Loeb S and Catalona WJ.

“What is the Role of Digital Rectal Examination in Men Undergoing Serial Screening of Serum PSA?”

Nature Clinical Practice Urology, February 2009; 6: 68.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19139742


Other Original Articles

Helfand BT, Loeb S, Hu Q, Cooper PR, Roehl KA, McGuire BB, Baumann NA, Catalona WJ.

“Personalized PSA Testing Using Genetic Variants May Reduce Unnecessary Biopsies.”

Journal of Urology 2012; epub December. PMID: 23246478.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631301/


Other Original Articles

Carvalhal GF, Daudi SN, Kan D, Mondo D, Roehl KA, Loeb S, and Catalona WJ.

“Correlation Between Serum Prostate-Specific Antigen and Cancer Volume in Prostate Glands of Different Sizes.”

Urology, September 2010 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20846711


Reviews/Editorials

Loeb S, Gashti SN, and Catalona WJ.

“Exclusion of Inflammation in the Differential Diagnosis of an Elevated Prostate-Specific Antigen (PSA).”

Urologic Oncology: Seminars and Original Investigations, Jan-Feb 2009; 27: 64.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19111800


Reviews/Editorials

Loeb S and Catalona WJ.

“Diagnosis and Treatment of Prostate Cancer. Beyond the controversy over whether and whom to screen, the appropriate method of screening is also subject to debate.”

Medical Economics, December 2008; 85: 36.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19209648


Other Original Articles

Loeb S, Carter HB, Walsh PC, Isaacs WB, Kettermann A, Tanaka T, Ferrucci L, and Metter EJ.

“Single Nucleotide Polymorphisms and the Likelihood of Prostate Cancer at a Given Prostate-Specific Antigen Level.”

Journal of Urology, July 2009; 182: 101.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19450841


Reviews/Editorials

Catalona WJ and Loeb S.

“Commentary on the Recommendations of The American College of Preventive Medicine on Prostate Cancer Screening.”

Medscape Urology (online)


Other Original Articles

Loeb S, Carter HB, Schaeffer EM, Ferrucci L, Kettermann A, and Metter EM.

“Should Prostate-specific Antigen be Adjusted for Body Mass Index? Data From the Baltimore Longitudinal Study of Aging.”

Journal of Urology, December 2009; 182: 2646.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19836806


Reviews/Editorials

Loeb S and Catalona WJ.

“What to do with an abnormal PSA test.”

The Oncologist, March 2008; 13: 299.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18378540


Other Original Articles

Meeks JJ, Loeb S, Helfand BT, Kan D, Smith ND, and Catalona WJ.

“Characteristics of Prostate Cancers Detected at Prostate-Specific Antigen Levels Less than 2.5 ng/ml.”

Journal of Urology, June 2009; 181: 2515.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19371879


Reviews/Editorials

Catalona WJ and Loeb S.

“PSA Is an Effective Marker for Prostate Cancer.”

AUANews, January 2007 (Part 1) and February 2007 (Part 2)

Link:


Other Original Articles

Loeb S, Chan DW, Sokoll L, Kan D, Mikolajczyk SD, Maggiore J, Mondo DM, Griffin CR, and Catalona WJ.

“PSA Standardization Bias Could Affect Clinical Decision-making.”

Journal of Urology, November 2008 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/18801532


Reviews/Editorials

Loeb S and Catalona WJ.

“Advances in Prostate Cancer Testing.”

Clinical Laboratory News, March 2007; 33: 12.


Other Original Articles

Okotie O, Roehl KA, Han M, Loeb S, Gashti SN, and Catalona WJ.

“Characteristics of Prostate Cancer Detected by Digital Rectal Examination Only.”

Urology December 2007; 70: 1117.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18158030


Reviews/Editorials

Loeb S and Catalona WJ.

“PSA as a Screening Test for Prostate Cancer.”

ACP Observer, April 2007


Other Original Articles

Sotelo R, Mora K. E, Perez L. H, Novoa J, Castillo M, Carmona O, De Andrade R, Loeb S, and Catalona WJ.

“Assay Standardization Bias: Different Prostate Cancer Detection Rates and Clinical Outcomes Resulting From Different Assays for Free and Total Prostate-Specific Antigen (PSA).”

Urology, June 2007; 69: 1143.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17572203


Reviews/Editorials

Loeb S and Catalona WJ.

“Prostate cancer screening: Where are we now?”

Contemporary Urology, May 2007

Link:


Other Original Articles

Roehl KA, Eggener SE, Loeb S, Smith ND, Antenor JAV, and Catalona WJ.

“Survival Results in Screen-Detected Prostate Cancer Patients Versus Physician-Referred Patients Treated With Radical Prostatectomy: Early Results.”

Urologic Oncology: Seminars and Original Investigations, November-December 2006; 24: 465.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17138126


Reviews/Editorials

Catalona WJ and Loeb S.

“More Effective Use of PSA”

Urologic Oncology: Seminars and Original Investigations, May-June 2006; 24: 177.


Other Original Articles

Loeb S, Gonzalez CM, Roehl KA, Han M, Antenor JV, Yap RL, and Catalona WJ.

“Pathologic Characteristics of Prostate Cancer Detected Through Prostate-Specific Antigen- Based Screening”

Journal of Urology, March 2006; 175: 902.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16469576


Reviews/Editorials

Catalona WJ, Loeb S, and Han M.

“Viewpoint: Expanding Prostate Cancer Screening.”

Annals of Internal Medicine, March 2006; 144: 441.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16549857


Other Original Articles

Nadler RB, Loeb S, Roehl KA, Antenor JV, Eggener SE, and Catalona WJ.

“Use of 2.6 ng/ml Prostate Specific Antigen (PSA) Prompt for Biopsy for Men Over Age 60”

Journal of Urology, December 2005; 174: 2154.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16280754


Other Original Articles

Donin N, Loeb S, Cooper PF, Roehl KA, Baumann NA, Catalona WJ, Helfand BT.

“Genetically-Adjusted PSA Values May Prevent Delayed Biopsies in African-American Men.”

BJU International 2014 Jan epub. PMID: 24712975

Link: http://www.ncbi.nlm.nih.gov/pubmed/24712975


Key Papers

Murphy DG, Ahlering T, Catalona WJ, Crowe H, Crowe J, Clarke N, Cooperberg M, Gillatt D, Gleave M, Loeb S, Roobol M, Sartor O, Pickles T, Wooten A, Walsh PC, Costello AJ.

“The Melbourne Consensus Statement on the Early Detection of Prostate Cancer.”

British Journal of Urology International 2012 epub Nov 8. PMID: 24206066

Link: http://www.ncbi.nlm.nih.gov/pubmed/24206066

 In light of numerous conflicting recommendations about prostate cancer screening, in August 2013 a multidisciplinary group convened in Melbourne, Australia to create consensus practice guidelines. Key areas of consensus are that level 1 evidence shows that prostate cancer screening saves lives among men ages 50-69, but that biopsy decisions should be made using PSA as part of a multivariable approach and that diagnosis must be uncoupled from treatment.


Key Papers

Loeb S, Carter HB, Catalona WJ, Moul JW, and Schroder FH.

Baseline Prostate-Specific Antigen Testing at a Young Age.

European Urology January 2012; 61: 1-7. PMID: 21862205.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21862205

This study reviews the published literature showing that baseline PSA measurements at a young age are significant predictors of later prostate cancer diagnosis and disease-specific outcomes. Baseline PSA testing should be offered to young men for risk stratification and to guide screening protocols.

 


Key Papers

Loeb S, Vonesh EF, Metter EJ, Carter HB, Gann PH, and Catalona WJ.

“What is the true number-needed-to-screen and treat to save a life with prostate-specific antigen (PSA) testing?”

Journal of Clinical Oncology January 2011; 29: 464.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21189374

Although number needed to screen (NNS) and number needed to treat (NNT) are useful statistics to assess the benefits and harms of an intervention, in a survival study setting such as the European Randomized Study of Screening for Prostate Cancer (ERSPC), NNS and NNT are time specific, and reporting values at one time point may lead to misinterpretation of results. We developed a model predicting that the NNS in this trial would decrease from 837 at year 10 to 503 at year 12, and NNT would decrease from 29 to 18.


Key Papers

Schaeffer EM, Carter HB, Kettermann A, Loeb S, Ferrucci L, Landis P, Trock BJ, and Metter EJ.

“Prostate Specific Antigen Testing Among the Elderly: When to Stop?”

Journal of Urology, April 2009; 181: 1606.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19246059

Men ages 75-80 with PSA levels <3 ng/ml are unlikely to die of or experience aggressive prostate cancer during their remaining life, suggesting that PSA testing might be safely discontinued for these men.


Key Papers

Loeb S, Roehl KA, Antenor JV, Catalona WJ, Suarez BK, and Nadler RB.

“Baseline Prostate Specific Antigen (PSA) Compared with Median PSA for Age Group as Predictor of Prostate Cancer Risk in Men Under 60 Years of Age”

Urology, February 2006; 67: 316.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16442597

In the general US population, the median PSA level is 0.7 ng/ml in the 40’s and 0.9 ng/ml in the 50’s. Young men with a baseline PSA level above the age-specific median are at significantly greater risk of future prostate cancer diagnosis and aggressive disease. Baseline PSA at a young age is a stronger predictor of prostate cancer than race, family history or digital rectal examination.

 


publications

Active Surveillance for Prostate Cancer: A Systematic Review of Clinicopathologic Variables and Biomarkers for Risk Stratification

Loeb S, Bruinsma SM, Nicholson J, Briganti A, Pickles T, Kakehi Y, Carlsson SV, Roobol MJ. “Active Surveillance for Prostate Cancer: A Systematic Review of Clinicopathologic Variables and Biomarkers for Risk Stratification.” European Urology 2014 Oct epub. PMID: 25457014

Link: http://www.ncbi.nlm.nih.gov/pubmed/25457014


Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.

Loeb S, Folkvaljon Y, Lambe M, Robinson D, Garmo H, Ingvar C, Stattin P. “Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.”  JAMA 2015; 313: 2449-55. PMID: 26103029.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26103029


Representation

Gender Bias in Medicine: Does it Exist at AUA Plenary Sessions?

Davuluri M, Barry E, Loeb S, Watts K.

“Does it Exist at AUA Plenary Sessions?”

Urology. 2020 May 18 epub. PMID: 32439553.

Link: https://pubmed.ncbi.nlm.nih.gov/32439553/


ILookLikeAUrologist: Using Twitter to Discuss Diversity and Inclusion in Urology

Loeb S, Byrne NK, Thakker S, Walter D, Katz MS.

“#ILookLikeAUrologist: Using Twitter to Discuss Diversity and Inclusion in Urology.”

European Urology Focus. 2020 Apr 12:S2405-4569(20)30093-6. PMID: 32295754

Link: https://pubmed.ncbi.nlm.nih.gov/32295754/

 


Racial Disparities and Online Health Information: YouTube and Prostate Cancer Clinical Trials

Borno HT, Zhang S, Bakke B, Bell A, Zuniga KB, Li P, Chao K, Sabol A, Killeen T, Hong H, Walter D, Loeb S.

“Racial Disparities and Online Health Information: YouTube and Prostate Cancer Clinical Trials.”

British Journal of Urology International. 2020 Apr 10 epub. PMID: 32275800

Link: https://pubmed.ncbi.nlm.nih.gov/32275800/

 


Reviews/Editorials

Russia

Russian Ministry of Health, Institute of Urology

Moscow, Russia. March 2014

Lecture topic: PSA Screening Cost-Effectiveness, Prostate Cancer Markers

Category: Prostate Cancer


Social media

An Evaluation of the Readability and Content-Quality of Pelvic Organ Prolapse YouTube Transcripts

Herbert AS, Nemirovsky A, Hess DS, Walter D, Abraham NE, Loeb S, Malik RD.

“An Evaluation of the Readability and Content-Quality of Pelvic Organ Prolapse YouTube Transcripts.”

Urology. 2021; S0090-4295(21)00266-1. PMID: 33775787

Link: https://pubmed.ncbi.nlm.nih.gov/33775787/


Guidelines Office Dissemination Committee. A Systematic Review of the Use of Social Media for Dissemination of Clinical Practice Guidelines

Bhatt NR, Czarniecki SW, Borgmann H, van Oort IM, Esperto F, Pradere B, van Gurp M, Bloemberg J, Darraugh J, Rouprêt M, Loeb S, N’Dow J, Ribal MJ, Giannarini G; EAU

“Guidelines Office Dissemination Committee. A Systematic Review of the Use of Social Media for Dissemination of Clinical Practice Guidelines.”

Eur Urol Focus. 2020 Nov 7:S2405-4569(20)30292-3. PMID: 33172773

Link: https://pubmed.ncbi.nlm.nih.gov/33172773/


Quality of Bladder Cancer Information on YouTube

Loeb S, Reines K, Abu-Salha Y, French W, Butaney M, Macaluso JN Jr, Steinberg GD, Walter D, Byrne N, la Garza D, Smith AB.

“Quality of Bladder Cancer Information on YouTube.”

Eur Urol. 2020 Sep 30: S0302-2838(20)30706-5. PMID: 33010986

Link: https://pubmed.ncbi.nlm.nih.gov/33010986/


Global Survey of the Roles and Attitudes Toward Social Media Platforms Amongst Urology Trainees

Dubin JM, Greer AB, Patel P, Carrion DM, Paesano N, Kettache RH, Haffaf M, Zouari S, Santillan D, Zotter Z, Chung A, Horie S, Koo KC, Teoh JY, Autrán Gómez AM, Ramasamy R, Loeb S, Rivas JG.

“Global Survey of the Roles and Attitudes Toward Social Media Platforms Amongst Urology Trainees.”

Urology. 2020 Sep 18:S0090-4295(20)31139-0. PMID: 32950594

Link: https://pubmed.ncbi.nlm.nih.gov/32950594/


Social Media Coverage of Scientific Articles Immediately After Publication Predicts Subsequent Citations- #SoMe_Impact Score: Observational Analysis

Sathianathen NJ, Lane Iii R, Murphy DG, Loeb S, Bakker C, Lamb AD, Weight CJ.

“Social Media Coverage of Scientific Articles Immediately After Publication Predicts Subsequent Citations- #SoMe_Impact Score: Observational Analysis.”

Journal of Medical Internet Research. 2020 Apr 17;22(4):e12288. PMID: 32301733

Link: https://pubmed.ncbi.nlm.nih.gov/32301733/


#ILookLikeAUrologist: Using Twitter to Discuss Diversity and Inclusion in Urology

Loeb S, Byrne NK, Thakker S, Walter D, Katz MS.

“#ILookLikeAUrologist: Using Twitter to Discuss Diversity and Inclusion in Urology.”

European Urology Focus. 2020 Apr 12:S2405-4569(20)30093-6. PMID: 32295754

Link: https://pubmed.ncbi.nlm.nih.gov/32295754/


Racial Disparities and Online Health Information: YouTube and Prostate Cancer Clinical Trials

Borno HT, Zhang S, Bakke B, Bell A, Zuniga KB, Li P, Chao K, Sabol A, Killeen T, Hong H, Walter D, Loeb S.

“Racial Disparities and Online Health Information: YouTube and Prostate Cancer Clinical Trials.”

British Journal of Urology International. 2020 Apr 10 epub. PMID: 32275800

Link: https://pubmed.ncbi.nlm.nih.gov/32275800/


Fake News about Benign Prostate Hyperplasia on YouTube

Loeb S.

“Fake News about Benign Prostate Hyperplasia on YouTube.”

British Journal of Urology International. 2020 Apr;125(4):477-478. PMID: 32250050

Link: https://pubmed.ncbi.nlm.nih.gov/32250050/


Global Survey Evaluating Drawbacks of Social Media Usage for Practicing Urologists

Dubin JM, Greer AB, Patel P, Carrion DM, Paesano N, Kettache RH, Haffaf M, Zouari S, Santillan D, Zotter Z, Chung A, Horie S, Koo KC, Teoh JYC, Autrán Gómez AM, Gomez Rivas J, Ramasamy R, Loeb S.

“Global Survey Evaluating Drawbacks of Social Media Usage for Practicing Urologists.”

BJU International. 2020 Mar 9 epub. PMID: 32147930.

Link: https://pubmed.ncbi.nlm.nih.gov/32147930/


Evaluating and Optimizing the Use of Social Media in Urology

Loeb S, Murphy DG.

“Evaluating and Optimizing the Use of Social Media in Urology.”

European Urology Focus. 2020 May 15;6(3):425-426. Epub 2020 Feb 29. PMID: 32127328.

Link: https://pubmed.ncbi.nlm.nih.gov/32127328/


Pelvic Organ Prolapse on YouTube: Evaluation of Consumer Information

Herbert AS, Nemirovsky A, Hess DS, Walter D, Abraham NE, Loeb S, Malik RD.

“Pelvic Organ Prolapse on YouTube: Evaluation of Consumer Information.”

British Journal of Urology International 2020 Feb 10 epub.  PMID: 32039554.

Link: https://pubmed.ncbi.nlm.nih.gov/32039554/


Using data from an online health community to examine the impact of prostate cancer on sleep

Robbins R, Jean-Louis G, Chanko N, Combs P, Byrne N, Loeb S.

“Using data from an online health community to examine the impact of prostate cancer on sleep.”

British Journal of Urology International. 2020 Jan 3 epub.  PMID: 31899938.

Link: https://pubmed.ncbi.nlm.nih.gov/31899938/


Loeb S, Taylor J, Borin JF, Mihalcea R, Perez-Rosas V, Byrne N, Chiang AL, Langford A.

“Fake News: Spread of Misinformation about Urological Conditions on Social Media.”

European Urology Focus. 2019 Dec 21 epub.  PMID: 31874796.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31874796


Untitled

Thangasamy IA, Loeb S, Sathianathen NJ, Leveridge M, Stork B, Davies BJ, Woo HH.

“Evaluating the Effectiveness of an Online Journal Club: Experience from the International Urology Journal Club.”

European Urology Focus. 2019 Oct 31 epub.PMID:31679867.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31679867


Untitled

Taylor J, Loeb S.

“Guideline of guidelines: social media in urology.”

British Journal of Urology International. 2019 Oct 20 epub. PMID: 31631471.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31631471


Untitled

Chandrasekar T, Goldberg H, Klaassen Z, Wallis CJD, Leong JY, Liem S, Teplitsky S, Noorani R, Loeb S.

“Twitter and academic Urology in the United States and Canada: a comprehensive assessment of the Twitterverse in 2019.”

British Journal of Urology International. 2019 Oct 10 epub. PMID: 31602782.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31602782


Untitled

Langford AT, Roberts T, Gupta J, Orellana KT, Loeb S.

“Impact of the Internet on Patient-Physician Communication.”

Eur Urol Focus. 2019 Sep 30 epub. PMID: 31582312.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31582312


Untitled

Teoh JY, Mackenzie G, Smith M, Yuen SK, Gudaru K, Leow J, Leung CH, Ng CF, Loeb S.

“Understanding the Composition of a Successful Tweet in Urology.”

Eur Urol Focus. 2019 Aug 27 epub. PMID:31471219.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31471219


Untitled

Loeb S, Carrick T, Frey C, Titus T.

“Increasing Social Media Use in Urology: 2017 American Urological Association Survey.”

European Urology Focus. 2019 Jul 24 epub. PMID: 31351900

Link: https://www.ncbi.nlm.nih.gov/pubmed/31351900

 


Untitled

Stork B, Loeb S.

“The Urology Care Foundation – trusted online resources in an era of misinformation.”

Nature Reviews Urology 2019 Jul 12 epub. PMID: 31300752

Link: https://www.ncbi.nlm.nih.gov/pubmed/31300752

 


Untitled

Loeb S, Katz MS, Stork B.

“Update on the Urology Tag Ontology: Standardized Hashtags for Social Media in Urology.”

Eur Urol. 2019 Jun epub. PMID: 31164252

Link: https://www.ncbi.nlm.nih.gov/pubmed/31164252


Untitled

Langford A, Loeb S.

“Perceived Patient-Provider Communication Quality and Sociodemographic Factors Associated With Watching Health-Related Videos on YouTube: A Cross-Sectional Analysis.”

J Med Internet Res. 2019 May 17;21(5):e13512. PMID:31102372.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31102372


Untitled

Ke Y, Taylor J, Gao L, Wang H, Zhao H, Byrne N, Modgil V, Butaney M, Makarov DV, Prabhu V, Loeb S.

“Twitter response to the 2018 US Preventive Services Task Force guidelines on prostate cancer screening.”

BJU International 2019 Feb 27 epub. PMID: 30811805

Link: https://www.ncbi.nlm.nih.gov/pubmed/30811805


Untitled

Loeb S, Taylor J, Butaney M, Byrne NK, Gao L, Soule HR, Miyahira AK.

“Twitter-based Prostate Cancer Journal Club (#ProstateJC) Promotes Multidisciplinary Global Scientific Discussion and Research Dissemination.”

European Urology 2019 Jan 30 epub. PMID: 30711329.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30711329

 


Untitled

Loeb S, Sengupta S, Butaney M, Macaluso JN Jr, Czarniecki SW, Robbins R, Braithwaite RS, Gao L, Byrne N, Walter D, Langford A.

“Dissemination of Misinformative and Biased Information about Prostate Cancer on YouTube.

European Urology. 2018 Nov 27 epub. PMID: 30502104.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30502104

In this study, we examined the first 150 YouTube videos about prostate cancer, showing that the majority had potentially biased and/or misinformative information in the video or comments.


Borgmann H, Cooperberg M, Murphy D, Loeb S, N’Dow J, Ribal MJ, Woo H, Rouprêt M, Winterbottom A, Wijburg C, Wirth M, Catto J, Kutikov A

 “Online Professionalism-2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media”

European Urology 2018 Aug epub..  PMID: 30177286.

    Link: https://www.ncbi.nlm.nih.gov/pubmed/30177286


Loeb S, Taneja S, Walter D, Zweifach S, Byrne N.

“Crowd-Funding for Prostate Cancer and Breast Cancer. “

BJU International. 2018 May 22. PMID: 29786946

Link: https://www.ncbi.nlm.nih.gov/pubmed/29786946


Untitled

Loeb S, Katz MS, Langford A, Byrne N, Ciprut S.

“Prostate Cancer and Social Media.”

Nature Reviews Urology 2018 Apr 11. PMID: 29643501.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29643501

 


Loeb S, Katz MS, Langford A, Byrne N, Ciprut S.

 “Prostate Cancer and Social Media.”

Nature Reviews Urology 2018 Apr 11. PMID: 29643501.

    Link: https://www.ncbi.nlm.nih.gov/pubmed/29643501


Ciprut S, Curnyn C, Davuluri M, Sternberg K, Loeb S.

 “Twitter Activity Associated with US News and World Report Reputation Scores for Urology Departments.”

 Urology. 2017 Jun 29 epub.  PMID: 28669746.

    Link: https://www.ncbi.nlm.nih.gov/pubmed/28669746


Sternberg KM, Loeb SL, Canes D, Donnelly L, Tsai MH.

“The use of Twitter to facilitate sharing of clinical expertise in urology.”

J Am Med Inform Assoc. 2017 epub Jun 7. PMID: 28591771.

 Link: https://www.ncbi.nlm.nih.gov/pubmed/28591771


Loeb S, Stork B, Gold HT, Stout NK, Makarov DV, Weight C, Borgmann H.

“Tweet this: how advocacy for breast and prostate cancers stacks up on social media.”

BJU International 2017 May epub.  PMID: 28471484

    Link: http://www.ncbi.nlm.nih.gov/pubmed/2847148


O’Connor EM, Nason GJ, O’Kelly F, Manecksha RP, Loeb S.

“Newsworthiness vs scientific impact: are the most highly cited urology papers the most widely disseminated in the media?”

BJU International 2017 Apr 18 epub.  PMID: 28418091

    Link: https://www.ncbi.nlm.nih.gov/pubmed/28418091


Loeb S, Roupret M, Van Oort I, N’dow J, Van Gurp M, Bloemberg J, Darraugh JA, Ribal M. 

“Novel Use of Twitter to Disseminate and Evaluate Adherence with Clinical Guidelines by the European Association of Urology”.

BJU Int. 2017 Feb 7 epub.  PMID: 28170154

Link: https://www.ncbi.nlm.nih.gov/pubmed/28170154

Herein, we demonstrate a proof-of-principal study on the use of twitter as a platform for the dissemination and real-time evaluation of the European Association of Urology clinical guidelines. These strategies can be considered by other medical societies to increase the reach and obtain rapid feedback on guidelines recommendations.


Other Papers

Loeb S. Editorial Comment on

“Digital Identity: Develop One Before You’re Given One”

Urology 2015; 85: 1222. PMID: 26099864.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26099864


Prabhu V, Lee T, Loeb S, Holmes JH, Gold HT, Lepor H, Penson DF, and Makarov DV.

“Twitter Response to the United States Preventive Services Task Force Recommendations Against Screening with Prostate Specific Antigen.” 

BJU International 2014 epub.

PMID: 24661474

Link: http://www.ncbi.nlm.nih.gov/pubmed/24661474

 


Prabhu V, Lee T, Loeb S, Holmes JH, Gold HT, Lepor H, Penson DF, and Makarov DV.

“Twitter Response to the United States Preventive Services Task Force Recommendations Against Screening with Prostate Specific Antigen.” 

BJU International 2014 epub.

PMID: 24661474

Link: http://www.ncbi.nlm.nih.gov/pubmed/24661474

 


Use of Social Media in Urology: Data from the American Urological Association

Loeb S, Bayne CE, Frey C, Davies BJ, Averch TD, Woo HH, Stork B, Cooperberg MR, Eggener SE.

“Use of Social Media in Urology: Data from the American Urological Association.”

British Journal of Urology International 2013 epub Nov 26. PMID: 24274744

Link: http://www.ncbi.nlm.nih.gov/pubmed/24274744


Social Media

An Evaluation of the Readability and Content-Quality of Pelvic Organ Prolapse YouTube Transcripts

Herbert AS, Nemirovsky A, Hess DS, Walter D, Abraham NE, Loeb S, Malik RD.

“An Evaluation of the Readability and Content-Quality of Pelvic Organ Prolapse YouTube Transcripts.”

Urology. 2021; S0090-4295(21)00266-1. PMID: 33775787

Link: https://pubmed.ncbi.nlm.nih.gov/33775787/


Guidelines Office Dissemination Committee. A Systematic Review of the Use of Social Media for Dissemination of Clinical Practice Guidelines

Bhatt NR, Czarniecki SW, Borgmann H, van Oort IM, Esperto F, Pradere B, van Gurp M, Bloemberg J, Darraugh J, Rouprêt M, Loeb S, N’Dow J, Ribal MJ, Giannarini G; EAU

“Guidelines Office Dissemination Committee. A Systematic Review of the Use of Social Media for Dissemination of Clinical Practice Guidelines.”

Eur Urol Focus. 2020 Nov 7:S2405-4569(20)30292-3. PMID: 33172773

Link: https://pubmed.ncbi.nlm.nih.gov/33172773/


Quality of Bladder Cancer Information on YouTube

Loeb S, Reines K, Abu-Salha Y, French W, Butaney M, Macaluso JN Jr, Steinberg GD, Walter D, Byrne N, la Garza D, Smith AB.

“Quality of Bladder Cancer Information on YouTube.”

Eur Urol. 2020 Sep 30: S0302-2838(20)30706-5. PMID: 33010986

Link: https://pubmed.ncbi.nlm.nih.gov/33010986/


Global Survey of the Roles and Attitudes Toward Social Media Platforms Amongst Urology Trainees

Dubin JM, Greer AB, Patel P, Carrion DM, Paesano N, Kettache RH, Haffaf M, Zouari S, Santillan D, Zotter Z, Chung A, Horie S, Koo KC, Teoh JY, Autrán Gómez AM, Ramasamy R, Loeb S, Rivas JG.

“Global Survey of the Roles and Attitudes Toward Social Media Platforms Amongst Urology Trainees.”

Urology. 2020 Sep 18:S0090-4295(20)31139-0. PMID: 32950594

Link: https://pubmed.ncbi.nlm.nih.gov/32950594/


Social Media Coverage of Scientific Articles Immediately After Publication Predicts Subsequent Citations- #SoMe_Impact Score: Observational Analysis

Sathianathen NJ, Lane Iii R, Murphy DG, Loeb S, Bakker C, Lamb AD, Weight CJ.

“Social Media Coverage of Scientific Articles Immediately After Publication Predicts Subsequent Citations- #SoMe_Impact Score: Observational Analysis.”

Journal of Medical Internet Research. 2020 Apr 17;22(4):e12288. PMID: 32301733

Link: https://pubmed.ncbi.nlm.nih.gov/32301733/


#ILookLikeAUrologist: Using Twitter to Discuss Diversity and Inclusion in Urology

Loeb S, Byrne NK, Thakker S, Walter D, Katz MS.

“#ILookLikeAUrologist: Using Twitter to Discuss Diversity and Inclusion in Urology.”

European Urology Focus. 2020 Apr 12:S2405-4569(20)30093-6. PMID: 32295754

Link: https://pubmed.ncbi.nlm.nih.gov/32295754/


Racial Disparities and Online Health Information: YouTube and Prostate Cancer Clinical Trials

Borno HT, Zhang S, Bakke B, Bell A, Zuniga KB, Li P, Chao K, Sabol A, Killeen T, Hong H, Walter D, Loeb S.

“Racial Disparities and Online Health Information: YouTube and Prostate Cancer Clinical Trials.”

British Journal of Urology International. 2020 Apr 10 epub. PMID: 32275800

Link: https://pubmed.ncbi.nlm.nih.gov/32275800/


Fake News about Benign Prostate Hyperplasia on YouTube

Loeb S.

“Fake News about Benign Prostate Hyperplasia on YouTube.”

British Journal of Urology International. 2020 Apr;125(4):477-478. PMID: 32250050

Link: https://pubmed.ncbi.nlm.nih.gov/32250050/


Global Survey Evaluating Drawbacks of Social Media Usage for Practicing Urologists

Dubin JM, Greer AB, Patel P, Carrion DM, Paesano N, Kettache RH, Haffaf M, Zouari S, Santillan D, Zotter Z, Chung A, Horie S, Koo KC, Teoh JYC, Autrán Gómez AM, Gomez Rivas J, Ramasamy R, Loeb S.

“Global Survey Evaluating Drawbacks of Social Media Usage for Practicing Urologists.”

BJU International. 2020 Mar 9 epub. PMID: 32147930.

Link: https://pubmed.ncbi.nlm.nih.gov/32147930/


Evaluating and Optimizing the Use of Social Media in Urology

Loeb S, Murphy DG.

“Evaluating and Optimizing the Use of Social Media in Urology.”

European Urology Focus. 2020 May 15;6(3):425-426. Epub 2020 Feb 29. PMID: 32127328.

Link: https://pubmed.ncbi.nlm.nih.gov/32127328/


Pelvic Organ Prolapse on YouTube: Evaluation of Consumer Information

Herbert AS, Nemirovsky A, Hess DS, Walter D, Abraham NE, Loeb S, Malik RD.

“Pelvic Organ Prolapse on YouTube: Evaluation of Consumer Information.”

British Journal of Urology International 2020 Feb 10 epub.  PMID: 32039554.

Link: https://pubmed.ncbi.nlm.nih.gov/32039554/


Using data from an online health community to examine the impact of prostate cancer on sleep

Robbins R, Jean-Louis G, Chanko N, Combs P, Byrne N, Loeb S.

“Using data from an online health community to examine the impact of prostate cancer on sleep.”

British Journal of Urology International. 2020 Jan 3 epub.  PMID: 31899938.

Link: https://pubmed.ncbi.nlm.nih.gov/31899938/


Loeb S, Taylor J, Borin JF, Mihalcea R, Perez-Rosas V, Byrne N, Chiang AL, Langford A.

“Fake News: Spread of Misinformation about Urological Conditions on Social Media.”

European Urology Focus. 2019 Dec 21 epub.  PMID: 31874796.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31874796


Untitled

Thangasamy IA, Loeb S, Sathianathen NJ, Leveridge M, Stork B, Davies BJ, Woo HH.

“Evaluating the Effectiveness of an Online Journal Club: Experience from the International Urology Journal Club.”

European Urology Focus. 2019 Oct 31 epub.PMID:31679867.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31679867


Untitled

Taylor J, Loeb S.

“Guideline of guidelines: social media in urology.”

British Journal of Urology International. 2019 Oct 20 epub. PMID: 31631471.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31631471


Untitled

Chandrasekar T, Goldberg H, Klaassen Z, Wallis CJD, Leong JY, Liem S, Teplitsky S, Noorani R, Loeb S.

“Twitter and academic Urology in the United States and Canada: a comprehensive assessment of the Twitterverse in 2019.”

British Journal of Urology International. 2019 Oct 10 epub. PMID: 31602782.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31602782


Untitled

Langford AT, Roberts T, Gupta J, Orellana KT, Loeb S.

“Impact of the Internet on Patient-Physician Communication.”

Eur Urol Focus. 2019 Sep 30 epub. PMID: 31582312.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31582312


Untitled

Teoh JY, Mackenzie G, Smith M, Yuen SK, Gudaru K, Leow J, Leung CH, Ng CF, Loeb S.

“Understanding the Composition of a Successful Tweet in Urology.”

Eur Urol Focus. 2019 Aug 27 epub. PMID:31471219.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31471219


Untitled

Loeb S, Carrick T, Frey C, Titus T.

“Increasing Social Media Use in Urology: 2017 American Urological Association Survey.”

European Urology Focus. 2019 Jul 24 epub. PMID: 31351900

Link: https://www.ncbi.nlm.nih.gov/pubmed/31351900

 


Untitled

Stork B, Loeb S.

“The Urology Care Foundation – trusted online resources in an era of misinformation.”

Nature Reviews Urology 2019 Jul 12 epub. PMID: 31300752

Link: https://www.ncbi.nlm.nih.gov/pubmed/31300752

 


Untitled

Loeb S, Katz MS, Stork B.

“Update on the Urology Tag Ontology: Standardized Hashtags for Social Media in Urology.”

Eur Urol. 2019 Jun epub. PMID: 31164252

Link: https://www.ncbi.nlm.nih.gov/pubmed/31164252


Untitled

Langford A, Loeb S.

“Perceived Patient-Provider Communication Quality and Sociodemographic Factors Associated With Watching Health-Related Videos on YouTube: A Cross-Sectional Analysis.”

J Med Internet Res. 2019 May 17;21(5):e13512. PMID:31102372.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31102372


Untitled

Ke Y, Taylor J, Gao L, Wang H, Zhao H, Byrne N, Modgil V, Butaney M, Makarov DV, Prabhu V, Loeb S.

“Twitter response to the 2018 US Preventive Services Task Force guidelines on prostate cancer screening.”

BJU International 2019 Feb 27 epub. PMID: 30811805

Link: https://www.ncbi.nlm.nih.gov/pubmed/30811805


Untitled

Loeb S, Taylor J, Butaney M, Byrne NK, Gao L, Soule HR, Miyahira AK.

“Twitter-based Prostate Cancer Journal Club (#ProstateJC) Promotes Multidisciplinary Global Scientific Discussion and Research Dissemination.”

European Urology 2019 Jan 30 epub. PMID: 30711329.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30711329

 


Untitled

Loeb S, Sengupta S, Butaney M, Macaluso JN Jr, Czarniecki SW, Robbins R, Braithwaite RS, Gao L, Byrne N, Walter D, Langford A.

“Dissemination of Misinformative and Biased Information about Prostate Cancer on YouTube.

European Urology. 2018 Nov 27 epub. PMID: 30502104.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30502104

In this study, we examined the first 150 YouTube videos about prostate cancer, showing that the majority had potentially biased and/or misinformative information in the video or comments.


Borgmann H, Cooperberg M, Murphy D, Loeb S, N’Dow J, Ribal MJ, Woo H, Rouprêt M, Winterbottom A, Wijburg C, Wirth M, Catto J, Kutikov A

 “Online Professionalism-2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media”

European Urology 2018 Aug epub..  PMID: 30177286.

    Link: https://www.ncbi.nlm.nih.gov/pubmed/30177286


Loeb S, Taneja S, Walter D, Zweifach S, Byrne N.

“Crowd-Funding for Prostate Cancer and Breast Cancer. “

BJU International. 2018 May 22. PMID: 29786946

Link: https://www.ncbi.nlm.nih.gov/pubmed/29786946


Untitled

Loeb S, Katz MS, Langford A, Byrne N, Ciprut S.

“Prostate Cancer and Social Media.”

Nature Reviews Urology 2018 Apr 11. PMID: 29643501.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29643501

 


Loeb S, Katz MS, Langford A, Byrne N, Ciprut S.

 “Prostate Cancer and Social Media.”

Nature Reviews Urology 2018 Apr 11. PMID: 29643501.

    Link: https://www.ncbi.nlm.nih.gov/pubmed/29643501


Ciprut S, Curnyn C, Davuluri M, Sternberg K, Loeb S.

 “Twitter Activity Associated with US News and World Report Reputation Scores for Urology Departments.”

 Urology. 2017 Jun 29 epub.  PMID: 28669746.

    Link: https://www.ncbi.nlm.nih.gov/pubmed/28669746


Sternberg KM, Loeb SL, Canes D, Donnelly L, Tsai MH.

“The use of Twitter to facilitate sharing of clinical expertise in urology.”

J Am Med Inform Assoc. 2017 epub Jun 7. PMID: 28591771.

 Link: https://www.ncbi.nlm.nih.gov/pubmed/28591771


Loeb S, Stork B, Gold HT, Stout NK, Makarov DV, Weight C, Borgmann H.

“Tweet this: how advocacy for breast and prostate cancers stacks up on social media.”

BJU International 2017 May epub.  PMID: 28471484

    Link: http://www.ncbi.nlm.nih.gov/pubmed/2847148


O’Connor EM, Nason GJ, O’Kelly F, Manecksha RP, Loeb S.

“Newsworthiness vs scientific impact: are the most highly cited urology papers the most widely disseminated in the media?”

BJU International 2017 Apr 18 epub.  PMID: 28418091

    Link: https://www.ncbi.nlm.nih.gov/pubmed/28418091


Loeb S, Roupret M, Van Oort I, N’dow J, Van Gurp M, Bloemberg J, Darraugh JA, Ribal M. 

“Novel Use of Twitter to Disseminate and Evaluate Adherence with Clinical Guidelines by the European Association of Urology”.

BJU Int. 2017 Feb 7 epub.  PMID: 28170154

Link: https://www.ncbi.nlm.nih.gov/pubmed/28170154

Herein, we demonstrate a proof-of-principal study on the use of twitter as a platform for the dissemination and real-time evaluation of the European Association of Urology clinical guidelines. These strategies can be considered by other medical societies to increase the reach and obtain rapid feedback on guidelines recommendations.


Other Papers

Loeb S. Editorial Comment on

“Digital Identity: Develop One Before You’re Given One”

Urology 2015; 85: 1222. PMID: 26099864.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26099864


Prabhu V, Lee T, Loeb S, Holmes JH, Gold HT, Lepor H, Penson DF, and Makarov DV.

“Twitter Response to the United States Preventive Services Task Force Recommendations Against Screening with Prostate Specific Antigen.” 

BJU International 2014 epub.

PMID: 24661474

Link: http://www.ncbi.nlm.nih.gov/pubmed/24661474

 


Prabhu V, Lee T, Loeb S, Holmes JH, Gold HT, Lepor H, Penson DF, and Makarov DV.

“Twitter Response to the United States Preventive Services Task Force Recommendations Against Screening with Prostate Specific Antigen.” 

BJU International 2014 epub.

PMID: 24661474

Link: http://www.ncbi.nlm.nih.gov/pubmed/24661474

 


Use of Social Media in Urology: Data from the American Urological Association

Loeb S, Bayne CE, Frey C, Davies BJ, Averch TD, Woo HH, Stork B, Cooperberg MR, Eggener SE.

“Use of Social Media in Urology: Data from the American Urological Association.”

British Journal of Urology International 2013 epub Nov 26. PMID: 24274744

Link: http://www.ncbi.nlm.nih.gov/pubmed/24274744


Social Media - Interviews

ZERO Summit

Prostate Cancer and Fake News (March 2, 2021)


Malecare Prostate Cancer Patient Conference

Navigating Fake News about Prostate Cancer and Social Media (12/12/20)


Integrating Social Media as an Effective Teaching Tool for Patients – Stacy Loeb

11/2018 Integrating Social Media as an Effective Teaching Tool for Patients

 


Urology Times on Twitter in Urology

5/2014 Urology Times on Twitter in Urology


Twitter and Urology- Targeted Oncology Interview

5/2014 Twitter and Urology- Targeted Oncology Interview


Social Media - Lectures

Social Media for Urologists

EMPIRE Urology Lecture Series (5/6/20)


Lecture on Social Media in Medicine at International Continence Society in Rio de Janiero

10/2014 Lecture on Social Media in Medicine at International Continence Society in Rio de Janiero


SocialMedia

An Evaluation of the Readability and Content-Quality of Pelvic Organ Prolapse YouTube Transcripts

Herbert AS, Nemirovsky A, Hess DS, Walter D, Abraham NE, Loeb S, Malik RD.

“An Evaluation of the Readability and Content-Quality of Pelvic Organ Prolapse YouTube Transcripts.”

Urology. 2021; S0090-4295(21)00266-1. PMID: 33775787

Link: https://pubmed.ncbi.nlm.nih.gov/33775787/


Guidelines Office Dissemination Committee. A Systematic Review of the Use of Social Media for Dissemination of Clinical Practice Guidelines

Bhatt NR, Czarniecki SW, Borgmann H, van Oort IM, Esperto F, Pradere B, van Gurp M, Bloemberg J, Darraugh J, Rouprêt M, Loeb S, N’Dow J, Ribal MJ, Giannarini G; EAU

“Guidelines Office Dissemination Committee. A Systematic Review of the Use of Social Media for Dissemination of Clinical Practice Guidelines.”

Eur Urol Focus. 2020 Nov 7:S2405-4569(20)30292-3. PMID: 33172773

Link: https://pubmed.ncbi.nlm.nih.gov/33172773/


Quality of Bladder Cancer Information on YouTube

Loeb S, Reines K, Abu-Salha Y, French W, Butaney M, Macaluso JN Jr, Steinberg GD, Walter D, Byrne N, la Garza D, Smith AB.

“Quality of Bladder Cancer Information on YouTube.”

Eur Urol. 2020 Sep 30: S0302-2838(20)30706-5. PMID: 33010986

Link: https://pubmed.ncbi.nlm.nih.gov/33010986/


Global Survey of the Roles and Attitudes Toward Social Media Platforms Amongst Urology Trainees

Dubin JM, Greer AB, Patel P, Carrion DM, Paesano N, Kettache RH, Haffaf M, Zouari S, Santillan D, Zotter Z, Chung A, Horie S, Koo KC, Teoh JY, Autrán Gómez AM, Ramasamy R, Loeb S, Rivas JG.

“Global Survey of the Roles and Attitudes Toward Social Media Platforms Amongst Urology Trainees.”

Urology. 2020 Sep 18:S0090-4295(20)31139-0. PMID: 32950594

Link: https://pubmed.ncbi.nlm.nih.gov/32950594/


Social Media Coverage of Scientific Articles Immediately After Publication Predicts Subsequent Citations- #SoMe_Impact Score: Observational Analysis

Sathianathen NJ, Lane Iii R, Murphy DG, Loeb S, Bakker C, Lamb AD, Weight CJ.

“Social Media Coverage of Scientific Articles Immediately After Publication Predicts Subsequent Citations- #SoMe_Impact Score: Observational Analysis.”

Journal of Medical Internet Research. 2020 Apr 17;22(4):e12288. PMID: 32301733

Link: https://pubmed.ncbi.nlm.nih.gov/32301733/


#ILookLikeAUrologist: Using Twitter to Discuss Diversity and Inclusion in Urology

Loeb S, Byrne NK, Thakker S, Walter D, Katz MS.

“#ILookLikeAUrologist: Using Twitter to Discuss Diversity and Inclusion in Urology.”

European Urology Focus. 2020 Apr 12:S2405-4569(20)30093-6. PMID: 32295754

Link: https://pubmed.ncbi.nlm.nih.gov/32295754/


Racial Disparities and Online Health Information: YouTube and Prostate Cancer Clinical Trials

Borno HT, Zhang S, Bakke B, Bell A, Zuniga KB, Li P, Chao K, Sabol A, Killeen T, Hong H, Walter D, Loeb S.

“Racial Disparities and Online Health Information: YouTube and Prostate Cancer Clinical Trials.”

British Journal of Urology International. 2020 Apr 10 epub. PMID: 32275800

Link: https://pubmed.ncbi.nlm.nih.gov/32275800/


Fake News about Benign Prostate Hyperplasia on YouTube

Loeb S.

“Fake News about Benign Prostate Hyperplasia on YouTube.”

British Journal of Urology International. 2020 Apr;125(4):477-478. PMID: 32250050

Link: https://pubmed.ncbi.nlm.nih.gov/32250050/


Global Survey Evaluating Drawbacks of Social Media Usage for Practicing Urologists

Dubin JM, Greer AB, Patel P, Carrion DM, Paesano N, Kettache RH, Haffaf M, Zouari S, Santillan D, Zotter Z, Chung A, Horie S, Koo KC, Teoh JYC, Autrán Gómez AM, Gomez Rivas J, Ramasamy R, Loeb S.

“Global Survey Evaluating Drawbacks of Social Media Usage for Practicing Urologists.”

BJU International. 2020 Mar 9 epub. PMID: 32147930.

Link: https://pubmed.ncbi.nlm.nih.gov/32147930/


Evaluating and Optimizing the Use of Social Media in Urology

Loeb S, Murphy DG.

“Evaluating and Optimizing the Use of Social Media in Urology.”

European Urology Focus. 2020 May 15;6(3):425-426. Epub 2020 Feb 29. PMID: 32127328.

Link: https://pubmed.ncbi.nlm.nih.gov/32127328/


Pelvic Organ Prolapse on YouTube: Evaluation of Consumer Information

Herbert AS, Nemirovsky A, Hess DS, Walter D, Abraham NE, Loeb S, Malik RD.

“Pelvic Organ Prolapse on YouTube: Evaluation of Consumer Information.”

British Journal of Urology International 2020 Feb 10 epub.  PMID: 32039554.

Link: https://pubmed.ncbi.nlm.nih.gov/32039554/


Using data from an online health community to examine the impact of prostate cancer on sleep

Robbins R, Jean-Louis G, Chanko N, Combs P, Byrne N, Loeb S.

“Using data from an online health community to examine the impact of prostate cancer on sleep.”

British Journal of Urology International. 2020 Jan 3 epub.  PMID: 31899938.

Link: https://pubmed.ncbi.nlm.nih.gov/31899938/


Loeb S, Taylor J, Borin JF, Mihalcea R, Perez-Rosas V, Byrne N, Chiang AL, Langford A.

“Fake News: Spread of Misinformation about Urological Conditions on Social Media.”

European Urology Focus. 2019 Dec 21 epub.  PMID: 31874796.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31874796


Untitled

Thangasamy IA, Loeb S, Sathianathen NJ, Leveridge M, Stork B, Davies BJ, Woo HH.

“Evaluating the Effectiveness of an Online Journal Club: Experience from the International Urology Journal Club.”

European Urology Focus. 2019 Oct 31 epub.PMID:31679867.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31679867


Untitled

Taylor J, Loeb S.

“Guideline of guidelines: social media in urology.”

British Journal of Urology International. 2019 Oct 20 epub. PMID: 31631471.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31631471


Untitled

Chandrasekar T, Goldberg H, Klaassen Z, Wallis CJD, Leong JY, Liem S, Teplitsky S, Noorani R, Loeb S.

“Twitter and academic Urology in the United States and Canada: a comprehensive assessment of the Twitterverse in 2019.”

British Journal of Urology International. 2019 Oct 10 epub. PMID: 31602782.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31602782


Untitled

Langford AT, Roberts T, Gupta J, Orellana KT, Loeb S.

“Impact of the Internet on Patient-Physician Communication.”

Eur Urol Focus. 2019 Sep 30 epub. PMID: 31582312.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31582312


Untitled

Teoh JY, Mackenzie G, Smith M, Yuen SK, Gudaru K, Leow J, Leung CH, Ng CF, Loeb S.

“Understanding the Composition of a Successful Tweet in Urology.”

Eur Urol Focus. 2019 Aug 27 epub. PMID:31471219.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31471219


Untitled

Loeb S, Carrick T, Frey C, Titus T.

“Increasing Social Media Use in Urology: 2017 American Urological Association Survey.”

European Urology Focus. 2019 Jul 24 epub. PMID: 31351900

Link: https://www.ncbi.nlm.nih.gov/pubmed/31351900

 


Untitled

Stork B, Loeb S.

“The Urology Care Foundation – trusted online resources in an era of misinformation.”

Nature Reviews Urology 2019 Jul 12 epub. PMID: 31300752

Link: https://www.ncbi.nlm.nih.gov/pubmed/31300752

 


Untitled

Loeb S, Katz MS, Stork B.

“Update on the Urology Tag Ontology: Standardized Hashtags for Social Media in Urology.”

Eur Urol. 2019 Jun epub. PMID: 31164252

Link: https://www.ncbi.nlm.nih.gov/pubmed/31164252


Untitled

Langford A, Loeb S.

“Perceived Patient-Provider Communication Quality and Sociodemographic Factors Associated With Watching Health-Related Videos on YouTube: A Cross-Sectional Analysis.”

J Med Internet Res. 2019 May 17;21(5):e13512. PMID:31102372.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31102372


Untitled

Ke Y, Taylor J, Gao L, Wang H, Zhao H, Byrne N, Modgil V, Butaney M, Makarov DV, Prabhu V, Loeb S.

“Twitter response to the 2018 US Preventive Services Task Force guidelines on prostate cancer screening.”

BJU International 2019 Feb 27 epub. PMID: 30811805

Link: https://www.ncbi.nlm.nih.gov/pubmed/30811805


Untitled

Loeb S, Taylor J, Butaney M, Byrne NK, Gao L, Soule HR, Miyahira AK.

“Twitter-based Prostate Cancer Journal Club (#ProstateJC) Promotes Multidisciplinary Global Scientific Discussion and Research Dissemination.”

European Urology 2019 Jan 30 epub. PMID: 30711329.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30711329

 


Untitled

Loeb S, Sengupta S, Butaney M, Macaluso JN Jr, Czarniecki SW, Robbins R, Braithwaite RS, Gao L, Byrne N, Walter D, Langford A.

“Dissemination of Misinformative and Biased Information about Prostate Cancer on YouTube.

European Urology. 2018 Nov 27 epub. PMID: 30502104.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30502104

In this study, we examined the first 150 YouTube videos about prostate cancer, showing that the majority had potentially biased and/or misinformative information in the video or comments.


Borgmann H, Cooperberg M, Murphy D, Loeb S, N’Dow J, Ribal MJ, Woo H, Rouprêt M, Winterbottom A, Wijburg C, Wirth M, Catto J, Kutikov A

 “Online Professionalism-2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media”

European Urology 2018 Aug epub..  PMID: 30177286.

    Link: https://www.ncbi.nlm.nih.gov/pubmed/30177286


Loeb S, Taneja S, Walter D, Zweifach S, Byrne N.

“Crowd-Funding for Prostate Cancer and Breast Cancer. “

BJU International. 2018 May 22. PMID: 29786946

Link: https://www.ncbi.nlm.nih.gov/pubmed/29786946


Untitled

Loeb S, Katz MS, Langford A, Byrne N, Ciprut S.

“Prostate Cancer and Social Media.”

Nature Reviews Urology 2018 Apr 11. PMID: 29643501.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29643501

 


Ciprut S, Curnyn C, Davuluri M, Sternberg K, Loeb S.

 “Twitter Activity Associated with US News and World Report Reputation Scores for Urology Departments.”

 Urology. 2017 Jun 29 epub.  PMID: 28669746.

    Link: https://www.ncbi.nlm.nih.gov/pubmed/28669746


Sternberg KM, Loeb SL, Canes D, Donnelly L, Tsai MH.

“The use of Twitter to facilitate sharing of clinical expertise in urology.”

J Am Med Inform Assoc. 2017 epub Jun 7. PMID: 28591771.

 Link: https://www.ncbi.nlm.nih.gov/pubmed/28591771


Loeb S, Stork B, Gold HT, Stout NK, Makarov DV, Weight C, Borgmann H.

“Tweet this: how advocacy for breast and prostate cancers stacks up on social media.”

BJU International 2017 May epub.  PMID: 28471484

    Link: http://www.ncbi.nlm.nih.gov/pubmed/2847148


O’Connor EM, Nason GJ, O’Kelly F, Manecksha RP, Loeb S.

“Newsworthiness vs scientific impact: are the most highly cited urology papers the most widely disseminated in the media?”

BJU International 2017 Apr 18 epub.  PMID: 28418091

    Link: https://www.ncbi.nlm.nih.gov/pubmed/28418091


Loeb S, Roupret M, Van Oort I, N’dow J, Van Gurp M, Bloemberg J, Darraugh JA, Ribal M. 

“Novel Use of Twitter to Disseminate and Evaluate Adherence with Clinical Guidelines by the European Association of Urology”.

BJU Int. 2017 Feb 7 epub.  PMID: 28170154

Link: https://www.ncbi.nlm.nih.gov/pubmed/28170154

Herein, we demonstrate a proof-of-principal study on the use of twitter as a platform for the dissemination and real-time evaluation of the European Association of Urology clinical guidelines. These strategies can be considered by other medical societies to increase the reach and obtain rapid feedback on guidelines recommendations.


Borghmann H, Loeb S, Salem J, Thomas C, Haferkamp A, Murphy DG, Tsaur I.

“Activity, content, contributors, and influencers of the twitter discussion on urologic oncology.”

Urologic Oncology 2016 epub. PMID: 27036217.

Link: http://www.ncbi.nlm.nih.gov/pubmed/27036217


Mata DA, Tilak G, Loeb S, Ramasamy R.

“Curating a Digital Identity: What Urologists Need to Know About Social Media.”

Urology 2016 Jul 6 epub. PMID: 27395795.

Link: http://www.ncbi.nlm.nih.gov/pubmed/27395795


Borgmann H, Woelm JH, Merseburger A, Nestler T, Salem J, Brandt MP, Haferkamp A, Loeb S.

Qualitative Twitter analysis of participants, tweet strategies, and tweet content at a major urologic conference.”  

Canadian Urological Association Journal 2016 Jan-Feb;10(1-2):39-44. PMID: 26977205.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26977205


Borgmann H, DeWitt S, Tsaur I, Haferkamp A, Loeb S.

 “Novel survey disseminated through Twitter supports its utility for networking, disseminating research, advocacy, clinical practice and other professional goals.”

 Canadian Urological Association Journal. 2015 Sep-Oct;9(9-10):E713-7. Epub 2015 Oct 13. PMID: 26664662

Link: http://www.ncbi.nlm.nih.gov/pubmed/26664662


Other Papers

Loeb S. Editorial Comment on

“Digital Identity: Develop One Before You’re Given One”

Urology 2015; 85: 1222. PMID: 26099864.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26099864


Other Papers

Borgmann H, Wölm JH, Vallo S, Mager R, Huber J, Breyer J, Salem J, Loeb S, Haferkamp A, Tsaur I.

“Prostate Cancer on the Web- Expedient Tool for Patients’ Decision-Making?”

Journal of Cancer Education 2015 epub Aug 4. PMID: 26234650.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26234650


Other Papers

Loeb S.

“Social media makes global urology meetings truly global.”

BJU International 2015 Feb; 115(2):175. PMID: 25604713

Link: http://www.ncbi.nlm.nih.gov/pubmed/25604713


Prabhu V, Lee T, Loeb S, Holmes JH, Gold HT, Lepor H, Penson DF, and Makarov DV.

“Twitter Response to the United States Preventive Services Task Force Recommendations Against Screening with Prostate Specific Antigen.” 

BJU International 2014 epub.

PMID: 24661474

Link: http://www.ncbi.nlm.nih.gov/pubmed/24661474

 


Other Papers

Bayne CE, Murphy DG, Loeb S.

“#Urology is Trending in Social Media.”

Reviews in Urology 2014; 16: 152. PMID: 25337049.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191639/


Key Papers

Murphy DG, Loeb S, Basto MY, Challacombe B, Trinh QD, Leveridge M, Morgan T, Dasgupta P, Bultitude M.

“Engaging Responsibly with Social Media: the BJUI Guidelines.”

BJU International 2014 Apr epub. PMID: 24774415

Link: http://www.ncbi.nlm.nih.gov/pubmed/24774415

This paper summarizes the British Journal of Urology International guidelines for physicians to engage responsibly with social media. They emphasize the importance of considering that online content may exist forever and be available to everyone, that doctors should identify themselves and that the views they express are their own. Digital behavior should align with professional standards, avoiding any impropriety or breach of patient privacy.


Other Papers

Loeb S, Catto J, Kutikov A.

“Social Media Offers Unprecedented Opportunities for Vibrant Exchange of Professional Ideas Across Continents.”

European Urology 2014 March epub. PMID 24630683

Link: http://www.ncbi.nlm.nih.gov/pubmed/24630683


Prabhu V, Lee T, Loeb S, Holmes JH, Gold HT, Lepor H, Penson DF, and Makarov DV.

“Twitter Response to the United States Preventive Services Task Force Recommendations Against Screening with Prostate Specific Antigen.” 

BJU International 2014 epub.

PMID: 24661474

Link: http://www.ncbi.nlm.nih.gov/pubmed/24661474

 


Use of Social Media in Urology: Data from the American Urological Association

Loeb S, Bayne CE, Frey C, Davies BJ, Averch TD, Woo HH, Stork B, Cooperberg MR, Eggener SE.

“Use of Social Media in Urology: Data from the American Urological Association.”

British Journal of Urology International 2013 epub Nov 26. PMID: 24274744

Link: http://www.ncbi.nlm.nih.gov/pubmed/24274744


South Africa

World Congress of Endourology 2016

Capetown, South Africa. November 8-12, 2016
Lecture topic: Social media in urology
Category: Social Media


Spain

Challenges in Laparoscopy and Robotics

Barcelona, Spain – July 3-4, 2019

Lecture Topics: Social Media in Prostate Cancer, Robotic Prostatectomy Moderation

Category: prostate cancer, surgical technique, social media


European Association of Urology 2015

Madrid, Spain. March 2015

Lecture Topics: Prognostic Factors in the Prostate Histology, Social Media

Categories: Prostate Cancer, Social Media, Erectile Dysfunction


International Genitourinary Cancer Symposium (IGUCC 6)

Madrid, Spain. February 2014

Lecture topic: Smarter Prostate Cancer Screening

Category: Prostate Cancer


Staging

A Clinical Reminder Order Check Intervention to Improve Guideline-concordant Imaging Practices for Men With Prostate Cancer: A Pilot Study

Ciprut SE, Kelly MD, Walter D, Hoffman R, Becker DJ, Loeb S, Sedlander E, Tenner CT, Sherman SE, Zeliadt SB, Makarov DV.

“A Clinical Reminder Order Check Intervention to Improve Guideline-concordant Imaging Practices for Men With Prostate Cancer: A Pilot Study.”

Urology. 2020 Nov;145:113-119. Epub 2020 Jul 25.PMID: 32721517.

Link: https://pubmed.ncbi.nlm.nih.gov/32721517/


Untitled

Drangsholt S, Walter D, Ciprut S, Lepor A, Sedlander E, Curnyn C, Loeb S, Malloy P, Winn AN, Makarov DV.

” Quantifying downstream impact of inappropriate staging imaging in a cohort of veterans with low- and intermediate-risk incident prostate cancer.”

Urologic Oncology 2019 Feb;37(2):145-149. PMID: 30578160.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30578160


Untitled

Stattin P, Sandin F, Loeb S, Robinson D, Lissbrant IF, Lambe M.

” Public online reporting from a nationwide population-based clinical prostate cancer register”

BJU International 2018 Jul; 122(1):8-10. PMID: 29577561.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29577561


Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choeurng V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll PR, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL.

“Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.”

 Journal of Clinical Oncology. 2017 Nov 29 epub. PMID: 29185869.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29185869


Thomsen FB, Folkvaljon Y, Brasso K, Loeb S, Robinson D, Egevad L, Stattin P.

Prognostic implications of 2005 Gleason grade modification. Population-based study of biochemical recurrence following radical prostatectomy.”

Journal of Surgical Oncology. 2016 Aug 11 epub. PMID: 27511833.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27511833


Loeb S, Folkvaljon Y, Robinson D, Lissbrant IF, Egevad L, Stattin P.

“Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort.” 

European Urology. 2015 Dec 17 epub. PMID: 26707871

Link: http://www.ncbi.nlm.nih.gov/pubmed/26707871


Danneman D, Drevin L, Delahunt B, Samaratunga H, Robinson D, Bratt O, Loeb S, Stattin P, Egevad L.

“The Accuracy of Prostate Biopsies for Predicting Gleason Score in Radical Prostatectomy Specimens. Nationwide trends 2000-2012.”

BJU International. 2016 Feb 25 epub. PMID:26918298.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26918298


Loeb S, Curnyn C, Sedlander E.

“Perspectives of Prostate Cancer Patients on Gleason Scores and the New Grade Groups: Initial Qualitative Study.”

European Urology 2016 Jun 6 epub. PMID: 27283215.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24439788

This is the first qualitative study to ask patients their perspectives on Gleason grading, which is a significant source of confusion. The majority of patients agreed that they would prefer to be told they have grade group 1 versus Gleason 6 cancer, and that this would encourage the use of active surveillance.


Other Papers

Bratt O, Folkvaljon Y, Loeb S, Klotz L, Egevad L, Stattin P.

“Upper Limit of Cancer Extent on Biopsy Defining Very Low Risk Prostate Cancer.”

BJU International 2014, July epub. PMID: 25053197.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25053197


Other Papers

Ohmann EL, Loeb S, Robinson D, Bill-Axelson A, Berglund A, and Stattin P.

“Nationwide Population-Based Study of Prostate Cancer Stage Migration Between and Within Clinical Risk Categories.”

Scandinavian Journal of Urology 2014 March epub. PMID: 24581522

Link: http://www.ncbi.nlm.nih.gov/pubmed/24611795


Other Papers

McGuire BB, Helfand BT, Loeb S, Hu Q, O’Brien D, Cooper P, Yang X, and Catalona WJ.

“Outcomes in Patients with Gleason Score 8-10 Prostate Cancer: Relation to Preoperative PSA Level.”

BJU International June 2012; 109: 1764-9. PMID: 22017732.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22017732


Other Papers

Loeb S, Carvalhal GF, Kan D, Desai A, and Catalona WJ.

“External Validation of the Cancer of the Prostate Risk Assessment (CAPRA) Score in a Single-Surgeon Radical Prostatectomy Series.”

Urologic Oncology: Seminars and Original Investigations, September 2010 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20822930


Other Papers

Loeb S, Schaeffer EM, Trock BJ, Humphreys EB, Epstein JI, and Walsh PC.

“What are the Outcomes of Radical Prostatectomy for High-Risk Prostate Cancer?”

Urology 2009, Nov 19 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19931898


Other Papers

Helfand BT, Mongiu AK, Kan D, Kim DY, Loeb S, Roehl KA, Meeks JJ, Smith ND, and Catalona WJ.

“Outcomes of Radical Prostatectomy for Patients with Clinical Stage T1a and T1b Disease.”

BJU International, February 2009 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/19239451


Other Papers

Loeb S, Hernandez DH, Mangold LA, Humphreys EB, Agro M, Walsh PC, Partin AW, and Han M.

“Progression after Radical Prostatectomy for Men in their Thirties Compared to Older Men.”

BJU International, June 2008; 101: 1503.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18341626


Other Papers

Loeb S, Roehl KA, Thaxton CS, and Catalona WJ.

“Combined Prostate-Specific Antigen Density and Biopsy Features to Predict ‘Clinically Insignificant’ Prostate Cancer.”

Urology, July 2008; 72: 143.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18436287

 


Reviews/Editorials

Loeb S.

“Is Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy Ready for ‘Prime Time’?”

European Urology 2014 Nov epub. PMID: 25465339.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25465339


Other Papers

Loeb S, Yu X, Nadler RB, Roehl KA, Han M, Hawkins SA, and Catalona WJ.

“Does Body Mass Index Affect Outcomes Following Radical Prostatectomy?”

Journal of Urology, January 2007; 177: 102.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17162013


Reviews/Editorials

Loeb S.

“Editorial comment on ‘Current Ability of Multiparametric Prostate MRI and Targeted Biopsy to Improve the Detection of Prostate Cancer’”

Urology Practice 2014 May; 1: 20.


Other Papers

Graif T, Yu Y, Loeb S, Gashti SN, Griffin S, Han M, Roehl KA, Suarez BK, and Catalona WJ.

“Underdiagnosis and Overdiagnosis of Prostate Cancer.”

Journal of Urology 2007; 178: 88.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17499308


Reviews/Editorials

Loeb S and Partin AW.

“Imaging Utilization for the Staging of Clinically Localized Prostate Cancer.”

Reviews in Urology 2011; 13: 63. PMID: 21845110.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155872/


Other Papers

Okotie O, Roehl KA, Han M, Loeb S, Gashti SN, and Catalona WJ.

“Characteristics of Prostate Cancer Detected by Digital Rectal Examination Only.”

Urology 2007; 70: 1117.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18158030


Reviews/Editorials

Loeb S.

“Editorial Comment on ‘Impact of Positive Apical Surgical Margins on Likelihood of Biochemical Recurrence After Radical Prostatectomy.”

Journal of Urology, December 2009; 182: 2701.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19836758


Other Papers

Loeb S, Gonzalez CM, Roehl KA, Han M, Antenor JV, Yap RL, and Catalona WJ.

“Pathologic Characteristics of Prostate Cancer Detected Through Prostate-Specific Antigen- Based Screening”

Journal of Urology, March 2006; 175: 902.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16469576


Key Papers

Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R.

“Overdiagnosis and Overtreatment of Prostate Cancer.”

European Urology 2014; epub Jan 9. PMID: 24439788

Link: http://www.ncbi.nlm.nih.gov/pubmed/24439788

This systematic review of epidemiological, clinical and autopsy studies found a very wide of estimates for prostate cancer overdiagnosis from 1.7-67%. Published estimates of overtreatment vary widely based on patient features and may be declining internationally. Careful patient selection for screening and reducing overtreatment are important to preserve the benefits and reduce the downstream harms of prostate-specific antigen testing. 


Reviews/Editorials

Loeb S and Catalona WJ.

“What is the prognostic impact of positive surgical margins in surgically treated prostate cancer?”

Nature Clinical Practice Urology, August 2006; 3: 418.

Link: http://www.nature.com/nrurol/journal/v3/n8/full/ncpuro0549.html


Other Papers

Loeb S, Yu X, Roehl KA, Antenor JV, Han M, and Catalona WJ.

“Lymphovascular Invasion in Radical Prostatectomy Specimens: Prediction of Adverse Pathology and Biochemical Progression”

Urology, July 2006; 68: 99.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16806410


Key Papers

Makarov DV, Loeb S, Ulmert D, Drevin L, Lambe M, Stattin P.

“Prostate Cancer Imaging Trends After a Nationwide Effort to Discourage Inappropriate Prostate Cancer Imaging.”

Journal of the National Cancer Institute (JNCI) 2013 July epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23853055

Imaging is very important for staging of high-risk prostate cancer, but is not recommended for low-risk disease. This study demonstrated that a nationwide Swedish campaign successfully reduced inappropriate imaging for low risk prostate cancer (from 45% to 3%), but also was associated with a slight reduction in appropriate imaging in high-risk patients.


Staging

A Clinical Reminder Order Check Intervention to Improve Guideline-concordant Imaging Practices for Men With Prostate Cancer: A Pilot Study

Ciprut SE, Kelly MD, Walter D, Hoffman R, Becker DJ, Loeb S, Sedlander E, Tenner CT, Sherman SE, Zeliadt SB, Makarov DV.

“A Clinical Reminder Order Check Intervention to Improve Guideline-concordant Imaging Practices for Men With Prostate Cancer: A Pilot Study.”

Urology. 2020 Nov;145:113-119. Epub 2020 Jul 25.PMID: 32721517.

Link: https://pubmed.ncbi.nlm.nih.gov/32721517/


Untitled

Drangsholt S, Walter D, Ciprut S, Lepor A, Sedlander E, Curnyn C, Loeb S, Malloy P, Winn AN, Makarov DV.

” Quantifying downstream impact of inappropriate staging imaging in a cohort of veterans with low- and intermediate-risk incident prostate cancer.”

Urologic Oncology 2019 Feb;37(2):145-149. PMID: 30578160.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30578160


Untitled

Stattin P, Sandin F, Loeb S, Robinson D, Lissbrant IF, Lambe M.

” Public online reporting from a nationwide population-based clinical prostate cancer register”

BJU International 2018 Jul; 122(1):8-10. PMID: 29577561.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29577561


Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choeurng V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll PR, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL.

“Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.”

 Journal of Clinical Oncology. 2017 Nov 29 epub. PMID: 29185869.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29185869


Thomsen FB, Folkvaljon Y, Brasso K, Loeb S, Robinson D, Egevad L, Stattin P.

Prognostic implications of 2005 Gleason grade modification. Population-based study of biochemical recurrence following radical prostatectomy.”

Journal of Surgical Oncology. 2016 Aug 11 epub. PMID: 27511833.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27511833


Loeb S, Folkvaljon Y, Robinson D, Lissbrant IF, Egevad L, Stattin P.

“Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort.” 

European Urology. 2015 Dec 17 epub. PMID: 26707871

Link: http://www.ncbi.nlm.nih.gov/pubmed/26707871


Danneman D, Drevin L, Delahunt B, Samaratunga H, Robinson D, Bratt O, Loeb S, Stattin P, Egevad L.

“The Accuracy of Prostate Biopsies for Predicting Gleason Score in Radical Prostatectomy Specimens. Nationwide trends 2000-2012.”

BJU International. 2016 Feb 25 epub. PMID:26918298.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26918298


Loeb S, Curnyn C, Sedlander E.

“Perspectives of Prostate Cancer Patients on Gleason Scores and the New Grade Groups: Initial Qualitative Study.”

European Urology 2016 Jun 6 epub. PMID: 27283215.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24439788

This is the first qualitative study to ask patients their perspectives on Gleason grading, which is a significant source of confusion. The majority of patients agreed that they would prefer to be told they have grade group 1 versus Gleason 6 cancer, and that this would encourage the use of active surveillance.


Other Papers

Bratt O, Folkvaljon Y, Loeb S, Klotz L, Egevad L, Stattin P.

“Upper Limit of Cancer Extent on Biopsy Defining Very Low Risk Prostate Cancer.”

BJU International 2014, July epub. PMID: 25053197.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25053197


Other Papers

Ohmann EL, Loeb S, Robinson D, Bill-Axelson A, Berglund A, and Stattin P.

“Nationwide Population-Based Study of Prostate Cancer Stage Migration Between and Within Clinical Risk Categories.”

Scandinavian Journal of Urology 2014 March epub. PMID: 24581522

Link: http://www.ncbi.nlm.nih.gov/pubmed/24611795


Other Papers

McGuire BB, Helfand BT, Loeb S, Hu Q, O’Brien D, Cooper P, Yang X, and Catalona WJ.

“Outcomes in Patients with Gleason Score 8-10 Prostate Cancer: Relation to Preoperative PSA Level.”

BJU International June 2012; 109: 1764-9. PMID: 22017732.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22017732


Other Papers

Loeb S, Carvalhal GF, Kan D, Desai A, and Catalona WJ.

“External Validation of the Cancer of the Prostate Risk Assessment (CAPRA) Score in a Single-Surgeon Radical Prostatectomy Series.”

Urologic Oncology: Seminars and Original Investigations, September 2010 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20822930


Other Papers

Loeb S, Schaeffer EM, Trock BJ, Humphreys EB, Epstein JI, and Walsh PC.

“What are the Outcomes of Radical Prostatectomy for High-Risk Prostate Cancer?”

Urology 2009, Nov 19 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19931898


Other Papers

Helfand BT, Mongiu AK, Kan D, Kim DY, Loeb S, Roehl KA, Meeks JJ, Smith ND, and Catalona WJ.

“Outcomes of Radical Prostatectomy for Patients with Clinical Stage T1a and T1b Disease.”

BJU International, February 2009 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/19239451


Other Papers

Loeb S, Hernandez DH, Mangold LA, Humphreys EB, Agro M, Walsh PC, Partin AW, and Han M.

“Progression after Radical Prostatectomy for Men in their Thirties Compared to Older Men.”

BJU International, June 2008; 101: 1503.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18341626


Other Papers

Loeb S, Roehl KA, Thaxton CS, and Catalona WJ.

“Combined Prostate-Specific Antigen Density and Biopsy Features to Predict ‘Clinically Insignificant’ Prostate Cancer.”

Urology, July 2008; 72: 143.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18436287

 


Reviews/Editorials

Loeb S.

“Is Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy Ready for ‘Prime Time’?”

European Urology 2014 Nov epub. PMID: 25465339.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25465339


Other Papers

Loeb S, Yu X, Nadler RB, Roehl KA, Han M, Hawkins SA, and Catalona WJ.

“Does Body Mass Index Affect Outcomes Following Radical Prostatectomy?”

Journal of Urology, January 2007; 177: 102.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17162013


Reviews/Editorials

Loeb S.

“Editorial comment on ‘Current Ability of Multiparametric Prostate MRI and Targeted Biopsy to Improve the Detection of Prostate Cancer’”

Urology Practice 2014 May; 1: 20.


Other Papers

Graif T, Yu Y, Loeb S, Gashti SN, Griffin S, Han M, Roehl KA, Suarez BK, and Catalona WJ.

“Underdiagnosis and Overdiagnosis of Prostate Cancer.”

Journal of Urology 2007; 178: 88.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17499308


Reviews/Editorials

Loeb S and Partin AW.

“Imaging Utilization for the Staging of Clinically Localized Prostate Cancer.”

Reviews in Urology 2011; 13: 63. PMID: 21845110.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155872/


Other Papers

Okotie O, Roehl KA, Han M, Loeb S, Gashti SN, and Catalona WJ.

“Characteristics of Prostate Cancer Detected by Digital Rectal Examination Only.”

Urology 2007; 70: 1117.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18158030


Reviews/Editorials

Loeb S.

“Editorial Comment on ‘Impact of Positive Apical Surgical Margins on Likelihood of Biochemical Recurrence After Radical Prostatectomy.”

Journal of Urology, December 2009; 182: 2701.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19836758


Other Papers

Loeb S, Gonzalez CM, Roehl KA, Han M, Antenor JV, Yap RL, and Catalona WJ.

“Pathologic Characteristics of Prostate Cancer Detected Through Prostate-Specific Antigen- Based Screening”

Journal of Urology, March 2006; 175: 902.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16469576


Key Papers

Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R.

“Overdiagnosis and Overtreatment of Prostate Cancer.”

European Urology 2014; epub Jan 9. PMID: 24439788

Link: http://www.ncbi.nlm.nih.gov/pubmed/24439788

This systematic review of epidemiological, clinical and autopsy studies found a very wide of estimates for prostate cancer overdiagnosis from 1.7-67%. Published estimates of overtreatment vary widely based on patient features and may be declining internationally. Careful patient selection for screening and reducing overtreatment are important to preserve the benefits and reduce the downstream harms of prostate-specific antigen testing. 


Reviews/Editorials

Loeb S and Catalona WJ.

“What is the prognostic impact of positive surgical margins in surgically treated prostate cancer?”

Nature Clinical Practice Urology, August 2006; 3: 418.

Link: http://www.nature.com/nrurol/journal/v3/n8/full/ncpuro0549.html


Other Papers

Loeb S, Yu X, Roehl KA, Antenor JV, Han M, and Catalona WJ.

“Lymphovascular Invasion in Radical Prostatectomy Specimens: Prediction of Adverse Pathology and Biochemical Progression”

Urology, July 2006; 68: 99.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16806410


Key Papers

Makarov DV, Loeb S, Ulmert D, Drevin L, Lambe M, Stattin P.

“Prostate Cancer Imaging Trends After a Nationwide Effort to Discourage Inappropriate Prostate Cancer Imaging.”

Journal of the National Cancer Institute (JNCI) 2013 July epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23853055

Imaging is very important for staging of high-risk prostate cancer, but is not recommended for low-risk disease. This study demonstrated that a nationwide Swedish campaign successfully reduced inappropriate imaging for low risk prostate cancer (from 45% to 3%), but also was associated with a slight reduction in appropriate imaging in high-risk patients.


Surgical

National Trends in the Utilization of Partial Nephrectomy Before and After the Establishment of AUA Guidelines for the Management of Renal Masses.

Bjurlin MA, Walter D, Taksler GB, Huang WC, Wysock JS, Sivarajan G, Loeb S, Taneja SS, Makarov DV.

“National Trends in the Utilization of Partial Nephrectomy Before and After the Establishment of AUA Guidelines for the Management of Renal Masses.”

Urology 2013; 82: 1283-9. PMID: 24295245.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24295245


Novel Technique for Fragment Removal After Percutaneous Management of Large-Volume Neobladder Calculi.

Loeb S, Semins MJ, and Matlaga BR.

“Novel Technique for Fragment Removal After Percutaneous Management of Large-Volume Neobladder Calculi.”

Urology, August 2012; 80: 474. PMID: 22857764.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22857764


Radical Retropubic Prostatectomy: Comparison of the Open and Robotic Approaches for Treatment of Prostate Cancer.

Tosoian J and Loeb S.

“Radical Retropubic Prostatectomy: Comparison of the Open and Robotic Approaches for Treatment of Prostate Cancer.”

Reviews in Urology 2012; 14: 1-8. PMID: 23172996.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502048/


The Impact of Anatomical Radical Retropubic Prostatectomy on Cancer Control: The 30-Year Anniversary.

Mullins JK, Feng Z, Trock BJ, Epstein JI, Walsh PC, Loeb S.

“The Impact of Anatomical Radical Retropubic Prostatectomy on Cancer Control: The 30-Year Anniversary.”

Journal of Urology epub October 18, 2012. PMID: 23083655.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23083655


Complications of Pelvic Lymphadenectomy: Do the Risks Outweigh the Benefits?

Loeb S, Partin AW, and Schaeffer EM.

“Complications of Pelvic Lymphadenectomy: Do the Risks Outweigh the Benefits?”

Reviews in Urology, Winter 2010; 12: 20.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859138/


Open versus minimally invasive radical prostatectomy.

Loeb S and Partin AW.

“Open versus minimally invasive radical prostatectomy.”

Reviews in Urology, Winter 2010; 12: 20.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859144/


The Case for Open Radical Prostatectomy.

Schaeffer EM, Loeb S, and Walsh PC.

“The Case for Open Radical Prostatectomy.”

Urological Clinics of North America 2010; 37: 49.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20152519


Reducing Blood Loss in Open Radical Retropubic Prostatectomy with Prophylactic Periprostatic Sutures.

Carvalhal GF, Griffin CR, Kan D, Loeb S, and Catalona WJ.

“Reducing Blood Loss in Open Radical Retropubic Prostatectomy with Prophylactic Periprostatic Sutures.”

BJU International 2010; 105: 1222.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19888968


Benign Prostate Glands at the Bladder Neck Margin in Robotic vs. Open Radical Prostatectomy.

Loeb S, Epstein JI, Ross AE, Schultz L, Humphreys EB, and Jarow JP.

“Benign Prostate Glands at the Bladder Neck Margin in Robotic vs. Open Radical Prostatectomy.”

BJU International 2010; 104: 1446

Link: http://www.ncbi.nlm.nih.gov/pubmed/20346031


Management of Distal Ureter in Laparoscopic Nephroureterectomy- A Comprehensive Review of Techniques.

Macejko AM, Pazona JF, Loeb S, Kimm S, and Nadler RB.

“Management of Distal Ureter in Laparoscopic Nephroureterectomy- A Comprehensive Review of Techniques.”

Urology, July 2008 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18602140


Thoracic Complications of Urological Laparoscopy: Correlation Between Radiographic Findings and Clinical Manifestations.

Zhao LC, Han JS, Loeb S, Tenggardjaja C, Rubenstein R, Smith ND, and Nadler RB.

“Thoracic Complications of Urological Laparoscopy: Correlation Between Radiographic Findings and Clinical Manifestations.”

J Endourol, April 2008; 22: 607.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18419207


The Use of BioGlue in Laparoscopic Partial Nephrectomy.

Nadler RB, Loeb S, and Vardi IY.

“The Use of BioGlue in Laparoscopic Partial Nephrectomy.”

Urology, August 2006; 68: 416.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16904466


A Prospective Study on Laparoscopic Radical Nephrectomy: Is Transperitoneal, Retroperitoneal, or Hand-Assisted the Best Approach?

Nadler RB, Loeb S, Clemens JQ, Batler RA, Gonzalez CM, and Vardi IY.

“A Prospective Study on Laparoscopic Radical Nephrectomy: Is Transperitoneal, Retroperitoneal, or Hand-Assisted the Best Approach?”

Journal of Urology, April 2006; 175: 1230.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16515966


Surgical Technique

Sweden

Uppsala University Honorary Doctorate

Uppsala, Sweden. January 2020

Lecture Topic: International Collaboration Using Swedish Registry Data to Improve Health

Category: Prostate Cancer, Men’s Health, Drug Safety


European Association of Urology 2014 Congress

Stockholm, Sweden. April 2014

Lecture Topic: Invited lecture on Standardizing Report and Outcome of Surgery in Prostate Cancer

Category: Prostate Cancer


ACME meeting

Hemavan, Sweden. January 2012

Lecture topic: Prostate Cancer Risk among immigrants to Sweden

Category: Prostate Cancer


Switzerland

Hot Topics in Uro-Oncology

Zurich, Switzerland – January 25, 2019

Lecture Topic: Prostate Cancer Screening in the Era of MRI and Novel Biomarkers

Category: Prostate Cancer, MRI, Screening, Markers


Tel Aviv - Israel

Telemedicine

Telemedicine Usage Among Urologists During the COVID-19 Pandemic: Cross-Sectional Study

Dubin JM, Wyant WA, Balaji NC, Ong WL, Kettache RH, Haffaf M, Zouari S, Santillan D, Autrán Gómez AM, Sadeghi-Nejad H, Loeb S, Borin JF, Gomez Rivas J, Grummet J, Ramasamy R, Teoh JYC.

“Telemedicine Usage Among Urologists During the COVID-19 Pandemic: Cross-Sectional Study.”

J Med Internet Res. 2020 Nov 5;22(11):e21875. PMID: 33031047

Link: https://pubmed.ncbi.nlm.nih.gov/33031047/


Telemedicine and Smart Working: Recommendations of the European Association of Urology

Rodriguez Socarrás M, Loeb S, Teoh JY, Ribal MJ, Bloemberg J, Catto J, N’Dow J, Van Poppel H, Gómez Rivas J.

“Telemedicine and Smart Working: Recommendations of the European Association of Urology.”

Eur Urol. 2020 Dec;78(6):812-819. PMID: 32654801

Link: https://pubmed.ncbi.nlm.nih.gov/32654801/


The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future

Wallis CJD, Catto JWF, Finelli A, Glaser AW, Gore JL, Loeb S, Morgan TM, Morgans AK, Mottet N, Neal R, O’Brien T, Odisho AY, Powles T, Skolarus TA, Smith AB, Szabados B, Klaassen Z, Spratt DE.

“The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future.”

Eur Urol. 2020 Nov;78(5):731-742. PMID: 32893062.

Link: https://pubmed.ncbi.nlm.nih.gov/32893062/

 


test

The Netherlands

Treatment

Using data from an online health community to examine the impact of prostate cancer on sleep.

Robbins R, Jean-Louis G, Chanko N, Combs P, Byrne N, Loeb S.

“Using data from an online health community to examine the impact of prostate cancer on sleep.”

British Journal of Urology International. 2020 Jan 3 epub.  PMID: 31899938.

Link: https://pubmed.ncbi.nlm.nih.gov/31899938/


Prostate Cancer. Nature Reviews Disease Primers

Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG.

“Prostate Cancer. Nature Reviews Disease Primers.”

2021 Feb 4;7(1):9. PMID: 33542230.

Link: https://pubmed.ncbi.nlm.nih.gov/33542230/


Racial Disparities and Online Health Information: YouTube and Prostate Cancer Clinical Trials

Borno HT, Zhang S, Bakke B, Bell A, Zuniga KB, Li P, Chao K, Sabol A, Killeen T, Hong H, Walter D, Loeb S.

“Racial Disparities and Online Health Information: YouTube and Prostate Cancer Clinical Trials.”

British Journal of Urology International. 2020 Apr 10 epub. PMID: 32275800.

Link: https://pubmed.ncbi.nlm.nih.gov/32275800/


Untitled

Loeb S, Salter CA, Nelson CJ, Mulhall JP, Wittmann D.

“A Call to Arms: Increasing Our Understanding of the Impact of Prostate Cancer on the Sexual Health of Partners.”

Journal of Sexual Medicine. 2019 Dec 10 epub. PMID: 31836299.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31836299


Untitled

Becker DJ, Iyengar AD, Punekar SR, Ng J, Zaman A, Loeb S, Becker KD, Makarov D.

“Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression. “

Anticancer Res.2019 May;39(5):2467-2473. PMID: 31092441.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31092441


Untitled

Stattin P, Sandin F, Loeb S, Robinson D, Lissbrant IF, Lambe M.

“Public online reporting from a nationwide population-based clinical prostate cancer register.”

BJU International 2018 Jul; 122(1):8-10. PMID: 29577561.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29577561/a>


Loeb S.

“Educational intervention in prostate cancer.”

BJU International 2017 Nov; 120(5B):E3. PMID: 29105995

Link: https://www.ncbi.nlm.nih.gov/pubmed/29105995


Loeb S, Meyer C, Krasnova A, Curnyn C, Reznor G, Lepor H, Kibel AS, Trinh QD.

“Risk of Small Bowel Obstruction After Robot-Assisted Versus Open Radical Prostatectomy.”

Journal of Endourology  2016 Sep 11 epub.  PMID: 27615204

Link: https://www.ncbi.nlm.nih.gov/pubmed/27615204


Adam M, Tennstedt P, Lanwehr D, Tilki D, Steuber T, Beyer B, Thederan I, Heinzer H, Haese A, Salomon G, Budäus L, Michl U, Pehrke D, Stattin P, Bernard J, Klaus B, Pompe RS, Petersen C, Huland H, Graefen M, Schwarz R, Huber W, Loeb S, Schlomm T.

“Functional Outcomes and Quality of Life After Radical Prostatectomy Only Versus a Combination of Prostatectomy with Radiation and Hormonal Therapy. European Urology.”

2016 Nov 22. PMID: 27887941

Link: https://www.ncbi.nlm.nih.gov/pubmed/27887941


Björklund J, Folkvaljon Y, Cole A, Carlsson S, Robinson D, Loeb S, Stattin P, Akre O.  

“Ninety-Day Postoperative Mortality after Robot-assisted Laparoscopic Prostatectomy and Retropubic Radical Prostatectomy. Nation-wide population-based study.”  

BJU International 2016 Jan 13 epub.  PMID: 26762928

Link: http://www.ncbi.nlm.nih.gov/pubmed/26762928


Loeb S, Folkvaljon Y, Robinson D, Makarov DV, Bratt O, Garmo H, and Stattin P.

“Immediate versus delayed prostatectomy: Nationwide population-based study.”

Scandinavian Journal of Urology 2016 Apr 12 epub. PMID: 27067998

Link: http://www.ncbi.nlm.nih.gov/pubmed/27067998


Sun M, Choueiri TK, Hamnvik OR, Preston MA, De Velasco G, Jiang W, Loeb S, Nguyen PL, Trinh QD.

“Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.”  

JAMA Oncology 2015 Dec 23:1-8 epub. PMID: 26720632

Link: http://www.ncbi.nlm.nih.gov/pubmed/26720632


Reviews/Editorials

Lynch J and Loeb S.

“The Role of HIFU in Prostate Cancer.”

Current Oncology Reports, May 2007; 9: 22.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17430694


Reviews/Editorials

Loeb S and Catalona WJ.

“Open Radical Retropubic Prostatectomy.”

Urologic Oncology: Seminars and Original Investigations 2007; 25: 494.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18047959


Reviews/Editorials

Loeb S and Catalona WJ.

“Counterpoint: the case for active treatment.”

Journal of the National Comprehensive Cancer Network, August 2007; 5: 699.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17692174

 


Reviews/Editorials

Loeb S and Catalona WJ.

“Early versus delayed intervention for prostate cancer: the case for early intervention.”

Nature Clinical Practice Urology, July 2007; 4: 348.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17563779


Reviews/Editorials

Loeb S and Schaeffer EM.

“Does Primary Androgen-Deprivation Therapy Improve Survival for Localized Prostate Cancer?”

Aging Health 2008; 4: 451.

Link: http://www.futuremedicine.com/doi/full/10.2217/1745509X.4.5.451


Reviews/Editorials

Loeb S, Schaeffer EM, and Epstein JI.

“The Vanishing Prostate Cancer Phenomenon.”

Urology, January 2010 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20079526


Reviews/Editorials

Loeb S, Partin AW, and Schaeffer EM.

“Complications of Pelvic Lymphadenectomy: Do the Risks Outweigh the Benefits?”

Reviews in Urology, Winter 2010; 12: 20.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859138/


Reviews/Editorials

Loeb S and Partin AW.

“Open versus minimally invasive radical prostatectomy.”

Reviews in Urology, Winter 2010; 12: 20.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859144/


Reviews/Editorials

Schaeffer EM, Loeb S, and Walsh PC.

“The Case for Open Radical Prostatectomy.”

Urological Clinics of North America 2010; 37: 49.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20152519


Reviews/Editorials

Loeb S.

“Prediction of Outcomes After Radical Prostatectomy in Patients Diagnosed with Prostate Cancer of Biopsy Gleason Score ≥8 Via Contemporary Multi (≥12)-Core Prostate Biopsy.”

BJU International July 2011; 108: 222. PMID: 21718432.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21718432


Reviews/Editorials

Tosoian J and Loeb S.

“Radical Retropubic Prostatectomy: Comparison of the Open and Robotic Approaches for Treatment of Prostate Cancer.”

Reviews in Urology 2012; 14: 1-8. PMID: 23172996.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502048/


Reviews/Editorials

Loeb S.

“The Age Old Question: Who Benefits From Prostate Cancer Treatment?”

British Journal of Urology International 2013; 1134: 4. PMID: 24330057

Link: http://www.ncbi.nlm.nih.gov/pubmed/24330057


Reviews/Editorials

Loeb S.

“Does Delaying Prostate Cancer Treatment Miss the Window of Curability?”

European Urology 2013 epub Apr 8. PMID: 23619388

Link: http://www.ncbi.nlm.nih.gov/pubmed/23619388


Reviews/Editorials

Stattin P and Loeb S.

‘To measure is to know. If you cannot measure it, you cannot improve it.’ Statistical Modeling Cannot Compensate for Unmeasured Bias.”

European Urology 2013; June epub

Link: http://www.ncbi.nlm.nih.gov/pubmed/23830142


Reviews/Editorials

Loeb S, Montorsi F, Catto JW.

“Future-Proofing Gleason Grading: What to Call Gleason 6 Prostate Cancer?”

European Urology 2015 epub. PMID: 25769986.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25769986


Reviews/Editorials

Loeb S, Schlomm T, Stattin P.

“Associations Do Not Equal Causation: Clinical Relevance of Statistical Associations of Phosphodiesterase Type 5 Inhibitors with Prostate Cancer Progression and Melanoma.”

European Urology 2015 epub July. PMID: 26238432.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26238432


Key Papers

Bratt O, Folkvaljon Y, Hjalm Eriksson M, Akre O, Carlsson S, Drevin L, Franck Lissbrant I, Makarov D, Loeb S, Stattin P.

“Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer.”

European Urology 2015 epub. PMID: 25813688.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25813688

Using data from national Swedish registries, this study showed that many healthy men in their seventies live for at least another 10 years. Despite this long life expectancy, men in their seventies with high-risk nonmetastatic prostate cancer often did not receive treatment with radical prostatectomy or radiotherapy, possibly because their life expectancy was underestimated. This study highlights the need for improved clinical decision-making, which should incorporate an assessment of the patient’s life expectancy.


Key Papers

Loeb S, Zhu X, Schroder FH, Roobol MJ.

“Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.”

BJU International epub Sept 21, 2012. PMID: 22998182.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22998182

This study compared the outcomes of prostate cancer treatment between men in the screening and control arms of the European Randomized Study of Prostate Cancer Screening (ERSPC). Men from the screening arm had a significantly higher progression-free survivial, metastasis-free survival, and cancer-specific survival compared to controls. Improved surgical outcomes among screened men appeared to be mediated by the lower tumor volume at diagnosis. These results show that early detection and successful treatment go hand-in-hand.


Key Papers

Mullins JK, Feng Z, Trock BJ, Epstein JI, Walsh PC, Loeb S.

“The Impact of Anatomical Radical Retropubic Prostatectomy on Cancer Control: The 30-Year Anniversary.”

Journal of Urology epub October 18, 2012. PMID: 23083655.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23083655

A total of 4,478 men underwent anatomical radical retropubic prostatectomy by Dr Patrick C. Walsh at the Johns Hopkins Medical Institutions from 1982-2011. To commemorate the 30th anniversary of the anatomic RRP, the long-term outcomes were examined. The overall 25-year progression-free, metastasis-free and cancer specific survival rates were 68%, 84% and 86%, respectively, although there were significant differences in treatment outcomes between men treated in the pre-PSA and PSA eras. Anatomical RRP continues to represent the gold standard in the surgical management of clinically localized prostate cancer to which alternate treatment options should be compared.


Other Papers

Carlsson S, Drevin L, Loeb S, Widmark A, Frank Lissbrant I, Robinson D, Johansson E, Stattin P, and Fransson P.

“Population-based study of long-term functional outcomes after prostate cancer treatment.”

BJU International 2014 epub. PMID: 25959859.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25959859


Other Papers

Vellekoop A, Loeb S, Folkvaljon Y, Stattin P.

“Population-Based Study of Predictors for Adverse Pathology Among Candidates for Active Surveillance With Gleason 6 Prostate Cancer.”

Journal of Urology 2013 epub September 23.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24071481


Other Papers

McGuire BB, Helfand BT, Loeb S, Hu Q, O’Brien D, Cooper P, Yang X, and Catalona WJ.

“Outcomes in Patients with Gleason Score 8-10 Prostate Cancer: Relation to Preoperative PSA Level.”

BJU International June 2012; 109: 1764-9. PMID: 22017732.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22017732


Other Papers

O’Brien D, Loeb S, Carvalhal GF, McGuire BB, Kan D, Hofer MD, Casey JT, Helfand BT, and Catalona WJ.

“Delay of Surgery in Men with Low Risk Prostate Cancer.”

Journal of Urology 2011; 185: 2143. PMID: 21496847.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21496847


Other Papers

Carvalhal GF, Griffin CR, Kan D, Loeb S, and Catalona WJ.

“Reducing Blood Loss in Open Radical Retropubic Prostatectomy with Prophylactic Periprostatic Sutures.”

BJU International 2010; 105: 1222.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19888968


Other Papers

Loeb S, Epstein JI, Ross AE, Schultz L, Humphreys EB, and Jarow JP.

“Benign Prostate Glands at the Bladder Neck Margin in Robotic vs. Open Radical Prostatectomy.”

BJU International 2010; 104: 1446

Link: http://www.ncbi.nlm.nih.gov/pubmed/20346031


Other Papers

Makarov DV, Loeb S, Landman AB, Nielsen ME, Gross CP, Leslie DL, Penson DF, and Desai RA.

“Regional Variation in Total Cost per Radical Prostatectomy in the Heathcare Cost and Utilization Project Nationwide Inpatient Sample Database.”

Journal of Urology 2010; 183: 1504.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20172559


Other Papers

Thaxton CS, Loeb S, Roehl KA, Kan D, and Catalona WJ.

“Treatment Outcomes of Radical Prostatectomy in Potential Candidates for 3 Published Active Surveillance Programs.”

Urology 2010; 75: 414.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3072831/


Other Papers

Loeb S, Carvalhal GF, Kan D, Desai A, and Catalona WJ.

“External Validation of the Cancer of the Prostate Risk Assessment (CAPRA) Score in a Single-Surgeon Radical Prostatectomy Series.”

Urologic Oncology: Seminars and Original Investigations, September 2010 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20822930


Key Papers

Loeb S, Schaeffer EM, Trock BJ, Humphreys EB, Epstein JI, and Walsh PC.

“What are the Outcomes of Radical Prostatectomy for High-Risk Prostate Cancer?”

Urology 2009, Nov 19 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19931898

Historically most men with D’Amico high-risk prostate cancer (clinical stage ≥T2c, biopsy Gleason score 8-10, or prostate-specific antigen >20 ng/mL) were treated with combined radiation therapy and hormonal therapy. This study shows that surgical treatment for carefully selected high risk patients can result in long-term progression–free survival.   At 10 years, biochemical recurrence-free survival was 68%, metastasis-free survival was 84%, and prostate cancer-specific survival was 92%. The 10-year rate of freedom from any hormonal therapy was 71%. Of the 3 high-risk criteria, a biopsy Gleason score of 8-10 (vs ≤7) was the strongest independent predictor of biochemical recurrence, metastases, and prostate cancer death.


Other Papers

Helfand BT, Mongiu AK, Kan D, Kim DY, Loeb S, Roehl KA, Meeks JJ, Smith ND, and Catalona WJ.

“Outcomes of Radical Prostatectomy for Patients with Clinical Stage T1a and T1b Disease.”

BJU International 2009 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/19239451


Reviews/Editorials

Loeb S and Schaeffer EM.

“Optimal Therapy in Localized Prostate Cancer: An Unfolding Story.’”

Oncology (Williston Park), September 2009; 23: 843.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19839426


Other Papers

Loeb S, Epstein JI, Humphreys EB, and Walsh PC.

“Does Perineural Invasion on Prostate Biopsy Predict Adverse Prostatectomy Outcomes?”

BJU International, August 2009 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19694710


Other Papers

Trock BJ, Guo CC, Gonzalgo ML, Magheli A, Loeb S, and Epstein JI.

“Impact of Tertiary Gleason Patterns on Biochemical Recurrence Following Radical Prostatectomy: Proposal for a Modified Gleason Scoring.”

Journal of Urology, August 2009 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19683280


Other Papers

Nguyen PL, Chen MH, Catalona WJ, Alexander BM, Roehl KA, Loeb S, and D’Amico AV.

“Biochemical Recurrence Following Radical Prostatectomy for Prevalent vs. Incident Cases of Prostate Cancer: Implications for Management.”

Cancer 2008 (epub)

Link: http://www.ncbi.nlm.nih.gov/pubmed/18932254


Other Papers

Loeb S, Roehl KA, Helfand BT, and Catalona WJ.

“Complications of open radical retropubic prostatectomy in potential candidates for active monitoring.”

Urology 2008; 72: 887.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18329080


Other Papers

Loeb S, Hernandez DH, Mangold LA, Humphreys EB, Agro M, Walsh PC, Partin AW, and Han M.

“Progression after Radical Prostatectomy for Men in their Thirties Compared to Older Men.”

BJU International, June 2008; 101: 1503.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18341626


Other Papers

Griffin C, Yu X, Loeb S, Desireddi VN, Han M, and Catalona WJ.

“Pathologic Features after Radical Prostatectomy for Potential Candidates for Active Monitoring.”

Journal of Urology 2007; 178: 860.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17631347


Other Papers

Loeb S, Yu X, Nadler RB, Roehl KA, Han M, Hawkins SA, and Catalona WJ.

“Does Body Mass Index Affect Outcomes Following Radical Prostatectomy?”

Journal of Urology 2007; 177: 102.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17162013


Other Papers

Desireddi VN, Roehl KA, Loeb S, Yu X, Griffin C, Kundu S, Han M, and Catalona WJ.

“Progression-Free Survival Rates for Radical Prostatectomy in the PSA Era.”

Urology 2007; 70: 950.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18068453


Other Papers

Loeb S, Smith N, Roehl KA, and Catalona WJ.

“Intermediate-Term Potency, Continence and Survival Outcomes of Radical Prostatectomy for Clinically High-Risk or Advanced Prostate Cancer.”

Urology 2007; 69: 1170.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17572209


Reviews/Editorials

Loeb S and Nadler RB.

“Management of the Complications of External Beam Radiotherapy and Brachytherapy.”

Current Urology Reports, May 2006; 7: 200.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16630523


Other Papers

Roehl KA, Eggener SE, Loeb S, Smith ND, Antenor JAV, and Catalona WJ.

“Survival Results in Screen-Detected Prostate Cancer Patients Versus Physician-Referred Patients Treated With Radical Prostatectomy: Early Results.”

Urologic Oncology: Seminars and Original Investigations 2006; 24: 465.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17138126


Other Papers

Loeb S, Yu X, Roehl KA, Antenor JV, Han M, and Catalona WJ.

“Lymphovascular Invasion in Radical Prostatectomy Specimens: Prediction of Adverse Pathology and Biochemical Progression”

Urology, 2006; 68: 99.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16806410


Other Papers

Loeb S, Gonzalez CM, Roehl KA, Han M, Antenor JV, Yap RL, and Catalona WJ.

“Pathologic Characteristics of Prostate Cancer Detected Through Prostate-Specific Antigen- Based Screening”

Journal of Urology 2006; 175: 902.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16469576


Treatment

Using data from an online health community to examine the impact of prostate cancer on sleep.

Robbins R, Jean-Louis G, Chanko N, Combs P, Byrne N, Loeb S.

“Using data from an online health community to examine the impact of prostate cancer on sleep.”

British Journal of Urology International. 2020 Jan 3 epub.  PMID: 31899938.

Link: https://pubmed.ncbi.nlm.nih.gov/31899938/


Prostate Cancer. Nature Reviews Disease Primers

Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG.

“Prostate Cancer. Nature Reviews Disease Primers.”

2021 Feb 4;7(1):9. PMID: 33542230.

Link: https://pubmed.ncbi.nlm.nih.gov/33542230/


Racial Disparities and Online Health Information: YouTube and Prostate Cancer Clinical Trials

Borno HT, Zhang S, Bakke B, Bell A, Zuniga KB, Li P, Chao K, Sabol A, Killeen T, Hong H, Walter D, Loeb S.

“Racial Disparities and Online Health Information: YouTube and Prostate Cancer Clinical Trials.”

British Journal of Urology International. 2020 Apr 10 epub. PMID: 32275800.

Link: https://pubmed.ncbi.nlm.nih.gov/32275800/


Untitled

Loeb S, Salter CA, Nelson CJ, Mulhall JP, Wittmann D.

“A Call to Arms: Increasing Our Understanding of the Impact of Prostate Cancer on the Sexual Health of Partners.”

Journal of Sexual Medicine. 2019 Dec 10 epub. PMID: 31836299.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31836299


Untitled

Becker DJ, Iyengar AD, Punekar SR, Ng J, Zaman A, Loeb S, Becker KD, Makarov D.

“Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression. “

Anticancer Res.2019 May;39(5):2467-2473. PMID: 31092441.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31092441


Untitled

Stattin P, Sandin F, Loeb S, Robinson D, Lissbrant IF, Lambe M.

“Public online reporting from a nationwide population-based clinical prostate cancer register.”

BJU International 2018 Jul; 122(1):8-10. PMID: 29577561.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29577561/a>


Loeb S.

“Educational intervention in prostate cancer.”

BJU International 2017 Nov; 120(5B):E3. PMID: 29105995

Link: https://www.ncbi.nlm.nih.gov/pubmed/29105995


Loeb S, Meyer C, Krasnova A, Curnyn C, Reznor G, Lepor H, Kibel AS, Trinh QD.

“Risk of Small Bowel Obstruction After Robot-Assisted Versus Open Radical Prostatectomy.”

Journal of Endourology  2016 Sep 11 epub.  PMID: 27615204

Link: https://www.ncbi.nlm.nih.gov/pubmed/27615204


Adam M, Tennstedt P, Lanwehr D, Tilki D, Steuber T, Beyer B, Thederan I, Heinzer H, Haese A, Salomon G, Budäus L, Michl U, Pehrke D, Stattin P, Bernard J, Klaus B, Pompe RS, Petersen C, Huland H, Graefen M, Schwarz R, Huber W, Loeb S, Schlomm T.

“Functional Outcomes and Quality of Life After Radical Prostatectomy Only Versus a Combination of Prostatectomy with Radiation and Hormonal Therapy. European Urology.”

2016 Nov 22. PMID: 27887941

Link: https://www.ncbi.nlm.nih.gov/pubmed/27887941


Björklund J, Folkvaljon Y, Cole A, Carlsson S, Robinson D, Loeb S, Stattin P, Akre O.  

“Ninety-Day Postoperative Mortality after Robot-assisted Laparoscopic Prostatectomy and Retropubic Radical Prostatectomy. Nation-wide population-based study.”  

BJU International 2016 Jan 13 epub.  PMID: 26762928

Link: http://www.ncbi.nlm.nih.gov/pubmed/26762928


Loeb S, Folkvaljon Y, Robinson D, Makarov DV, Bratt O, Garmo H, and Stattin P.

“Immediate versus delayed prostatectomy: Nationwide population-based study.”

Scandinavian Journal of Urology 2016 Apr 12 epub. PMID: 27067998

Link: http://www.ncbi.nlm.nih.gov/pubmed/27067998


Sun M, Choueiri TK, Hamnvik OR, Preston MA, De Velasco G, Jiang W, Loeb S, Nguyen PL, Trinh QD.

“Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.”  

JAMA Oncology 2015 Dec 23:1-8 epub. PMID: 26720632

Link: http://www.ncbi.nlm.nih.gov/pubmed/26720632


Reviews/Editorials

Lynch J and Loeb S.

“The Role of HIFU in Prostate Cancer.”

Current Oncology Reports, May 2007; 9: 22.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17430694


Reviews/Editorials

Loeb S and Catalona WJ.

“Open Radical Retropubic Prostatectomy.”

Urologic Oncology: Seminars and Original Investigations 2007; 25: 494.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18047959


Reviews/Editorials

Loeb S and Catalona WJ.

“Counterpoint: the case for active treatment.”

Journal of the National Comprehensive Cancer Network, August 2007; 5: 699.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17692174

 


Reviews/Editorials

Loeb S and Catalona WJ.

“Early versus delayed intervention for prostate cancer: the case for early intervention.”

Nature Clinical Practice Urology, July 2007; 4: 348.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17563779


Reviews/Editorials

Loeb S and Schaeffer EM.

“Does Primary Androgen-Deprivation Therapy Improve Survival for Localized Prostate Cancer?”

Aging Health 2008; 4: 451.

Link: http://www.futuremedicine.com/doi/full/10.2217/1745509X.4.5.451


Reviews/Editorials

Loeb S, Schaeffer EM, and Epstein JI.

“The Vanishing Prostate Cancer Phenomenon.”

Urology, January 2010 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20079526


Reviews/Editorials

Loeb S, Partin AW, and Schaeffer EM.

“Complications of Pelvic Lymphadenectomy: Do the Risks Outweigh the Benefits?”

Reviews in Urology, Winter 2010; 12: 20.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859138/


Reviews/Editorials

Loeb S and Partin AW.

“Open versus minimally invasive radical prostatectomy.”

Reviews in Urology, Winter 2010; 12: 20.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859144/


Reviews/Editorials

Schaeffer EM, Loeb S, and Walsh PC.

“The Case for Open Radical Prostatectomy.”

Urological Clinics of North America 2010; 37: 49.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20152519


Reviews/Editorials

Loeb S.

“Prediction of Outcomes After Radical Prostatectomy in Patients Diagnosed with Prostate Cancer of Biopsy Gleason Score ≥8 Via Contemporary Multi (≥12)-Core Prostate Biopsy.”

BJU International July 2011; 108: 222. PMID: 21718432.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21718432


Reviews/Editorials

Tosoian J and Loeb S.

“Radical Retropubic Prostatectomy: Comparison of the Open and Robotic Approaches for Treatment of Prostate Cancer.”

Reviews in Urology 2012; 14: 1-8. PMID: 23172996.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502048/


Reviews/Editorials

Loeb S.

“The Age Old Question: Who Benefits From Prostate Cancer Treatment?”

British Journal of Urology International 2013; 1134: 4. PMID: 24330057

Link: http://www.ncbi.nlm.nih.gov/pubmed/24330057


Reviews/Editorials

Loeb S.

“Does Delaying Prostate Cancer Treatment Miss the Window of Curability?”

European Urology 2013 epub Apr 8. PMID: 23619388

Link: http://www.ncbi.nlm.nih.gov/pubmed/23619388


Reviews/Editorials

Stattin P and Loeb S.

‘To measure is to know. If you cannot measure it, you cannot improve it.’ Statistical Modeling Cannot Compensate for Unmeasured Bias.”

European Urology 2013; June epub

Link: http://www.ncbi.nlm.nih.gov/pubmed/23830142


Reviews/Editorials

Loeb S, Montorsi F, Catto JW.

“Future-Proofing Gleason Grading: What to Call Gleason 6 Prostate Cancer?”

European Urology 2015 epub. PMID: 25769986.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25769986


Reviews/Editorials

Loeb S, Schlomm T, Stattin P.

“Associations Do Not Equal Causation: Clinical Relevance of Statistical Associations of Phosphodiesterase Type 5 Inhibitors with Prostate Cancer Progression and Melanoma.”

European Urology 2015 epub July. PMID: 26238432.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26238432


Key Papers

Bratt O, Folkvaljon Y, Hjalm Eriksson M, Akre O, Carlsson S, Drevin L, Franck Lissbrant I, Makarov D, Loeb S, Stattin P.

“Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer.”

European Urology 2015 epub. PMID: 25813688.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25813688

Using data from national Swedish registries, this study showed that many healthy men in their seventies live for at least another 10 years. Despite this long life expectancy, men in their seventies with high-risk nonmetastatic prostate cancer often did not receive treatment with radical prostatectomy or radiotherapy, possibly because their life expectancy was underestimated. This study highlights the need for improved clinical decision-making, which should incorporate an assessment of the patient’s life expectancy.


Key Papers

Loeb S, Zhu X, Schroder FH, Roobol MJ.

“Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.”

BJU International epub Sept 21, 2012. PMID: 22998182.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22998182

This study compared the outcomes of prostate cancer treatment between men in the screening and control arms of the European Randomized Study of Prostate Cancer Screening (ERSPC). Men from the screening arm had a significantly higher progression-free survivial, metastasis-free survival, and cancer-specific survival compared to controls. Improved surgical outcomes among screened men appeared to be mediated by the lower tumor volume at diagnosis. These results show that early detection and successful treatment go hand-in-hand.


Key Papers

Mullins JK, Feng Z, Trock BJ, Epstein JI, Walsh PC, Loeb S.

“The Impact of Anatomical Radical Retropubic Prostatectomy on Cancer Control: The 30-Year Anniversary.”

Journal of Urology epub October 18, 2012. PMID: 23083655.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23083655

A total of 4,478 men underwent anatomical radical retropubic prostatectomy by Dr Patrick C. Walsh at the Johns Hopkins Medical Institutions from 1982-2011. To commemorate the 30th anniversary of the anatomic RRP, the long-term outcomes were examined. The overall 25-year progression-free, metastasis-free and cancer specific survival rates were 68%, 84% and 86%, respectively, although there were significant differences in treatment outcomes between men treated in the pre-PSA and PSA eras. Anatomical RRP continues to represent the gold standard in the surgical management of clinically localized prostate cancer to which alternate treatment options should be compared.


Other Papers

Carlsson S, Drevin L, Loeb S, Widmark A, Frank Lissbrant I, Robinson D, Johansson E, Stattin P, and Fransson P.

“Population-based study of long-term functional outcomes after prostate cancer treatment.”

BJU International 2014 epub. PMID: 25959859.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25959859


Other Papers

Vellekoop A, Loeb S, Folkvaljon Y, Stattin P.

“Population-Based Study of Predictors for Adverse Pathology Among Candidates for Active Surveillance With Gleason 6 Prostate Cancer.”

Journal of Urology 2013 epub September 23.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24071481


Other Papers

McGuire BB, Helfand BT, Loeb S, Hu Q, O’Brien D, Cooper P, Yang X, and Catalona WJ.

“Outcomes in Patients with Gleason Score 8-10 Prostate Cancer: Relation to Preoperative PSA Level.”

BJU International June 2012; 109: 1764-9. PMID: 22017732.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22017732


Other Papers

O’Brien D, Loeb S, Carvalhal GF, McGuire BB, Kan D, Hofer MD, Casey JT, Helfand BT, and Catalona WJ.

“Delay of Surgery in Men with Low Risk Prostate Cancer.”

Journal of Urology 2011; 185: 2143. PMID: 21496847.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21496847


Other Papers

Carvalhal GF, Griffin CR, Kan D, Loeb S, and Catalona WJ.

“Reducing Blood Loss in Open Radical Retropubic Prostatectomy with Prophylactic Periprostatic Sutures.”

BJU International 2010; 105: 1222.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19888968


Other Papers

Loeb S, Epstein JI, Ross AE, Schultz L, Humphreys EB, and Jarow JP.

“Benign Prostate Glands at the Bladder Neck Margin in Robotic vs. Open Radical Prostatectomy.”

BJU International 2010; 104: 1446

Link: http://www.ncbi.nlm.nih.gov/pubmed/20346031


Other Papers

Makarov DV, Loeb S, Landman AB, Nielsen ME, Gross CP, Leslie DL, Penson DF, and Desai RA.

“Regional Variation in Total Cost per Radical Prostatectomy in the Heathcare Cost and Utilization Project Nationwide Inpatient Sample Database.”

Journal of Urology 2010; 183: 1504.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20172559


Other Papers

Thaxton CS, Loeb S, Roehl KA, Kan D, and Catalona WJ.

“Treatment Outcomes of Radical Prostatectomy in Potential Candidates for 3 Published Active Surveillance Programs.”

Urology 2010; 75: 414.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3072831/


Other Papers

Loeb S, Carvalhal GF, Kan D, Desai A, and Catalona WJ.

“External Validation of the Cancer of the Prostate Risk Assessment (CAPRA) Score in a Single-Surgeon Radical Prostatectomy Series.”

Urologic Oncology: Seminars and Original Investigations, September 2010 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20822930


Key Papers

Loeb S, Schaeffer EM, Trock BJ, Humphreys EB, Epstein JI, and Walsh PC.

“What are the Outcomes of Radical Prostatectomy for High-Risk Prostate Cancer?”

Urology 2009, Nov 19 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19931898

Historically most men with D’Amico high-risk prostate cancer (clinical stage ≥T2c, biopsy Gleason score 8-10, or prostate-specific antigen >20 ng/mL) were treated with combined radiation therapy and hormonal therapy. This study shows that surgical treatment for carefully selected high risk patients can result in long-term progression–free survival.   At 10 years, biochemical recurrence-free survival was 68%, metastasis-free survival was 84%, and prostate cancer-specific survival was 92%. The 10-year rate of freedom from any hormonal therapy was 71%. Of the 3 high-risk criteria, a biopsy Gleason score of 8-10 (vs ≤7) was the strongest independent predictor of biochemical recurrence, metastases, and prostate cancer death.


Other Papers

Helfand BT, Mongiu AK, Kan D, Kim DY, Loeb S, Roehl KA, Meeks JJ, Smith ND, and Catalona WJ.

“Outcomes of Radical Prostatectomy for Patients with Clinical Stage T1a and T1b Disease.”

BJU International 2009 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/19239451


Reviews/Editorials

Loeb S and Schaeffer EM.

“Optimal Therapy in Localized Prostate Cancer: An Unfolding Story.’”

Oncology (Williston Park), September 2009; 23: 843.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19839426


Other Papers

Loeb S, Epstein JI, Humphreys EB, and Walsh PC.

“Does Perineural Invasion on Prostate Biopsy Predict Adverse Prostatectomy Outcomes?”

BJU International, August 2009 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19694710


Other Papers

Trock BJ, Guo CC, Gonzalgo ML, Magheli A, Loeb S, and Epstein JI.

“Impact of Tertiary Gleason Patterns on Biochemical Recurrence Following Radical Prostatectomy: Proposal for a Modified Gleason Scoring.”

Journal of Urology, August 2009 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19683280


Other Papers

Nguyen PL, Chen MH, Catalona WJ, Alexander BM, Roehl KA, Loeb S, and D’Amico AV.

“Biochemical Recurrence Following Radical Prostatectomy for Prevalent vs. Incident Cases of Prostate Cancer: Implications for Management.”

Cancer 2008 (epub)

Link: http://www.ncbi.nlm.nih.gov/pubmed/18932254


Other Papers

Loeb S, Roehl KA, Helfand BT, and Catalona WJ.

“Complications of open radical retropubic prostatectomy in potential candidates for active monitoring.”

Urology 2008; 72: 887.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18329080


Other Papers

Loeb S, Hernandez DH, Mangold LA, Humphreys EB, Agro M, Walsh PC, Partin AW, and Han M.

“Progression after Radical Prostatectomy for Men in their Thirties Compared to Older Men.”

BJU International, June 2008; 101: 1503.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18341626


Other Papers

Griffin C, Yu X, Loeb S, Desireddi VN, Han M, and Catalona WJ.

“Pathologic Features after Radical Prostatectomy for Potential Candidates for Active Monitoring.”

Journal of Urology 2007; 178: 860.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17631347


Other Papers

Loeb S, Yu X, Nadler RB, Roehl KA, Han M, Hawkins SA, and Catalona WJ.

“Does Body Mass Index Affect Outcomes Following Radical Prostatectomy?”

Journal of Urology 2007; 177: 102.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17162013


Other Papers

Desireddi VN, Roehl KA, Loeb S, Yu X, Griffin C, Kundu S, Han M, and Catalona WJ.

“Progression-Free Survival Rates for Radical Prostatectomy in the PSA Era.”

Urology 2007; 70: 950.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18068453


Other Papers

Loeb S, Smith N, Roehl KA, and Catalona WJ.

“Intermediate-Term Potency, Continence and Survival Outcomes of Radical Prostatectomy for Clinically High-Risk or Advanced Prostate Cancer.”

Urology 2007; 69: 1170.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17572209


Reviews/Editorials

Loeb S and Nadler RB.

“Management of the Complications of External Beam Radiotherapy and Brachytherapy.”

Current Urology Reports, May 2006; 7: 200.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16630523


Other Papers

Roehl KA, Eggener SE, Loeb S, Smith ND, Antenor JAV, and Catalona WJ.

“Survival Results in Screen-Detected Prostate Cancer Patients Versus Physician-Referred Patients Treated With Radical Prostatectomy: Early Results.”

Urologic Oncology: Seminars and Original Investigations 2006; 24: 465.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17138126


Other Papers

Loeb S, Yu X, Roehl KA, Antenor JV, Han M, and Catalona WJ.

“Lymphovascular Invasion in Radical Prostatectomy Specimens: Prediction of Adverse Pathology and Biochemical Progression”

Urology, 2006; 68: 99.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16806410


Other Papers

Loeb S, Gonzalez CM, Roehl KA, Han M, Antenor JV, Yap RL, and Catalona WJ.

“Pathologic Characteristics of Prostate Cancer Detected Through Prostate-Specific Antigen- Based Screening”

Journal of Urology 2006; 175: 902.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16469576


Uncategorized

Dr Loeb on Tests for the Management of Prostate Cancer (published June 6, 2017)

OncLive: Dr Loeb on Tests for the Management of Prostate Cancer (published June 6, 2017)

https://www.youtube.com/watch?v=RexdoXUbF98


Dr Loeb on Active Surveillance for Prostate Cancer (published May 12, 2017)

OncLive: Dr Loeb on Active Surveillance for Prostate Cancer (published May 12, 2017)


Prostate Cancer Foundation: Women in Prostate Cancer Research- Dr Stacy Loeb (published March 17, 2017)

Prostate Cancer Foundation:  Women in Prostate Cancer Research- Dr Stacy Loeb (published March 17, 2017)

https://www.youtube.com/watch?v=PJIEald08kU&t=37s


Upcoming

Sirius XM Channel 110 Doctor Radio Host

Dr Stacy Loeb hosts the Men’s Health Show on US/Canada Satellite Radio (SiriusXM Channel 110) on Wednesdays from 6-8pmEST.

Next shows: August 30, September 27, October 25


Uro-Oncology

UroOncology

Quality of Bladder Cancer Information on YouTube

Loeb S, Reines K, Abu-Salha Y, French W, Butaney M, Macaluso JN Jr, Steinberg GD, Walter D, Byrne N, la Garza D, Smith AB.

“Quality of Bladder Cancer Information on YouTube.”

Eur Urol. 2020 Sep 30: S0302-2838(20)30706-5. PMID: 33010986

Link: https://pubmed.ncbi.nlm.nih.gov/33010986/


Controversies in Management of High-Risk Prostate and Bladder Cancer.

Loeb S, Ribal MJ.

“Controversies in Management of High-Risk Prostate and Bladder Cancer.”

BJU International 2015 Nov; 116: 675. PMID: 26449166.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26449166


Outcomes of a Bladder Cancer Screening Program Using Home Hematuria Testing and Molecular Markers.

Bangma CH, Loeb S, Susstra M, Zhu X, Bouazzaoui SE, Refos J, Van Der Keur KA, Tijn S, Franken CG, van Leenders GJ, Zwarthoff EC, Roobol MJ.

“Outcomes of a Bladder Cancer Screening Program Using Home Hematuria Testing and Molecular Markers.”

European Urology 2013 epub March 4. PMID: 23478169

Link: http://www.ncbi.nlm.nih.gov/pubmed/23478169


National Trends in the Utilization of Partial Nephrectomy Before and After the Establishment of AUA Guidelines for the Management of Renal Masses.

Bjurlin MA, Walter D, Taksler GB, Huang WC, Wysock JS, Sivarajan G, Loeb S, Taneja SS, Makarov DV.

“National Trends in the Utilization of Partial Nephrectomy Before and After the Establishment of AUA Guidelines for the Management of Renal Masses.”

Urology 2013; 82: 1283-9. PMID: 24295245.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24295245


Is Prostate Specific Antigen Surveillance Necessary in Men with Benign Prostate Pathology Following Radical Cystoprostatectomy for Bladder Cancer?

Bivalacqua TJ, Loeb S, Pierorazio PM, Schoenberg MP, Partin AW, Guzzo TJ.

“Is Prostate Specific Antigen Surveillance Necessary in Men with Benign Prostate Pathology Following Radical Cystoprostatectomy for Bladder Cancer?”

Urologia Internationalis epub November 2010; 85: 466.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21071926


A Case of Gastrointestinal Stromal Tumor Diagnosed on Prostate Biopsy.

Loeb S, Lotan T, Thornton K, and Schoenberg MP.

“A Case of Gastrointestinal Stromal Tumor Diagnosed on Prostate Biopsy.”

Nature Clinical Practice Urology, December 2008 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/19048005


Thoracic Complications of Urological Laparoscopy: Correlation Between Radiographic Findings and Clinical Manifestations.

Zhao LC, Han JS, Loeb S, Tenggardjaja C, Rubenstein R, Smith ND, and Nadler RB.

“Thoracic Complications of Urological Laparoscopy: Correlation Between Radiographic Findings and Clinical Manifestations.”

J Endourol 2008; 22: 607.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18419207


Management of Distal Ureter in Laparoscopic Nephroureterectomy- A Comprehensive Review of Techniques.

Macejko AM, Pazona JF, Loeb S, Kimm S, and Nadler RB.

“Management of Distal Ureter in Laparoscopic Nephroureterectomy- A Comprehensive Review of Techniques.”

Urology 2008 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/18602140


Pathologic Findings and Clinical Outcomes of Patients Undergoing Retroperitoneal Lymph Node Dissection Following Multiple Chemotherapy Regimens for Metastatic Testicular Germ Cell Tumors.

Eggener SE, Carver BS, Loeb S, Kondagunta GV, Bosl GJ, and Sheinfeld J.

“Pathologic Findings and Clinical Outcomes of Patients Undergoing Retroperitoneal Lymph Node Dissection Following Multiple Chemotherapy Regimens for Metastatic Testicular Germ Cell Tumors.”

Cancer, February 2007; 109: 528.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17177200

 


A Prospective Study on Laparoscopic Radical Nephrectomy: Is Transperitoneal, Retroperitoneal, or Hand-Assisted the Best Approach?

Nadler RB, Loeb S, Clemens JQ, Batler RA, Gonzalez CM, and Vardi IY.

“A Prospective Study on Laparoscopic Radical Nephrectomy: Is Transperitoneal, Retroperitoneal, or Hand-Assisted the Best Approach?”

Journal of Urology, April 2006; 175: 1230.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16515966


The Use of BioGlue in Laparoscopic Partial Nephrectomy.

Nadler RB, Loeb S, and Vardi IY.

“The Use of BioGlue in Laparoscopic Partial Nephrectomy.

Urology, August 2006; 68: 416.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16904466


USA

Sexual Medicine Society of North America Journal Club

USA (Virtual). March 2021

Topic: Roles and Attitudes Toward Social Media Platforms Amongst Urology Trainees

Category: Social Media


NYU Department of Population Health

NYC (Virtual). March 2021

Topic: Social Media Best Practices Workshop

Category: Social Media


ASCO Genitourinary Symposium

USA (Virtual). February 2021

Topic: Moderator

Category: Prostate Cancer


Grand Rounds, Weill Cornell University Urology

NYC (Virtual). January 2021

Topic: Promise and Peril of Digital Technology in Urology

Category: Social Media


Society of Urologic Oncology Young Urologic Oncologists Lecture Series

USA (Virtual). November 2020

Topic: Use of Social Media in Urology

Category: Social Media


Sexual Medicine Society of North America

USA (Virtual). October 2020

Topic: Social Media in Sexual Medicine

Category: Men’s Health, Social Media


Memorial Sloan Kettering Cancer Center

NYC (Virtual). October 2020

Topic: Social Media in Prostate Cancer

Category: Prostate Cancer, Social Media


Texas A&M University College of Medicine Health & Wellness Grand Rounds

Texas (Virtual). October 2020

Topic: Online Professionalism and the Pros/Cons of Social Media for Medical Trainees and Health Professionals

Category: Social Media


Weill Cornell University Urology

NYC (Virtual). August 2020

Topic: Prostate Cancer Screening

Category: Prostate Cancer


Association for Healthcare Social Media

Pennsylvania (Virtual). August 2020

Topic: Researching Social Media

Category: Social Media


Texas A&M Baylor, Scott & White Health Graduate Medical Education

Texas (Virtual). May 2020

Topic: Social Media

Category: Social Media


EMPIRE Lecture Series

NY (Virtual). May 2020

Topic: Social Media for Urologists

Category: Social Media


Memorial Sloan Kettering Cancer Center

New York, NY – December 17, 2019

Lecture topic: Social Media and Academics

Category: Social media


Culture Leap

Malibu, CA – November 7, 2019

Lecture Topic: Role of Social Media in Science Information

Category: Social media


Division of General Internal Medicine, NYU

NY, NY – October 8, 2019
Lecture Topic: The Promise and Peril of Social Media in Prostate Cancer
Category: Social Media, Prostate Cancer

 

 


Inspire Seminar Series, Manhattan Veterans Affairs

NY, NY – October 17, 2019
Lecture Topic: The Promise and Peril of Social Media in Prostate Cancer
Category: Social Media, Prostate Cancer

 

 


Prostate Cancer Foundation 2019 Retreat

Carlsbad, CA – October 1-4, 2019

Lecture Topics: Panel at the PCF Women’s Forum on Navigating Confidence; Moderator and Presenter about Online Information and Side Effects at PCF-Us TOO Patient Advocacy Session

Category: Women In Science, Prostate Cancer, Social Media, Survivorship


American Association of Clinical Urologists (AACU)

Washington DC –  October 12-14, 2019

Lecture Topic: Online Presence for Urologists, Clinical Urology in 2019 (Panel)

Category: Social Media, Urology


Hackensack University Medical Center Visiting Professor

Hackensack, New Jersey – October 15, 2019

Lecture Topic: Social Media in Medicine

Category: Social Media


Northeastern Section of the American Urological Association

Syracuse, NY – September, 2019

Lecture topics: Reducing prostate cancer overtreatment with active surveillance; Biomarkers-  how do we use them

Category: Prostate Cancer, Active Surveillance, Markers


American Urological Association 2019 Annual Meeting

Chicago, IL – May 2-5, 2019

Lecture Topics: Plenary on Top 10 Apps for Wellness, Work and Study; Prostate Cancer Update Course

Category: Apps, Social Media, Prostate Cancer


University of California San Francisco Urology Grand Rounds

San Francisco, CA  – January 9, 2019

Lecture Topic: Social Media in Urology

Category: Social Media


Henry Ford Vattikuti Urology Institute Visiting Professor

Detroit, MI – December 11-12, 2018

Lecture topics: Active Surveillance, Social Media

Category: Prostate cancer, active surveillance, social media


American Urological Association 2018 Meeting

San Francisco, CA.  May 18-22, 2018

Lecture topic: Optimizing Technique and Selection for Prostate Biopsy, Prostate Cancer Press Conferences, Prostate Cancer Updates Course

Category: Prostate Cancer


LA Live Advanced Robotic & Open Surgery Symposium

Los Angeles, CA.  May 16-17, 2018

Lecture topic: Active surveillance for prostate cancer, Live surgery panel

Category: Prostate Cancer


3rd Annual USC L.A. Live Practical Urology Conference

Los Angeles, California . February 1-3, 2018

Lecture Topic:Using markers to improve selection for prostate biopsy, prostate biopsy complications

Category: Prostate Cancer


Society of Women in Urology

Las Vegas, Nevada. January 19-21, 2018

Lecture Topic: Genomic markers for prostate cancer, social media

Category: Prostate Cancer, Social Media


Chairman’s Rounds at Johns Hopkins Hospital

Baltimore, Maryland. November 16, 2017

Lecture Topic: Update on active surveillance and dissemination of knowledge in urology

Category: prostate cancer, social media, dissemination and implementation science (D&I)


Prostate Cancer Foundation 24th Annual Scientific Retreat

Washington, DC . October 4-7, 2017

Lecture Topic: Women in science panel, poster on crowdfunding in prostate cancer

Category: Women in science, Social Media


Grand Rounds at Washington University

St, Louis, Missouri. June 9, 2017

Lecture Topic: Social media in urology

Category: Social media


Grand Rounds at University of Pennsylvania

Philadelphia, Pennsylvania. May 18, 2017

Lecture Topic: Biomarkers in the diagnosis and management of localized prostate cancer

Category: Prostate Cancer


Royal Society of Medicine Winter Meeting

Lake Tahoe (Northstar, California).  January 28-30, 2017

Lecture Topics: Urology Highlights of 2016 as Seen Through the Eyes of Twitter, What Has Happened to Screening for Prostate Cancer in the US?

Categories: Social Media, Prostate Cancer


LA Live 2nd University of Southern California Annual Conference: Practical Urology

Los Angeles, California. January 26, 2017

Lecture Topic: Prostate Cancer Markers

Category: Prostate Cancer Markers


Prostate Cancer Foundation 2016 Scientific Retreat

 Carlsbad, California. October 26-29, 2016

Lecture topic: Social media in prostate cancer

Category: Social Media


Advanced Robotic Urology and Prostate Cancer Update (Napa, California)Advanced Robotic Urology and Prostate Cancer Update

Napa, California. August 2016

Lecture Topics: Who to Biopsy and Rebiopsy, Tissue-Based Markers for Prostate Cancer Risk Stratification, Biomarker Panel

Category: Prostate Cancer, Biopsy, Markers


Visiting professor at University of Rochester

Rochester, New York. June 8, 2016

Lecture Topic: Markers in Prostate Cancer Screening and Active Surveillance

Category: Prostate Cancer


American Society of Clinical Oncology (ASCO) 2016 Annual Meeting

Chicago, Illinois. June 3-5, 2016

Lecture Topic: Active Surveillance for Prostate Cancer

Category: Prostate Cancer


American Urological Association (AUA) 2016 Annual Meeting

USA. May 2016

Lecture Topics: Dr Loeb gave a plenary presentation on Prostate Cancer Screening and participated on a panel with Drs Scardino, Catalona, and Hamdy. She also presented a late-breaking abstract at the plenary on Testosterone therapy and Prostate Cancer risk. Dr Loeb also gave invited lectures on Prostate Cancer at the International Prostate Forum and on Social Media at the BAUS/BJUI/USANZ plenary. She chaired the AUA press conference on Prostate Cancer and served as faculty for the Prostate Cancer Updates course.

Categories: Prostate Cancer, Men’s Health, Testosterone, Social Media


Visiting Professor at SUNY Downstate

New York.  March 23, 2016

Lecture Topics: Prostate Biopsy Indications, Active Surveillance

Category: Prostate Cancer


UNIVERSITY OF SOUTHERN CALIFORNIA INSTITUTE OF UROLOGY 1ST ANNUAL PRACTICAL UROLOGY CONFERENCE

California, USA. February 4-6, 2016

Lecture Topics: Prostate Xancer surgical Masterclass, Biomarkers and Active Surveillance for Prostate Cancer, Social Media in Urology

Category: Prostate Cancer, Social Media


Society of Women in Urology (SWIU)

USA. January 22-23, 2016

Lecture Topic: Serum, Urine and Tissue Markers in Prostate Cancer

Category: Prostate cancer


26th International Prostate Cancer Update (IPCU)

Colorado, USA. January 20-22, 2016

Lecture Topics: When to do prostate biopsy: Role for PSA and novel biomarkers

Category: Prostate cancer


Visiting Professor at the Division of Urology at Albany Medical College

USA. October 2015

Lecture Topics: Markers in Prostate Cancer Screening and Active Surveillance, Social Media in Urology

Categories: Prostate cancer, Social media


Florida Urological Society meeting

Florida, USA. September 2015

Lectures topics: 1) The Dilemma of an Elevated PSA: The Role of New Biomarkers to Determine When to Biopsy, 2) 4K Score, 3) Social Media in Urology

Categories: Prostate Cancer, Social Media


NYC Urological Research Society 2016

New York, Usa. Sptember 2015

Lecture topic: Decipher test in potential candidates for Active Surveillance

Category: Prostate Cancer, Active Surveillance, Markers


FDUS Future Directions in Urology

Colorado, USA. August 2015

Lecture topic: Social Media in Urology

Category: Social Media


Video

NYU Langone Health

Spotlight on Prostate Cancer (October 6, 2020)


ZERO Summit

Prostate Cancer and Fake News (March 2, 2021)


Malecare Prostate Cancer Patient Conference

Navigating Fake News about Prostate Cancer and Social Media (12/12/20)


Fans for the Cure Stay in the Game Podcast

Early Detection of Prostate Cancer (9/30/20)

Link: https://fansforthecure.org/podcast/early-detection-of-prostate-cancer/


Social Media for Urologists

EMPIRE Urology Lecture Series (5/6/20)


International Volunteers in Urology Virtual Visiting Professor Panel Discussion on COVID-19 (5/4/20)


New York University Langone Health Webinar

Plant-Based Diet: Impact for Health, the Environment, and Social Justice (Jan 15, 2021)


PIX11 News

Eat It to Beat It’ Challenge Promotes Prostate Cancer Awareness Month (Sept 16, 2020)


Plant Powered Metro New York

A Key To Men’s Health is in the Kitchen (July 8, 2020)


Bill Martinez Live – Empowering Men to Take Charge of Their Life for Men’s Health Month

https://billmartinezlive.com/stacy-loeb-june-13-2019/


Integrating Social Media as an Effective Teaching Tool for Patients – Stacy Loeb

11/2018 Integrating Social Media as an Effective Teaching Tool for Patients

 


Use of Conservative Management for Low-Risk Prostate Cancer

https://www.urotoday.com/video-lectures/prostate-cancer/video/970-embedded-media2018-06-14-16-15-42.html


Dr. Loeb on Determining Beneficial Test Options for Prostate Cancer (published July 2017)

OncLive: Dr. Loeb on Determining Beneficial Test Options for Prostate Cancer (published July 2017)


Dr. Loeb on the Impact of Additional Testing for Prostate Cancer

OncLive: Dr. Loeb on the Impact of Additional Testing for Prostate Cancer (published Oct 11, 2017)


Dr Loeb on the Results of Active Surveillance for Prostate Cancer (published August 2017)

OncLive: Dr Loeb on the Results of Active Surveillance for Prostate Cancer (published August 2017)


OncLive: Dr. Loeb on Tests for the Management of Prostate Cancer (published June 6, 2017)

OncLive: Dr. Loeb on Tests for the Management of Prostate Cancer (published June 6, 2017)


Dr Loeb on Active Surveillance for Prostate Cancer (published May 12, 2017)

OncLive: Dr Loeb on Active Surveillance for Prostate Cancer (published May 12, 2017)


Lecture on “When to Biopsy: The Role for PSA and Novel Biomarkers”

01/2016

Lecture on “When to Biopsy: The Role for PSA and Novel Biomarkers” at the International Prostate Cancer Update in Vail, Colorado (January 2016)


Prostate Cancer Foundation: Women in Prostate Cancer Research- Dr Stacy Loeb (published March 17, 2017)

Prostate Cancer Foundation:  Women in Prostate Cancer Research- Dr Stacy Loeb (published March 17, 2017


Interview on Katz’s Corner

Interview on Katz’s Corner on 77 WABC Radio about Erectile Dysfunction Medications and Risk of Melanoma (June 28, 2015)

https://audioboom.com/boos/3323526-6-28-15-dr-stacy-loeb-prostate-cancer-supplements


Onc Live Interview on Considerations for Screening in Prostate Cancer (June 2016)

Onc Live Interview on Considerations for Screening in Prostate Cancer (June 2016)


Lecture on the Role of Biomarkers in Prostate Cancer Surveillance

Lecture on the Role of Biomarkers in Prostate Cancer Surveillance for the NYU Cancer Center Community Education Series (October 2015)


MedPage Today Interview on Viagra and Melanoma: Search for Link Inconclusive

6/2015 MedPage Today Interview on Viagra and Melanoma: Search for Link Inconclusive

http://www.medpagetoday.com/Urology/ErectileDysfunction/52272


Urology Times on Twitter in Urology

5/2014 Urology Times on Twitter in Urology


Twitter and Urology- Targeted Oncology Interview

5/2014 Twitter and Urology- Targeted Oncology Interview


Lecture on Social Media in Medicine at International Continence Society in Rio de Janiero

10/2014 Lecture on Social Media in Medicine at International Continence Society in Rio de Janiero


Australia TV appearance video

8/2013 Australia TV appearance video

http://mobile.abc.net.au/news/2013-08-06/new-blood-test-offers-improved-treatment-for/4867150


Arise TV appearance on prostate cancer

6/2014 Arise TV appearance on prostate cancer


ASCO/MedPage Today video on Active Surveillance

5/2015 ASCO/MedPage Today video on Active Surveillance

http://www.medpagetoday.com/ASCOVideoConferenceReporterAUA/special-reports/AUA2015Video-Videos/1143


Seminar on prostate cancer screening at Laura and Isaac Perlmutter NYU Cancer Center

Seminar on prostate cancer screening at Laura and Isaac Perlmutter NYU Cancer Center


Global Congress on Prostate Cancer Panel Discussion: “Turning the tables: putting the expert in the patient’s seat”

2/2015 Global Congress on Prostate Cancer Panel Discussion: “Turning the tables: putting the expert in the patient’s seat”

http://library.mirrorsmed.org/sessions/turning-tables-putting-expert-patients-seat


Global Congress on Prostate Cancer Lecture on Screening and Early Diagnosis of Prostate Cancer

2/2015 Global Congress on Prostate Cancer Lecture on Screening and Early Diagnosis of Prostate Cancer

http://library.mirrorsmed.org/sessions/screening-and-early-diagnosis-prostate-cancer


Cancer Research and Oncology Virtual Conference: Lecture on Active Surveillance: Trends in Use, Patient Selection & Monitoring

10/2015 Cancer Research and Oncology Virtual Conference: Lecture on Active Surveillance: Trends in Use, Patient Selection & Monitoring September 30, 2015

Lecture topic: Active Surveillance: Trends in Use, Patient Selection and Monitoring

Category: prostate cancer

Location: online


Uro Today Video on Guideline of Guidelines: Prostate Cancer Screening

9/2014 Uro Today Video on Guideline of Guidelines: Prostate Cancer Screening

http://www.urotoday.com/urology-tube/2014-09-18-03-04-51/urology-tube-prostate-cancer/460-guideline-of-guidelines-prostate-cancer-screening.html


Congreso Centroamericano y Del Caribe de Urologia- Highlights of the 2014 AUA

8/2014 Congreso Centroamericano y Del Caribe de Urologia- Highlights of the 2014 AUA


American Urological Association Prostate Cancer Updates Course

5/2014 American Urological Association Prostate Cancer Updates Course

English links:

https://www.auanet.org/university/live-course-video.cfm?id=767&video=478&agenda=3298

https://www.auanet.org/university/live-course-video.cfm?id=767&video=520&agenda=3298

Spanish links:

https://www.auanet.org/university/live-course-video.cfm?id=767&video=521&agenda=3298

https://www.auanet.org/university/live-course-video.cfm?id=767&video=522&agenda=3298


Lecture on Prostate Cancer Screening in USA

Lecture on Prostate Cancer Screening in USA at the Russian Ministry of Health, Institute of Urology in Moscow (Russian translation)  (March 2014)

Скрининг РПЖ цели, эффективность, экономическая оценка на примере исследований ERSPC


Lecture on Prostate Cancer Markers at the Russian Ministry of Health

Lecture on Prostate Cancer Markers at the Russian Ministry of Health, Institute of Urology in Moscow (Russian translation)  (March 2014)

Место современных биомаркеров в ранней диагностике и динамическом наблюдении пациентов


The Doctor’s Channel video on PSA Screening- Decision Making at the Individual Level

6/2012 The Doctor’s Channel video on PSA Screening- Decision Making at the Individual Level

http://www.thedoctorschannel.com/view/psa-screening-decision-making-at-the-individual-level/collection/prostatecancer/


Australasian Prostate Cancer Conference- Lecture on prostate cancer overdiagnosis and overtreatment

8/2012 Australasian Prostate Cancer Conference- Lecture on prostate cancer overdiagnosis and overtreatment


The Doctor’s Channel video on Prostate Cancer Biopsy Guidelines and Procedures

6/2012 The Doctor’s Channel video on Prostate Cancer Biopsy Guidelines and Procedures

http://www.thedoctorschannel.com/view/prostate-cancer-biopsy-guidelines-and-procedures/collection/prostatecancer/


West Africa

International Volunteers in Urology

Ghana (Virtual). April 2020

Topic: Virtual Visiting Professor Panel Discussion on COVID-19

Category: COVID-19


whatisnew

WALL STREET JOURNAL ARTICLE ON PROSTATE CANCER TESTS

Wall Street Journal New prostate cancer tests May 10_1


Sirius XM Channel 110 Doctor Radio

Dr. Loeb

Hosts the Men’s Health Show on US/Canada satellite radio Sirius XM channel 110

On Wednesdays from 6-8pm EST.

https://www.siriusxm.com/doctorradio/weeklyschedule

 


Report: Forbes article about Viagra & Melanoma

Ever since a paper was released last year detailing cases of melanoma found in men taking the billion-dollar erectile dysfunction (ED) blockbuster Viagra, urologist Stacy Loeb of New York University has been fielding questions from worried patients about whether they should risk the little blue pill…

 


EUROPE / MIDDLE EAST

Active

Exploring Variation in the Use of Conservative Management for Prostate Cancer in the Veterans Affairs Healthcare System

Loeb S, Byrne NK, Wang B, Makarov DV, Becker D, Wise DR, Lepor H, Walter D.

 “Exploring Variation in the Use of Conservative Management for Prostate Cancer in the Veterans Affairs Healthcare System.”

European Urology. 2020 Feb 22:S0302-2838(20)30101-9. PMID: 32098730.

Link: https://pubmed.ncbi.nlm.nih.gov/32098730/


Untitled

Butler SS, Loeb S, Cole AP, Zaslowe-Dude C, Muralidhar V, Kim DW, Schaeffer EM, Trinh QD, Nguyen PL, Mahal BA.

 “United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015. Prostate Cancer Prostatic Dis.”

 2019 Oct 7 epub. PMID: 31591454.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31591454


Untitled

Loeb S.

 ” Overactive Surveillance: Is “Conservative” Management for Low-risk Prostate Cancer Too Aggressive?”

 Eur Urol. 2019 May epub. PMID:31060823.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31060823


Untitled

Loeb S, Folkvaljon Y, Bratt O, Robinson D, Stattin P.

 “Defining Intermediate-Risk Prostate Cancer Suitable for Active Surveillance.”

 Journal of Urology. 2018 Sep 18 epub. PMID: 30240688.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30240688


Loeb S, Byrne N, Makarov DV, Lepor H, Walter D.

“Use of Conservative Management for Low-Risk Prostate Cancer in the Veterans Affairs Integrated Health Care System From 2005-2015.”

JAMA. 2018 Jun 5; 319(21):2231-2233. PMID: 29800017

Link: https://www.ncbi.nlm.nih.gov/pubmed/29800017

In the U.S. Veterans Affairs healthcare system, we found a substantial increase in the use of conservative management for low-risk prostate cancer over the past decade. By 2015, 72% of veterans <65 years and 79% ages ≥65 with low-risk prostate cancer were managed conservatively.


Untitled

Loeb S, Curnyn C, Walter D, Fagerlin A, Siebert U, Mühlberger N, Braithwaite RS, Schwartz MD, Lepor H, Sedlander E.

 “Health state utilities among contemporary prostate cancer patients on active surveillance.”

Translational Andrology and Urology. 2018 Apr; 7(2):197-202. PMID: 29732277.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29732277


Loeb S, Curnyn C, Walter D, Fagerlin A, Siebert U, Mühlberger N, Braithwaite RS, Schwartz MD, Lepor H, Sedlander E.

“Health state utilities among contemporary prostate cancer patients on active surveillance.”

Translational Andrology and Urology. 2018 Apr; 7(2):197-202. PMID: 29732277.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29732277


Untitled

Loeb S, Tosoian JJ.

 “Biomarkers in Active Surveillance.”

 Translational Andrology and Urology 2018 Feb; 7(1):155-159. PMID: 29594029.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29594029


Untitled

Loeb S.

 “Active Surveillance for Prostate Cancer.”

 Reviews in Urology 2018; 20: 101-103. PMID: 30288148.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30288148


Loeb S.

 ” Active Surveillance Offers Functional Advantages Without Impacting Survival for Low-risk Prostate Cancer.”

European Urology. 2017 Nov 20. PMID: 29169932

Link: https://www.ncbi.nlm.nih.gov/pubmed/29169932


Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Sedlander E.

 “Informational needs during active surveillance for prostate cancer: A qualitative study.”

Patient Education Counseling 2017 Sep 1 epub.  PMID: 28886974

Link: https://www.ncbi.nlm.nih.gov/pubmed/28886974


Loeb S, Zhou Q, Siebert U, Rochau U, Jahn B, Mühlberger N, Carter HB, Lepor H, Braithwaite RS.  

“Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions”.

European Urology 2017 Aug 22 epub.  PMID: 28844371

Link: https://www.ncbi.nlm.nih.gov/pubmed/28844371

We designed a Markov model showing that active surveillance extends life more than watchful waiting, particularly for men with higher risk features, but this is partly offset by decrements in quality of life from delayed treatment. Trade-offs about the intensity of surveillance should be discussed with patients.


Loeb S, Ross AE.  

“Genomic testing for localized prostate cancer: where do we go from here?” 

Current Opinion in Urology. 2017 Jun 28 epub. PMID: 28661898

    Link: https://www.ncbi.nlm.nih.gov/pubmed/28621058

 


Choyke PL and Loeb S.

“Active Surveillance of Prostate Cancer.” 

Oncology (Williston Park) 2017; 31 (1).

PMID 8090626

Link: https://www.ncbi.nlm.nih.gov/pubmed/28090626


Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Sedlander E.

 “A Qualitative Study on Decision-Making by Prostate Cancer Physicians during Active Surveillance.”

BJU International. 2016 epub.  PMID: 27611479.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27611479


Loeb S, Folkvaljon Y, Curnyn C, Robinson D, Bratt O, Stattin P.

“Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden”.

JAMA Oncology. 2016 Oct 20. PMID: 27768168.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27768168

Using nationwide Sweden data, this study showed that by 2014, active surveillance was selected by 91% of very low risk, 74% of low risk and 19% of intermediate risk patients across the country.  These rates are the highest yet reported internationally. Dissociating diagnosis from treatment in men with a low risk of progression can decrease the rate of overtreatment.


Loeb S. Editorial Comment on

“Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices.” 

Journal of Urology 2016 epub Nov 28. PMID: 27908693.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27908693


Tosoian JJ, Carter HB, Lepor A, Loeb S.

Active surveillance for prostate cancer: current evidence and contemporary state of practice.”

Nature Reviews Urology 2016 Mar 8 epub. PMID: 26954332.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26954332


Tosoian JJ, Loeb S, Epstein JI, Turkbey B, Choyke PL, Schaeffer EM.

“Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools.”

American Society of Clinical Oncology Educational Book. 2016;35:e235-45. PMID: 27249729

Link: http://www.ncbi.nlm.nih.gov/pubmed/26954332


Loeb S, Folkvaljon Y, Robinson D, Makarov DV, Bratt O, Garmo H, and Stattin P.

“Immediate versus delayed prostatectomy: Nationwide population-based study.”

Scandinavian Journal of Urology 2016 Apr 12 epub. PMID: 27067998.

Link: http://www.ncbi.nlm.nih.gov/pubmed/27067998


Loeb S, Curnyn C, Sedlander E.

“Perspectives of Prostate Cancer Patients on Gleason Scores and the New Grade Groups: Initial Qualitative Study.”

European Urology 2016 Jun 6 epub. PMID: 27283215.

Link: http://www.ncbi.nlm.nih.gov/pubmed/27283215


Loeb S, Walter D, Curnyn C, Gold HT, Lepor H, Makarov DV.

“How Active is Active Surveillance? Intensity of Follow-Up During Active Surveillance for Prostate Cancer in the United States.”

Journal of Urology 2016 Mar 2 epub. PMID: 26946161.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26946161


Reviews/Editorials

Murphy DG, Loeb S.

“Prostate Cancer: Growth of AS in the USA Signals Reduction in Overtreatment.”

Nature Reviews Urology 2015 epub. PMID: 26390970.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26390970


Reviews/Editorials

Loeb S.

“Re: Long-Term Follow-up of a Large Active Surveillance Cohort of Patients with Prostate Cancer.”

European Urology 2015 Nov; 68: 907. PMID: 26460874.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26460874


Other Original Papers

Griffin C, Yu X, Loeb S, Desireddi VN, Han M, and Catalona WJ.

“Pathologic Features after Radical Prostatectomy for Potential Candidates for Active Monitoring.”

Journal of Urology, September 2007; 178: 860.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17631347


Other Original Papers

Thaxton CS, Loeb S, Roehl KA, Kan D, and Catalona WJ.

“Treatment Outcomes of Radical Prostatectomy in Potential Candidates for 3 Published Active Surveillance Programs.”

Urology, February 2010; 75: 414.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3072831/


Other Original Papers

Tosoian JJ, Loeb S, Kettermann A, Landis P, Elliot DJ, Epstein JI, Partin AW, Carter HB, and Sokoll LJ.

“Accuracy of PCA3 Measurement in Predicting Short-Term Biopsy Progression in an Active Surveillance Program.”

Journal of Urology, February 2010; 183: 534.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20006883


Other Original Papers

O’Brien D, Loeb S, Carvalhal GF, McGuire BB, Kan D, Hofer MD, Casey JT, Helfand BT, and Catalona WJ.

“Delay of Surgery in Men with Low Risk Prostate Cancer.”

Journal of Urology June 2011; 185: 2143. PMID: 21496847.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21496847


Key Papers

Loeb S, Bruinsma SM, Nicholson J, Briganti A, Pickles T, Kakehi Y, Carlsson SV, Roobol MJ.

“Active Surveillance for Prostate Cancer: A Systematic Review of Clinicopathologic Variables and Biomarkers for Risk Stratification.”

European Urology 2014 Oct epub. PMID: 25457014

Link: http://www.ncbi.nlm.nih.gov/pubmed/25457014

This systematic review examined the utility of markers, genetic factors and risk stratification for active surveillance. The patient factors associated with active surveillance outcomes in some studies include age, race, and family history. Multiple studies provide consistent evidence that a lower percentage of free PSA, a higher Prostate Health Index (PHI), a higher PSA density (PSAD), and greater biopsy core involvement at baseline predict a greater risk of progression. During follow-up, serial measurements of PHI and PSAD, as well as repeat biopsy results, predict later biopsy progression. No conclusive data support the use of genetic tests in active surveillance. 


Reviews/Editorials

Loeb S, Carter HB, Schwartz M, Fagerlin A, Braithwaite RS, Lepor H.

“Heterogeneity in active surveillance protocols worldwide.”

Reviews in Urology 2014;16(4):202-3. PMID: 25548550.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4274180/


Loeb S, Folkvaljon Y, Makarov DV, Bratt O, Bill-Axelson A, Stattin P.

“Five-Year Nationwide Follow-up Study of Active Surveillance for Prostate Cancer.”

Eur Urol 2014, June epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24993868


Other Original Papers

Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R.

“Overdiagnosis and Overtreatment of Prostate Cancer.”

European Urology 2014; epub Jan 9. PMID: 24439788

Link: http://www.ncbi.nlm.nih.gov/pubmed/24439788


Other Original Papers

Vellekoop A, Loeb S, Folkvaljon Y, Stattin P.

“Population-Based Study of Predictors for Adverse Pathology Among Candidates for Active Surveillance With Gleason 6 Prostate Cancer.”

Journal of Urology 2013 epub September 23.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24071481


Key Papers

Loeb S, Berglund A, Stattin P.

“Population-Based Study of Utilization and Determinants of Active Surveillance and Watchful Waiting for Low- and Intermediate-Risk Prostate Cancer”

Journal of Urology 2013 May 29 epub. PMID: 23727309

Link: http://www.ncbi.nlm.nih.gov/pubmed/23727309

Using nationwide Sweden data, this study showed that from 2007 to 2011, active surveillance was selected by 59% of very low risk, 41% of low risk and 16% of intermediate risk patients across the country. These rates are the highest yet reported internationally. Dissociating diagnosis from treatment in men with a low risk of progression can decrease the rate of overtreatment.


Reviews/Editorials

Loeb S.

“Does Delaying Prostate Cancer Treatment Miss the Window of Curability?”

European Urology 2013 epub Apr 8. PMID: 23619388

Link: http://www.ncbi.nlm.nih.gov/pubmed/23619388


Key Papers

Tosoian JJ, Loeb S, Feng Z, Isharwal S, Landis P, Elliot DJ, Veltri R, Epstein JI, Partin AW, Carter HB, Trock B, Sokoll LJ.

“Association of [-2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer.”

Journal of Urology October 2012; 188: 1131-6. PMID: 22901577.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22901577

Longitudinal measurements of the Prostate Health Index (phi) during active surveillance were a robust predictor of biopsy reclassification (C-index 0.82). These results have since been validated in other surveillance populations. Since PSA kinetics are unreliable and biopsies are invasive, phi offers another non-invasive test that can be used to monitor patients during active surveillance.


Key Papers

Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, Feng Z, Carter HB, and Walsh PC.

“Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.”

Journal of Clinical Oncology, June 2010; 28: 2810.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20439642

PSA doubling time and PSA velocity are frequently used to monitor patients during active surveillance. Among men in the Johns Hopkins active surveillance program, PSA kinetics during active surveillance were not reliable predictors of adverse pathology on repeat biopsy. This suggests that PSA kinetics should not be used as a trigger for intervention during active surveillance.


Reviews/Editorials

Loeb S and Catalona WJ.

“Counterpoint: the case for active treatment.”

Journal of the National Comprehensive Cancer Network, August 2007; 5: 699.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17692174


Reviews/Editorials

Loeb S and Catalona WJ.

“Early versus delayed intervention for prostate cancer: the case for early intervention.”

Nature Clinical Practice Urology, July 2007; 4: 348.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17563779


Active Surveillance

Exploring Variation in the Use of Conservative Management for Prostate Cancer in the Veterans Affairs Healthcare System

Loeb S, Byrne NK, Wang B, Makarov DV, Becker D, Wise DR, Lepor H, Walter D.

 “Exploring Variation in the Use of Conservative Management for Prostate Cancer in the Veterans Affairs Healthcare System.”

European Urology. 2020 Feb 22:S0302-2838(20)30101-9. PMID: 32098730.

Link: https://pubmed.ncbi.nlm.nih.gov/32098730/


Untitled

Butler SS, Loeb S, Cole AP, Zaslowe-Dude C, Muralidhar V, Kim DW, Schaeffer EM, Trinh QD, Nguyen PL, Mahal BA.

 “United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015. Prostate Cancer Prostatic Dis.”

 2019 Oct 7 epub. PMID: 31591454.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31591454


Untitled

Loeb S.

 ” Overactive Surveillance: Is “Conservative” Management for Low-risk Prostate Cancer Too Aggressive?”

 Eur Urol. 2019 May epub. PMID:31060823.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31060823


Untitled

Loeb S, Folkvaljon Y, Bratt O, Robinson D, Stattin P.

 “Defining Intermediate-Risk Prostate Cancer Suitable for Active Surveillance.”

 Journal of Urology. 2018 Sep 18 epub. PMID: 30240688.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30240688


Untitled

Loeb S, Curnyn C, Walter D, Fagerlin A, Siebert U, Mühlberger N, Braithwaite RS, Schwartz MD, Lepor H, Sedlander E.

 “Health state utilities among contemporary prostate cancer patients on active surveillance.”

Translational Andrology and Urology. 2018 Apr; 7(2):197-202. PMID: 29732277.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29732277


Untitled

Loeb S, Tosoian JJ.

 “Biomarkers in Active Surveillance.”

 Translational Andrology and Urology 2018 Feb; 7(1):155-159. PMID: 29594029.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29594029


Untitled

Loeb S.

 “Active Surveillance for Prostate Cancer.”

 Reviews in Urology 2018; 20: 101-103. PMID: 30288148.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30288148


Loeb S.

 ” Active Surveillance Offers Functional Advantages Without Impacting Survival for Low-risk Prostate Cancer.”

European Urology. 2017 Nov 20. PMID: 29169932

Link: https://www.ncbi.nlm.nih.gov/pubmed/29169932


Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Sedlander E.

 “Informational needs during active surveillance for prostate cancer: A qualitative study.”

Patient Education Counseling 2017 Sep 1 epub.  PMID: 28886974

Link: https://www.ncbi.nlm.nih.gov/pubmed/28886974


Loeb S, Zhou Q, Siebert U, Rochau U, Jahn B, Mühlberger N, Carter HB, Lepor H, Braithwaite RS.  

“Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions”.

European Urology 2017 Aug 22 epub.  PMID: 28844371

Link: https://www.ncbi.nlm.nih.gov/pubmed/28844371

We designed a Markov model showing that active surveillance extends life more than watchful waiting, particularly for men with higher risk features, but this is partly offset by decrements in quality of life from delayed treatment. Trade-offs about the intensity of surveillance should be discussed with patients.


Loeb S, Ross AE.  

“Genomic testing for localized prostate cancer: where do we go from here?” 

Current Opinion in Urology. 2017 Jun 28 epub. PMID: 28661898

    Link: https://www.ncbi.nlm.nih.gov/pubmed/28621058

 


Choyke PL and Loeb S.

“Active Surveillance of Prostate Cancer.” 

Oncology (Williston Park) 2017; 31 (1).

PMID 8090626

Link: https://www.ncbi.nlm.nih.gov/pubmed/28090626


Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Sedlander E.

 “A Qualitative Study on Decision-Making by Prostate Cancer Physicians during Active Surveillance.”

BJU International. 2016 epub.  PMID: 27611479.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27611479


Loeb S, Folkvaljon Y, Curnyn C, Robinson D, Bratt O, Stattin P.

“Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden”.

JAMA Oncology. 2016 Oct 20. PMID: 27768168.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27768168

Using nationwide Sweden data, this study showed that by 2014, active surveillance was selected by 91% of very low risk, 74% of low risk and 19% of intermediate risk patients across the country.  These rates are the highest yet reported internationally. Dissociating diagnosis from treatment in men with a low risk of progression can decrease the rate of overtreatment.


Loeb S. Editorial Comment on

“Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices.” 

Journal of Urology 2016 epub Nov 28. PMID: 27908693.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27908693


Africa

International Volunteers in Urology

Ghana (Virtual). April 2020

Topic: Virtual Visiting Professor Panel Discussion on COVID-19

Category: COVID-19


World Congress of Endourology 2016

Capetown, South Africa. November 8-12, 2016
Lecture topic: Social media in urology
Category: Social Media


ASIA

Chinese University of Hong Kong Urology Symposium

Hong Kong (Virtual). November 2020

Topic: Prostate Cancer Screening: Evidence, Guidelines and Implementation; Updates on Prostate Cancer in 2019-2020

Category: Prostate Cancer


21st Asia-Pacific Prostate Cancer Conference

Australia (Virtual). October 2020

Topic: Key Papers in Detection and Localized Prostate Cancer, Women in Urology and Leveraging Social Media

Category: Prostate Cancer, Social Media, Representation


Clinical Oncology Society of Australia

Adelaide, Australia – November 12-14, 2019

Lecture topics: Latest developments in prostate cancer surgery and active surveillance; Promise and peril of social media for clinicians, researchers and patients

Category: Prostate Cancer Treatment, Active Surveillance, Social Media


2018 Prostate Cancer World Congress

Brisbane Australia . August 22-246, 2018

Lecture Topic: Active surveillance for prostate cancer, Social media in prostate cancer

Category: Prostate Cancer, Social Media


USANZ New Zealand Section

Tauranga, New Zealand . October 11-13, 2017

Lecture Topic: Localized prostate cancer update, active surveillance, prostate cancer markers, social media

Category: prostate cancer, social media


Astellas Prostate Cancer Meeting

Hobart, Australia. April 8, 2017

Lecture topic: Markers and Prostate Cancer Screening

Category: Prostate Cancer


Astellas Prostate Cancer Meeting

Melbourne, Australia. April 7, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer


Astellas Prostate Cancer Meeting

Sydney, Australia. April 5-6, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer


Astellas Prostate Cancer Meeting

Adelaide, Australia. April 4, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer


Astellas Prostate Cancer Meeting

Brisbane, Australia. April 3, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer


Annual Meeting of the Korean Urological Association

Seoul, Korea. October 12-15, 2016

Lecture Topics: Prostate Cancer Markers, Active Surveillance, BPH

Category: Prostate Cancer, Benign Prostatic Hyperplasia

 

 


Macquarie University Markers Symposium

Sidney, Australia. September 2016

Lecture Topics: Prostate Cancer Markers

Category: Prostate Cancer, Markers


Prostate Cancer World Congress

Cairns, Australia. August 2015

Lecture Topics: Key publications in prostate cancer, Active Surveillance for prostate cancer, Updates to Gleason grading, Social Media and Prostate Cancer.

Category: Prostate Cancer


Philippines Society of Uro-Oncology

Manila, Philippines. September 2014

Lectures topic: Smarter PSA screening, Novel Prostate Cancer Markers, and Active Surveillance

Category: Prostate Cancer


Prostate Cancer World Congress

 Melbourne, Australia. August 2013

Lecture Topics: Practice changing publications in Prostate Cancer, Smarter PSA Screening with Isoforms and Kinetics, Selecting patients for Prostate Biopsy, Selection and monitoring during Active Surveillance

Category: Prostate Cancer


Australian Prostate Cancer Conference

 Melbourne, Australia. August 2012

Lecture Topics: Prostate biopsy complications, Overdiagnosis and Overtreatment of Prostate Cancer

Category: Prostate Complications


Australia

21st Asia-Pacific Prostate Cancer Conference

Australia (Virtual). October 2020

Topic: Key Papers in Detection and Localized Prostate Cancer, Women in Urology and Leveraging Social Media

Category: Prostate Cancer, Social Media, Representation


Clinical Oncology Society of Australia

Adelaide, Australia – November 12-14, 2019

Lecture topics: Latest developments in prostate cancer surgery and active surveillance; Promise and peril of social media for clinicians, researchers and patients

Category: Prostate Cancer Treatment, Active Surveillance, Social Media


2018 Prostate Cancer World Congress

Brisbane Australia . August 22-246, 2018

Lecture Topic: Active surveillance for prostate cancer, Social media in prostate cancer

Category: Prostate Cancer, Social Media


USANZ New Zealand Section

Tauranga, New Zealand . October 11-13, 2017

Lecture Topic: Localized prostate cancer update, active surveillance, prostate cancer markers, social media

Category: prostate cancer, social media


Astellas Prostate Cancer Meeting

Hobart, Australia. April 8, 2017

Lecture topic: Markers and Prostate Cancer Screening

Category: Prostate Cancer


Astellas Prostate Cancer Meeting

Melbourne, Australia. April 7, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer


Astellas Prostate Cancer Meeting

Sydney, Australia. April 5-6, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer


Astellas Prostate Cancer Meeting

Adelaide, Australia. April 4, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer


Astellas Prostate Cancer Meeting

Brisbane, Australia. April 3, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer


Macquarie University Markers Symposium

Sidney, Australia. September 2016

Lecture Topics: Prostate Cancer Markers

Category: Prostate Cancer, Markers


Prostate Cancer World Congress

Cairns, Australia. August 2015

Lecture Topics: Key publications in prostate cancer, Active Surveillance for prostate cancer, Updates to Gleason grading, Social Media and Prostate Cancer.

Category: Prostate Cancer


Prostate Cancer World Congress

 Melbourne, Australia. August 2013

Lecture Topics: Practice changing publications in Prostate Cancer, Smarter PSA Screening with Isoforms and Kinetics, Selecting patients for Prostate Biopsy, Selection and monitoring during Active Surveillance

Category: Prostate Cancer


Australian Prostate Cancer Conference

 Melbourne, Australia. August 2012

Lecture Topics: Prostate biopsy complications, Overdiagnosis and Overtreatment of Prostate Cancer

Category: Prostate Complications


Benign Disease

BenignDisease

An Evaluation of the Readability and Content-Quality of Pelvic Organ Prolapse YouTube Transcripts

Herbert AS, Nemirovsky A, Hess DS, Walter D, Abraham NE, Loeb S, Malik RD.

“An Evaluation of the Readability and Content-Quality of Pelvic Organ Prolapse YouTube Transcripts.”

Urology 2021; S0090-4295(21)00266-1. PMID: 33775787.

Link: https://pubmed.ncbi.nlm.nih.gov/33775787/


Fake News about Benign Prostate Hyperplasia on YouTube

Loeb S.

“Fake News about Benign Prostate Hyperplasia on YouTube.”

British Journal of Urology International. 2020 Apr;125(4):477-478. PMID: 32250050

Link: https://pubmed.ncbi.nlm.nih.gov/32250050/


Pelvic Organ Prolapse on YouTube: Evaluation of Consumer Information

Herbert AS, Nemirovsky A, Hess DS, Walter D, Abraham NE, Loeb S, Malik RD.

“Pelvic Organ Prolapse on YouTube: Evaluation of Consumer Information.”

British Journal of Urology International 2020 Feb 10 epub.  PMID: 32039554.

Link: https://pubmed.ncbi.nlm.nih.gov/32039554/


Key Paper

Loeb S, Folkvaljon Y, Lambe M, Robinson D, Garmo H, Ingvar C, Stattin P.

“Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.”

JAMA 2015; 313: 2449-55. PMID: 26103029.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26103029

A recent study suggested a possible link between phosphodiesterase inhibitors used for erectile dysfunction and risk of malignant melanoma. Through a large collaboration with the national registries of Sweden, we performed a large study that raised questions about a causal relationship including lack of a dose-response relationship. Instead, the observed association between erectile dysfunction drugs and melanoma likely reflects shared risk factors including lifestyle and socioeconomic status.


Genetic Sequence Variants are Associated with Severity of Lower Urinary Tract Symptoms and Prostate Cancer Susceptibility.

Helfand BT, Hu Q, Loeb S, McVary KT, Catalona WJ.

“Genetic Sequence Variants are Associated with Severity of Lower Urinary Tract Symptoms and Prostate Cancer Susceptibility.”

Journal of Uroloy 2012 epub November. PMID: 23159463.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23159463


Novel Technique for Fragment Removal After Percutaneous Management of Large-Volume Neobladder Calculi.

Loeb S, Semins MJ, and Matlaga BR.

“Novel Technique for Fragment Removal After Percutaneous Management of Large-Volume Neobladder Calculi.”

Urology, August 2012; 80: 474. PMID: 22857764.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22857764


Unusual Presentation of a Mullerian Remnant in an Infant with Recurrent Epididymo-orchitis.

Gupta AD, Loeb S, Stec A, and Wang MH.

“Unusual Presentation of a Mullerian Remnant in an Infant with Recurrent Epididymo-orchitis.”

Urology December 2011; 78: 1414-6. PMID: 21676451.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21676451


Prestenting Improves Ureteroscopic Stone-Free Rates.

Rubenstein RA, Zhao LC, Loeb S, Shore DM, and Nadler RB.

“Prestenting Improves Ureteroscopic Stone-Free Rates.”

J Endourol, November 2007; 21: 1277.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18042014


Contemporary Management of Urosepsis: Updated Critical Care Guidelines.

Loeb S, Vardi IY, and Nadler RB.

“Contemporary Management of Urosepsis: Updated Critical Care Guidelines.”

Contemporary Urology, July 2005


Biomarkers

Concordance and Performance of 4KScore and SelectMDx for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer

Wysock JS, Becher E, Persily J, Loeb S, Lepor H.

“Concordance and Performance of 4KScore and SelectMDx for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer.”

Urology. 2020 Apr 12:S0090-4295(20)30339-3. PMID: 32294481

Link: https://pubmed.ncbi.nlm.nih.gov/32294481/


Untitled

Fine ND, LaPolla F, Epstein M, Loeb S, Dani H.

” Genomic Classifiers for Treatment Selection in Newly Diagnosed Prostate Cancer.”

 BJU International 2019 May epub. PMID:31055874.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31055874


Loeb S, Tosoian JJ.

 “Biomarkers in Active Surveillance. “

BJU International. 2018 May 22. PMID: 29786946

    Link: https://www.ncbi.nlm.nih.gov/pubmed/29594029c


Loeb S, Tosoian JJ.

 “Biomarkers in Active Surveillance.”

Translational Andrology and Urology 2018 Feb; 7(1):155-159. PMID: 29594029.

    Link: https://www.ncbi.nlm.nih.gov/pubmed/29594029


Punnen S, Freedland SJ, Polascik TJ, Loeb S, Risk MC, Savage S, Mathur SC, Uchio E, Dong Y, Silberstein JL.

” A Multi-institutional Prospective Trial in the Veterans Affairs Health System confirms the 4Kscore maintains its Predictive value among African American Men.”

Journal of Urology 2017, epub Dec 6. PMID: 29223389

Link: https://www.ncbi.nlm.nih.gov/pubmed/29223389


Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choeurng V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll PR, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL

” Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.”

Journal of Clinical Oncology. 2017 Nov 29 epub. PMID: 29185869.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29185869


Loeb S, Dani H.

 “Whom to Biopsy: Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators.”

Urol Clin North Am. 2017 Nov; 44(4):517-524. PMID: 29107268

    Link: https://www.ncbi.nlm.nih.gov/pubmed/29107268


Dani H, Loeb S.

“The Role of Prostate Cancer Biomarkers in Undiagnosed Men.”

Current Opinion Urology 2017; 27: 210-216. PMID 28212119

Link: https://www.ncbi.nlm.nih.gov/pubmed/28212119


Loeb S.

“Biomarkers for Prostate Biopsy and Risk Stratification of Newly Diagnosed Prostate Cancer Patients.”

Urology Practice. 2017 Jul;4(4):315-321. PMID: 29104903

Link: https://www.ncbi.nlm.nih.gov/pubmed/29104903


Loeb S, Ross AE.

 “Genomic testing for localized prostate cancer: where do we go from here?”

 Current Opinion in Urology. 2017 Jun 28 epub. PMID: 28661898

    Link: https://www.ncbi.nlm.nih.gov/pubmed/28661898


Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, Partin AW, Sokoll L, Chan DW, Bangma CH, van Schaik RH, Slawin KM, Marks LS, Catalona WJ.

“Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer”

BJU International. 2016 Oct 15. PMID:27743489

Link: https://www.ncbi.nlm.nih.gov/pubmed/27743489


Lepor A, Catalona WJ, Loeb S.

“The Prostate Health Index: Its Utility in Prostate Cancer Detection. Urologic Clinics North America.”  

2016 Feb;43(1):1-6. PMID: 26614024

Link: http://www.ncbi.nlm.nih.gov/pubmed/26614024


Loeb S, Lilja H, Vickers A.

“Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer.”

Current Opinion in Urology 2016 Jun 3 epub. PMID: 27262138

Link: http://www.ncbi.nlm.nih.gov/pubmed/27262138


Other Original Articles

Bostrӧm PJ, Bjartell AS, Catto JW, Eggener SE, Lilja H, Loeb S, Schalken J, Schlomm T, and Cooperberg MR.

“Genomic Predictors of Outcome in Prostate Cancer.”

European Urology 2015 epub. PMID: 25913390.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25913390


Reviews/Editorials

Loeb S.

“Prostate Biopsy Decisions: One Size Fits All Approach with Total PSA is Out and a Multivariable Approach with the Prostate Health Index is In.”

BJU International 2015 June epub. PMID: 26054000.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26054000


Other Original Articles

Loeb S, Bruinsma SM, Nicholson J, Briganti A, Pickles T, Kakehi Y, Carlsson SV, Roobol MJ.

“Active Surveillance for Prostate Cancer: A Systematic Review of Clinicopathologic Variables and Biomarkers for Risk Stratification.”

European Urology 2014 Oct epub. PMID: 25457014

Link: http://www.ncbi.nlm.nih.gov/pubmed/25457014


Reviews/Editorials

Loeb S.

“Time to replace prostate-specific antigen (PSA) with the Prostate Health Index (PHI)? Yet more evidence that PHI consistently outperforms PSA across diverse populations.”

BJU International 2015; 115: 500. PMID: 25808708

Link: http://www.ncbi.nlm.nih.gov/pubmed/25808708


Other Original Articles

Loeb S, Sokoll LJ, Broyles DL, Bangma CH, van Schaik RH, Klee GG, Wei JT, Sanda MG, Partin AW, Slawin KM, Marks LS, Mizrahi IA, Shin SS, Cruz AB, Chan DW, Roberts WL, Catalona WJ.

“Prospective Multicenter Evaluation of the Beckman Coulter Prostate Health Index Using WHO Calibration.”

Journal of Urology 2012; epub November. PMID: 23206426.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23206426


Reviews/Editorials

Loeb S.

“Prostate cancer: Predicting prostate biopsy results- PCA3 versus phi.”

Nature Reviews Urology 2015 epub Feb 3. PMID: 25644161

Link: http://www.ncbi.nlm.nih.gov/pubmed/25644161

 


Other Original Articles

Tosoian JJ, Loeb S, Feng Z, Isharwal S, Landis P, Elliot DJ, Veltri R, Epstein JI, Partin AW, Carter HB, Trock B, Sokoll LJ.

“Association of [-2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer.”

Journal of Urology 2012; 188: 1131-6. PMID: 22901577.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22901577


Reviews/Editorials

Lundon D, Loeb S.

“Prostate-Specific Antigen Velocity Risk Count to Discern Significant From Indolent Prostate Cancer.”

Reviews in Urology 2014; 16: 154. PMID: 25337050.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191640/


Other Original Articles

Nichols JH, Loeb S, Metter EJ, Ferrucci L, Carter HB.

“The Relationship Between Prostate Volume and Prostate-Specific Antigen Variability: Data from the Baltimore Longitudinal Study of Aging and the Johns Hopkins Active Surveillance Program.”

BJU International 2012; 109: 1304-8. PMID: 22093443.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22093443


Reviews/Editorials

Loeb S. Editorial Comment on

“Low percentage of free prostate-specific antigen (PSA) is a strong predictor of later detection of prostate cancer among Japanese men with serum levels of total PSA of 4.0 ng/mL or less”

Urology 2014; 84: 1167. PMID: 25443924.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25443924


Other Original Articles

Roobol MJ, van Vugt HA, Loeb S, Zhu X, Bul M, Bangma CH, van Leenders AG, Steyerberg EW, and Schroder FH.

“Prediction of Prostate Cancer Risk: The Role of Prostate Volume and Digital Rectal Examination in the ERSPC Risk Calculators.”

European Urology 2012; 61: 577-83. PMID: 22104592.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22104592


Reviews/Editorials

Loeb S, Catalona WJ.

“The Prostate Health Index: A New Test for the Detection of Prostate Cancer.”

Therapeutic Advances in Urology 2014; 6: 74. PMID: 24688603

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943368/


Other Original Articles

Makarov DV, Loeb S, Magheli A, Zhao K, Humphreys E, Gonzalgo ML, Partin AW, and Han M.

“Significance of Preoperative PSA Velocity in Men with Low Serum PSA and Normal DRE.”

World Journal of Urology 2011; 29: 11.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21153643


Reviews/Editorials

Loeb S.

“Editorial Comment on: A Commentary on PSA Velocity and doubling time for clinical decisions in prostate cancer”

Urology 2014; 83: 596. PMID: 24581522

Link: http://www.ncbi.nlm.nih.gov/pubmed/24581522


Other Original Articles

Loeb S, Carter HB, Schaeffer EM, Kettermann A, Ferrucci L, and Metter EJ.

“Distribution of PSA Velocity by Total PSA Levels: Data from the Baltimore Longitudinal Study of Aging.”

Urology January 2011; 77: 143.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21195835


Reviews/Editorials

Loeb S. Editorial Comment on

“Prostate-Specific Antigen Density: Toward a Better Cutoff to Identify Better Candidates for Active Surveillance.”

Urology 2014; 84: 371.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24925831


Reviews/Editorials

Loeb S.

“Prostate Health Index (PHI): Golden Bullet or Just Another Prostate Cancer Marker?”

European Urology epub 2013 Feb 14. PMID: 23453055

Link: http://www.ncbi.nlm.nih.gov/pubmed/23453055

 


Other Original Articles

Le BV, Griffin CR, Loeb S, Carvalhal GF, Kan D, Baumann NA, and Catalona WJ.

“[-2] Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study.”

Journal of Urology 2010; 183: 1355.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20171670


Reviews/Editorials

Loeb S.

“Prostate Cancer: Prostate Health Index- Improving Screening in Men with a Positive Family History.”

Nature Reviews in Urology 2013; 10: 497

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943368/


Other Original Articles

Tosoian JJ, Loeb S, Kettermann A, Landis P, Elliot DJ, Epstein JI, Partin AW, Carter HB, and Sokoll LJ.

“Accuracy of PCA3 Measurement in Predicting Short-Term Biopsy Progression in an Active Surveillance Program.”

Journal of Urology, February 2010; 183: 534.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20006883


Reviews/Editorials

Loeb S, Carter HB.

“Point: Impact of Prostate-Specific Antigen Velocity on Management Decisions and Recommendations.”

Journal of the National Comprehensive Cancer Network 2013; 11: 281. PMID: 23486454

Link: http://www.ncbi.nlm.nih.gov/pubmed/23486454


Other Original Articles

Kettermann AE, Ferrucci L, Trock BJ, Metter EJ, Loeb S and Carter HB.

“Interpretation of the prostate-specific antigen history in assessing life-threatening prostate cancer.”

BJU International 2010 epub.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928882/


Reviews/Editorials

Loeb S.

“An Examination of the Dynamic Changes in Prostate-Specific Antigen Occurring in a Population-Based Cohort of Men Over Time.”

BJU International August 2012; 110: 381-2. PMID: 22313542.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22313542


Other Original Articles

Loeb S, Kan D, Yu X, Roehl KA, and Catalona WJ.

“Preoperative Prostate Specific Antigen Doubling Time is Not a Useful Predictor of Biochemical Progression After Radical Prostatectomy.”

Journal of Urology, May 2010; 183: 1816.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20303104


Reviews/Editorials

Loeb S.

“Editorial comment re: Longitudinal Changes of Benign Prostate-Specific Antigen and [-2]ProProstate-Specific Antigen in Seven Years in a Community-Based Sample of Men.”

Urology, March 2012; 79: 661. PMID: 22386421.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22386421


Other Original Articles

Loeb S, Roehl KA, Helfand BT, Kan D, and Catalona WJ.

“Can PSA Velocity Thresholds Reduce the Detection of Insignificant Prostate Cancer?”

Journal of Urology 2010; 183: 112.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140466/

 


Reviews/Editorials

Loeb S, Metter EJ, and Carter HB.

“Re: An Empirical Evaluation of Guidelines on Prostate-Specific Antigen Velocity in Prostate Cancer Detection.”

Journal of the National Cancer Institute November 2011; 103: 1636. PMID: 21926375.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21926375


Other Original Articles

Loeb S, Kettermann A, Carter HB, Metter EJ, Ferrucci L, and Walsh PC.

“Prostate Volume Changes Over Time: Results From the Baltimore Longitudinal Study of Aging.”

Journal of Urology 2009 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19683305


Other Original Articles

Loeb S, Sutherland DE, D’Amico AV, Roehl KA, and Catalona WJ.

“PSA Velocity is Associated with Gleason Score in Radical Prostatectomy Specimen: Marker for Prostate Cancer Aggressiveness.”

Urology, June 2008 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/18571700


Reviews/Editorials

Loeb S.

“Prediction of Outcomes After Radical Prostatectomy in Patients Diagnosed with Prostate Cancer of Biopsy Gleason Score ≥8 Via Contemporary Multi (≥12)-Core Prostate Biopsy.”

BJU International 2011; 108: 222. PMID: 21718432.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21718432


Reviews/Editorials

Loeb S. Editorial comment re:

“Prostate Specific Antigen Velocity per Prostate Volume: A Novel Tool for Prostate Biopsy Prediction.”

Urology 2011; 78: 879. PMID: 21982006

Link: http://www.ncbi.nlm.nih.gov/pubmed/21982006


Other Original Articles

Loeb S, Kettermann A, Ferrucci L, Landis P, Metter EJ, and Carter HB.

“PSA Doubling Time Versus PSA Velocity to Predict High-Risk Prostate Cancer: Data from the Baltimore Longitudinal Study of Aging.”

European Urology, July 2008 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/18614274


Reviews/Editorials

Loeb S and Carter HB.

“Should prostate-specific antigen velocity be abandoned?”

Asian Journal of Andrology 2011; 12: 359. PMID: 21499277.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3739355/


Other Original Articles

Martin NE, Chen MH, Catalona WJ, Loeb S, Roehl KA, and D’Amico AV.

“The Influence of Serial Prostate-Specific Antigen Screening on the PSA Velocity at Diagnosis.”

Cancer, 2008; 113: 717.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18615505

 


Reviews/Editorials

Loeb S.

“Editorial Comment Re: Evaluation of Prostate Specific Antigen Acceleration for Prostate Cancer Diagnosis.”

Journal of Urology March 2011; 185: 826. PMID: 21239022.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21239022


Other Original Articles

Loeb S, Kettermann A, Carter HB, Ferrucci L, Metter EJ, and Walsh PC.

“Does Prostate Growth Confound PSA Velocity: Data from the Baltimore Longitudinal Study of Aging.”

Journal of Urology, 2008; 180: 1314

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2575041/


Reviews/Editorials

Loeb S and Partin AW.

“PCA3 Urinary Biomarker for Prostate Cancer.”

Reviews in Urology Fall 2010; 12: e205. PMID: 21234266.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020285/


Other Original Articles

Meeks JJ, Thaxton CS, Loeb S, Roehl KA, Helfand BT, and Catalona WJ.

“Comparison of PSA Velocity of Screened Versus Referred Patients with Prostate Cancer.”

Journal of Urology 2008; 179: 1340.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18289590


Reviews/Editorials

Tosoian J and Loeb S.

“PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer.”

TheScientificWorldJOURNAL: TSW Urology October 2010; 10: 1919–1931.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20890581


Other Original Articles

Eggener SE, Yossepowitch O, Roehl KA, Loeb S, Yu X, and Catalona WJ.

“The Relationship of PSA Velocity to Histologic Findings in a Prostate Cancer Screening Program.”

Urology 2008; 71: 1016.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18358515


Reviews/Editorials

Loeb S and Carter HB.

“Limitations and Use of PSA Derivatives in the Screening and Risk Stratification of Prostate Cancer.”

Urologic Oncology: Seminars and Original Investigations, Nov-Dec 2009; 27: 583.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19879470


Other Original Articles

Loeb S, Roehl KA, Yu X, Han M, and Catalona WJ.

“Use of PSAV to Follow Patients with Isolated High-Grade Prostatic Intraepithelial Neoplasia (HG-PIN) on Prostate Biopsy.”

Urology, January 2007; 69: 108.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17270629


Other Original Articles

Loeb S, Roehl KA, Catalona WJ, and Nadler RB.

“PSA Velocity Threshold for Predicting Prostate Cancer in Young Men.”

Journal of Urology, March 2007; 177: 899.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17296371


Reviews/Editorials

Loeb S.

“Prostate Cancer: Is PSA Velocity Useful?”

Nature Reviews Urology, June 2009; 6: 305.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19498408


Reviews/Editorials

Loeb S and Carter HB.

“Words of Wisdom: Re: Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.”

European Urology, February 2009; 55: 523.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19606535


Other Original Articles

Yu X, Loeb S, Han M, Suarez BK, Roehl KA, and Catalona WJ.

“The Association Between Total PSA and PSA Velocity.”

Journal of Urology, April 2007; 177: 1298.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17382716


Reviews/Editorials

Loeb S, Kettermann A, Ferrucci L, Landis P, Metter EJ, and Carter HB.

“The Optimal Application of Prostate-Specific Antigen (PSA) Velocity to Predict High-Risk Disease.”

European Urology, November 2008 54: 978.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2603630/


Other Original Articles

Loeb S, Yu X, Roehl KA, Nadler RB and Catalona WJ.

“PSA Velocity Thresholds in Men with Total PSA <4 ng/ml.”

Journal of Urology, December 2007; 178; 2348.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17936844


Reviews/Editorials

Makarov DV, Loeb S, Getzenberg RH, and Partin AW.

“Biomarkers for Prostate Cancer.”

Annual Reviews in Medicine, October 2008 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/18947298


Other Original Articles

Loeb S, Roehl KA, Catalona WJ, and Nadler RB.

“Is the Utility of PSA Velocity for Prostate Cancer Detection Affected by Age?”

BJU International, April 2008; 101: 817.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18321315


Other Original Articles

Yu X, Han M, Loeb S, Gashti SN, Yeh JT, Roehl KA, and Catalona WJ.

“Comparison of Different Methods for Calculating PSA Velocity: Importance of Time Interval Prior to Diagnosis of Prostate Cancer.”

Journal of Urology, December 2006; 176: 2427.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17085120


Reviews/Editorials

Loeb S.

“Does PCA3 Help Identify Clinically Significant Prostate Cancer?”

European Urology, July 2008 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/18684556


Other Original Articles

Loeb S, Han M, Roehl KA, Antenor JV, and Catalona WJ.

“Accuracy of Prostate Weight Estimation by Digital Rectal Exam (DRE) Versus Transrectal Ultrasonography (TRUS).”

Journal of Urology, January 2005; 173: 63-5.

Link: http://www.ncbi.nlm.nih.gov/pubmed/15592029


Reviews/Editorials

Loeb S and Catalona WJ.

“Cancer Biomarkers: Discovery and Validation.”

Cancer Letters, January 2007

 


Key Papers

Loeb S, Sanda MG, Broyles DL, Shin SS, Bangma CH, Wei JT, Partin AW, Klee GG, Slawin KM, Marks LS, van Schaik RH, Chan DW, Sokoll LJ, Cruz AB, Mizrahi IA, Catalona WJ.

“The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer.”

Journal of Urology 2014 Nov 15 epub. PMID:25463993

Link: http://www.ncbi.nlm.nih.gov/pubmed/25463993

Among men from the US FDA registration trial, we found that the Prostate Health Index was a better predictor of clinically significant prostate cancer compared to any of its component parts (total, free or -2proPSA). At the 90% sensitivity cut point for phi (a score less than 28.6), 30% of patients could have been spared an unnecessary biopsy for benign disease or insignificant prostate cancer compared to 21.7% using percent free PSA.


Key Papers

Loeb S, Metter EJ, Kan D, Roehl KA, Catalona WJ.

“Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer.”

BJU International. 2012 Feb;109(4):508-13. PMID: 22296334

Link: http://www.ncbi.nlm.nih.gov/pubmed/22296334

Sustained rises in PSA indicate a significantly greater risk of prostate cancer, particularly high-grade disease. Men with 2 successive PSA velocity measurements >0.4 ng/ml/year (a “risk count” of 2) have an 8-fold increased risk of prostate cancer and 5.4-fold increased risk of Gleason 8-10 disease on biopsy compared to those with ≤1 serial PSAV exceeding 0.4 (risk count 0-1), adjusting for age and PSA level. Compared to PSA alone, PSA velocity risk count may reduce unnecessary biopsies and overdiagnosis of low-risk prostate cancer


Key Papers

Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL, Shin SS, Cruz AB, Chan DW, Sokoll LJ, Roberts WL, van Schaik RH, Mizrahi IA.

“A Multicenter Study of [-2] Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range.”

Journal of Urology May 2011; 185: 1650. PMID: 21419439.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21419439

This prospective, multicenter US trial led to the FDA approval of the Prostate Health Index (phi) in 2012. Phi is a new serum marker test combining total, free and -2proPSA. Among 892 men undergoing prostate biopsy at PSA levels of 2-10 ng/ml, phi was more specific for prostate cancer than either total or free PSA.


Other Original Articles

Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, Feng Z, Carter HB, and Walsh PC.

“Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.”

Journal of Clinical Oncology 2010; 28: 2810.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20439642


BioMarkers

Concordance and Performance of 4KScore and SelectMDx for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer

Wysock JS, Becher E, Persily J, Loeb S, Lepor H.

“Concordance and Performance of 4KScore and SelectMDx for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer.”

Urology. 2020 Apr 12:S0090-4295(20)30339-3. PMID: 32294481

Link: https://pubmed.ncbi.nlm.nih.gov/32294481/


Untitled

Fine ND, LaPolla F, Epstein M, Loeb S, Dani H.

” Genomic Classifiers for Treatment Selection in Newly Diagnosed Prostate Cancer.”

 BJU International 2019 May epub. PMID:31055874.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31055874


Loeb S, Tosoian JJ.

 “Biomarkers in Active Surveillance. “

BJU International. 2018 May 22. PMID: 29786946

    Link: https://www.ncbi.nlm.nih.gov/pubmed/29594029c


Loeb S, Tosoian JJ.

 “Biomarkers in Active Surveillance.”

Translational Andrology and Urology 2018 Feb; 7(1):155-159. PMID: 29594029.

    Link: https://www.ncbi.nlm.nih.gov/pubmed/29594029


Punnen S, Freedland SJ, Polascik TJ, Loeb S, Risk MC, Savage S, Mathur SC, Uchio E, Dong Y, Silberstein JL.

” A Multi-institutional Prospective Trial in the Veterans Affairs Health System confirms the 4Kscore maintains its Predictive value among African American Men.”

Journal of Urology 2017, epub Dec 6. PMID: 29223389

Link: https://www.ncbi.nlm.nih.gov/pubmed/29223389


Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choeurng V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll PR, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL

” Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.”

Journal of Clinical Oncology. 2017 Nov 29 epub. PMID: 29185869.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29185869


Loeb S, Dani H.

 “Whom to Biopsy: Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators.”

Urol Clin North Am. 2017 Nov; 44(4):517-524. PMID: 29107268

    Link: https://www.ncbi.nlm.nih.gov/pubmed/29107268


Dani H, Loeb S.

“The Role of Prostate Cancer Biomarkers in Undiagnosed Men.”

Current Opinion Urology 2017; 27: 210-216. PMID 28212119

Link: https://www.ncbi.nlm.nih.gov/pubmed/28212119


Loeb S.

“Biomarkers for Prostate Biopsy and Risk Stratification of Newly Diagnosed Prostate Cancer Patients.”

Urology Practice. 2017 Jul;4(4):315-321. PMID: 29104903

Link: https://www.ncbi.nlm.nih.gov/pubmed/29104903


Loeb S, Ross AE.

 “Genomic testing for localized prostate cancer: where do we go from here?”

 Current Opinion in Urology. 2017 Jun 28 epub. PMID: 28661898

    Link: https://www.ncbi.nlm.nih.gov/pubmed/28661898


Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, Partin AW, Sokoll L, Chan DW, Bangma CH, van Schaik RH, Slawin KM, Marks LS, Catalona WJ.

“Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer”

BJU International. 2016 Oct 15. PMID:27743489

Link: https://www.ncbi.nlm.nih.gov/pubmed/27743489


Lepor A, Catalona WJ, Loeb S.

“The Prostate Health Index: Its Utility in Prostate Cancer Detection. Urologic Clinics North America.”  

2016 Feb;43(1):1-6. PMID: 26614024

Link: http://www.ncbi.nlm.nih.gov/pubmed/26614024


Loeb S, Lilja H, Vickers A.

“Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer.”

Current Opinion in Urology 2016 Jun 3 epub. PMID: 27262138

Link: http://www.ncbi.nlm.nih.gov/pubmed/27262138


Other Original Articles

Bostrӧm PJ, Bjartell AS, Catto JW, Eggener SE, Lilja H, Loeb S, Schalken J, Schlomm T, and Cooperberg MR.

“Genomic Predictors of Outcome in Prostate Cancer.”

European Urology 2015 epub. PMID: 25913390.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25913390


Reviews/Editorials

Loeb S.

“Prostate Biopsy Decisions: One Size Fits All Approach with Total PSA is Out and a Multivariable Approach with the Prostate Health Index is In.”

BJU International 2015 June epub. PMID: 26054000.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26054000


Other Original Articles

Loeb S, Bruinsma SM, Nicholson J, Briganti A, Pickles T, Kakehi Y, Carlsson SV, Roobol MJ.

“Active Surveillance for Prostate Cancer: A Systematic Review of Clinicopathologic Variables and Biomarkers for Risk Stratification.”

European Urology 2014 Oct epub. PMID: 25457014

Link: http://www.ncbi.nlm.nih.gov/pubmed/25457014


Reviews/Editorials

Loeb S.

“Time to replace prostate-specific antigen (PSA) with the Prostate Health Index (PHI)? Yet more evidence that PHI consistently outperforms PSA across diverse populations.”

BJU International 2015; 115: 500. PMID: 25808708

Link: http://www.ncbi.nlm.nih.gov/pubmed/25808708


Other Original Articles

Loeb S, Sokoll LJ, Broyles DL, Bangma CH, van Schaik RH, Klee GG, Wei JT, Sanda MG, Partin AW, Slawin KM, Marks LS, Mizrahi IA, Shin SS, Cruz AB, Chan DW, Roberts WL, Catalona WJ.

“Prospective Multicenter Evaluation of the Beckman Coulter Prostate Health Index Using WHO Calibration.”

Journal of Urology 2012; epub November. PMID: 23206426.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23206426


Reviews/Editorials

Loeb S.

“Prostate cancer: Predicting prostate biopsy results- PCA3 versus phi.”

Nature Reviews Urology 2015 epub Feb 3. PMID: 25644161

Link: http://www.ncbi.nlm.nih.gov/pubmed/25644161

 


Other Original Articles

Tosoian JJ, Loeb S, Feng Z, Isharwal S, Landis P, Elliot DJ, Veltri R, Epstein JI, Partin AW, Carter HB, Trock B, Sokoll LJ.

“Association of [-2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer.”

Journal of Urology 2012; 188: 1131-6. PMID: 22901577.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22901577


Reviews/Editorials

Lundon D, Loeb S.

“Prostate-Specific Antigen Velocity Risk Count to Discern Significant From Indolent Prostate Cancer.”

Reviews in Urology 2014; 16: 154. PMID: 25337050.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191640/


Other Original Articles

Nichols JH, Loeb S, Metter EJ, Ferrucci L, Carter HB.

“The Relationship Between Prostate Volume and Prostate-Specific Antigen Variability: Data from the Baltimore Longitudinal Study of Aging and the Johns Hopkins Active Surveillance Program.”

BJU International 2012; 109: 1304-8. PMID: 22093443.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22093443


Reviews/Editorials

Loeb S. Editorial Comment on

“Low percentage of free prostate-specific antigen (PSA) is a strong predictor of later detection of prostate cancer among Japanese men with serum levels of total PSA of 4.0 ng/mL or less”

Urology 2014; 84: 1167. PMID: 25443924.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25443924


Other Original Articles

Roobol MJ, van Vugt HA, Loeb S, Zhu X, Bul M, Bangma CH, van Leenders AG, Steyerberg EW, and Schroder FH.

“Prediction of Prostate Cancer Risk: The Role of Prostate Volume and Digital Rectal Examination in the ERSPC Risk Calculators.”

European Urology 2012; 61: 577-83. PMID: 22104592.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22104592


Reviews/Editorials

Loeb S, Catalona WJ.

“The Prostate Health Index: A New Test for the Detection of Prostate Cancer.”

Therapeutic Advances in Urology 2014; 6: 74. PMID: 24688603

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943368/


Other Original Articles

Makarov DV, Loeb S, Magheli A, Zhao K, Humphreys E, Gonzalgo ML, Partin AW, and Han M.

“Significance of Preoperative PSA Velocity in Men with Low Serum PSA and Normal DRE.”

World Journal of Urology 2011; 29: 11.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21153643


Reviews/Editorials

Loeb S.

“Editorial Comment on: A Commentary on PSA Velocity and doubling time for clinical decisions in prostate cancer”

Urology 2014; 83: 596. PMID: 24581522

Link: http://www.ncbi.nlm.nih.gov/pubmed/24581522


Other Original Articles

Loeb S, Carter HB, Schaeffer EM, Kettermann A, Ferrucci L, and Metter EJ.

“Distribution of PSA Velocity by Total PSA Levels: Data from the Baltimore Longitudinal Study of Aging.”

Urology January 2011; 77: 143.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21195835


Reviews/Editorials

Loeb S. Editorial Comment on

“Prostate-Specific Antigen Density: Toward a Better Cutoff to Identify Better Candidates for Active Surveillance.”

Urology 2014; 84: 371.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24925831


Reviews/Editorials

Loeb S.

“Prostate Health Index (PHI): Golden Bullet or Just Another Prostate Cancer Marker?”

European Urology epub 2013 Feb 14. PMID: 23453055

Link: http://www.ncbi.nlm.nih.gov/pubmed/23453055

 


Other Original Articles

Le BV, Griffin CR, Loeb S, Carvalhal GF, Kan D, Baumann NA, and Catalona WJ.

“[-2] Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study.”

Journal of Urology 2010; 183: 1355.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20171670


Reviews/Editorials

Loeb S.

“Prostate Cancer: Prostate Health Index- Improving Screening in Men with a Positive Family History.”

Nature Reviews in Urology 2013; 10: 497

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943368/


Other Original Articles

Tosoian JJ, Loeb S, Kettermann A, Landis P, Elliot DJ, Epstein JI, Partin AW, Carter HB, and Sokoll LJ.

“Accuracy of PCA3 Measurement in Predicting Short-Term Biopsy Progression in an Active Surveillance Program.”

Journal of Urology, February 2010; 183: 534.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20006883


Reviews/Editorials

Loeb S, Carter HB.

“Point: Impact of Prostate-Specific Antigen Velocity on Management Decisions and Recommendations.”

Journal of the National Comprehensive Cancer Network 2013; 11: 281. PMID: 23486454

Link: http://www.ncbi.nlm.nih.gov/pubmed/23486454


Other Original Articles

Kettermann AE, Ferrucci L, Trock BJ, Metter EJ, Loeb S and Carter HB.

“Interpretation of the prostate-specific antigen history in assessing life-threatening prostate cancer.”

BJU International 2010 epub.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928882/


Reviews/Editorials

Loeb S.

“An Examination of the Dynamic Changes in Prostate-Specific Antigen Occurring in a Population-Based Cohort of Men Over Time.”

BJU International August 2012; 110: 381-2. PMID: 22313542.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22313542


Other Original Articles

Loeb S, Kan D, Yu X, Roehl KA, and Catalona WJ.

“Preoperative Prostate Specific Antigen Doubling Time is Not a Useful Predictor of Biochemical Progression After Radical Prostatectomy.”

Journal of Urology, May 2010; 183: 1816.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20303104


Reviews/Editorials

Loeb S.

“Editorial comment re: Longitudinal Changes of Benign Prostate-Specific Antigen and [-2]ProProstate-Specific Antigen in Seven Years in a Community-Based Sample of Men.”

Urology, March 2012; 79: 661. PMID: 22386421.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22386421


Other Original Articles

Loeb S, Roehl KA, Helfand BT, Kan D, and Catalona WJ.

“Can PSA Velocity Thresholds Reduce the Detection of Insignificant Prostate Cancer?”

Journal of Urology 2010; 183: 112.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140466/

 


Reviews/Editorials

Loeb S, Metter EJ, and Carter HB.

“Re: An Empirical Evaluation of Guidelines on Prostate-Specific Antigen Velocity in Prostate Cancer Detection.”

Journal of the National Cancer Institute November 2011; 103: 1636. PMID: 21926375.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21926375


Other Original Articles

Loeb S, Kettermann A, Carter HB, Metter EJ, Ferrucci L, and Walsh PC.

“Prostate Volume Changes Over Time: Results From the Baltimore Longitudinal Study of Aging.”

Journal of Urology 2009 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19683305


Other Original Articles

Loeb S, Sutherland DE, D’Amico AV, Roehl KA, and Catalona WJ.

“PSA Velocity is Associated with Gleason Score in Radical Prostatectomy Specimen: Marker for Prostate Cancer Aggressiveness.”

Urology, June 2008 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/18571700


Reviews/Editorials

Loeb S.

“Prediction of Outcomes After Radical Prostatectomy in Patients Diagnosed with Prostate Cancer of Biopsy Gleason Score ≥8 Via Contemporary Multi (≥12)-Core Prostate Biopsy.”

BJU International 2011; 108: 222. PMID: 21718432.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21718432


Reviews/Editorials

Loeb S. Editorial comment re:

“Prostate Specific Antigen Velocity per Prostate Volume: A Novel Tool for Prostate Biopsy Prediction.”

Urology 2011; 78: 879. PMID: 21982006

Link: http://www.ncbi.nlm.nih.gov/pubmed/21982006


Other Original Articles

Loeb S, Kettermann A, Ferrucci L, Landis P, Metter EJ, and Carter HB.

“PSA Doubling Time Versus PSA Velocity to Predict High-Risk Prostate Cancer: Data from the Baltimore Longitudinal Study of Aging.”

European Urology, July 2008 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/18614274


Reviews/Editorials

Loeb S and Carter HB.

“Should prostate-specific antigen velocity be abandoned?”

Asian Journal of Andrology 2011; 12: 359. PMID: 21499277.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3739355/


Other Original Articles

Martin NE, Chen MH, Catalona WJ, Loeb S, Roehl KA, and D’Amico AV.

“The Influence of Serial Prostate-Specific Antigen Screening on the PSA Velocity at Diagnosis.”

Cancer, 2008; 113: 717.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18615505

 


Reviews/Editorials

Loeb S.

“Editorial Comment Re: Evaluation of Prostate Specific Antigen Acceleration for Prostate Cancer Diagnosis.”

Journal of Urology March 2011; 185: 826. PMID: 21239022.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21239022


Other Original Articles

Loeb S, Kettermann A, Carter HB, Ferrucci L, Metter EJ, and Walsh PC.

“Does Prostate Growth Confound PSA Velocity: Data from the Baltimore Longitudinal Study of Aging.”

Journal of Urology, 2008; 180: 1314

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2575041/


Reviews/Editorials

Loeb S and Partin AW.

“PCA3 Urinary Biomarker for Prostate Cancer.”

Reviews in Urology Fall 2010; 12: e205. PMID: 21234266.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020285/


Other Original Articles

Meeks JJ, Thaxton CS, Loeb S, Roehl KA, Helfand BT, and Catalona WJ.

“Comparison of PSA Velocity of Screened Versus Referred Patients with Prostate Cancer.”

Journal of Urology 2008; 179: 1340.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18289590


Reviews/Editorials

Tosoian J and Loeb S.

“PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer.”

TheScientificWorldJOURNAL: TSW Urology October 2010; 10: 1919–1931.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20890581


Other Original Articles

Eggener SE, Yossepowitch O, Roehl KA, Loeb S, Yu X, and Catalona WJ.

“The Relationship of PSA Velocity to Histologic Findings in a Prostate Cancer Screening Program.”

Urology 2008; 71: 1016.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18358515


Reviews/Editorials

Loeb S and Carter HB.

“Limitations and Use of PSA Derivatives in the Screening and Risk Stratification of Prostate Cancer.”

Urologic Oncology: Seminars and Original Investigations, Nov-Dec 2009; 27: 583.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19879470


Other Original Articles

Loeb S, Roehl KA, Yu X, Han M, and Catalona WJ.

“Use of PSAV to Follow Patients with Isolated High-Grade Prostatic Intraepithelial Neoplasia (HG-PIN) on Prostate Biopsy.”

Urology, January 2007; 69: 108.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17270629


Other Original Articles

Loeb S, Roehl KA, Catalona WJ, and Nadler RB.

“PSA Velocity Threshold for Predicting Prostate Cancer in Young Men.”

Journal of Urology, March 2007; 177: 899.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17296371


Reviews/Editorials

Loeb S.

“Prostate Cancer: Is PSA Velocity Useful?”

Nature Reviews Urology, June 2009; 6: 305.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19498408


Reviews/Editorials

Loeb S and Carter HB.

“Words of Wisdom: Re: Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.”

European Urology, February 2009; 55: 523.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19606535


Other Original Articles

Yu X, Loeb S, Han M, Suarez BK, Roehl KA, and Catalona WJ.

“The Association Between Total PSA and PSA Velocity.”

Journal of Urology, April 2007; 177: 1298.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17382716


Reviews/Editorials

Loeb S, Kettermann A, Ferrucci L, Landis P, Metter EJ, and Carter HB.

“The Optimal Application of Prostate-Specific Antigen (PSA) Velocity to Predict High-Risk Disease.”

European Urology, November 2008 54: 978.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2603630/


Other Original Articles

Loeb S, Yu X, Roehl KA, Nadler RB and Catalona WJ.

“PSA Velocity Thresholds in Men with Total PSA <4 ng/ml.”

Journal of Urology, December 2007; 178; 2348.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17936844


Reviews/Editorials

Makarov DV, Loeb S, Getzenberg RH, and Partin AW.

“Biomarkers for Prostate Cancer.”

Annual Reviews in Medicine, October 2008 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/18947298


Other Original Articles

Loeb S, Roehl KA, Catalona WJ, and Nadler RB.

“Is the Utility of PSA Velocity for Prostate Cancer Detection Affected by Age?”

BJU International, April 2008; 101: 817.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18321315


Other Original Articles

Yu X, Han M, Loeb S, Gashti SN, Yeh JT, Roehl KA, and Catalona WJ.

“Comparison of Different Methods for Calculating PSA Velocity: Importance of Time Interval Prior to Diagnosis of Prostate Cancer.”

Journal of Urology, December 2006; 176: 2427.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17085120


Reviews/Editorials

Loeb S.

“Does PCA3 Help Identify Clinically Significant Prostate Cancer?”

European Urology, July 2008 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/18684556


Other Original Articles

Loeb S, Han M, Roehl KA, Antenor JV, and Catalona WJ.

“Accuracy of Prostate Weight Estimation by Digital Rectal Exam (DRE) Versus Transrectal Ultrasonography (TRUS).”

Journal of Urology, January 2005; 173: 63-5.

Link: http://www.ncbi.nlm.nih.gov/pubmed/15592029


Reviews/Editorials

Loeb S and Catalona WJ.

“Cancer Biomarkers: Discovery and Validation.”

Cancer Letters, January 2007

 


Key Papers

Loeb S, Sanda MG, Broyles DL, Shin SS, Bangma CH, Wei JT, Partin AW, Klee GG, Slawin KM, Marks LS, van Schaik RH, Chan DW, Sokoll LJ, Cruz AB, Mizrahi IA, Catalona WJ.

“The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer.”

Journal of Urology 2014 Nov 15 epub. PMID:25463993

Link: http://www.ncbi.nlm.nih.gov/pubmed/25463993

Among men from the US FDA registration trial, we found that the Prostate Health Index was a better predictor of clinically significant prostate cancer compared to any of its component parts (total, free or -2proPSA). At the 90% sensitivity cut point for phi (a score less than 28.6), 30% of patients could have been spared an unnecessary biopsy for benign disease or insignificant prostate cancer compared to 21.7% using percent free PSA.


Key Papers

Loeb S, Metter EJ, Kan D, Roehl KA, Catalona WJ.

“Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer.”

BJU International. 2012 Feb;109(4):508-13. PMID: 22296334

Link: http://www.ncbi.nlm.nih.gov/pubmed/22296334

Sustained rises in PSA indicate a significantly greater risk of prostate cancer, particularly high-grade disease. Men with 2 successive PSA velocity measurements >0.4 ng/ml/year (a “risk count” of 2) have an 8-fold increased risk of prostate cancer and 5.4-fold increased risk of Gleason 8-10 disease on biopsy compared to those with ≤1 serial PSAV exceeding 0.4 (risk count 0-1), adjusting for age and PSA level. Compared to PSA alone, PSA velocity risk count may reduce unnecessary biopsies and overdiagnosis of low-risk prostate cancer


Key Papers

Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL, Shin SS, Cruz AB, Chan DW, Sokoll LJ, Roberts WL, van Schaik RH, Mizrahi IA.

“A Multicenter Study of [-2] Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range.”

Journal of Urology May 2011; 185: 1650. PMID: 21419439.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21419439

This prospective, multicenter US trial led to the FDA approval of the Prostate Health Index (phi) in 2012. Phi is a new serum marker test combining total, free and -2proPSA. Among 892 men undergoing prostate biopsy at PSA levels of 2-10 ng/ml, phi was more specific for prostate cancer than either total or free PSA.


Other Original Articles

Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, Feng Z, Carter HB, and Walsh PC.

“Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.”

Journal of Clinical Oncology 2010; 28: 2810.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20439642


Blog

Urology Care Foundation- A Great Source of Patient Information

I recently returned from a meeting of the Technology and Publications Committee of the Urology Care Foundation.  This is the official foundation of the American Urological Association, which provides educational materials and other resources for patients.
One particularly impressive resource that our committee oversees is the patient magazine called Urology Health Extra.  Here is a link to the current issue: http://www.urologyhealth.org/patient-magazine/current-issue. It has timely information on urologic conditions reviewed by experts, presented in a reader-friendly format.  I highly recommend this as an excellent resource for patients, and suggest that urology offices order free copies of this for their waiting rooms (http://www.urologyhealth.org/educational-materials/magazine-subscription-bulk).
In addition to these printed materials, our committee plans to expand the digital initiatives of the Urology Care Foundation. Stay tuned for much more on Twitter, Facebook, YouTube, Instagram and Pinterest this coming year!
Urology Care Foundation


Welcome to Dr. Stacy Loeb’s blog!

Welcome to Dr. Stacy Loeb’s blog!  Stay tuned to this section for urology updates, research findings and conference highlights. Check the publications tab for previous research related to:
  • prostate cancer: PSA Screening, biomarkers, genetics, epidemiology, prostate biopsy, staging, active surveillance, treatment.
  • other urology topics: surgical technique, uro-oncology, benign disease
  • social media


Brazil

Paulista Congress of Urology

Brazil (Virtual). October 2020

Topic: Prostate Cancer Screening, Markers and Genetic Testing

Category: Prostate Cancer, Genetics


International Continence Society

Rio de Janiero, Brazil. October 2014

Lecture Topic: Social Media in Medicine

Category: Social media


Canada

Société Internationale d’Urologie

Montreal (Virtual). April 2020

Topic: Webinar on Economic and Financial Burden of COVID-19

Category: COVID-19


Queens University Visiting Professor

Kingston, Ontario – October 18-19, 2018

Lecture Topics: Social Media in Men’s Health (6th Annual Alvaro and Diane Morales Public Lecture in Men’s Health); Active Surveillance for Prostate Cancer.

Category: Men’s Health, Social Media, Prostate Cancer, Active Surveillance


Canadian Urological Association 2017 Meeting

Toronto, Canada- June 24-27, 2017

Lecture topics: Optimizing Active Surveillance for Prostate Cancer, Serum and Urine Markers to Select Patient for Initial and Repeat Prostate Biopsy

Category: Prostate cancer


Issues & Controversies in Urologic Cancer (ICUC) Conference 2017

Mony Tremblant, Canada. January 19-21, 2017

Lecture Topics: Prostate Cancer Markers, Active Surveillance, Prostate Biopsy

Category: Prostate Cancer


The 10th Atlantic Uro Oncology Meeting

 Halifax, Canada. November 14, 2015

Lecture Topics: Prostate Cancer Markers and Active Surveillance

Category: Prostate Cancer


Visiting professor at University of Toronto

 Toronto, Canada. October 2014

Lecture Topics: Prostate Biopsy, Active Surveillance

Category: Prostate Cancer


Colombia

1ER CURSO BIENAL DE INNOVACÍON UROLÓGICA SOCIEDAD COLOMBIANA DE UROLOGÍA

 Barranquilla, Colombia. October 2015

Lecture Topics (all in Spanish):  Prostate -specific Antigen and Biomarkers, Prevention and Management of Prostate Biopsy Complications, Active Surveillance

Category: Prostate Cancer


Second Update Course in Urology (Curso de Actualización en Urología)

 Barranquilla, Colombia. March 2015

Lecture Topics: Prostate cancer screening, prostate cancer markers, prostate biopsy

Category: Prostate Cancer


Visiting Professor at Fundación Santa Fe de Bogotá Fundación

 Barranquilla, Colombia. March 2015

Lecture Topics: Prostate Cancer Screening, Serum and Urine Markers for Prostate Cancer, Contemporary Prostate Biopsy, Active Surveillance, Social Media in Urology

Categories: Prostate Cancer, Social Media


Sociedad Colombiana de Urologia

Cartagena, Colombia. March 2014

Lectures Topics: PSA screening, Risks of Prostate Biopsy, Active Surveillance, Prostate MRI-based Detection, Castration Resistant Prostate Cancer, and Twitter in Urology

Categories: Prostate Cancer, Social Media


Colorado - USA

Conference Highlights

ConferenceHighlights

Nickel JC, Gorin MA, Alan W P, Loeb S, Ellen S, Chancellor MB, Assimos DG, Brawer MK, Brucker BM.

“Best of the 2016 AUA Annual Meeting: Highlights From the 2016 American Urological Association Annual Meeting, May 6-10, 2016, San Diego, CA.”

Reviews in Urology 2016;18(3):159-173.  PMID: 27833468.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27833468


Nickel JC, Gorin MA, Partin AW, Assimos D, Brawer M, Nicolai H, Chancellor MB, Goggins Á, Loeb S, Shapiro E.  

“Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL.”

Reviews in Urology 2015;17(3):179-89. PMID: 26543434

Link: http://www.ncbi.nlm.nih.gov/pubmed/26543434


Prostate Cancer Screening Highlights from the 29th European Association of Urology Congress Stockholm, Sweden, April 11-15, 2014.

Loeb S.

“Prostate Cancer Screening Highlights from the 29th European Association of Urology Congress Stockholm, Sweden, April 11-15, 2014.”

Reviews in Urology 2014; 16: 90. PMID: 25009450.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4080855/


Advances in Localized Prostate Cancer: Highlights From the 2012 Friends of Israel Urological Symposium, July 3-5, 2012, Tel Aviv, Israel.

Loeb S, Borin JF.

“Advances in Localized Prostate Cancer: Highlights From the 2012 Friends of Israel Urological Symposium, July 3-5, 2012, Tel Aviv, Israel.”

Reviews in Urology 2013; 15: 82.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784972/


Best of the 2013 AUA Annual Meeting: Highlights From the 2013 American Urological Association Meeting, May 4-8, 2013, San Diego, CA.

Loeb S, Assimos D, Chancellor MB, Nickel JC, Brawer MK, Kern AJ, Partin AW.

“Best of the 2013 AUA Annual Meeting: Highlights From the 2013 American Urological Association Meeting, May 4-8, 2013, San Diego, CA..”

Reviews in Urology 2013; 15: 72.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784971/


Best of 2012 AUA Annual Meeting: Highlights from the 2012 American Urological Association Meeting, May 19-23, 2012, Atlanta, GA.

Nickel JC, Partin AW, Nirmal J, Chancellor MB, Loeb S, Brawer MK, Assimos D, and Shapiro E.

“Best of 2012 AUA Annual Meeting: Highlights from the 2012 American Urological Association Meeting, May 19-23, 2012, Atlanta, GA.”

Reviews in Urology 2012; 14: 90-103. PMID: 23526762

Link: http://www.ncbi.nlm.nih.gov/pubmed/23526762


Prostate Cancer Screening and Surgical Management of Localized Disease: Highlights from the 27th Annual Congress of the European Association of Urology, February 24-28, 2012, Paris, France.

Loeb S.

“Prostate Cancer Screening and Surgical Management of Localized Disease: Highlights from the 27th Annual Congress of the European Association of Urology, February 24-28, 2012, Paris, France.”

Reviews in Urology 2012; 14: 87-9. PMID: 23526727

Link: http://www.ncbi.nlm.nih.gov/pubmed/23526727


Novel approaches to improve prostate cancer diagnosis and management in early-stage disease.

Marberger M, Barentsz J, Emberton M, Hugosson J, Loeb S, Klotz L, Koch M, Shariat SF, Vickers A.

“Novel approaches to improve prostate cancer diagnosis and management in early-stage disease.”

BJU International 2012; 109 Suppl 2: 1-7. PMID: 22257098.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22257098


Best of the AUA Annual Meeting: Highlights from the 2011 American Urological Association Meeting, May 14-19, 2011, Washington, DC.

Brawer MK, Loeb S, Partin AW, Nirmal J, Chancellor MB, Nickel JC, Rajfer J, Shapiro E, and Roehrborn CG.

“Best of the AUA Annual Meeting: Highlights from the 2011 American Urological Association Meeting, May 14-19, 2011, Washington, DC.”

Reviews in Urology 2011; 13: 151-72. PMID: 22114546.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2725309/


Innovation in Endourology and Minimally Invasive Surgery. Highlights from the 29th World Congress of Endourology and SWL 2011, November 30-December 3, 2011, Kyoto, Japan.

Loeb S and Borin JF.

“Innovation in Endourology and Minimally Invasive Surgery. Highlights from the 29th World Congress of Endourology and SWL 2011, November 30-December 3, 2011, Kyoto, Japan.”

Reviews in Urology 2012; 14: 28-30. PMID: 23172997.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502049/


Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL.

Brawer MK, Loeb S, Partin AW, Yoshimura N, Chancellor MB, Roehrborn CG, Assimos DG, Nickel JC, Shuch B, Pouliot F, Belldegrun AS, and Shapiro E.

“Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL.”

Reviews in Urology, Spring 2009; 11: 82.


Costa Rica

Congreso Centroamericano y del Caribe de Urología y II Highlights of the 2014 American Urological Association Meeting

San Jose, Costa Rica. August 2014

Lectures on: Active surveillance for prostate cancer, Highlights of the AUA meeting on Localized Prostate Cancer

Category: Prostate Cancer


Covid19

Telemedicine Usage Among Urologists During the COVID-19 Pandemic: Cross-Sectional Study

Dubin JM, Wyant WA, Balaji NC, Ong WL, Kettache RH, Haffaf M, Zouari S, Santillan D, Autrán Gómez AM, Sadeghi-Nejad H, Loeb S, Borin JF, Gomez Rivas J, Grummet J, Ramasamy R, Teoh JYC.

“Telemedicine Usage Among Urologists During the COVID-19 Pandemic: Cross-Sectional Study.”

J Med Internet Res. 2020 Nov 5;22(11):e21875. PMID: 33031047.

Link: https://pubmed.ncbi.nlm.nih.gov/33031047/

 


The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future

Wallis CJD, Catto JWF, Finelli A, Glaser AW, Gore JL, Loeb S, Morgan TM, Morgans AK, Mottet N, Neal R, O’Brien T, Odisho AY, Powles T, Skolarus TA, Smith AB, Szabados B, Klaassen Z, Spratt DE.

“The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future.”

Eur Urol. 2020 Nov;78(5):731-742. PMID: 32893062.

Link: https://pubmed.ncbi.nlm.nih.gov/32893062/

 


Urologic Services in Public Hospitals Suffered a Greater Detriment Than Private Hospitals During the Battle of COVID-19

Ong WLK, Lechmiannandan S, Loeb S, Teoh JY.

“Urologic Services in Public Hospitals Suffered a Greater Detriment Than Private Hospitals During the Battle of COVID-19.”

Urology. 2020 Oct; 144:269-270. Epub 2020 Jul 18.PMID: 32687841.

Link: https://pubmed.ncbi.nlm.nih.gov/32687841/

 


Telemedicine and Smart Working: Recommendations of the European Association of Urology

Rodriguez Socarrás M, Loeb S, Teoh JY, Ribal MJ, Bloemberg J, Catto J, N’Dow J, Van Poppel H, Gómez Rivas J.

“Telemedicine and Smart Working: Recommendations of the European Association of Urology”

Eur Urol. 2020 Dec;78(6):812-819. PMID: 32654801.

Link: https://pubmed.ncbi.nlm.nih.gov/32654801/

 


A Systematic Review on Guidelines and Recommendations for Urology Standard of Care During the COVID-19 Pandemic

Heldwein FL, Loeb S, Wroclawski ML, Sridhar AN, Carneiro A, Lima FS, Teoh JY.

“A Systematic Review on Guidelines and Recommendations for Urology Standard of Care During the COVID-19 Pandemic.”

Eur Urol Focus. 2020 Jun 5 epub. PMID: 32532703.

Link: https://pubmed.ncbi.nlm.nih.gov/32532703/

 


A Global Survey on the Impact of COVID-19 on Urological Services

Teoh JY, Ong WLK, Gonzalez-Padilla D, Castellani D, Dubin JM, Esperto F, Campi R, Gudaru K, Talwar R, Okhunov Z, Ng CF, Jain N, Gauhar V, Wong MC, Wroclawski ML, Tanidir Y, Rivas JG, Tiong HY, Loeb S; UroSoMe Working Group.

“A Global Survey on the Impact of COVID-19 on Urological Services.”

Eur Urol. 2020 May 26 epub. PMID: 32507625.

Link: https://pubmed.ncbi.nlm.nih.gov/32507625/

 


Dominican Republic

Sociedad Dominicana de Urologia

 Punta Cana, Dominican Republic. November 2013

Lectures Topics: PSA Screening, Prostate Cancer Markers, and Prostate Biopsy Complications

Category: Prostate Cancer


Drugsafety

 Key Papers


drug safety

 

 

  • Loeb S, Lambe M, Stattin P.

    “Re: Editorial Comment on Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma: D.F. Penson J Urol 2015; 194: 1710-1711.”

    Journal of Urology 2016 epub. PMID: 26783933

    Link: http://www.ncbi.nlm.nih.gov/pubmed/26783933

  • Loeb S, Gupta A. Losonczy L, Tosoian J, Walsh PC.

    “Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk?”

    Curr Opin Urol January 2013; 23: 2-4. PMID: 23159990.

 

  • Loeb S.

    “Invited Editorial Comment Re: Long-Term Fluoroquinolone Use Before the Prostate Biopsy May Increase the Risk of Sepsis Caused by Resistant Microorganisms.”

    Urology August 2011; 78: 255. PMID: 21820566.


England

Royal Society of Medicine

UK (Virtual). June 2020

Topic: COVID-19 and Active Surveillance

Category: Prostate Cancer, COVID-19


European Association of Urology 2017 Congress

London, England. 2017

Lecture topic: Social Media

Category: Social Media


Royal Society of Medicine Urology Section Prostate Cancer Conference

London, England. Ocrober 21, 2016

Lecture topic: Active Surveillance- USA Perspective

Category: Prostate Cancer


Epidemiology

Prostate Cancer. Nature Reviews Disease Primers

Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG.

“Prostate Cancer. Nature Reviews Disease Primers.” 

2021 Feb 4;7(1):9. PMID: 33542230

    Link: https://pubmed.ncbi.nlm.nih.gov/33542230/


Loeb S, Peskoe SB, Joshu CE, Huang WY, Hayes RB, Carter HB, Isaacs WB, Platz EA

“Do Environmental Factors Modify the Genetic Risk of Prostate Cancer?”

Cancer Epidemiology Biomarkers Prevention 2015; 24: 213. PMID: 25342390.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25342390

 

This study examined effect modification by environmental factors of the association between single nucleotide polymorphisms with prostate cancer risk.  Among men at high risk for prostate cancer based on their genotype, use of selenium was associated with a lower risk of advanced prostate cancer, while aspirin, ibuprofen and vegetables were associated with lower risk of nonadvanced prostate cancer.


Loeb S, Folkvaljon Y, Damber JE, Alukal J, Lambe M, Stattin P.  

“Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.” 

Journal of Clinical Oncology 2017;35(13):1430-1436.  PMID: 28447913.

    Link: https://www.ncbi.nlm.nih.gov/pubmed/28447913


Other Original Articles

Thomsen FB, Folkvaljon Y, Garmo H, Robinson D, Loeb S, Ingvar C, Lambe M, Stattin P.

“Risk of malignant melanoma in men with prostate cancer. Nationwide, population-based cohort study.”

International Journal of Cancer. 2015 Dec 14 epub. PMID: 26662367

Link: http://www.ncbi.nlm.nih.gov/pubmed/26662367


Reviews/Editorials

Loeb S, Gupta A. Losonczy L, Tosoian J, Walsh PC.

“Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk?”

Curr Opin Urol January 2013; 23: 2-4. PMID: 23159990.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23159990


Mullins JK, Loeb S.

“Environmental exposures and prostate cancer.”

Urologic Oncology: Seminars and Investigations, March 2012; 30: 216. PMID: 22385992.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22385992


REVIEWS/EDITORIALS

Mullins JK and Loeb S.

“Diabetes Mellitus and Prostate Cancer Risk.”

Expert Review of Endocrinology and Metabolism November 2010; 5: 787.


Other Original Articles

Loeb S, Carter HB, Schaeffer EM, Ling SM, Kettermann A, Ferrucci L, and Metter EJ.

“Bone Mineral Content and Prostate Cancer Risk: Data from the Baltimore Longitudinal Study of Aging.”

BJU International, July 2010; 106: 28.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20067459


Other Original Articles

Loeb S, Helfand BT, Kan D, Isaacs WB, and Catalona WJ.

“Does Diabetes Mellitus Modify the Association between 17q12 Risk Variant and Prostate Cancer Aggressiveness?”

BJU International, November 2009; 104: 1200.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19627283


Reviews/Editorials

Loeb S and Partin AW.

“Randomized Trials of Selenium, Vitamin E, or Vitamin C for Prostate Cancer Prevention.”

Reviews in Urology, Spring 2009; 11: 114.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2725311/


Loeb S and Schaeffer EM.

“Risk Factors, Prevention, and Early Detection of Prostate Cancer.”

Primary Care Clinics of North America, September 2009; 36: 603.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19616157


Other Original Articles

Loeb S, Kan D, Helfand BT, Gashti SN, Nadler RB, and Catalona WJ.

“Is Statin Use Associated with Prostate Cancer Aggressiveness?”

BJU International 2009, Nov 3 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19888973


Epidemiology

Prostate Cancer. Nature Reviews Disease Primers

Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG.

“Prostate Cancer. Nature Reviews Disease Primers.” 

2021 Feb 4;7(1):9. PMID: 33542230

    Link: https://pubmed.ncbi.nlm.nih.gov/33542230/


Loeb S, Peskoe SB, Joshu CE, Huang WY, Hayes RB, Carter HB, Isaacs WB, Platz EA

“Do Environmental Factors Modify the Genetic Risk of Prostate Cancer?”

Cancer Epidemiology Biomarkers Prevention 2015; 24: 213. PMID: 25342390.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25342390

 

This study examined effect modification by environmental factors of the association between single nucleotide polymorphisms with prostate cancer risk.  Among men at high risk for prostate cancer based on their genotype, use of selenium was associated with a lower risk of advanced prostate cancer, while aspirin, ibuprofen and vegetables were associated with lower risk of nonadvanced prostate cancer.


Loeb S, Folkvaljon Y, Damber JE, Alukal J, Lambe M, Stattin P.  

“Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.” 

Journal of Clinical Oncology 2017;35(13):1430-1436.  PMID: 28447913.

    Link: https://www.ncbi.nlm.nih.gov/pubmed/28447913


Other Original Articles

Thomsen FB, Folkvaljon Y, Garmo H, Robinson D, Loeb S, Ingvar C, Lambe M, Stattin P.

“Risk of malignant melanoma in men with prostate cancer. Nationwide, population-based cohort study.”

International Journal of Cancer. 2015 Dec 14 epub. PMID: 26662367

Link: http://www.ncbi.nlm.nih.gov/pubmed/26662367


Reviews/Editorials

Loeb S, Gupta A. Losonczy L, Tosoian J, Walsh PC.

“Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk?”

Curr Opin Urol January 2013; 23: 2-4. PMID: 23159990.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23159990


Mullins JK, Loeb S.

“Environmental exposures and prostate cancer.”

Urologic Oncology: Seminars and Investigations, March 2012; 30: 216. PMID: 22385992.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22385992


REVIEWS/EDITORIALS

Mullins JK and Loeb S.

“Diabetes Mellitus and Prostate Cancer Risk.”

Expert Review of Endocrinology and Metabolism November 2010; 5: 787.


Other Original Articles

Loeb S, Carter HB, Schaeffer EM, Ling SM, Kettermann A, Ferrucci L, and Metter EJ.

“Bone Mineral Content and Prostate Cancer Risk: Data from the Baltimore Longitudinal Study of Aging.”

BJU International, July 2010; 106: 28.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20067459


Other Original Articles

Loeb S, Helfand BT, Kan D, Isaacs WB, and Catalona WJ.

“Does Diabetes Mellitus Modify the Association between 17q12 Risk Variant and Prostate Cancer Aggressiveness?”

BJU International, November 2009; 104: 1200.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19627283


Reviews/Editorials

Loeb S and Partin AW.

“Randomized Trials of Selenium, Vitamin E, or Vitamin C for Prostate Cancer Prevention.”

Reviews in Urology, Spring 2009; 11: 114.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2725311/


Loeb S and Schaeffer EM.

“Risk Factors, Prevention, and Early Detection of Prostate Cancer.”

Primary Care Clinics of North America, September 2009; 36: 603.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19616157


Other Original Articles

Loeb S, Kan D, Helfand BT, Gashti SN, Nadler RB, and Catalona WJ.

“Is Statin Use Associated with Prostate Cancer Aggressiveness?”

BJU International 2009, Nov 3 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19888973


EUROPE

Uppsala University Honorary Doctorate

Uppsala, Sweden. January 2020

Lecture Topic: International Collaboration Using Swedish Registry Data to Improve Health

Category: Prostate Cancer, Men’s Health, Drug Safety


Royal Society of Medicine

UK (Virtual). June 2020

Topic: COVID-19 and Active Surveillance

Category: Prostate Cancer, COVID-19


Challenges in Laparoscopy and Robotics

Barcelona, Spain – July 3-4, 2019

Lecture Topics: Social Media in Prostate Cancer, Robotic Prostatectomy Moderation

Category: prostate cancer, surgical technique, social media


Surgery in the 3rd Millennium: The Future is Female

Milan, Italy – April 4-5, 2019

Lecture Topics: When not to do surgery: expanding active surveillance for low-risk prostate cancer; Moderation for Retzius-Sparing Robotic Prostatectomy

Category: Prostate Cancer, Active Surveillance, Surgical Technique


Hot Topics in Uro-Oncology

Zurich, Switzerland – January 25, 2019

Lecture Topic: Prostate Cancer Screening in the Era of MRI and Novel Biomarkers

Category: Prostate Cancer, MRI, Screening, Markers


Association of Academic European Urologists (AAEU) Meeting

Rome, Italy . November 30, 2018

Lecture Topic: Prostate Cancer Journal Club #ProstateJC on Twitter

Category: Social Media, Prostate Cancer


State-of-the-Art Lecture, Association of Academic European Urologists

Roma, Italy .November, 2018

Lecture Topic: Prostate Cancer Journal Club #ProstateJC on Twitter

Category: Social Media, Prostate Cancer


iTRUST International Translational Research Uro-Sciences Team

Roma, Italy .September 26-27, 2018

Lecture Topic: Social Media & Cancer Care: Where are we going?

Category: Cancer, Social Media


Association of Academic European Urologists (AAEU)

Dresden, Germany . December 15-16, 2017

Lecture Topic: Active surveillance for prostate cancer

Category: Prostate Cancer


European Association of Urology 2017 Congress

London, England. 2017

Lecture topic: Social Media

Category: Social Media


PROSCA 2017

Lisbon, Portugal. June 28-30, 2017

Lecture topics: Screening for prostate cancer: where do we stand?

Category: Prostate Cancer


Heinrich Warner Symposium

Hamburgo, Germany. June 23-24, 2017

Lecture Topic: Clinical Use of Markers in Localized Prostate Cancer

Category: Prostate Cancer


Royal Society of Medicine Urology Section Prostate Cancer Conference

London, England. Ocrober 21, 2016

Lecture topic: Active Surveillance- USA Perspective

Category: Prostate Cancer


European Association of Urology

Munich, Germany. March 11-14, 2016

Lecture Topics: Prostate Cancer Markers

Category: Prostate Cancer


Friends of Israel Urology Symposium

Israel. July 7-8, 2016

Lecture Topics: Active Surveillance, Prostate Cancer Treatment

Category: Prostate Cancer


John Fitzpatrick Irish Prostate Cancer Conference

Ireland. April 21-22, 2016

Lecture Topics: Smarter Prostate Cancer Screening; Prostate Cancer Treatment

Category: Prostate Cancer


Heinrich Warner Symposium

Hamburg, Germany. January 2015

Lecture Topics : Genomic and Epigenetic Variations in Prostate Cancer

Category: Prostate Cancer


Urological Research Society meeting

Jerusalem, Israel. September 2015

Lecture Topic: Utilization of Active Surveillance

Category: Prostate Cancer


American Urological Association New York Section Meeting

Lisbon, Portugal. September 10-12, 2015
Lecture Topic: Markers in Screening and Active Surveillance
Category: Prostate Cancer


Friends of Israel Urological Symposium

Tel Aviv, Israel. July 2012

Lecture Topic: Prostate Cancer Screening

Category: Prostate Cancer


Active Surveillance for Low Risk Prostate Cancer Conference

Amsterdam, Netherlands. February 2014

Lecture topic: Risk based prediction models for indolent Prostate Cancer

Category: Prostate Cancer


Russian Ministry of Health, Institute of Urology

Moscow, Russia. March 2014

Lecture topic: PSA Screening Cost-Effectiveness, Prostate Cancer Markers

Category: Prostate Cancer


Global Congress on Prostate Cancer (PROSCA)

 Rome, Italy. February 2015

Lecture topic: PSA Screening Yes or No

Category: Prostate Cancer


European Association of Urology Guidelines Office Chairs Meeting

Florence, Italy. October 2014

Lecture Topic: Social Media in Urology

Category: Social Media


International Genitourinary Cancer Symposium (IGUCC 5)

Rome, Italy. April 2013

Lectures Topic: Nature vs Nurture in Prostate Cancer, and Prostate Specific Antigen Velocity

Category: Prostate Cancer


European Association of Urology 2015

Madrid, Spain. March 2015

Lecture Topics: Prognostic Factors in the Prostate Histology, Social Media

Categories: Prostate Cancer, Social Media, Erectile Dysfunction


International Genitourinary Cancer Symposium (IGUCC 6)

Madrid, Spain. February 2014

Lecture topic: Smarter Prostate Cancer Screening

Category: Prostate Cancer


Erasmus University Medical Center

Rotterdam, Netherlands. November 2010

Lecture Topic: Prostate Cancer

Category: Prostate Cancer


International Genitourinary Cancer Symposium (IGUCC 3)

Budapest, Hungary. March 2011

Lecture Topics: Debate on Active Surveillance, Panel on Controversies in Prostate Cancer

Category: Prostate Cancer


European Association of Urology 2014 Congress

Stockholm, Sweden. April 2014

Lecture Topic: Invited lecture on Standardizing Report and Outcome of Surgery in Prostate Cancer

Category: Prostate Cancer


ACME meeting

Hemavan, Sweden. January 2012

Lecture topic: Prostate Cancer Risk among immigrants to Sweden

Category: Prostate Cancer


Event

WALL STREET JOURNAL ARTICLE ON PROSTATE CANCER TESTS

Wall Street Journal New prostate cancer tests May 10_1


Genetics

Prostate Cancer. Nature Reviews Disease Primers

Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG.

“Prostate Cancer. Nature Reviews Disease Primers.”

2021 Feb 4;7(1):9. PMID: 33542230.

Link: https://pubmed.ncbi.nlm.nih.gov/33542230/


Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer

Loeb S. and Giri VN.

“Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer.”

Eur Urol Oncol. 2021 Feb;4(1):1-9. Epub 2020 Dec 31. PMID: 33390340

Link: https://pubmed.ncbi.nlm.nih.gov/33390340/


Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.

Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, O’Neil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG

“Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.”

Journal of Clinical Oncology 2020 Jun 9 epub. PMID: 32516092.

Link: https://pubmed.ncbi.nlm.nih.gov/32516092/

The 2019 Philadelphia Prostate Cancer Consensus Conference was a multidisciplinary conference including experts and other stakeholders to create a series of recommendations surrounding germline genetic evaluation for prostate cancer.


Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation.

Loeb S, Byrne N, Walter D, Makarov DV, Wise DR, Becker D, Giri VN.

“Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation.”

Cancer Treat Res Commun. 2020 Sep 28;25:100212. PMID: 33091732

Link: https://pubmed.ncbi.nlm.nih.gov/33091732/


Loeb S, Braithwaite RS, Hayes RB.

Utility of single nucleotide polymorphisms in prostate biopsy decisions.” 

Reviews in Urology 2012; 14: 115-7.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602735/


Loeb S. Editorial Comment on

Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.”

Urology 2015; 85: 170. PMID: 25530380.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25530379


Lynch HT, Kosoko-Lasaki O, Leslie SW, Rendell M, Shaw T, Snyder C, D’Amico AV, Buxbaum S, Isaacs WB, Loeb S, Moul JW, Powell I.

Screening for Familial and Hereditary Prostate Cancer.

International Journal of Cancer.

2015 Dec 5 epub. PMID: 26638190

Link: http://www.ncbi.nlm.nih.gov/pubmed/26638190


Other Original Articles

Bostrӧm PJ, Bjartell AS, Catto JW, Eggener SE, Lilja H, Loeb S, Schalken J, Schlomm T, and Cooperberg MR.

“Genomic Predictors of Outcome in Prostate Cancer.”

European Urology 2015 epub. PMID: 25913390.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25913390


Other Original Articles

Loeb S, Peskoe SB, Joshu CE, Huang WY, Hayes RB, Carter HB, Isaacs WB, Platz EA.

“Do Environmental Factors Modify the Genetic Risk of Prostate Cancer?”

Cancer Epidemiology Biomarkers Prevention 2015; 24: 213. PMID: 25342390.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25342390


Other Original Articles

Reinhardt D, Helfand BT, Cooper PR, Roehl KA, Catalona WJ, and Loeb S.

“Prostate Cancer Risk Alleles are Associated with Prostate Cancer Tumor Volume and Prostate Size.”

Journal of Urology 2013; epub Dec 14. PMID: 24345439

Link: http://www.ncbi.nlm.nih.gov/pubmed/24345439


Other Original Articles

Helfand BT, Hu Q, Loeb S, McVary KT, Catalona WJ.

“Genetic Sequence Variants are Associated with Severity of Lower Urinary Tract Symptoms and Prostate Cancer Susceptibility.”

Journal of Uroloy 2012 epub November. PMID: 23159463.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23159463


Other Original Articles

Cooper PR, McGuire BB, Helfand BT, Loeb S, Hu Q, and Catalona WJ.

“Prostate Cancer Risk Alleles and Their Associations with Other Malignancies.”

Urology October 2011; 78: 970 .e 15-20. PMID: 21820706.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3190015/


Other Original Articles

Helfand BT, Fought AJ, Loeb S, Meeks JJ, Kan D, and Catalona WJ.

“Genetic prostate cancer risk assessment: common variants in 9 genomic regions are associated with cumulative risk.”

Journal of Urology, August 2010; 184: 501.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20620408


Other Original Articles

Helfand BT, Loeb S, Kan D, Catalona WJ.

“Number of prostate cancer risk alleles may identify possibly ‘insignificant’ disease.”

BJU International, June 2010 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20590552


Reviews/Editorials

Loeb S. Editorial Comment on

“Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.”

Urology 2015; 85: 170. PMID: 25530380.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25530379


Other Original Articles

Loeb S, Helfand BT, Kan D, Isaacs WB, and Catalona WJ.

“Does Diabetes Mellitus Modify the Association between 17q12 Risk Variant and Prostate Cancer Aggressiveness?”

BJU International, November 2009; 104: 1200.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19627283


Donin N, Loeb S, Cooper PF, Roehl KA, Baumann NA, Catalona WJ, Helfand BT.

Genetically-Adjusted PSA Values May Prevent Delayed Biopsies in African-American Men.”

BJU International 2014 Jan epub.PMID: 24712975

Link: http://www.ncbi.nlm.nih.gov/pubmed/24712975

 


Other Original Articles

Donin N, Loeb S, Cooper PF, Roehl KA, Baumann NA, Catalona WJ, Helfand BT.

“Genetically-Adjusted PSA Values May Prevent Delayed Biopsies in African-American Men.”

BJU International 2014 Jan epub. PMID: 24712975

Link: http://www.ncbi.nlm.nih.gov/pubmed/24712975


Other Original Articles

Grin B, Loeb S, Roehl K, Cooper PR, Catalona WJ, Helfand BT.

“A rare 8q24 single nucleotide polymorphism (SNP) predisposes North American men to prostate cancer and possibly more aggressive disease.”

BJU International 2014, June epub. PMID: 24952954.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24952954


Key Papers

Helfand BT, Loeb S, Hu Q, Cooper PR, Roehl KA, McGuire BB, Baumann NA, Catalona WJ.

“Personalized PSA Testing Using Genetic Variants May Reduce Unnecessary Biopsies.”

Journal of Urology 2012; epub December. PMID: 23246478.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631301/

Correcting the PSA level for a man’s genotype could potentially reduce the number of men referred for prostate biopsy by up to 20%, while reducing the number of potentially delayed diagnoses by 3% for men with genetically lower PSA levels.


Key Papers

Loeb S, Drevin L, Robinson D, Holmberg E, Carlsson S, Lambe M, Stattin P.

“Risk of localized and advanced prostate cancer among immigrants versus native-born Swedish men: a nation-wide population-based study.”

Cancer Causes Control 2012; December epub. PMID: 23266834.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23266834

First-generation immigrants to Sweden (a high risk country for prostate cancer) have a lower risk of all stages of prostate cancer compared to native-born men, especially men who immigrated to Sweden recently or at an older age.


Reviews/Editorials

Loeb S, Braithwaite RS, Hayes RB.

“Utility of single nucleotide polymorphisms in prostate biopsy decisions.”

Reviews in Urology 2012; 14: 115-7.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602735/


Reviews/Editorials

Loeb S.

“Germline Sequence Variants and Prostate Specific Antigen Interpretation.”

Clinical Chemistry May 2011; 57: 662-3. PMID: 21411622.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21411622


Loeb S.
“Germline Sequence Variants and Prostate Specific Antigen Interpretation.”

Clinical Chemistry May 2011; 57: 662-3.  PMID: 21411622.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21411622


Helfand BT, Loeb S, Meeks JJ, Fought AJ, Kan D, and Catalona WJ.

“Pathological Outcomes Associated with the 17q Prostate Cancer Risk Variants.”

Journal of Urology, June 2009; 181: 2502.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19371897


Key Papers

Loeb S, Carter HB, Walsh PC, Isaacs WB, Kettermann A, Tanaka T, Ferrucci L, and Metter EJ.

“Single Nucleotide Polymorphisms and the Likelihood of Prostate Cancer at a Given Prostate-Specific Antigen Level.”

Journal of Urology, July 2009; 182: 101.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19450841

Genotype influences the risk of prostate cancer per unit increase in PSA. Prostate cancer risk stratification using PSA and genotype together could improve PSA test performance.

 


Other Original Articles

Helfand BT, Loeb S, Meeks JJ, Fought AJ, Kan D, and Catalona WJ.

“Pathological Outcomes Associated with the 17q Prostate Cancer Risk Variants.”

Journal of Urology, June 2009; 181: 2502.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19371897


Reviews/Editorials

Loeb S and Partin AW.

“Single Nucleotide Polymorphisms and Prostate Cancer Susceptibility.”

Reviews in Urology, Fall 2008; 10: 304.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2615108/


Loeb S and Partin AW.

“Single Nucleotide Polymorphisms and Prostate Cancer Susceptibility.”

Reviews in Urology, Fall 2008; 10: 304.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2615108/

 


Helfand BT, Loeb S, Cashy J, Meeks JJ, Thaxton CS, Han M, and Catalona WJ.

“Tumor Characteristics of Carriers and Noncarriers of the deCODE 8q24 Prostate Cancer Susceptibility Alleles.”

Journal of Urology, June 2008; 179: 2197.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18423739


Other Original Articles

Helfand BT, Loeb S, Cashy J, Meeks JJ, Thaxton CS, Han M, and Catalona WJ.

“Tumor Characteristics of Carriers and Noncarriers of the deCODE 8q24 Prostate Cancer Susceptibility Alleles.”

Journal of Urology, June 2008; 179: 2197.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18423739


Other Original Articles

Roehl KA, Loeb S, Antefnor JA, Corbin N, and Catalona WJ.

“Characteristics of Patients with Familial Prostate Cancer Versus Sporadic Cases.”

Journal of Urology, December 2006; 176: 2438.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17085123


Roehl KA, Loeb S, Antefnor JA, Corbin N, and Catalona WJ.

“Characteristics of Patients with Familial Prostate Cancer Versus Sporadic Cases.”

Journal of Urology, December 2006; 176: 2438.
Link: http://www.ncbi.nlm.nih.gov/pubmed/17085123


Genetics

Prostate Cancer. Nature Reviews Disease Primers

Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG.

“Prostate Cancer. Nature Reviews Disease Primers.”

2021 Feb 4;7(1):9. PMID: 33542230.

Link: https://pubmed.ncbi.nlm.nih.gov/33542230/


Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer

Loeb S. and Giri VN.

“Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer.”

Eur Urol Oncol. 2021 Feb;4(1):1-9. Epub 2020 Dec 31. PMID: 33390340

Link: https://pubmed.ncbi.nlm.nih.gov/33390340/


Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.

Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, O’Neil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG

“Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.”

Journal of Clinical Oncology 2020 Jun 9 epub. PMID: 32516092.

Link: https://pubmed.ncbi.nlm.nih.gov/32516092/

The 2019 Philadelphia Prostate Cancer Consensus Conference was a multidisciplinary conference including experts and other stakeholders to create a series of recommendations surrounding germline genetic evaluation for prostate cancer.


Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation.

Loeb S, Byrne N, Walter D, Makarov DV, Wise DR, Becker D, Giri VN.

“Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation.”

Cancer Treat Res Commun. 2020 Sep 28;25:100212. PMID: 33091732

Link: https://pubmed.ncbi.nlm.nih.gov/33091732/


Loeb S, Braithwaite RS, Hayes RB.

Utility of single nucleotide polymorphisms in prostate biopsy decisions.” 

Reviews in Urology 2012; 14: 115-7.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602735/


Loeb S. Editorial Comment on

Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.”

Urology 2015; 85: 170. PMID: 25530380.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25530379


Lynch HT, Kosoko-Lasaki O, Leslie SW, Rendell M, Shaw T, Snyder C, D’Amico AV, Buxbaum S, Isaacs WB, Loeb S, Moul JW, Powell I.

Screening for Familial and Hereditary Prostate Cancer.

International Journal of Cancer.

2015 Dec 5 epub. PMID: 26638190

Link: http://www.ncbi.nlm.nih.gov/pubmed/26638190


Other Original Articles

Bostrӧm PJ, Bjartell AS, Catto JW, Eggener SE, Lilja H, Loeb S, Schalken J, Schlomm T, and Cooperberg MR.

“Genomic Predictors of Outcome in Prostate Cancer.”

European Urology 2015 epub. PMID: 25913390.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25913390


Other Original Articles

Loeb S, Peskoe SB, Joshu CE, Huang WY, Hayes RB, Carter HB, Isaacs WB, Platz EA.

“Do Environmental Factors Modify the Genetic Risk of Prostate Cancer?”

Cancer Epidemiology Biomarkers Prevention 2015; 24: 213. PMID: 25342390.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25342390


Other Original Articles

Reinhardt D, Helfand BT, Cooper PR, Roehl KA, Catalona WJ, and Loeb S.

“Prostate Cancer Risk Alleles are Associated with Prostate Cancer Tumor Volume and Prostate Size.”

Journal of Urology 2013; epub Dec 14. PMID: 24345439

Link: http://www.ncbi.nlm.nih.gov/pubmed/24345439


Other Original Articles

Helfand BT, Hu Q, Loeb S, McVary KT, Catalona WJ.

“Genetic Sequence Variants are Associated with Severity of Lower Urinary Tract Symptoms and Prostate Cancer Susceptibility.”

Journal of Uroloy 2012 epub November. PMID: 23159463.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23159463


Other Original Articles

Cooper PR, McGuire BB, Helfand BT, Loeb S, Hu Q, and Catalona WJ.

“Prostate Cancer Risk Alleles and Their Associations with Other Malignancies.”

Urology October 2011; 78: 970 .e 15-20. PMID: 21820706.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3190015/


Other Original Articles

Helfand BT, Fought AJ, Loeb S, Meeks JJ, Kan D, and Catalona WJ.

“Genetic prostate cancer risk assessment: common variants in 9 genomic regions are associated with cumulative risk.”

Journal of Urology, August 2010; 184: 501.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20620408


Other Original Articles

Helfand BT, Loeb S, Kan D, Catalona WJ.

“Number of prostate cancer risk alleles may identify possibly ‘insignificant’ disease.”

BJU International, June 2010 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20590552


Reviews/Editorials

Loeb S. Editorial Comment on

“Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.”

Urology 2015; 85: 170. PMID: 25530380.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25530379


Other Original Articles

Loeb S, Helfand BT, Kan D, Isaacs WB, and Catalona WJ.

“Does Diabetes Mellitus Modify the Association between 17q12 Risk Variant and Prostate Cancer Aggressiveness?”

BJU International, November 2009; 104: 1200.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19627283


Donin N, Loeb S, Cooper PF, Roehl KA, Baumann NA, Catalona WJ, Helfand BT.

Genetically-Adjusted PSA Values May Prevent Delayed Biopsies in African-American Men.”

BJU International 2014 Jan epub.PMID: 24712975

Link: http://www.ncbi.nlm.nih.gov/pubmed/24712975

 


Other Original Articles

Donin N, Loeb S, Cooper PF, Roehl KA, Baumann NA, Catalona WJ, Helfand BT.

“Genetically-Adjusted PSA Values May Prevent Delayed Biopsies in African-American Men.”

BJU International 2014 Jan epub. PMID: 24712975

Link: http://www.ncbi.nlm.nih.gov/pubmed/24712975


Other Original Articles

Grin B, Loeb S, Roehl K, Cooper PR, Catalona WJ, Helfand BT.

“A rare 8q24 single nucleotide polymorphism (SNP) predisposes North American men to prostate cancer and possibly more aggressive disease.”

BJU International 2014, June epub. PMID: 24952954.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24952954


Key Papers

Helfand BT, Loeb S, Hu Q, Cooper PR, Roehl KA, McGuire BB, Baumann NA, Catalona WJ.

“Personalized PSA Testing Using Genetic Variants May Reduce Unnecessary Biopsies.”

Journal of Urology 2012; epub December. PMID: 23246478.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631301/

Correcting the PSA level for a man’s genotype could potentially reduce the number of men referred for prostate biopsy by up to 20%, while reducing the number of potentially delayed diagnoses by 3% for men with genetically lower PSA levels.


Key Papers

Loeb S, Drevin L, Robinson D, Holmberg E, Carlsson S, Lambe M, Stattin P.

“Risk of localized and advanced prostate cancer among immigrants versus native-born Swedish men: a nation-wide population-based study.”

Cancer Causes Control 2012; December epub. PMID: 23266834.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23266834

First-generation immigrants to Sweden (a high risk country for prostate cancer) have a lower risk of all stages of prostate cancer compared to native-born men, especially men who immigrated to Sweden recently or at an older age.


Reviews/Editorials

Loeb S, Braithwaite RS, Hayes RB.

“Utility of single nucleotide polymorphisms in prostate biopsy decisions.”

Reviews in Urology 2012; 14: 115-7.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602735/


Reviews/Editorials

Loeb S.

“Germline Sequence Variants and Prostate Specific Antigen Interpretation.”

Clinical Chemistry May 2011; 57: 662-3. PMID: 21411622.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21411622


Loeb S.
“Germline Sequence Variants and Prostate Specific Antigen Interpretation.”

Clinical Chemistry May 2011; 57: 662-3.  PMID: 21411622.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21411622


Helfand BT, Loeb S, Meeks JJ, Fought AJ, Kan D, and Catalona WJ.

“Pathological Outcomes Associated with the 17q Prostate Cancer Risk Variants.”

Journal of Urology, June 2009; 181: 2502.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19371897


Key Papers

Loeb S, Carter HB, Walsh PC, Isaacs WB, Kettermann A, Tanaka T, Ferrucci L, and Metter EJ.

“Single Nucleotide Polymorphisms and the Likelihood of Prostate Cancer at a Given Prostate-Specific Antigen Level.”

Journal of Urology, July 2009; 182: 101.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19450841

Genotype influences the risk of prostate cancer per unit increase in PSA. Prostate cancer risk stratification using PSA and genotype together could improve PSA test performance.

 


Other Original Articles

Helfand BT, Loeb S, Meeks JJ, Fought AJ, Kan D, and Catalona WJ.

“Pathological Outcomes Associated with the 17q Prostate Cancer Risk Variants.”

Journal of Urology, June 2009; 181: 2502.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19371897


Reviews/Editorials

Loeb S and Partin AW.

“Single Nucleotide Polymorphisms and Prostate Cancer Susceptibility.”

Reviews in Urology, Fall 2008; 10: 304.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2615108/


Loeb S and Partin AW.

“Single Nucleotide Polymorphisms and Prostate Cancer Susceptibility.”

Reviews in Urology, Fall 2008; 10: 304.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2615108/

 


Helfand BT, Loeb S, Cashy J, Meeks JJ, Thaxton CS, Han M, and Catalona WJ.

“Tumor Characteristics of Carriers and Noncarriers of the deCODE 8q24 Prostate Cancer Susceptibility Alleles.”

Journal of Urology, June 2008; 179: 2197.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18423739


Other Original Articles

Helfand BT, Loeb S, Cashy J, Meeks JJ, Thaxton CS, Han M, and Catalona WJ.

“Tumor Characteristics of Carriers and Noncarriers of the deCODE 8q24 Prostate Cancer Susceptibility Alleles.”

Journal of Urology, June 2008; 179: 2197.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18423739


Other Original Articles

Roehl KA, Loeb S, Antefnor JA, Corbin N, and Catalona WJ.

“Characteristics of Patients with Familial Prostate Cancer Versus Sporadic Cases.”

Journal of Urology, December 2006; 176: 2438.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17085123


Roehl KA, Loeb S, Antefnor JA, Corbin N, and Catalona WJ.

“Characteristics of Patients with Familial Prostate Cancer Versus Sporadic Cases.”

Journal of Urology, December 2006; 176: 2438.
Link: http://www.ncbi.nlm.nih.gov/pubmed/17085123


Germany

Association of Academic European Urologists (AAEU)

Dresden, Germany . December 15-16, 2017

Lecture Topic: Active surveillance for prostate cancer

Category: Prostate Cancer


Heinrich Warner Symposium

Hamburgo, Germany. June 23-24, 2017

Lecture Topic: Clinical Use of Markers in Localized Prostate Cancer

Category: Prostate Cancer


European Association of Urology

Munich, Germany. March 11-14, 2016

Lecture Topics: Prostate Cancer Markers

Category: Prostate Cancer


Heinrich Warner Symposium

Hamburg, Germany. January 2015

Lecture Topics : Genomic and Epigenetic Variations in Prostate Cancer

Category: Prostate Cancer


Grants Completed

Grants Current

Hong Kong

Chinese University of Hong Kong Urology Symposium

Hong Kong (Virtual). November 2020

Topic: Prostate Cancer Screening: Evidence, Guidelines and Implementation; Updates on Prostate Cancer in 2019-2020

Category: Prostate Cancer


Hungary

International Genitourinary Cancer Symposium (IGUCC 3)

Budapest, Hungary. March 2011

Lecture Topics: Debate on Active Surveillance, Panel on Controversies in Prostate Cancer

Category: Prostate Cancer


Ireland

John Fitzpatrick Irish Prostate Cancer Conference

Ireland. April 21-22, 2016

Lecture Topics: Smarter Prostate Cancer Screening; Prostate Cancer Treatment

Category: Prostate Cancer


Israel

Friends of Israel Urology Symposium

Israel. July 7-8, 2016

Lecture Topics: Active Surveillance, Prostate Cancer Treatment

Category: Prostate Cancer


Urological Research Society meeting

Jerusalem, Israel. September 2015

Lecture Topic: Utilization of Active Surveillance

Category: Prostate Cancer


Friends of Israel Urological Symposium

Tel Aviv, Israel. July 2012

Lecture Topic: Prostate Cancer Screening

Category: Prostate Cancer


Italy

Surgery in the 3rd Millennium: The Future is Female

Milan, Italy – April 4-5, 2019

Lecture Topics: When not to do surgery: expanding active surveillance for low-risk prostate cancer; Moderation for Retzius-Sparing Robotic Prostatectomy

Category: Prostate Cancer, Active Surveillance, Surgical Technique


Association of Academic European Urologists (AAEU) Meeting

Rome, Italy . November 30, 2018

Lecture Topic: Prostate Cancer Journal Club #ProstateJC on Twitter

Category: Social Media, Prostate Cancer


State-of-the-Art Lecture, Association of Academic European Urologists

Roma, Italy .November, 2018

Lecture Topic: Prostate Cancer Journal Club #ProstateJC on Twitter

Category: Social Media, Prostate Cancer


iTRUST International Translational Research Uro-Sciences Team

Roma, Italy .September 26-27, 2018

Lecture Topic: Social Media & Cancer Care: Where are we going?

Category: Cancer, Social Media


Global Congress on Prostate Cancer (PROSCA)

 Rome, Italy. February 2015

Lecture topic: PSA Screening Yes or No

Category: Prostate Cancer


European Association of Urology Guidelines Offic